17.01.2015 Views

Final Program - American Society of Gene & Cell Therapy

Final Program - American Society of Gene & Cell Therapy

Final Program - American Society of Gene & Cell Therapy

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

ASGCT Officers and Board <strong>of</strong> Directors<br />

President<br />

Xandra O. Breakeield, PhD<br />

President-Elect<br />

David W. Russell, MD, PhD<br />

Vice President<br />

Harry L. Malech, MD<br />

Secretary<br />

John J. Rossi, PhD<br />

Treasurer<br />

David V. Schaffer, PhD<br />

Board Members<br />

Chiara Bonini, MD<br />

Barry J. Byrne, MD, PhD<br />

Fabio Candotti, MD<br />

Roberto Cattaneo, PhD<br />

Marina Cavazzana-Calvo, MD, PhD<br />

Jeffrey Chamberlain, PhD<br />

Brendan Lee, MD, PhD<br />

John J. Nemunaitis, MD<br />

Xiao Xiao, PhD<br />

Ex-Oficio Board Members<br />

Malcolm K. Brenner, MD, PhD<br />

Katherine P. Ponder, MD<br />

Table <strong>of</strong> Contents<br />

A Welcome from Xandra O. Breakeield, PhD ................2<br />

Annual Meeting Exhibitors ....................................................3<br />

Annual Meeting Supporters ..................................................4<br />

Committee Meeting Schedule and Rosters ....................6<br />

Abstract Planning Committee & Reviewers ................ 12<br />

Excellence in Research Awards<br />

& Travel Grant Recipients .................................................. 14<br />

Award Recipients .................................................................... 15<br />

Faculty List ................................................................................ 16<br />

<strong>Gene</strong>ral Meeting Information ............................................ 22<br />

Hotel Information and Area Map ..................................... 26<br />

Convention Center Plans...................................................... 27<br />

Schedule-at-a-Glance ............................................................. 30<br />

<strong>Program</strong> Schedule ................................................................... 31<br />

Exhibit Hall Floor Plan .......................................................... 78<br />

Exhibitor Descriptions .......................................................... 79<br />

Exhibitor Information ........................................................... 86<br />

ASGCT Executive Office<br />

555 East Wells Street, Suite 1100<br />

Milwaukee, Wisconsin 53202<br />

Phone: 414.278.1341<br />

Fax: 414.276.3349<br />

Email: info@asgct.org<br />

Website: www.asgct.org<br />

Abstract Directory .................................................................. 87<br />

Abstract Author Index ........................................................ 139<br />

Mary Dean, JD, CAE<br />

Executive Director<br />

Ken Janowski<br />

Education & Meetings Manager<br />

Shaun Kramer<br />

Marketing & Outreach Manager<br />

Tara Withington, CAE<br />

Consulting Partner<br />

David Wood<br />

Senior <strong>Program</strong> Manager<br />

Rebecca Zimmer<br />

Membership & Administrative Coordinator<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

1


A Welcome from Xandra O. Breakefield, PhD<br />

Dear Colleagues,<br />

Welcome to the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> (ASGCT) 16th Annual<br />

Meeting! Salt Lake City’s rich history in the study <strong>of</strong> genetics and genealogy<br />

makes it a perfect city to feature this year’s latest advancements in our vibrant<br />

ield. The environs are also rich in majestic state parks and I hope you will<br />

take advantage <strong>of</strong> the chance to visit them, including Antelope Island State<br />

Park, as well as a guided tour <strong>of</strong> Temple Square on May 14 as part <strong>of</strong> an ASGCT<br />

networking adventure series.<br />

The program this year relects the increasing focus on reaching the<br />

commercialization phase <strong>of</strong> gene and cell therapeutics. On Wednesday evening,<br />

the Outreach Committee and BioIndustry Liaison Committee developed a two<br />

hour workshop on commercialization to discuss the low <strong>of</strong> funding in pipeline<br />

development along with some <strong>of</strong> the key conditions that must be in place in<br />

order to insure appropriate and eficient utilization <strong>of</strong> resources. On Saturday,<br />

the Translational Science & Product Development Committee will explore the<br />

unique issues we face in manufacturing biologics. Lastly, the BioIndustry Liaison<br />

Committee has organized a symposium on Friday comprising a series <strong>of</strong> talks<br />

and panel discussion aimed towards the latter steps <strong>of</strong> commercialization.<br />

In addition, we will continue to focus on our historic strengths in novel<br />

technologies in delivery platforms for oligonucleotide, gene and cell<br />

therapies, as well as advances in preclinical and clinical trials, with important<br />

breakthroughs on many fronts. I hope you will be able to stay for the full four<br />

days <strong>of</strong> programming, including the series <strong>of</strong> evening symposia sponsored by<br />

our foundation partners – the Foundation Fighting Blindness, the Muscular<br />

Dystrophy Association, the French Muscular Dystrophy Association, and the<br />

Alliance for Cancer <strong>Gene</strong> <strong>Therapy</strong>.<br />

My special thanks to all the ASGCT members, exhibitors, sponsors and attendees<br />

who are making this such an exciting meeting!<br />

Sincerely,<br />

Xandra O. Breakeield, PhD<br />

President, ASGCT<br />

2<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Annual Meeting Exhibitors – as <strong>of</strong> April 2013<br />

The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> would like to acknowledge and thank the following exhibitors for their<br />

participation at the ASGCT 16 th Annual Meeting. ASGCT greatly appreciates their support and encourages all attendees to<br />

make time each day to visit each <strong>of</strong> these exhibitors in Hall C/D.<br />

Aldevron<br />

AltheaDx<br />

<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

Biomiga, Inc.<br />

BTX/Harvard Apparatus<br />

<strong>Cell</strong>Genix GmbH<br />

Charles River<br />

Children’s Hospital <strong>of</strong> Philadelphia<br />

Cincinnati Children’s Hospital Medical Center<br />

First Biotech Inc.<br />

Florida Biologix<br />

GE Healthcare<br />

GenScript USA Inc<br />

HypOxygen<br />

Lovelace Respiratory Research Institute<br />

Mary Ann Liebert, Inc.<br />

Miltenyi Biotec<br />

MPI Research<br />

NanoSight<br />

National <strong>Gene</strong> Vector Biorepository (NGVB)<br />

Nature Publishing Group<br />

Nature Technology Corporation<br />

Nexcelom Bioscience<br />

NHLBI <strong>Gene</strong> <strong>Therapy</strong> Resource <strong>Program</strong><br />

NIH Ofice <strong>of</strong> Biotechnology Activities<br />

Panasonic Healthcare Company <strong>of</strong> North America<br />

Penn Vector Core<br />

PerkinElmer<br />

PolyPlus-Transfection<br />

REGENX Biosciences, LLC<br />

SAFC<br />

St. Jude Children’s Research Hospital<br />

The Baker Company<br />

TriLink BioTechnologies, Inc.<br />

UAB Vector Production Facility<br />

UNC <strong>Gene</strong> <strong>Therapy</strong> Vector Core<br />

University <strong>of</strong> Iowa/<strong>Gene</strong> Transfer Vector Core<br />

University <strong>of</strong> Utah Blood & Marrow Transplant <strong>Program</strong> –<br />

<strong>Cell</strong> <strong>Therapy</strong> & Regenerative Medicine Facility<br />

VGXI, Inc.<br />

Waisman Biomanufacturing<br />

Wilson Wolf Corporation<br />

Thank you 16 th Annual Meeting Exhibitors!<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

3


Annual Meeting Supporters – as <strong>of</strong> April 2013<br />

The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> is honored to acknowledge the following organizations for their support <strong>of</strong> the<br />

16th Annual Meeting:<br />

Partner Level Support<br />

Printing <strong>of</strong> the Abstract Supplement<br />

Registration Bags<br />

Contributor Level Support<br />

Foundation Symposium<br />

Foundation Symposium<br />

Patron Level Support<br />

Conference Grant Support<br />

Foundation Symposium<br />

Excellence in Research Award (1)<br />

Conference Grant Support<br />

Outstanding New Investigator Award (1)<br />

Travel Grant (5)<br />

Excellence in Research Awards (2)<br />

Travel Grant (1)<br />

Travel Grant (4)<br />

Travel Grant (1)<br />

Travel Grant (2)<br />

Excellence in Research Award (1)<br />

Excellence in Research Award (1)<br />

Travel Grant (1)<br />

4<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Annual Meeting Supporters<br />

Patron Level Support, continued<br />

Excellence in Research Award (1)<br />

Outstanding New Investigator Award (1)<br />

Conference Grant Support<br />

Supported in part by March <strong>of</strong> Dimes<br />

Travel C<strong>of</strong>fee Mugs Travel Grant (1)<br />

Foundation Grant No. 4-FY13-234<br />

Foundation Symposium<br />

Travel Grant (2)<br />

Outstanding New Investigator Award (1)<br />

<strong>Gene</strong>ral Meeting Support<br />

Travel Grant (3)<br />

Outstanding New Investigator Award (1)<br />

Travel Grants (10)<br />

Travel Grants (4)<br />

Travel Grants (5)<br />

Shenzhen SiBono <strong>Gene</strong> Tech<br />

Conference Grant Support<br />

Travel Grant (1) Travel Grants (5)<br />

National Institutes <strong>of</strong> Health Grant Support<br />

This conference was supported by Grant Number 1R13NS083180-01<br />

from the National Institute <strong>of</strong> Neurological Disorders and Stroke.<br />

The content is solely the responsibility <strong>of</strong> the authors and does not<br />

necessarily represent the <strong>of</strong>icial views <strong>of</strong> the National Institute <strong>of</strong><br />

Neurological Disorders and Stroke or the National Institutes <strong>of</strong> Health.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

5


Committee Meeting Schedule – as <strong>of</strong> April 2013<br />

Wednesday – May 15<br />

12:00 pm – 1:15 pm Advisory Council 250D<br />

12:00 pm – 1:15 pm Translational Science & Product Development Committee 250E<br />

12:00 pm – 1:15 pm Host Committee 251A<br />

12:00 pm – 1:15 pm Membership Committee 251B<br />

7:30 pm – 9:00 pm Molecular <strong>Therapy</strong> Editorial Board Meeting Room: Canyon BC (Hilton<br />

Salt Lake City Center)<br />

Thursday – May 16<br />

12:30 pm – 2:00 pm Publications Committee 250D<br />

12:30 pm – 2:00 pm Education Committee 250E<br />

12:30 pm – 2:00 pm Exhibitor Relations Committee 251A<br />

12:30 pm – 2:00 pm Clinical Trials & Regulatory Affairs Committee 251E<br />

8:00 pm – 9:30 pm Molecular <strong>Therapy</strong>: Nucleic Acids Editorial Board Meeting Room: Salon 3 (Hilton<br />

Salt Lake City Center)<br />

Friday – May 17<br />

11:45 am – 1:00 pm Cancer <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee 250D<br />

11:45 am – 1:00 pm Development Committee 250E<br />

11:45 am – 1:00 pm Bio-Industry Liaison Committee 251A<br />

11:45 am – 1:00 pm New Investigator Committee 251B<br />

11:45 am – 1:00 pm Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee 251D<br />

11:45 am – 1:00 pm Outreach Committee 251E<br />

Saturday – May 18<br />

7:30 am – 8:00 am ASGCT Annual Business Meeting 150ABC<br />

12:15 pm – 1:45 pm<br />

Scientiic Committee Meetings:<br />

Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>;<br />

Chemical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>;<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> <strong>Gene</strong>tic and Metabolic Diseases;<br />

Hematologic & Immunologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>;<br />

Immune Responses to <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>;<br />

Infectious Diseases & Vaccines;<br />

Musculo-Skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>;<br />

Oligonucleotide and RNAi Therapeutics;<br />

Physical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> & Vectorology;<br />

Respiratory Tract <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>;<br />

Stem <strong>Cell</strong>;<br />

Viral <strong>Gene</strong> Transfer Vectors Committee<br />

255EF<br />

12:15 pm – 1:45 pm Board <strong>of</strong> Directors Meeting 250D<br />

<strong>Society</strong> Annual Business Meeting<br />

The ASGCT Annual Business Meeting will be conducted on Saturday, May 18, 7:30 am – 8:00 am. A continental breakfast will<br />

be served at 7:15 am in room 150ABC <strong>of</strong> the Convention Center.<br />

All ASGCT Members are welcome to attend. Election results will be announced, new <strong>of</strong>icers will be installed, and the<br />

<strong>Society</strong>’s inances and membership statistics will be reviewed. We welcome your input and participation!<br />

6<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Committee Rosters<br />

Advisory Council<br />

Chair<br />

Terence R. Flotte, MD (2013 - 2014)<br />

Katherine P. Ponder, MD (2011 - 2013)<br />

Members<br />

David M. Bodine, PhD (2009 - 2014)<br />

Xandra O. Breakeield, PhD (2013 - 2018)<br />

Barrie J. Carter, PhD (2011 - 2016)<br />

Kenneth Cornetta, MD (2010 - 2015)<br />

Beverly L. Davidson, PhD (2012 - 2017)<br />

Terence R. Flotte, MD (2011 - 2016)<br />

Carl H. June, MD (2010 - 2015)<br />

Luigi M. Naldini, MD, PhD (2008 - 2013)<br />

Arthur W. Nienhuis, MD (2008 - 2013)<br />

Katherine P. Ponder, MD (2009 - 2014)<br />

R. Jude Samulski, PhD (2012 - 2017)<br />

Bio Industry Liaison Committee<br />

Chair<br />

Estuardo Aguilar-Cordova (2012 - 2014)<br />

Members<br />

Dale G. Ando, MD (2010 - 2016)<br />

Joseph T. Bruder, PhD (2010 - 2013)<br />

Sunil Chada, PhD (2012 - 2015)<br />

Anthony T. Cheung, PhD (2008 - 2014)<br />

Olivier Danos, PhD (2013 - 2016)<br />

Mitchell H. Finer, PhD (2013 - 2016)<br />

Douglas J. Jolly, PhD (2013 - 2016)<br />

William F. Kaemmerer, PhD (2010 - 2016)<br />

David Kirn, MD (2012 - 2015)<br />

Karen Kozarsky, PhD (2007 - 2013)<br />

Timothy K. MacLachlan, PhD (2012 - 2015)<br />

Gabor M. Rubanyi, MD, PhD (2010 - 2013)<br />

Sean M. Sullivan, PhD (2010 - 2013)<br />

Thomas Tillett (2010 - 2013)<br />

Bruce Martin Wentworth, PhD (2013 - 2016)<br />

Cancer <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee<br />

Chair<br />

Chiara Bonini, MD (2012 - 2014)<br />

Members<br />

Karen S. Aboody, MD (2011 - 2014)<br />

Margaret E. Black, PhD (2012 - 2013)<br />

Renier J. Brentjens, MD, PhD (2010 - 2013)<br />

Evanthia Galanis, MD, DSc (2011 - 2014)<br />

Stephen Gottschalk, MD (2007 - 2013)<br />

Paola Grandi, PhD (2011 - 2014)<br />

Akseli Hemminki, MD, PhD (2012 - 2015)<br />

Scott Lonning, DVM, PhD (2012 - 2015)<br />

J. Michael Mathis, PhD (2013 - 2016)<br />

John J. Nemunaitis, MD (2008 - 2014)<br />

Selvarangan Ponnazhagan, PhD (2012 - 2015)<br />

Barbara Savoldo, MD, PhD (2013 - 2016)<br />

Bakhos A. Tannous, PhD (2011 - 2014)<br />

Savio L.C. Woo, PhD (2010 - 2013)<br />

Masato Yamamoto, MD, PhD (2013 - 2016)<br />

Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee<br />

Chair<br />

David A. Dichek, MD (2012 - 2014)<br />

Members<br />

Michael P. Murphy, MD (2009 - 2015)<br />

Timothy O’Brien, MD, PhD (2009 - 2015)<br />

Michael J. Passineau, PhD (2010 - 2016)<br />

Lucio Pastore, MD, PhD (2013 - 2016)<br />

Gabor M. Rubanyi, MD, PhD (2010 - 2016)<br />

Matthew L. Springer, PhD (2007 - 2013)<br />

Ba-Bie Teng, PhD (2013 - 2016)<br />

Karen A. Vincent, PhD (2008 - 2014)<br />

Chemical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee<br />

Chair<br />

Ian MacLachlan, PhD (2011 - 2013)<br />

Kevin G. Rice, PhD (2013 - 2014)<br />

Members<br />

Stephen L. Hart, PhD (2011 - 2014)<br />

Philip L. Leopold, PhD (2012 - 2015)<br />

Ian MacLachlan, PhD (2010 - 2013)<br />

Suzie H. Pun, PhD (2007 - 2013)<br />

Kevin G. Rice, PhD (2010 - 2013)<br />

Cyrus R. Sainya, PhD (2010 - 2013)<br />

David B. Weiner, PhD (2010 - 2013)<br />

Clinical Trials and Regulatory Affairs Committee<br />

Chair<br />

Barry J. Byrne, MD, PhD (2012 - 2014)<br />

Members<br />

Dale G. Ando, MD (2012 - 2013)<br />

Wilson W. Bryan, MD (2012 - 2015)<br />

Jacqueline Corrigan-Curay, MD, JD (2008 - 2014)<br />

Katherine A. High, MD (2012 - 2015)<br />

David Kirn, MD (2012 - 2015)<br />

Maritza C. McIntyre, PhD (2013 - 2016)<br />

Peter K. Working, PhD, DABT (2010 - 2013)<br />

Development Committee<br />

Chair<br />

Barrie J. Carter, PhD (2012 - 2013)<br />

James M. Wilson, MD, PhD (2013 - 2014)<br />

Members<br />

Claudio Bordignon, MD (2012 - 2015)<br />

Malcolm K. Brenner, MD, PhD (2012 - 2015)<br />

Barrie J. Carter, PhD (2011 - 2014)<br />

E. Antonio Chiocca, MD, PhD (2012 - 2015)<br />

Terence R. Flotte, MD (2013 - 2016)<br />

Ryszard Kole, PhD (2012 - 2015)<br />

Brendan Lee, MD, PhD (2013 - 2016)<br />

Arthur W. Nienhuis, MD (2012 - 2015)<br />

John J. Rossi, PhD (2012 - 2015)<br />

James M. Wilson, MD, PhD (2012 - 2014)<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

7


Committee Rosters<br />

Education Committee<br />

Co-Chairs<br />

Hans-Peter Kiem, MD, FACP (2013 - 2014)<br />

Sonia I. Skarlatos, PhD (2011 - 2013)<br />

Luk H. Vandenberghe, PhD (2012 - 2014)<br />

Members<br />

Aravind Asokan, PhD (2013 - 2016)<br />

Terry R. Bishop, PhD (2013 - 2016)<br />

Brian D. Brown, PhD (2011 - 2014)<br />

Nathalie Cartier-Lacave, MD (2011 - 2014)<br />

William F. Goins, PhD (2007 - 2013)<br />

Dirk Grimm, PhD (2011 - 2014)<br />

Richard P. Harbottle, PhD (2013 - 2016)<br />

Scott Q. Harper, PhD (2010 - 2013)<br />

Tal Kafri, MD, PhD (2007 - 2013)<br />

Elizabeth Kang, MD (2011 - 2014)<br />

Hans-Peter Kiem, MD, FACP (2011 - 2013)<br />

Harry L. Malech, MD (2010 - 2013)<br />

Matthew H. Porteus, MD, PhD (2010 - 2016)<br />

Sonia I. Skarlatos, PhD (2011 - 2014)<br />

James Yockman, PhD (2012 - 2015)<br />

Ethics Committee<br />

Chair<br />

Theodore Friedmann, MD (2012 - 2013)<br />

Members<br />

R. Michael Blaese, MD (2010 - 2013)<br />

Theodore Friedmann, MD (2008 - 2014)<br />

Dieter C. Gruenert, PhD (2010 - 2013)<br />

Nancy M.P. King, JD (2012 - 2015)<br />

Bruce E. Torbett, PhD, MSPH (2012 - 2015)<br />

Nelson A. Wivel, MD (2010 - 2016)<br />

Exhibitor Relations Committee<br />

Chair<br />

Larry A. Couture, PhD (2013 - 2014)<br />

Members<br />

Janet Benson, PhD, DABT (2013 - 2016)<br />

Linda B. Couto, PhD (2013 - 2016)<br />

J. David Enloe, Jr., BBA CPA (2013 - 2016)<br />

Clague Hodgson, PhD (2013 - 2016)<br />

Ian Johnston, PhD (2013 - 2016)<br />

Karen Kozarsky, PhD (2013 - 2016)<br />

Financial Affairs Committee<br />

Chair<br />

Xandra O. Breakeield, PhD (2012 - 2013)<br />

Members<br />

Harry L. Malech, MD (2012 - 2015)<br />

John J. Rossi, PhD (2010 - 2013)<br />

David W. Russell, MD, PhD (2011 - 2014)<br />

David V. Schaffer, PhD (2011 - 2014)<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> <strong>Gene</strong>tic & Metabolic<br />

Diseases and Diabetes Committee<br />

Chair<br />

Lawrence C. Chan, MD (2012 - 2014)<br />

Members<br />

Valder R. Arruda, MD, PhD (2012 - 2013)<br />

Alessandra Bifi, MD (2011 - 2014)<br />

Fatima Bosch, PhD (2010 - 2016)<br />

Nicola Brunetti-Pierri, MD (2012 - 2015)<br />

Randy J. Chandler, PhD, MB (2012 - 2015)<br />

Seng H. Cheng, PhD (2013 - 2016)<br />

Stephanie Cherqui, PhD (2011 - 2014)<br />

Andrew M. David<strong>of</strong>f, MD (2010 - 2016)<br />

Dwight Koeberl, MD, PhD (2013 - 2016)<br />

Federico Mingozzi, PhD (2012 - 2015)<br />

Philip Ng, PhD (2013 - 2016)<br />

Sihong Song, PhD (2011 - 2014)<br />

Peter M. Thule, MD (2013 - 2016)<br />

Charles P. Venditti, MD, PhD (2008 - 2014)<br />

<strong>Gene</strong>tic Vaccines Committee<br />

Chair<br />

Jeffrey J. Molldrem, MD (2011 - 2013)<br />

Members<br />

Austin J. Barrett, MD (2010 - 2013)<br />

William J. Bowers, PhD (2012 - 2013)<br />

J. Keith Joung, MD, PhD (2012 - 2013)<br />

Sattva S. Neelapu, MD (2010 - 2013)<br />

Hematologic and Immunologic <strong>Gene</strong> and <strong>Cell</strong><br />

<strong>Therapy</strong> Committee<br />

Chair<br />

Alessandro Aiuti, MD, PhD (2013 - 2014)<br />

Cynthia Dunbar, MD (2012 - 2013)<br />

Members<br />

Alessandro Aiuti, MD, PhD (2008 - 2013)<br />

Fabio Candotti, MD (2013 - 2016)<br />

Gianpietro Dotti, MD (2010 - 2013)<br />

John T. Gray, PhD (2011 - 2014)<br />

Helen E. Heslop, MD (2011 - 2014)<br />

Dennis D. Hickstein, MD (2013 - 2016)<br />

J. Keith Joung, MD, PhD (2012 - 2015)<br />

Punam Malik, MD, PhD (2013 - 2016)<br />

Paris Margaritis, DPhil (2011 - 2014)<br />

Derek A. Persons, MD, PhD (2007 - 2013)<br />

Pankaj Qasba, PhD (2013 - 2016)<br />

Barbara Savoldo, MD, PhD (2010 - 2013)<br />

Evangelia Yannaki, MD (2012 - 2015)<br />

8<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Committee Rosters<br />

Host Committee<br />

Chair<br />

Xandra O. Breakeield, PhD (2011 - 2013)<br />

David W. Russell, MD, PhD (2013 - 2014)<br />

Members<br />

Janet Benson, PhD, DABT (2011 - 2013)<br />

James Brown, PhD (2013 – 2014)<br />

Xavier Danthinne, PhD (2011 - 2013)<br />

Giovanni Di Pasquale, PhD (2013 - 2014)<br />

Boro Dropulic, PhD (2013 - 2014)<br />

Howard J. Feder<strong>of</strong>f, MD, PhD (2013 - 2014)<br />

David T. Harris, PhD (2011 - 2013)<br />

Eric H<strong>of</strong>fman, PhD (2013 - 2014)<br />

Sung Wan Kim, PhD (2011 - 2013)<br />

Catherine McKeon, PhD (2013 - 2014)<br />

Paul Muhlrad, PhD (2011 - 2013)<br />

Immune Responses to <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

Chair<br />

Shulin Li, PhD (2012 - 2014)<br />

Members<br />

Catherine M. Bollard, MBChB, FRACP, FRCPA (2011 - 2014)<br />

Andrew P. Byrnes, PhD (2010 - 2016)<br />

Vincenzo Cerullo, PhD (2013 - 2016)<br />

Jonathan D. Finn, PhD (2013 - 2016)<br />

Roland W. Herzog, PhD (2010 - 2016)<br />

Song Li, MD, PhD (2012 - 2015)<br />

Gerald S. Lipshutz, MD (2010 - 2016)<br />

Pedro Lowenstein, MD, PhD (2012 - 2013)<br />

J. Michael Mathis, PhD (2013 - 2016)<br />

John D. Mountz, MD, PhD (2007 - 2013)<br />

Alistair Ramsay, PhD (2012 - 2015)<br />

Denise Sabatino, PhD (2008 - 2014)<br />

Renata Stripecke, PhD (2013 - 2016)<br />

Yiping Yang, MD, PhD (2010 - 2016)<br />

Xianzheng Zhou, MD, PhD (2012 - 2015)<br />

Infectious Diseases and Vaccines Committee<br />

Chair<br />

Margaret A. Liu, MD (2011 - 2013)<br />

Eric Poeschla, MD (2013 - 2014)<br />

Members<br />

William J. Bowers, PhD (2012 - 2015)<br />

Thomas W. Dubensky, Jr., PhD (2012 - 2015)<br />

Philip R. Johnson, MD (2010 - 2016)<br />

David Klatzmann, MD, PhD (2012 - 2015)<br />

Margaret A. Liu, MD (2011 - 2014)<br />

Jeffrey J. Molldrem, MD (2011 - 2014)<br />

Sattva S. Neelapu, MD (2010 - 2016)<br />

Eric Poeschla, MD (2010 - 2013)<br />

Steven Polyak, MD (2010 - 2013)<br />

Alain Rolland, PharmD, PhD (2012 - 2015)<br />

James M. Wilson, MD, PhD (2007 - 2013)<br />

International Committee<br />

Chair<br />

Bobby Gaspar, MD, PhD (2013 - 2014)<br />

Thierry C. VandenDriessche, PhD (2011 - 2013)<br />

Members<br />

Alberto Auricchio, MD (2010 - 2013)<br />

Etiena Basner-Tschakarjan, MD, PhD (2013 - 2016)<br />

Christopher Baum, MD (2010 - 2013)<br />

John C. Bell, PhD (2012 - 2015)<br />

Bobby Gaspar, MD, PhD (2008 - 2013)<br />

Salima Hacein-Bey Abina, PharmD, PhD (2008 - 2014)<br />

Yasufumi Kaneda, MD, PhD (2012 - 2015)<br />

Kazunori Kataoka, PhD (2012 - 2015)<br />

Paula Y. P. Lam, PhD (2013 - 2016)<br />

Kyriacos A. Mitrophanous, PhD (2012 - 2015)<br />

Amit Nathwani, MD, PhD (2011 - 2014)<br />

Thierry C. VandenDriessche, PhD (2010 - 2014)<br />

Chae-Ok Yun, PhD (2012 - 2015)<br />

Membership Committee<br />

Chair<br />

Guangping Gao, PhD (2011 - 2013)<br />

Thomas Conlon, PhD (2013 - 2014)<br />

Members<br />

Donna Armentano, PhD (2011 - 2014)<br />

Alberto Auricchio, MD (2011 - 2014)<br />

Margaret E. Black, PhD (2010 - 2013)<br />

Michele P. Calos, PhD (2010 - 2013)<br />

Resy Cavallesco Wharton, PhD (2013 - 2016)<br />

Thomas Conlon, PhD (2012 - 2015)<br />

Guangping Gao, PhD (2011 - 2014)<br />

David Kirn, MD (2011 - 2014)<br />

Toya Ohashi, MD (2008 - 2014)<br />

Keiya Ozawa, MD, PhD (2011 - 2014)<br />

Ex-Oficio<br />

Robert M. Frederickson, PhD (2005 - 2014)<br />

Musculo-Skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee<br />

Chair<br />

Kathryn R. Wagner, MD, PhD (2012 - 2014)<br />

Members<br />

Jeffrey Chamberlain, PhD (2010 - 2013)<br />

Joel R. Chamberlain, PhD (2013 - 2016)<br />

Charles A. Gersbach, PhD (2012 - 2015)<br />

Richard J. Gregory, PhD (2010 - 2013)<br />

Dwight Koeberl, MD, PhD (2010 - 2016)<br />

Gloria Matthews, DVM, PhD,DACVS (2013 - 2016)<br />

Jerry R. Mendell, MD (2012 - 2013)<br />

Alan J. Nixon, DVM, MS (2007 - 2013)<br />

Shin’ichi Takeda, MD, PhD (2010 - 2016)<br />

Bing Wang, MD, PhD (2010 - 2016)<br />

Xiao Xiao, PhD (2012 - 2015)<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

9


Committee Rosters<br />

Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

Committee<br />

Chair<br />

Anne Messer, PhD (2012 - 2014)<br />

Members<br />

Robin R. Ali, PhD (2010 - 2016)<br />

Alessandra Bifi, MD (2011 - 2014)<br />

Thomas W. Chalberg, Jr., PhD (2011 - 2014)<br />

Florian Eichler, MD (2011 - 2014)<br />

David J. Fink, MD (2010 - 2016)<br />

William W. Hauswirth, PhD (2010 - 2016)<br />

Alfred S. Lewin, PhD (2012 - 2015)<br />

Jacques JB Mallet, PhD (2012 - 2015)<br />

Jodi L. McBride, PhD (2013 – 2016)<br />

Seshidhar Reddy Police, DVM, MS, PhD (2011 - 2014)<br />

Miguel Sena-Esteves, PhD (2012 - 2015)<br />

Mark H. Tuszynski, MD, PhD (2012 - 2013)<br />

John H. Wolfe, VMD, PhD (2010 - 2016)<br />

New Investigator Committee<br />

Chair<br />

Matthew D. Weitzman, PhD (2011 - 2014)<br />

Members<br />

Jennifer E. Adair, PhD (2011 - 2014)<br />

F. Charles Brunicardi, MD (2011 - 2014)<br />

Paul Gadue, PhD (2011 - 2014)<br />

Scott Q. Harper, PhD (2011 - 2014)<br />

Brian K. Kaspar, PhD (2011 - 2014)<br />

Maria P. Limberis, PhD (2012 - 2015)<br />

Casey A. Maguire, PhD (2012 - 2015)<br />

Eirini P. Papapetrou, MD, PhD (2011 - 2014)<br />

Miguel Sena-Esteves, PhD (2011 - 2014)<br />

Johan Skog, PhD (2012 - 2015)<br />

Luk H. Vandenberghe, PhD (2011 - 2014)<br />

Andy Wilber, PhD (2011 - 2014)<br />

Nominating Committee<br />

Chair<br />

Kenneth Cornetta, MD (2012 - 2014)<br />

Members<br />

Dale G. Ando, MD (2012 - 2013)<br />

Helen E. Heslop, MD (2012 - 2013)<br />

Brendan Lee, MD, PhD (2011 - 2013)<br />

Kevin V. Morris, PhD (2012 - 2013)<br />

Oligonucleotide and RNAi Therapeutics Committee<br />

Chair<br />

Paloma H. Giangrande, PhD (2013 - 2014)<br />

Kevin V. Morris, PhD (2011 - 2013)<br />

Members<br />

C. Frank Bennett, PhD (2010 - 2016)<br />

Brian D. Brown, PhD (2010 - 2013)<br />

Paloma H. Giangrande, PhD (2012 - 2013)<br />

Dirk Grimm, PhD (2010 - 2013)<br />

Scott Q. Harper, PhD (2013 - 2016)<br />

Ryszard Kole, PhD (2011 - 2014)<br />

Matthew Levy, PhD (2011 - 2014)<br />

Paul B. McCray, Jr., MD (2008 - 2014)<br />

Nuria Morral, PhD (2012 - 2015)<br />

Kevin V. Morris, PhD (2011 - 2014)<br />

Marco S. Weinberg, PhD (2010 - 2016)<br />

Outreach Committee<br />

Chair<br />

Rachel Salzman, DVM (2013 - 2014)<br />

Savio L.C. Woo, PhD (2011 - 2013)<br />

Members<br />

Timothy R. Cote, MD, MPH (2011 - 2014)<br />

Joseph C. Glorioso, III, PhD (2011 - 2014)<br />

Jane S. Lebkowski, PhD (2011 - 2014)<br />

Brendan Lee, MD, PhD (2012 - 2013)<br />

Harry L. Malech, MD (2011 - 2014)<br />

Andra E. Miller, PhD (2011 - 2014)<br />

Rachel Salzman, DVM (2011 - 2014)<br />

James M. Wilson, MD, PhD (2012 - 2015)<br />

Savio L.C. Woo, PhD (2011 - 2014)<br />

Physical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> and Vectorology<br />

Committee<br />

Chair<br />

Richard Heller, PhD (2011 - 2013)<br />

R. Scott McIvor, PhD (2013 - 2014)<br />

Members<br />

Michele P. Calos, PhD (2007 - 2013)<br />

David A. Dean, PhD (2013 - 2016)<br />

Julie Gehl, MD, Dr.Med.Sci. (2013 - 2016)<br />

James G. Hecker, MD, PhD (2013 - 2016)<br />

Richard Heller, PhD (2011 - 2014)<br />

Dexi Liu, PhD (2013 - 2016)<br />

R. Scott McIvor, PhD (2009 - 2015)<br />

Carol H. Miao, PhD (2009 - 2015)<br />

Sean M. Sullivan, PhD (2010 - 2013)<br />

Ernst Wagner, PhD (2012 - 2015)<br />

10<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Committee Rosters<br />

<strong>Program</strong> Committee<br />

Co-Chairs<br />

Daniel G. Anderson, PhD (2012 - 2013)<br />

Xandra O. Breakeield, PhD (2012 - 2013)<br />

Maria G. Castro, PhD (2011 - 2013)<br />

Gay Crooks, MD (2011 - 2013)<br />

R. Scott McIvor, PhD (2013 – 2015)<br />

John J. Nemunaitis, MD (2013 - 2015)<br />

David W. Russell, MD, PhD (2013 - 2014)<br />

Sonia I. Skarlatos, PhD (2013 - 2015)<br />

Publications Committee<br />

Chair<br />

Cynthia Dunbar, MD (2013 - 2014)<br />

Francis C. Szoka, Jr., PhD (2011 - 2013)<br />

Members<br />

Hans-Peter Kiem, MD, FACP (2007 - 2013)<br />

Arthur W. Nienhuis, MD (2010 - 2016)<br />

Stephen J. Russell, MD, PhD (2012 - 2015)<br />

Michel Sadelain, MD, PhD (2007 - 2013)<br />

Rachel Salzman, DVM (2008 - 2014)<br />

Francis C. Szoka, Jr., PhD (2011 - 2014)<br />

Respiratory Tract <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee<br />

Chair<br />

John F. Engelhardt, PhD (2013 - 2014)<br />

Terence R. Flotte, MD (2011 - 2013)<br />

Members<br />

Mark J. Cooper, MD (2012 - 2015)<br />

David A. Dean, PhD (2010 - 2013)<br />

John F. Engelhardt, PhD (2010 - 2013)<br />

Terence R. Flotte, MD (2011 - 2014)<br />

Uta Griesenbach, PhD (2010 - 2013)<br />

Dieter C. Gruenert, PhD (2013 - 2016)<br />

William B. Guggino, PhD (2013 - 2016)<br />

Jay K. Kolls, MD (2007 - 2013)<br />

Maria P. Limberis, PhD (2013 - 2016)<br />

Christian Mueller, PhD (2012 - 2015)<br />

David W. Parsons, PhD (2007 - 2013)<br />

Stem <strong>Cell</strong> Committee<br />

Chair<br />

Karen S. Aboody, MD (2012 - 2014)<br />

Members<br />

James Ellis, PhD (2009 - 2015)<br />

Paul Gadue, PhD (2013 - 2016)<br />

Jane S. Lebkowski, PhD (2010 - 2016)<br />

Carolyn Lutzko, PhD (2013 - 2016)<br />

Eirini P. Papapetrou, MD, PhD (2013 - 2016)<br />

Alice F. Tarantal, PhD (2009 - 2015)<br />

Translational Science and Product Development<br />

Committee<br />

Chair<br />

Boro Dropulic, PhD (2012 - 2014)<br />

Members<br />

Joy Cavagnaro, PhD, DABT, ATS (2010 - 2016)<br />

Douglas J. Jolly, PhD (2010 - 2016)<br />

<strong>Gene</strong> Liau, PhD (2012 - 2015)<br />

Dexi Liu, PhD (2013 - 2016)<br />

Ian MacLachlan, PhD (2010 - 2013)<br />

Phillip B. Maples, PhD (2013 - 2016)<br />

Maritza C. McIntyre, PhD (2012 - 2013)<br />

Alain Rolland, PharmD, PhD (2010 - 2016)<br />

Richard O. Snyder, PhD (2010 - 2016)<br />

Ge<strong>of</strong>f P. Symonds, PhD (2012 - 2015)<br />

Dale VanderPutten, MBA, PhD (2010 - 2013)<br />

Gabor Veres, PhD (2012 - 2015)<br />

Liaison<br />

Jakob Reiser, PhD (2011 - 2014)<br />

Viral <strong>Gene</strong> Transfer Vectors Committee<br />

Chair<br />

John T. Gray, PhD (2012 - 2014)<br />

Members<br />

Mavis Agbandje-McKenna, PhD (2010 - 2016)<br />

Ian E. Alexander, MBBS, PhD (2011 - 2014)<br />

Jeffrey S. Bartlett, PhD (2013 - 2016)<br />

Haifeng Chen, PhD (2013 - 2016)<br />

John A. Chiorini, PhD (2010 - 2016)<br />

Kevin D. Foust, PhD (2012 - 2015)<br />

Guangping Gao, PhD (2013 - 2016)<br />

Stephen J. Russell, MD, PhD (2010 - 2016)<br />

Dmitry M. Shayakhmetov, PhD (2009 - 2015)<br />

Jackie Sheng, PhD (2011 - 2014)<br />

H. Trent Spencer, PhD (2012 - 2015)<br />

Weidong Xiao, PhD (2012 - 2015)<br />

To learn how to serve on an ASGCT Committee, visit the ASGCT Membership Booth!<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

11


Abstract Planning Committee<br />

Each year this committee, which is made up <strong>of</strong> the ASGCT President, President-Elect, Abstract Review Chair, <strong>Program</strong><br />

Committee Co-Chairs and two invited members, reviews abstracts that are suggested by the various categories for the<br />

Presidential Symposium and the Clinical Oral Abstract Session.<br />

Daniel G. Anderson, PhD<br />

Massachusetts Institute <strong>of</strong> Technology<br />

Cambridge, MA<br />

Xandra O. Breakefield, PhD<br />

Massachusetts <strong>Gene</strong>ral Hospital and<br />

Harvard Medical School<br />

Charlestown, MA<br />

Abstract Reviewers<br />

Abstract Committee Chair<br />

Kenneth Cornetta, MD<br />

Kenneth Cornetta, MD<br />

Indiana University<br />

Indianapolis, IN<br />

Pedro Lowenstein, MD, PhD<br />

University <strong>of</strong> Michigan School <strong>of</strong><br />

Medicine<br />

Ann Arbor, MI<br />

David W. Russell, MD, PhD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

Michel Sadelain, MD, PhD<br />

Memorial Sloan-Kettering Cancer<br />

Center<br />

New York, NY<br />

RNA Virus Vectors<br />

Abstract Review Chair<br />

Dorothee von Laer, MD<br />

Reviewers<br />

Jennifer Adair, PhD*<br />

Brian D. Brown, PhD<br />

Cynthia Dunbar, MD<br />

Rik Gijsbers, PhD*<br />

AAV Vectors<br />

Abstract Review Chair<br />

Aravind Asokan, PhD<br />

Reviewers<br />

Mavis Agbandje-McKenna, PhD<br />

Casey A. Maguire, PhD*<br />

Hiroyuki Nakai, MD, PhD<br />

David V. Schaffer, PhD<br />

Adenovirus and<br />

Other DNA Virus Vectors<br />

Abstract Review Chair<br />

James M. Wilson, MD, PhD<br />

Reviewers<br />

Soumitra Roy, MD, PhD*<br />

Miguel Sena-Esteves, PhD<br />

Prem Seth, PhD*<br />

William S.M. Wold, PhD<br />

DNA Vectorology & <strong>Gene</strong><br />

Targeting<br />

Abstract Review Chair<br />

Matthew H. Porteus, MD, PhD<br />

Reviewers<br />

Matthew Hirsch, PhD*<br />

Carol Miao, PhD<br />

Shondra Miller, PhD*<br />

Andy Wilber, PhD<br />

Physical Methods <strong>of</strong> Delivery<br />

Abstract Review Chair<br />

Kevin G. Rice, PhD<br />

Reviewers<br />

Todd Giorgio, PhD<br />

Richard Heller, PhD<br />

King F. Kwong, MD*<br />

Sean M. Sullivan, PhD<br />

Chemical and Molecular<br />

Conjugates<br />

Abstract Review Chair<br />

Young Jik Kwon, PhD<br />

Reviewers<br />

Hai-Quan Mao, PhD<br />

Tatiana Segura, PhD<br />

Lonnie D. Shea, PhD<br />

Chun Wang, PhD<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes<br />

and Metabolic and <strong>Gene</strong>tic<br />

Diseases<br />

Abstract Review Chair<br />

Nuria Morral, PhD<br />

Reviewers<br />

Nicola Brunetti-Pierri, MD<br />

Stephanie Cherqui, PhD*<br />

Gerald S. Lipshutz, MD*<br />

Sihong Song, PhD*<br />

Cardiovascular <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong><br />

Abstract Review Chair<br />

Thomas Weber, PhD<br />

Reviewers<br />

Michael A. Barry, PhD<br />

Dongsheng Duan, PhD<br />

Katherine P. Ponder, MD<br />

Joseph E. Rabinowitz, PhD<br />

Neurologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

Abstract Review Chair<br />

Nicholas Boulis, MD<br />

Reviewers<br />

Mimoun Azzouz, PhD*<br />

David J. Fink, MD<br />

Brian Kaspar, PhD<br />

Scott McPhee, PhD*<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong><br />

Abstract Review Chair<br />

Charles A. Gersbach, PhD<br />

Reviewers<br />

Annemieke Aartsma-Rus, PhD*<br />

Louise Rodino-Klapac, PhD*<br />

Jacques Tremblay, PhD<br />

Xiao Xiao, PhD<br />

Infectious Diseases and Vaccines<br />

Abstract Review Chair<br />

Grant D. Trobridge, PhD<br />

Reviewers<br />

Dong Sung An, MD, PhD*<br />

K. Reed Clark, PhD<br />

Bruce L. Levine, PhD<br />

Renata Stripecke, PhD*<br />

12<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Reviewers<br />

Cancer - Immunotherapy<br />

Abstract Review Chair<br />

Richard G. Vile, PhD<br />

Reviewers<br />

Steven M. Albelda, MD*<br />

Vincenzo Cerullo, PhD<br />

Jeffrey J. Molldrem, MD<br />

Michael I. Nishimura, PhD*<br />

Cancer – Oncolytic Viruses<br />

Abstract Review Chair<br />

Grant McFadden, PhD<br />

Reviewers<br />

John C. Bell, PhD*<br />

David Kirn, MD<br />

Brian Lichty, PhD*<br />

Stephen J. Russell, MD, PhD<br />

Cancer - Targeted <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong><br />

Abstract Review Chair<br />

Evanthia Galanis, MD, DSc<br />

Reviewers<br />

Karen S. Aboody, MD<br />

Helen E. Heslop, MD<br />

Noriyuki Kasahara, MD, PhD<br />

Janaiah Kota, PhD*<br />

Hematologic and Immunologic<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

Abstract Review Chair<br />

Fabio Candotti, MD<br />

Reviewers<br />

Marina Cavazzana-Calvo, MD, PhD<br />

Bobby Gaspar, MD, PhD<br />

Arnab Ghosh, MD, PhD*<br />

David A. Wilcox, PhD*<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> for<br />

Pulmonary Diseases<br />

Abstract Review Chair<br />

Uta Griesenbach, PhD<br />

Reviewers<br />

Katherine J. Exc<strong>of</strong>fon, PhD*<br />

Stephen L. Hart, PhD<br />

Jim Hu, PhD<br />

Maria P. Limberis, PhD<br />

Immunologic & Host Responses<br />

in <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

Abstract Review Chair<br />

Pedro Lowenstein, MD, PhD<br />

Reviewers<br />

Renier J. Brentjens, MD, PhD<br />

Antonia Follenzi, MD, PhD*<br />

Maciej S. Lesniak, MD, MHCM, FACS<br />

Federico Mingozzi, PhD*<br />

Sensory (Ophthalmic and<br />

Auditory) <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

Abstract Review Chair<br />

Jean Bennett, MD, PhD<br />

Reviewers<br />

Alberto Auricchio, MD<br />

Rajendra Kumar-Singh, PhD*<br />

Tonia Rex, PhD*<br />

Luk H. Vandenberghe, PhD<br />

<strong>Gene</strong> Regulation<br />

Abstract Review Chair<br />

David W. Emery, PhD<br />

Reviewers<br />

Donna Armentano, PhD<br />

Michelle P. Calos, PhD<br />

Punam Malik, MD, PhD<br />

David M. Spencer, PhD<br />

Oligonucleotide & RNAi<br />

Therapeutics<br />

Abstract Review Chair<br />

Paloma H. Giangrande, PhD<br />

Reviewers<br />

Scott Q. Harper, PhD<br />

Shawn E. Lupold, PhD*<br />

M. Corinna Palanca-Wessels, MD, PhD*<br />

Laura Sepp-Lorenzino, PhD<br />

Stem <strong>Cell</strong> Therapies<br />

Abstract Review Chair<br />

Michel Sadelain, MD, PhD<br />

Reviewers<br />

Paul Gadue, PhD<br />

Hans-Peter Kiem, MD, FACP<br />

Jan A. Nolta, PhD<br />

Darwin J. Prockop, MD, PhD<br />

<strong>Cell</strong> Processing and Vector<br />

Production<br />

Abstract Review Chair<br />

Adrian P. Gee, PhD<br />

Reviewers<br />

Gerhard Bauer, PhD<br />

Steven A. Feldman, PhD*<br />

Isabelle Riviere, PhD<br />

Sowmya Viswanathan, PhD*<br />

Special thanks to the abstract reviewers for their time and expertise!<br />

*Indicates irst time reviewer for ASGCT.<br />

To volunteer to review abstracts for the 17th Annual Meeting, visit the ASGCT Membership booth.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

13


Excellence in Research Awards & Travel Grant Recipients<br />

Excellence in Research Awards – For Students and Postdoctoral Fellows<br />

Luca Biasco<br />

San Raffaele Telethon Institute for <strong>Gene</strong> <strong>Therapy</strong><br />

Comprehensive Study <strong>of</strong> Lentiviral [quot]Integrome[quot] in<br />

WAS <strong>Gene</strong> <strong>Therapy</strong> Patients<br />

Sourav Choudhury<br />

University <strong>of</strong> Massachusetts Medical School<br />

Identiication <strong>of</strong> Novel Vectors Capable <strong>of</strong> CNS Transduction<br />

in Adult Mice after Single Round Selection Using DNA Shufled<br />

AAV Capsid Library<br />

Drew Deniger<br />

University <strong>of</strong> Texas MD Anderson Cancer Center<br />

Clinical Implications <strong>of</strong> ROR1-Speciic T <strong>Cell</strong>s That Target<br />

B-<strong>Cell</strong> Leukemia<br />

Charles Lai<br />

Massachusetts <strong>Gene</strong>ral Hospital<br />

Non-Invasive In Vivo Imaging, Biodistribution and Clearance<br />

Analyses <strong>of</strong> Intravenously Administered Extracellular Vesicles<br />

Rajiv Sharma<br />

Children’s Hospital <strong>of</strong> Philadelphia<br />

In Vivo ZFN Mediated Targeting <strong>of</strong> Albumin as a Platform for<br />

Expression <strong>of</strong> Multiple Therapeutic <strong>Gene</strong>s<br />

Barbara Smith<br />

University <strong>of</strong> Florida<br />

Acid alpha-Glucosidase <strong>Gene</strong> Replacement <strong>Therapy</strong> to the<br />

Diaphragm in Ventilator-Dependent Pompe Disease: One-Year<br />

Respiratory Motor Outcomes<br />

Travel Grants – For Students and Postdoctoral Fellows<br />

Erik Abels<br />

Kei Adachi<br />

Seemin Ahmed<br />

Mahzad Akbarpour<br />

Andrea Annoni<br />

Usanarat Anurathapan<br />

Claudia Arambula<br />

Cynthia Bartholomae<br />

Luca Biasco<br />

Aaron Black<br />

Kathleen Boerner<br />

Nicolas Boisgerault<br />

Florie Borel<br />

Francesca Bortolotti<br />

Allison Bradbury<br />

Elizabeth Brooks<br />

Christopher Burtner<br />

Leah Byrne<br />

Andrea Calabria<br />

Hua Cao<br />

Michael Castle<br />

Anna Castleton<br />

Soo Kyung Cho<br />

Szu-Ting Chou<br />

Sourav Choudhury<br />

Julie Crudele<br />

Drew Deniger<br />

Mark Doyal<br />

Theodore Drivas<br />

Brett Dufour<br />

F. Jason Duncan<br />

Frank Dyka<br />

Lauriel Earley<br />

Salim El-Amouri<br />

Colin Exline<br />

Susan Faust<br />

Antonio Filareto<br />

Eli Fine<br />

Richard Gabriel<br />

Pietro Genovese<br />

Evelyne Gicquel<br />

Melissa Goddard<br />

Diane Golebiowski<br />

Sara Gombash<br />

German Gornalusse<br />

Yue Guan<br />

Dwijit GuhaSarkar<br />

Marie Reine Haddad<br />

Chady Hakim<br />

Jingfen Han<br />

Jayson Hardcastle<br />

Hiromi<br />

Hayashita-Kinoh<br />

Kristin Heller<br />

Luiza Hernandez<br />

Mari Hirvinen<br />

Eloise Hudry<br />

Eric Irons<br />

Alok Joglekar<br />

Ami Kabadi<br />

Christine Kaeppel<br />

Shuichi Kamijima<br />

Kerstin Kaufmann<br />

Omkar Kawalekar<br />

Christiaan King<br />

Nico Lachmann<br />

Charles Lai<br />

Hongtao Li<br />

Li Li<br />

Shaoyong Li<br />

Nick Llewellyn<br />

Chantale Maltais<br />

Victoria McCurdy<br />

Tanner Miest<br />

Yoshiaki Miura<br />

Shohei Miyamoto<br />

Giridhar Murlidharan<br />

Bartholomew<br />

Naughton<br />

Sarah Nicolson<br />

Kyla Ortved<br />

David Ousterout<br />

Nunzia Pastore<br />

Pasquale Piccolo<br />

Karin Pike-Overzet<br />

Eric Pozsgai<br />

Jan-Michael Prill<br />

Marco Ranzani<br />

Maximillian Richter<br />

Fabrizio Rinaldi<br />

Julie Riviere<br />

Zhechao Ruan<br />

Giulia Ruozi<br />

Anna Sacher<br />

Lluis Samaranch<br />

Dwaipayan Sen<br />

Julien Senac<br />

Anurag Sharma<br />

Rajiv Sharma<br />

Shen Shen<br />

Kahori Shimizu<br />

Barbara Smith<br />

Arati Sridharan<br />

Merel Stok<br />

Rui-Jun Su<br />

Colin Sweeney<br />

Mehran Taherian<br />

William Thiel<br />

Lisa Tobin<br />

Shengdar Tsai<br />

Mallory Turner<br />

Niek van Til<br />

Hiu Man Viecelli<br />

Olga Villamizar<br />

Monica Volpin<br />

Hongjie Wang<br />

Rachael Watson<br />

Korashon Watts<br />

Cara Weismann<br />

Anna-Sophia<br />

Wiekmeijer<br />

Jun Xie<br />

Sea Young Yoon<br />

Roma Yumul<br />

The Excellence in Research Awards and Travel Awards were made possible through grant support from:<br />

14<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Outstanding New Investigator Awards<br />

The following Outstanding New Investigator Award winners were selected by the ASGCT Advisory Council based on<br />

merit and their contributions to the ield <strong>of</strong> gene and cell therapy. The recipients will present their work at the special<br />

Outstanding New Investigator Symposium on Saturday, May 18th from 8:00 am – 10:00 am.<br />

Aravind Asokan, PhD<br />

University <strong>of</strong> North Carolina at Chapel Hill<br />

A Sweet Side to AAV Biology<br />

Michael A. Laflamme, MD, PhD<br />

University <strong>of</strong> Washington<br />

Cardiac Repair with Human Pluripotent Stem<br />

<strong>Cell</strong>s<br />

Paloma H. Giangrande, PhD<br />

University <strong>of</strong> Iowa<br />

Targeted-Image Guided RNA Therapies<br />

Ann M. Leen, PhD<br />

Baylor College <strong>of</strong> Medicine - CAGT<br />

T cell <strong>Therapy</strong> for Viruses and Cancer (TIGR)<br />

The Outstanding New Investigator Awards were made possible through grant support from:<br />

Distinguished Service Award<br />

The ASGCT Distinguished Service Award recognizes a person or group that has consistently fostered and enhanced<br />

the ield <strong>of</strong> genetic and cellular therapy.<br />

Sonia I. Skarlatos, PhD<br />

National Heart Lung Blood Institute<br />

National Institutes <strong>of</strong> Health<br />

Catherine McKeon, PhD<br />

National Institute <strong>of</strong> Diabetes and Digestive<br />

and Kidney Diseases<br />

National Institutes <strong>of</strong> Health<br />

Outstanding Achievement Award<br />

The Outstanding Achievement Award winner was selected<br />

by the ASGCT Advisory Council as an example <strong>of</strong> an ASGCT<br />

member who has achieved a pioneering research success<br />

through a lifetime <strong>of</strong> signiicant scientiic contributions to the<br />

ield <strong>of</strong> gene and cell therapy.<br />

Mark A. Kay, MD, PhD<br />

Stanford University School <strong>of</strong> Medicine<br />

Deciphering Vector and Non-coding RNA<br />

Biology: A New Frontier in Nucleic Acid based<br />

Therapies.<br />

Special Recognition Award<br />

The Special Recognition Award is given in acknowledgement<br />

and appreciation <strong>of</strong> an individual’s many scientiic<br />

contributions and dedication to not only the <strong>Society</strong> itself,<br />

but to the ield <strong>of</strong> gene and cell therapy.<br />

John J. Rossi, PhD<br />

Beckman Research Institute<br />

City <strong>of</strong> Hope<br />

The Distinguished Service Award, Special Recognition Award, and Outstanding Achievement Award Lecture will be presented<br />

on Friday, May 17 from 8:00 am – 9:00 am.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

15


Faculty List<br />

Annemieke Aartsma-Rus, PhD<br />

Leiden University Medical Center<br />

Leiden, Netherlands<br />

Karen S. Aboody, MD<br />

Beckman Research Institute <strong>of</strong> the City<br />

<strong>of</strong> Hope<br />

Duarte, CA<br />

Jennifer E. Adair, PhD<br />

Fred Hutchinson Cancer Research<br />

Center<br />

Seattle, WA<br />

Mavis Agbandje-McKenna, PhD<br />

University <strong>of</strong> Florida<br />

Gainesville, FL<br />

Estuardo Aguilar-Cordova, PhD<br />

Advantagene, Inc.<br />

Auburndale, MA<br />

Alessandro Aiuti, MD, PhD<br />

San Raffaele-Telethon Institute for <strong>Gene</strong><br />

<strong>Therapy</strong><br />

Milano, Italy<br />

Ian E. Alexander, MBBS, PhD<br />

The Children’s Hospital at Westmead<br />

Sydney, Australia<br />

Daniel G. Anderson, PhD<br />

Massachusetts Institute <strong>of</strong> Technology<br />

Cambridge, MA<br />

Dale G. Ando, MD<br />

Sangamo BioSciences, Inc.<br />

Richmond, CA<br />

Khursheed Anwer, PhD<br />

Expression <strong>Gene</strong>tics, Inc.<br />

Huntsville, AL<br />

Aravind Asokan, PhD<br />

University <strong>of</strong> North Carolina at<br />

Chapel Hill<br />

Chapel Hill, NC<br />

Alberto Auricchio, MD<br />

Telethon Institute <strong>of</strong> <strong>Gene</strong>tics &<br />

Medicine<br />

Napoli, Italy<br />

You Han Bae, PhD<br />

University <strong>of</strong> Utah<br />

Salt Lake City, UT<br />

Andrew H. Baker, PhD<br />

University <strong>of</strong> Glasgow<br />

Glasgow, United Kingdom<br />

Alejandro B. Balazs, PhD<br />

California Institute <strong>of</strong> Technology<br />

Pasadena, CA<br />

Andrea Ballabio, MD<br />

Telethon Institute <strong>of</strong> <strong>Gene</strong>tics and<br />

Medicine<br />

Naples, Italy<br />

David Baltimore, PhD<br />

California Institute <strong>of</strong> Technology<br />

Pasadena, CA<br />

Kryst<strong>of</strong> Bankiewicz, MD, PhD<br />

University <strong>of</strong> California San Francisco<br />

San Francisco, CA<br />

Raymond T. Bartus, PhD<br />

Ceregene, Inc.<br />

San Diego, CA<br />

John C. Bell, PhD<br />

Ottawa Hospital Research Institute<br />

Ottawa, Canada<br />

C. Frank Bennett, PhD<br />

Isis Pharmaceuticals, Inc.<br />

Carlsbad, CA<br />

Janet Benson, PhD, DABT<br />

Lovelace Respiratory Research Institute<br />

Albuquerque, NM<br />

Alessandra Biffi, MD<br />

Telethon Institute <strong>of</strong> <strong>Gene</strong>tics and<br />

Medicine<br />

Milano, Italy<br />

Brian W. Bigger, PhD<br />

University <strong>of</strong> Manchester<br />

Manchester, United Kingdom<br />

Fabrizia Bignami, PhD<br />

GlaxoSmithKline<br />

Brentford, United Kingdom<br />

Nicholas Boulis, MD<br />

Emory University School <strong>of</strong> Medicine<br />

Atlanta, GA<br />

Shannon E. Boye, PhD<br />

University <strong>of</strong> Florida<br />

Gainesville, FL<br />

Xandra O. Breakefield, PhD<br />

Massachusetts <strong>Gene</strong>ral Hospital<br />

Harvard Medical School<br />

Charlestown, MA<br />

Malcolm K. Brenner, MD, PhD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Renier J. Brentjens, MD, PhD<br />

Memorial Sloan-Kettering Cancer<br />

Center<br />

New York, NY<br />

Charles R. Bridges, MD, ScD<br />

Sanger Heart and Vascular Institute<br />

Charlotte, NC<br />

Philip J. Brooks, PhD<br />

National Center for Advancing<br />

Translational Sciences (NCATS)<br />

National Institutes <strong>of</strong> Health<br />

Bethesda, MD<br />

Brian D. Brown, PhD<br />

Mount Sinai School <strong>of</strong> Medicine<br />

New York, NY<br />

Nicola Brunetti-Pierri, MD<br />

Telethon Institute <strong>of</strong> <strong>Gene</strong>tics and<br />

Medicine<br />

Napoli, Italy<br />

Ana Buj Bello, MD, PhD<br />

<strong>Gene</strong>thon<br />

Evry, France<br />

Barry J. Byrne, MD, PhD<br />

University <strong>of</strong> Florida College <strong>of</strong><br />

Medicine<br />

Gainesville, FL<br />

Fabio Candotti, MD<br />

National Institutes <strong>of</strong> Health<br />

National Human Genome Research<br />

Institute<br />

Bethesda, MD<br />

Mario R. Capecchi, PhD<br />

University <strong>of</strong> Utah<br />

Salt Lake City, UT<br />

Drew E. Carlson, PhD<br />

National Institutes <strong>of</strong> Health<br />

National Heart, Lung, and Blood<br />

Institute<br />

Bethesda, MD<br />

Dana Carroll, PhD<br />

University <strong>of</strong> Utah School <strong>of</strong> Medicine<br />

Salt Lake City, UT<br />

Barrie J. Carter, PhD<br />

BioMarin Pharmaceutical<br />

Seattle, WA<br />

16<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Faculty List<br />

Thomas W. Chalberg, Jr., PhD<br />

Avalanche Biotechnologies, Inc.<br />

San Francisco, CA<br />

Jeffrey Chamberlain, PhD<br />

University <strong>of</strong> Washington School <strong>of</strong><br />

Medicine<br />

Seattle, WA<br />

Lawrence C. Chan, MD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Randy J. Chandler, PhD, MB<br />

National Institutes <strong>of</strong> Health<br />

National Human Genome Research<br />

Institute<br />

Bethesda, MD<br />

Lieping Chen, MD, PhD<br />

Yale University <strong>of</strong> School <strong>of</strong> Medicine<br />

New Haven, CT<br />

Theresa Chen, PhD<br />

Food and Drug Administration<br />

Rockville, MD<br />

Jianjun Cheng, PhD<br />

University <strong>of</strong> Illinois at<br />

Urbana-Champaign<br />

Urbana, IL<br />

Stephanie Cherqui, PhD<br />

University <strong>of</strong> California, San Diego<br />

La Jolla, CA<br />

Anthony T. Cheung, PhD<br />

En<strong>Gene</strong>, Inc.<br />

Vancouver, Canada<br />

Ian Constable, AO<br />

Lions Eye Institute<br />

Nedlands, Australia<br />

Laurence JN Cooper, MD, PhD<br />

University <strong>of</strong> Texas M.D. Anderson<br />

Cancer Center<br />

Houston, TX<br />

Kenneth Cornetta, MD<br />

Indiana University<br />

Indianapolis, IN<br />

Ronald G. Crystal, MD<br />

Weill Medical College <strong>of</strong> Cornell<br />

University<br />

New York, NY<br />

Andrew M. David<strong>of</strong>f, MD<br />

St. Jude Children’s Research Hospital<br />

Memphis, TN<br />

Michele De Luca, MD<br />

University <strong>of</strong> Modena and Reggio<br />

Emilia<br />

Modena, Italy<br />

David A. Dean, PhD<br />

University <strong>of</strong> Rochester<br />

Rochester, NY<br />

Vojo Deretic, PhD<br />

University <strong>of</strong> New Mexico School <strong>of</strong><br />

Medicine<br />

Albuquerque, NM<br />

David A. Dichek, MD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

Gianpietro Dotti, MD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Dongsheng Duan, PhD<br />

University <strong>of</strong> Missouri School <strong>of</strong><br />

Medicine<br />

Columbia, MO<br />

Cynthia Dunbar, MD<br />

National Institutes <strong>of</strong> Health<br />

National Heart Lung and Blood<br />

Institute<br />

Bethesda, MD<br />

Anja Ehrhardt, PhD<br />

Private University Witten/Herdecke<br />

Witten, Germany<br />

David W. Emery, PhD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

Christine Esau, PhD<br />

Regulus Therapeutics<br />

Carlsbad, CA<br />

Katherine J. Exc<strong>of</strong>fon, PhD<br />

Wright State University<br />

Dayton, OH<br />

Lukas Flatz, MD<br />

University Hospital <strong>of</strong> Lausanne<br />

Lausanne, Switzerland<br />

Leonard M. Fleck, PhD<br />

Michigan State University<br />

East Lansing, MI<br />

Terence R. Flotte, MD<br />

University <strong>of</strong> Massachusetts Medical<br />

School<br />

Worcester, MA<br />

Antonia Follenzi, MD, PhD<br />

University <strong>of</strong> Piemonte Orientale ‘A.<br />

Avogadro’<br />

Novara, Italy<br />

Zoe Fonseca-Kelly, PhD<br />

Harvard Medical School<br />

Boston, MA<br />

Robert M. Frederickson, PhD<br />

Molecular <strong>Therapy</strong><br />

Seattle, WA<br />

Svend O. Freytag, PhD<br />

Henry Ford Health System<br />

Detroit, MI<br />

Keith Gagnon, PhD<br />

University <strong>of</strong> Texas Southwestern<br />

Medical Center<br />

Dallas, TX<br />

Evanthia Galanis, MD, DSc<br />

Mayo Clinic<br />

Rochester, MN<br />

Daniel Gaudet, MD, PhD<br />

University <strong>of</strong> Montreal<br />

Montreal, Canada<br />

Andrew Geall, PhD<br />

Novartis<br />

Cambridge, MA<br />

Adrian P. Gee, PhD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Charles A. Gersbach, PhD<br />

Duke University<br />

Durham, NC<br />

Hamid Ghandehari, PhD<br />

University <strong>of</strong> Utah<br />

Salt Lake City, UT<br />

Arnab Ghosh, MD, PhD<br />

Memorial Sloan-Kettering Cancer<br />

Center<br />

New York, NY<br />

Paloma H. Giangrande, PhD<br />

University <strong>of</strong> Iowa<br />

Iowa City, IA<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

17


Faculty List<br />

Harvinder Singh Gill, PhD<br />

Texas Tech University<br />

Lubbock, TX<br />

Joseph C. Glorioso, III, PhD<br />

University <strong>of</strong> Pittsburgh<br />

Pittsburgh, PA<br />

William F. Goins, PhD<br />

University <strong>of</strong> Pittsburgh School <strong>of</strong><br />

Medicine<br />

Pittsburgh, PA<br />

Stephen Gottschalk, MD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

John T. Gray, PhD<br />

St. Jude Children’s Research Hospital<br />

Memphis, TN<br />

Uta Griesenbach, PhD<br />

Imperial College Faculty <strong>of</strong> Medicine<br />

London, United Kingdom<br />

Dirk Grimm, PhD<br />

University <strong>of</strong> Heidelberg<br />

Heidelberg, Germany<br />

Markus Grompe, MD<br />

Oregon Health & Science University<br />

Portland, OR<br />

Farshid Guilak, PhD<br />

Duke University Medical Center<br />

Durham, NC<br />

Roger J. Hajjar, MD<br />

Mount Sinai School <strong>of</strong> Medicine<br />

New York, NY<br />

Joshua Hare, MD<br />

University <strong>of</strong> Miami Health System<br />

Miami, FL<br />

Scott Q. Harper, PhD<br />

Ohio State University & Nationwide<br />

Children’s Hospital<br />

Columbus, OH<br />

Richard Heller, PhD<br />

Old Dominion University<br />

Norfolk, VA<br />

Akseli Hemminki, MD, PhD<br />

University <strong>of</strong> Helsinki<br />

Helsinki, Finland<br />

Wim E. Hennink, PhD<br />

Utrecht Institute for Pharmaceutical<br />

Sciences<br />

Utrecht, Netherlands<br />

Roland W. Herzog, PhD<br />

University <strong>of</strong> Florida<br />

Gainesville, FL<br />

Helen E. Heslop, MD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Matthew Hirsch, PhD<br />

University <strong>of</strong> North Carolina at<br />

Chapel Hill<br />

Chapel Hill, NC<br />

Jeffrey R. Holt, Ph.D.<br />

Boston Children’s Hospital<br />

Harvard Medical School<br />

Boston, MA<br />

Artur Isaev, PhD<br />

Human Stem <strong>Cell</strong>s Institute<br />

Moscow, Russia<br />

Brian Johnstone, PhD<br />

Oregon Health and Science University<br />

Portland, OR<br />

J. Keith Joung, MD, PhD<br />

Massachusetts <strong>Gene</strong>ral Hospital<br />

Charlestown, MA<br />

Carl H. June, MD<br />

University <strong>of</strong> Pennsylvania<br />

Philadelphia, PA<br />

Tal Kafri, MD, PhD<br />

University <strong>of</strong> North Carolina at<br />

Chapel Hill<br />

Chapel Hill, NC<br />

Noriyuki Kasahara, MD, PhD<br />

University <strong>of</strong> California, Los Angeles<br />

Los Angeles, CA<br />

Brian K. Kaspar, PhD<br />

The Research Institute at Nationwide<br />

Children’s Hospital<br />

Columbus, OH<br />

Kazunori Kataoka, PhD<br />

University <strong>of</strong> Tokyo<br />

Bunkyo-Ku, Japan<br />

Mark A. Kay, MD, PhD<br />

Stanford University School <strong>of</strong> Medicine<br />

Stanford, CA<br />

Hans-Peter Kiem, MD, FACP<br />

Fred Hutchinson Cancer Research<br />

Center<br />

Seattle, WA<br />

Sung Wan Kim, PhD<br />

University <strong>of</strong> Utah<br />

Salt Lake City, UT<br />

David Kirn, MD<br />

Jennerex, Inc.<br />

San Francisco, CA<br />

Thomas Knotts, PhD<br />

Brigham Young University<br />

Provo, UT<br />

Donald B. Kohn, MD<br />

University <strong>of</strong> California, Los Angeles<br />

Los Angeles, CA<br />

Peter Kolchinsky<br />

RA Capital<br />

Boston, MA<br />

Janaiah Kota, PhD<br />

Indiana University School <strong>of</strong> Medicine<br />

Indianapolis, IN<br />

Karen Kozarsky, PhD<br />

ReGenX Biosciences, LLC<br />

Washington, DC<br />

H. Teresa Ku, PhD<br />

City <strong>of</strong> Hope<br />

Duarte, CA<br />

Rajendra Kumar-Singh, PhD<br />

Tufts University School <strong>of</strong> Medicine<br />

Boston, MA<br />

Young Jik Kwon, PhD<br />

University <strong>of</strong> California, Irvine<br />

Irvine, CA<br />

King F. Kwong, MD<br />

National Institutes <strong>of</strong> Health<br />

National Cancer Institute<br />

Bethesda, MD<br />

Michael A. Laflamme, MD, PhD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

Jane S. Lebkowski, PhD<br />

Menlo Park, CA<br />

Brendan Lee, MD, PhD<br />

Baylor College <strong>of</strong> Medicine<br />

Howard Hughes Medical Institute<br />

Houston, TX<br />

18<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Faculty List<br />

Ann M. Leen, PhD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Nick Leschly<br />

bluebird bio<br />

Cambridge, MA<br />

Bruce L. Levine, PhD<br />

University <strong>of</strong> Pennsylvania<br />

Philadelphia, PA<br />

Shulin Li, PhD<br />

MD Anderson Cancer Center<br />

Houston, TX<br />

<strong>Gene</strong> Liau, PhD<br />

Pizer WRD<br />

Cambridge, MA<br />

Judy Lieberman, MD, PhD<br />

Harvard Medical School<br />

Boston, MA<br />

Maria P. Limberis, PhD<br />

University <strong>of</strong> Pennsylvania<br />

Philadelphia, PA<br />

Gerald S. Lipshutz, MD<br />

University <strong>of</strong> California, Los Angeles<br />

Los Angeles, CA<br />

Cecilia Lo, PhD<br />

University <strong>of</strong> Pittsburgh<br />

Pittsburgh, PA<br />

Shan Lu, MD, PhD<br />

University <strong>of</strong> Massachusetts Medical<br />

School<br />

Worcester , MA<br />

Katarina Luptakova, MD<br />

Beth Israel Deaconess Medical Center<br />

Boston, MA<br />

Lawrence Lustig, MD<br />

University <strong>of</strong> California, San Francisco<br />

San Francisco, CA<br />

Ian MacLachlan, PhD<br />

Tekmira Pharmaceuticals Corp.<br />

Burnaby, Canada<br />

Casey A. Maguire, PhD<br />

Massachusetts <strong>Gene</strong>ral Hospital<br />

Charlestown, MA<br />

Ram I. Mahato, PhD<br />

University <strong>of</strong> Tennessee Health Science<br />

Center<br />

Memphis, TN<br />

Harry L. Malech, MD<br />

National Institutes <strong>of</strong> Health<br />

National Institute <strong>of</strong> Allergy and<br />

Infectious Diseases<br />

Bethesda, MD<br />

Punam Malik, MD, PhD<br />

Cincinnati Children’s Hospital Medical<br />

Center<br />

Cincinnati, OH<br />

Paris Margaritis, DPhil<br />

Children’s Hospital <strong>of</strong> Philadelphia<br />

Philadelphia, PA<br />

Jeffrey R. Martens, PhD<br />

University <strong>of</strong> Michigan<br />

Ann Arbor, MI<br />

Fulvio Mavilio, PhD<br />

Généthon<br />

Evry, France<br />

Jodi L. McBride, PhD<br />

Oregon National Primate Research<br />

Center<br />

Beaverton, OR<br />

Cheryl L. McDonald, MD<br />

National Institutes <strong>of</strong> Health<br />

National Heart, Lung, and Blood<br />

Institute<br />

Germantown, MD<br />

R. Scott McIvor, PhD<br />

University <strong>of</strong> Minnesota<br />

Minneapolis, MN<br />

Olivia Merkel, PhD<br />

Wayne State University<br />

Detroit, MI<br />

Anne Messer, PhD<br />

David Axelrod Institute/Wadsworth<br />

Center<br />

Albany, NY<br />

Carol H. Miao, PhD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

Jeffrey S. Miller, MD<br />

University <strong>of</strong> Minnesota<br />

Minneapolis, MN<br />

Shondra M. Miller, PhD<br />

Washington University<br />

St. Louis, MO<br />

Federico Mingozzi, PhD<br />

University Pierre Et Marie Curie-Paris 6<br />

<strong>Gene</strong>thon<br />

Paris, France<br />

Elizabeth A. Mittendorf, MD, PhD<br />

The University <strong>of</strong> Texas MD Anderson<br />

Cancer Center<br />

Houston, TX<br />

Kevin V. Morris, PhD<br />

Scripps Research Institute<br />

La Jolla, CA<br />

Christian Mueller, PhD<br />

University <strong>of</strong> Massachusetts Medical<br />

School<br />

Worcester, MA<br />

Thomas H. Murray, PhD<br />

The Hastings Center<br />

Garrison, NY<br />

Muna I. Naash, PhD<br />

University <strong>of</strong> Oklahoma Health Sciences<br />

Center<br />

Oklahoma City, OK<br />

Hiroyuki Nakai, MD, PhD<br />

Oregon Health & Science University<br />

School <strong>of</strong> Medicine<br />

Portland, OR<br />

Luigi M. Naldini, MD, PhD<br />

University Vita-Salute San Raffaele<br />

Milan, Italy<br />

Amit Nathwani, MD, PhD<br />

University College London Cancer<br />

Institute<br />

London, United Kingdom<br />

Yoichi Negishi, PhD<br />

Tokyo University <strong>of</strong> Pharmacy and Life<br />

Sciences<br />

Hachioji, Japan<br />

John J. Nemunaitis, MD<br />

Mary Crowley Cancer Research Centers<br />

Dallas, TX<br />

Philip Ng, PhD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Arthur W. Nienhuis, MD<br />

St. Jude Children’s Research Hospital<br />

Memphis, TN<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

19


Faculty List<br />

Alan J. Nixon, DVM, MS<br />

Cornell University<br />

Ithaca, NY<br />

Ryan M. O’Connell, PhD<br />

University <strong>of</strong> Utah<br />

Salt Lake City, UT<br />

Maria C. Palanca-Wessels, MD, PhD<br />

Fred Hutchinson Cancer Research<br />

Center<br />

Seattle, WA<br />

Eirini P. Papapetrou, MD, PhD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

David W. Parsons, PhD<br />

Women’s & Children’s Hospital<br />

Adelaide, Australia<br />

Michael J. Passineau, PhD<br />

West Penn Allegheny Health System<br />

Pittsburgh, PA<br />

Marc Penn, MD, PhD<br />

Summa Health System<br />

Northeast Ohio Medical University<br />

Akron, OH<br />

Rita Perlingeiro, PhD<br />

University <strong>of</strong> Minnesota<br />

Minneapolis, MN<br />

Harold Petry, PhD<br />

UniQure, B.V.<br />

Amsterdam, Netherlands<br />

Eric A. Pierce, MD, PhD<br />

Massachusetts Eye and Ear<br />

Boston, MA<br />

Eric Poeschla, MD<br />

Mayo Clinic<br />

Rochester, MN<br />

Katherine P. Ponder, MD<br />

Washington University School <strong>of</strong><br />

Medicine<br />

St. Louis, MO<br />

David L. Porter, MD<br />

Hospital <strong>of</strong> the University <strong>of</strong><br />

Pennsylvania<br />

Philadelphia, PA<br />

Matthew H. Porteus, MD, PhD<br />

Stanford University School <strong>of</strong> Medicine<br />

Stanford, CA<br />

Pankaj Qasba, PhD<br />

National Institute <strong>of</strong> Health<br />

National Heart Lung and Blood<br />

Institute<br />

Bethesda, MD<br />

Joseph E. Rabinowitz, PhD<br />

Temple University School <strong>of</strong> Medicine<br />

Philadelphia, PA<br />

Daniel Rader, MD<br />

University <strong>of</strong> Pennsylvania Medical<br />

Center<br />

Philadelphia, PA<br />

Nicholas Restifo, MD<br />

National Institutes <strong>of</strong> Health<br />

National Cancer Institute<br />

Bethesda, MD<br />

Tonia S. Rex, PhD<br />

Vanderbilt University<br />

Nashville, TN<br />

Kevin G. Rice, PhD<br />

University <strong>of</strong> Iowa College <strong>of</strong> Pharmacy<br />

Iowa City, IA<br />

Isabelle Riviere, PhD<br />

Memorial Sloan-Kettering Cancer<br />

Center<br />

New York, NY<br />

Marcelo N. Rivolta, MD, PhD<br />

The University <strong>of</strong> Shefield<br />

Shefield, United Kingdom<br />

Scott H. Robbins, PhD<br />

Immune Design Corp.<br />

Seattle, WA<br />

Louise Rodino-Klapac, PhD<br />

Research Institute at Nationwide<br />

Children’s Hospital<br />

Columbus, OH<br />

Maria-Grazia Roncarolo, MD, PhD<br />

San Raffaele Scientiic Institute<br />

Milano, Italy<br />

Stephen M. Rose, PhD<br />

Foundation Fighting Blindness<br />

Columbia, MD<br />

Steven M. Rowe, MD<br />

University <strong>of</strong> Alabama at Birmingham<br />

Birmingham, AL<br />

David W. Russell, MD, PhD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

Stephen J. Russell, MD, PhD<br />

Mayo Clinic<br />

Rochester, MN<br />

Denise Sabatino, PhD<br />

The Children’s Hospital <strong>of</strong> Philadelphia<br />

Philadelphia, PA<br />

Aliasger K. Salem, PhD<br />

University <strong>of</strong> Iowa<br />

Iowa City, IA<br />

Robert A. Sandhaus, MD, PhD<br />

Alpha-1 Foundation<br />

Miami, FL<br />

David V. Schaffer, PhD<br />

University <strong>of</strong> California Berkeley<br />

Berkeley, CA<br />

Andrew M. Scharenberg, MD<br />

Seattle Children’s Research Institute<br />

Seattle, WA<br />

Daniel Scherman, PhD<br />

INSERM U1022 - CNRS UMR8151<br />

- ParisDescares University<br />

- ChimieParisTech<br />

Paris, France<br />

Manfred Schmidt, PhD<br />

Deutsches Krebsforschungszentrum<br />

Heidelberg<br />

National Center for Tumor Diseases<br />

Heidelberg, Germany<br />

Miguel Sena-Esteves, PhD<br />

University <strong>of</strong> Massachusetts Medical<br />

School<br />

Worcester, MA<br />

Susan B. Sepelak, MS, MSM<br />

Social and Scientiic Systems, Inc<br />

Silver Spring, MD<br />

Prem Seth, PhD<br />

NorthShore University HealthSystem<br />

Evanston, IL<br />

Dmitry M. Shayakhmetov, PhD<br />

University <strong>of</strong> Washington<br />

Seattle, WA<br />

Sonia I. Skarlatos, PhD<br />

National Institutes <strong>of</strong> Health<br />

National Heart, Lung, Blood Institute<br />

Bethesda, MD<br />

20<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Faculty List<br />

Evan Y. Snyder, MD PhD FAAP<br />

Sanford-Burnham Medical Research<br />

Institute<br />

La Jolla, CA<br />

Sihong Song, PhD<br />

University <strong>of</strong> Florida<br />

Gainesville, FL<br />

David M. Spencer, PhD<br />

Bellicum Pharmaceuticals, Inc.<br />

Houston, TX<br />

H. Trent Spencer, PhD<br />

Emory University School <strong>of</strong> Medicine<br />

Atlanta, GA<br />

Gary K. Steinberg, MD, PhD<br />

Stanford School <strong>of</strong> Medicine<br />

Stanford, CA<br />

Renata Stripecke, PhD<br />

Hannover Medical School<br />

Hannover, Germany<br />

Stephen C. Strom, PhD<br />

Karolinska Institutet<br />

Stockholm, Sweden<br />

Suzannah Sundby<br />

Smith, Gambrell & Russell, LLP<br />

Washington DC<br />

Kenzaburo Tani, MD, PhD<br />

Kyushu University<br />

Higashi-ku, Japan<br />

Doris A. Taylor, PhD<br />

Texas Heart Institute at St. Luke’s<br />

Episcopal Hospital<br />

Houston, TX<br />

David H. Thompson, PhD<br />

Purdue University<br />

West Lafayette, IN<br />

John F. Tisdale, MD<br />

National Institutes <strong>of</strong> Health<br />

National Heart, Lung, and Blood<br />

Institute<br />

Bethesda, MD<br />

Jacques P. Tremblay, PhD<br />

Centre de recherche du Centre<br />

hospitalier de l’Université Laval<br />

Sainte-Foy, Canada<br />

Grant D. Trobridge, PhD<br />

Washington State University<br />

Pullman, WA<br />

Rocky S. Tuan, PhD<br />

McGowan Institute for Regenerative<br />

Medicine<br />

Pittsburgh, PA<br />

Evan C. Unger, MD<br />

University <strong>of</strong> Arizona Cancer Center<br />

Tucson, AZ<br />

Ludovic Vallier, PhD<br />

Anne McLaren Laboratory for<br />

Regenerative Medicine<br />

Cambridge, United Kingdom<br />

Sander van Deventer, MD, PhD<br />

Forbion Capital Partners<br />

Naarden, Netherlands<br />

Luk H. Vandenberghe, PhD<br />

Harvard Medical School<br />

Boston, MA<br />

Thierry C. VandenDriessche, PhD<br />

University <strong>of</strong> Brussels<br />

Leuven, Belgium<br />

Juan F. Vera, MD<br />

Baylor College <strong>of</strong> Medicine<br />

Houston, TX<br />

Gabor Veres, PhD<br />

bluebird bio<br />

Cambridge, MA<br />

Richard G. Vile, PhD<br />

Mayo Clinic<br />

Rochester, MN<br />

Samuel C. Wadsworth, PhD<br />

Genzyme Corporation - a Sanoi<br />

Company<br />

Framingham, MA<br />

Kathryn R. Wagner, MD, PhD<br />

The Kennedy Krieger Institute<br />

The Johns Hopkins School <strong>of</strong> Medicine<br />

Baltimore, MD<br />

Claes Wahlestedt, MD, PhD<br />

University <strong>of</strong> Miami Miller School <strong>of</strong><br />

Medicine<br />

Jupiter, FL<br />

Bing Wang, MD, PhD<br />

University <strong>of</strong> Pittsburgh School <strong>of</strong><br />

Medicine<br />

Pittsburgh, PA<br />

Sue Washer, MBA<br />

Applied <strong>Gene</strong>tics Technologies,<br />

Corporation<br />

Alachua, FL<br />

Yu-Quan Wei, MD, PhD<br />

State Key Laboratory <strong>of</strong> Biotherapy<br />

Chengdu, Peoples Republic <strong>of</strong> China<br />

Marco S. Weinberg, PhD<br />

The Scripps Research Institute<br />

Johannesburg, South Africa<br />

Andy Wilber, PhD<br />

Southern Illinois University School <strong>of</strong><br />

Medicine<br />

Springield, IL<br />

James M. Wilson, MD, PhD<br />

University <strong>of</strong> Pennsylvania Perelman<br />

School <strong>of</strong> Medicine<br />

Philadelphia, PA<br />

Savio L.C. Woo, PhD<br />

Mount Sinai School <strong>of</strong> Medicine<br />

New York, NY<br />

J. Fraser Wright, PhD<br />

Children’s Hospital <strong>of</strong> Philadelphia<br />

University <strong>of</strong> Pennsylvania<br />

Philadelphia, PA<br />

Xiao Xiao, PhD<br />

University <strong>of</strong> North Carolina at Chapel<br />

Hill<br />

Chapel Hill, NC<br />

James Yockman, PhD<br />

University <strong>of</strong> Utah<br />

Salt Lake City, UT<br />

Michael Young, PhD<br />

Schepens Eye Research Institute<br />

Boston, MA<br />

Chae-Ok Yun, PhD<br />

Hanyang University<br />

Seoul, Korea<br />

Assem Ziady<br />

Emory University<br />

Atlanta, GA<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

21


<strong>Gene</strong>ral Meeting Information<br />

AMERICAN SOCIETY OF GENE & CELL THERAPY<br />

Mission and Vision<br />

ASGCT’s mission is to advance knowledge, awareness, and<br />

education leading to the discovery and clinical application <strong>of</strong><br />

genetic and cellular therapies to alleviate human disease.<br />

ASGCT’s strategic vision is to be a catalyst for bringing<br />

together scientists, physicians, patient advocates, and other<br />

stakeholders to transform the practice <strong>of</strong> medicine by<br />

incorporating the use <strong>of</strong> genetic and cellular therapies to<br />

control and cure human disease.<br />

Abstract Volume - Molecular <strong>Therapy</strong><br />

All abstracts, except Late Abstract Submissions, accepted for<br />

presentation at the ASGCT 16th Annual Meeting have been<br />

published in the May supplement <strong>of</strong> Molecular <strong>Therapy</strong>.<br />

Attendees will receive one copy <strong>of</strong> the supplement along<br />

with their registration materials. Late Abstract Submissions<br />

accepted for presentation have been printed in a booklet<br />

that will be distributed to each attendee. In addition, the<br />

Late Abstract Submissions will be published in the July 2013<br />

online issue <strong>of</strong> Molecular <strong>Therapy</strong>.<br />

Admission<br />

Oficial name badges will be required for admission to all<br />

ASGCT sessions. All Annual Meeting attendees receive a<br />

name badge with their registration bag. Name badges should<br />

be worn at all times inside the convention center, as badges<br />

will be used to control access to sessions and activities.<br />

Attendees are cautioned against wearing their name badges<br />

while away from the convention center as badges may draw<br />

unwanted attention to your status as visitors to Salt Lake<br />

City, Utah.<br />

Admission by Ticket Only<br />

Some sessions at the Annual Meeting will require an<br />

additional ticket to control access and capacity. The Meetthe-Investigator<br />

sessions scheduled at the 16th Annual<br />

Meeting require tickets for admittance, which are not<br />

included in the regular registration fees. These sessions<br />

are designed to provide an opportunity for participants<br />

to interact with experts and discuss topics related to their<br />

research. Sessions will begin promptly and a lunch will be<br />

served during the program, which will last for approximately<br />

one hour. Each ticket is $25.<br />

Please Note: Tickets for the Meet-the-Investigator sessions<br />

are limited to 30 participants and will be sold on a irstcome,<br />

irst-serve basis. You must have a ticket to gain<br />

entrance to a session. Ushers will be collecting tickets at<br />

the door <strong>of</strong> each session. Tickets may be obtained at the<br />

Registration Desk.<br />

Boxed Lunches<br />

Pre-ordered boxed lunches will be available for pick-up<br />

at the registration desk from 12:00 pm – 12:30 pm on<br />

Wednesday, 12:30 pm – 1:00 pm on Thursday, 11:45 am –<br />

12:15 pm on Friday, and 12:15 pm – 12:45 pm on Satur day.<br />

All boxed lunches must have been pre-ordered.<br />

Business Center<br />

There is a Business Center located in the Salt Palace<br />

Convention Center on the Second Level Upper Concourse,<br />

near Room 252. The Business Center is open from<br />

8:00 am – 5:00 pm. Phone: (385) 468-2228.<br />

Business Meeting<br />

Join the <strong>Society</strong>’s leadership for a business meeting and<br />

continental breakfast.<br />

Saturday, May 18, 2013<br />

7:30 am – 8:00 am<br />

A light continental breakfast will be <strong>of</strong>fered at 7:15 am<br />

Room 150 ABC, Level 1.<br />

All members are welcome. See page 6 for more details.<br />

Camera/Recording Policy<br />

It is the policy <strong>of</strong> ASGCT that no cameras are permitted in<br />

the meeting sessions, exhibit hall, or poster sessions, with<br />

the exception <strong>of</strong> the <strong>of</strong>icial ASGCT photographer assigned<br />

by ASGCT to capture images for use in <strong>Society</strong> archival and<br />

promotional materials. Please refrain from taking any photos<br />

in those locations. Audio and/or videotaping is strictly<br />

prohibited.<br />

Your attendance at ASGCT events implies your permission<br />

for images captured during these events to be used for the<br />

purposes <strong>of</strong> ASGCT archival and promotional material and<br />

publications and waives your rights for compensation or<br />

ownership <strong>of</strong> these images.<br />

<strong>Cell</strong> Phones & PDAs<br />

For the courtesy <strong>of</strong> all presenters and attendees, please<br />

ensure that cell phone and PDA ringers are turned <strong>of</strong>f or<br />

silenced during all sessions as they may interfere with<br />

session audio.<br />

Committee Meetings<br />

Most standing and scientiic committees will meet during<br />

the Annual Meeting. See page 6 for Committee Meeting<br />

information.<br />

Concierge Desk<br />

Salt Lake City <strong>of</strong>fers a wide variety <strong>of</strong> activities and<br />

restaurants to meet all tastes and budgets. A Concierge Desk<br />

will be located outside the Exhibit Hall <strong>of</strong> the Salt Palace<br />

Convention Center, staffed by the Salt Lake Convention &<br />

Visitors Bureau, who can help you with your city needs and<br />

reservations.<br />

Concierge Desk Hours<br />

Wednesday through Saturday 10:00 am – 6:00 pm<br />

22<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Gene</strong>ral Meeting Information<br />

Continuing Medical Education<br />

The ASGCT Board <strong>of</strong> Directors decided that the <strong>Society</strong> will<br />

not <strong>of</strong>fer CME credit for the 16th Annual Meeting due to<br />

rising costs.<br />

Disclosure<br />

In keeping with good practices, ASGCT requires faculty,<br />

planning committee and oral abstract presenters to disclose<br />

any relevant inancial interest or other relationship with<br />

the manufacturer(s) <strong>of</strong> any commercial product(s) and/or<br />

provider(s) <strong>of</strong> commercial services that are discussed in this<br />

educational activity.<br />

Educational Methods and Materials<br />

Lectures, Case Presentations, Panel Discussions, Question<br />

and Answer Sessions, Audio/Video Presentations, Abstracts,<br />

Posters<br />

Educational Objectives<br />

At the conclusion <strong>of</strong> the activity, the participant should be<br />

able to:<br />

• Provide advice to patients who inquire about the<br />

potential <strong>of</strong> gene and cell therapy or the availability <strong>of</strong><br />

open clinical trials, based on their exposure to the current<br />

clinical trials in gene and cell therapies.<br />

• Better instruct their students in medical school and other<br />

health venues using the state-<strong>of</strong>-the-art basic science and<br />

clinical trials data presented at the meeting.<br />

• Use the latest advances in gene and cell therapy to<br />

enhance their research mission, as physician scientists<br />

conducting basic and clinical research.<br />

• Demonstrate improved regulatory compliance in<br />

conducting gene and cell therapy clinical trials, through<br />

exposure to NIH and FDA faculty during the educational<br />

program.<br />

Evaluation Method<br />

Evaluation by questionnaire will address program content,<br />

presentation, and possible bias.<br />

Needs<br />

Clinical gene transfer has become increasingly complex<br />

due to ongoing developments in the ields <strong>of</strong> gene and cell<br />

therapy itself, together with bioethics, research integrity, and<br />

inancial conlicts, as well as federal mandates, regulations<br />

and guidelines. Oligonucleotide Therapies, Novel Vector<br />

Development, Host-Vector Interactions and Vaccine<br />

Therapies will be discussed as well as many other scientiic<br />

topics. This meeting will provide an educational forum for<br />

scientists and clinicians to expand their knowledge about the<br />

broad developments in these ields.<br />

Target Audience<br />

The target audience includes basic science and translational<br />

researchers, clinical investigators, physicians, postdoctoral<br />

fellows, graduate students, employees <strong>of</strong> federal government<br />

and regulatory agencies, and other healthcare pr<strong>of</strong>essionals<br />

with an interest in the latest advancements in the ield <strong>of</strong><br />

gene and cell therapy.<br />

Dates<br />

The ASGCT 16th Annual Meeting will begin on the morning<br />

<strong>of</strong> Wednesday, May 15 and continue through the evening <strong>of</strong><br />

Saturday, May 18, 2013. Exhibits will be open Wednesday,<br />

May 15 through Friday, May 17.<br />

Exhibits<br />

Exhibits will be located in Exhibit Hall C/D <strong>of</strong> the Salt Palace<br />

Convention Center. The companies, organizations and<br />

institutions exhibiting at the ASGCT Annual Meeting provide<br />

the latest information on products and services directly<br />

related to your pr<strong>of</strong>essional needs as well as recruit for open<br />

positions. An Exhibit Hall Social will be held on Wednesday<br />

evening and a c<strong>of</strong>fee social will be <strong>of</strong>fered on Thursday<br />

and Friday in the exhibit hall. All participants are urged to<br />

allow adequate time daily to visit the exhibits, as they are an<br />

integral part <strong>of</strong> the success <strong>of</strong> the meeting.<br />

Exhibit Hall Hours<br />

Exhibits will be open Wednesday, May 15 through Friday,<br />

May 17, 2013.<br />

Wednesday, May 15 5:15 pm – 7:15 pm<br />

Thursday, May 16 9:35 am – 10:30 am<br />

Thursday, May 16 4:00 pm – 6:00 pm<br />

Friday, May 17<br />

9:00 am – 9:45 am<br />

Friday, May 17<br />

5:30 pm – 7:30 pm<br />

Guest Attendance<br />

ASGCT asks registered attendees to refrain from taking<br />

children, spouses, or guests to any educational session or<br />

functions <strong>of</strong>fered at the 16th Annual Meeting.<br />

Internet Access & Policy<br />

Internet access will be available in public areas at the Salt<br />

Palace Convention Center to all meeting attendees. Limited<br />

computer stations will be provided in Exhibit Hall C/D.<br />

When others are waiting at the internet kiosks, please limit<br />

your Internet use to 15 minutes at a time so other attendees<br />

can access the internet as well.<br />

Job Bank<br />

At the 16th Annual Meeting, there will be a forum for<br />

academic institutions and companies to promote open<br />

positions to meeting attendees. If you have open positions,<br />

please bring multiple copies <strong>of</strong> your job posting to the<br />

meeting. Similarly, if you are seeking a job, please bring<br />

multiple copies <strong>of</strong> your résumé to submit. ASGCT will<br />

not take responsibility for résumés sent to the ASGCT<br />

<strong>of</strong>ice in response to a job posting. If you would like more<br />

information about this service, please contact Shaun Kramer<br />

at skramer@asgct.org. The Job exchange area will be located<br />

inside the Exhibit Hall.<br />

Lead Retrieval<br />

A lead retrieval system has been made available to all<br />

exhibitors <strong>of</strong> the ASGCT 16th Annual Meeting. Exhibitors<br />

may ask to scan attendee name badges with a hand held<br />

scanner in order to obtain attendee contact information.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

23


<strong>Gene</strong>ral Meeting Information<br />

Location<br />

• The 16th Annual Meeting will be held at the Salt Palace<br />

Convention Center , 100 SW Temple, Salt Lake City, UT<br />

84101, USA<br />

• Exhibits and Posters will take place in Hall C/D.<br />

• Registration will be located on the East Registration Area<br />

– by the East Entrance on the 2nd loor <strong>of</strong> the Salt Palace<br />

Convention Center<br />

Materials Distribution<br />

Please refrain from distributing promotional materials<br />

throughout the meeting; these may only be distributed from<br />

an exhibit booth in Exhibit Hall C/D.<br />

No Smoking<br />

Smoking is prohibited at all 16th Annual Meeting sessions<br />

and events.<br />

Posters<br />

Abstract Posters will be on display in Exhibit Hall C/D.<br />

Thursday, May 16<br />

Abstract Poster Session I<br />

7:00 am – 12:30 pm Poster Setup by Authors<br />

12:30 pm – 6:00 pm Poster Viewing (authors present<br />

from 4:00 pm – 6:00 pm)<br />

4:00 pm – 6:00 pm Networking Reception, Exhibits, and<br />

Poster Session I<br />

6:00 pm – 6:30 pm Authors Remove Posters<br />

Friday, May 17<br />

Abstract Poster Session II<br />

7:00 am – 11:45 am Poster Setup by Authors<br />

11:45 am – 7:30 pm Poster Viewing (authors present<br />

from 5:30 pm – 7:30 pm)<br />

5:30 pm – 7:30 pm Networking Reception, Exhibits, and<br />

Poster Session II<br />

7:30 pm – 8:00 pm Authors Remove Posters<br />

Saturday, May 18<br />

Abstract Poster Session III<br />

7:00 am – 12:15 pm Poster Setup by Authors<br />

12:15 pm – 5:45 pm Poster Viewing (authors present<br />

from 3:45 pm – 5:45 pm)<br />

3:45 pm – 5:45 pm Poster Session III<br />

5:45 pm – 6:15 pm Authors Remove Posters<br />

Call4Posters ® Pick-up Schedule<br />

Once again this year the ASGCT arranged with Marathon<br />

Multimedia to provide poster authors with the opportunity<br />

to create their poster online using the Call4Posters® service.<br />

Poster presenters who took advantage <strong>of</strong> this service may<br />

pick-up their pre-ordered poster at the ASGCT Registration<br />

Desk during the following hours.<br />

Tuesday, May 14 5:00 pm – 7:00 pm<br />

Wednesday, May 15 7:00 am – 7:30 pm<br />

Thursday, May 16 7:00 am – 6:30 pm<br />

Friday, May 17 7:30 am – 7:30 pm<br />

Saturday, May 18 7:30 am – 4:00 pm<br />

Press<br />

Members <strong>of</strong> the working media may register for the 16th<br />

Annual Meeting in the Press Room – Room 252 AB. Interview<br />

space, computers and internet services are available for the<br />

convenience <strong>of</strong> media representatives covering the meeting.<br />

Press must register, provide credentials, and wear their<br />

press badge for admittance to ASGCT sessions. Assistance<br />

will be provided to members <strong>of</strong> the media that would like to<br />

schedule interviews.<br />

Press Room<br />

The Press Room is located in the Salt Palace Convention<br />

Center, 252 AB.<br />

Press Room Hours<br />

Wednesday, May 15 5:15 pm – 7:15 pm<br />

Thursday, May 16 4:00 pm – 6:00 pm<br />

Friday, May 17 5:30 pm – 7:30 pm<br />

Registration Desk<br />

Name badges, inal programs, and abstract supplements will<br />

be distributed at the registration desk located in the East<br />

Registration Area (Level 2) <strong>of</strong> the Salt Palace Convention<br />

Center, just inside the East Entrance.<br />

Registration Desk Hours<br />

Tuesday, May 14 5:00 pm – 7:00 pm<br />

Wednesday, May 15 7:00 am – 7:30 pm<br />

Thursday, May 16 7:00 am – 6:30 pm<br />

Friday, May 17 7:30 am – 7:30 pm<br />

Saturday, May 18 7:30 am – 4:00 pm<br />

Cancellation Refund Policy<br />

Refund requests should have been submitted in writing to<br />

the ASGCT Executive Ofice prior to May 3, 2013.<br />

Salt Lake City Information<br />

Please abide by the trafic signs and lights and utilize the<br />

designated crosswalks at all times. See Salt Lake Fun Facts<br />

on the next page for more information on Salt Lake City.<br />

Shuttle Bus<br />

ASGCT will not be providing shuttle transportation for the<br />

16th Annual Meeting.<br />

24<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Gene</strong>ral Meeting Information<br />

Speaker Ready Room<br />

There will be a Speaker Ready Room located in Room 250 A<br />

on the second level <strong>of</strong> the Salt Palace Convention Center, near<br />

the ASGCT Registration Desk.<br />

All speakers, including oral abstract presenters, must deliver<br />

their presentations to the Speaker Ready Room the day<br />

before their session or at least four hours prior to their<br />

presentations. Equipment is available for faculty to review<br />

their materials. Audiovisual personnel will be available for<br />

assistance. Please mark your materials (your name, session<br />

and speaker order) so the materials can be returned to<br />

you. The <strong>Society</strong> strongly encourages faculty to pre-load<br />

presentations in the Speaker Ready Room; those faculty who<br />

load presentations in the meeting rooms during the sessions<br />

will have that time deducted from their presentation time by<br />

the Chair.<br />

ASGCT strongly encourages faculty presenting on<br />

Wednesday <strong>of</strong> the Annual Meeting to check-in at the Speaker<br />

Ready Room on Tuesday, May 14 to avoid congestion.<br />

Avoid delays and check-in early!<br />

Speaker Ready Room Hours<br />

Tuesday, May 14 5:00 pm – 7:00 pm<br />

Wednesday, May 15 7:00 am – 7:30 pm<br />

Thursday, May 16 7:00 am – 6:30 pm<br />

Friday, May 17<br />

7:30 am – 7:30 pm<br />

Saturday, May 18 7:30 am – 4:00 pm<br />

Special Accessibility Needs<br />

If you require special accommodations under the ADA in<br />

order to fully participate in the meeting or the course, please<br />

visit the Registration Desk; ASGCT staff will be happy to<br />

assist you with your speciic needs.<br />

Salt Lake City & Utah “Fun Facts”<br />

• The State name Utah comes from the Native <strong>American</strong><br />

Ute Tribe meaning “people <strong>of</strong> the mountains”<br />

• The State nickname is the Beehive State – for the<br />

industriousness <strong>of</strong> the Utah Pioneer<br />

• Utah’s state motto is “Industry”<br />

• On December 3, 1933 Utah became the deciding US state<br />

to approve the repeal <strong>of</strong> prohibition<br />

• There are 21 National Parks within a day’s drive<br />

• The original Harman’s Kentucky Fried Chicken, the irst<br />

KFC franchise, still operates at 3900 South State Street<br />

• Utah is ranked #1 for happy people<br />

• Utah is ranked #1 for the best hiking State in the US<br />

• Utah is the number one per-capita consumer <strong>of</strong> Jell-O<br />

brand gelatin<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

25


Hotel Information and Area Map<br />

ASGCT 16 th Annual Meeting<br />

May 15-18, 2013<br />

1. Hilton Salt Lake City Center – HEADQUARTERS HOTEL<br />

2. Salt Lake Marriott Downtown at City Creek<br />

3. Sheraton Salt Lake City Hotel<br />

26<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Salt Palace Convention Center Floor Plan<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

27


Salt Palace Convention Center Floor Plan<br />

First Level — Exhibit Hall C/D and Meeting Rooms<br />

• Exhibits<br />

• Posters<br />

• Job Exchange<br />

• Internet Kiosks<br />

First Level<br />

• Plenary Lectures<br />

• Session Rooms<br />

(Education, Oral Abstracts,<br />

Scientiic Symposia)<br />

28<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Salt Palace Convention Center Floor Plan<br />

Second Level<br />

• Registration<br />

• Speaker Ready Room<br />

• Meet-the-Investigators<br />

• Committee Meetings<br />

• Receptions<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

29


Schedule-at-a-Glance (<strong>Program</strong> subject to change)<br />

Tuesday, May 14, 2013 (Pre-Meeting)<br />

11:00 am – 6:00 pm Salt Lake City Fun Day Activities<br />

4:00 pm – 6:00 pm Public Education Events<br />

Wednesday, May 15, 2013<br />

7:30 am – 8:00 am C<strong>of</strong>fee Break<br />

8:00 am – 10:00 am Scientiic Symposia Session I<br />

10:30 am – 12:00 pm Education Session I<br />

12:00 pm – 1:15 pm Lunch Break (Lunch Not Provided)<br />

1:15 pm – 2:45 pm Education Session II<br />

3:15 pm – 5:15 pm Oral Abstract Session I<br />

5:15 pm – 7:15 pm Exhibit Hall Welcome Reception<br />

7:30 pm – 8:30 pm New Member Welcome Reception<br />

7:30 pm – 9:30 pm Commercialization Workshop<br />

Thursday, May 16, 2013<br />

8:30 am – 9:35 am George Stamatoyannopoulos Lecture<br />

9:35 am – 10:30 am Exhibit Hall C<strong>of</strong>fee Social<br />

10:30 am – 12:30 pm Scientiic Symposia Session II<br />

12:30 pm – 2:00 pm Lunch Break (Lunch Not Provided)<br />

Meet-the-Investigator Session & Offsite Tour<br />

2:00 pm – 4:00 pm Oral Abstract Session II<br />

4:00 pm – 6:00 pm Exhibit Hall Open: Networking Reception & Poster Session I<br />

6:00 pm – 7:00 pm Canadian Attendee Reception<br />

6:00 pm – 8:00 pm Alliance for Cancer <strong>Gene</strong> <strong>Therapy</strong> Foundation Symposium<br />

Muscular Dystrophy Association & Association-Francaise Contre Les Myopathies Foundation<br />

Symposium<br />

Friday, May 17, 2013<br />

8:00 am – 9:00 am Outstanding Achievement Award Lecture with<br />

Distinguished Service Award and Special Recognition Award Presentations<br />

9:00 am – 9:45 am Exhibit Hall C<strong>of</strong>fee Social<br />

9:45 am – 11:45 am Scientiic Symposia Session III<br />

11:45 am – 1:00 pm Lunch Break (Lunch Not Provided)<br />

1:00 pm – 3:00 pm Oral Abstract Session III<br />

3:15 pm – 5:30 pm Presidential Symposium Lecture & Top Abstracts<br />

5:30 pm – 7:30 pm Exhibit Hall Open: Networking Reception & Poster Session II<br />

7:30 pm – 9:30 pm Foundation Fighting Blindness Foundation Symposium<br />

International Consortium for <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> Workshop<br />

New Investigator Town Hall & Mentoring Reception<br />

Saturday, May 18, 2013<br />

7:30 am – 8:00 am ASGCT Business Meeting<br />

8:00 am – 10:00 am Outstanding New Investigator Symposium<br />

10:15 am – 12:15 pm Oral Abstract Session IV<br />

12:15 pm – 1:45 pm Lunch Break (Lunch Not Provided)<br />

Meet-the-Investigator Session & Offsite Tour<br />

1:45 pm – 3:45 pm Scientiic Symposia Session IV<br />

3:45 pm – 5:45 pm Poster Session III & Reception<br />

5:45 pm Annual Meeting Concludes<br />

30<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

C<strong>of</strong>fee Break<br />

7:30 am – 8:00 am<br />

Scientific Symposium 100<br />

8:00 am - 10:00 am<br />

ROOM: BALLROOM D<br />

Challenges and Success <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> Product Approval<br />

CO-CHAIRS: Dale G. Ando, MD and Barry J. Byrne, MD, PhD<br />

SPEAKERS<br />

Dale G. Ando, MD<br />

Clinical Studies <strong>of</strong> the Infusion <strong>of</strong> ZFN CCR5 Modiied Autologous CD4 T cells (SB-728T) in HIV Subjects<br />

CCR5 is the second receptor for HIV in R5 trophic HIV strains and the CCR5Δ32 gene mutation confers resistance to HIV infection in<br />

humans. This resistance to HIV infection can be recreated in CD4 T cells by ex-vivo modiication <strong>of</strong> the CCR5 gene locus by speciic<br />

Zinc Finger Nucleases Clinical studies treating HIV subjects with autologous CD4 T cells modiied at CCR5 by ZFN (SB-728T) in<br />

order to protect against HIV have been performed. Clinical data on the pharmacology, immunologic effects and safety <strong>of</strong> these<br />

treatments will be presented.<br />

Wednesday, May 15, 2013<br />

Theresa Chen, PhD<br />

CBER Regulatory/Preclinical Considerations for AAV Products<br />

The presentation will provide an overview <strong>of</strong> the current CBER perspective regarding the preclinical evaluation <strong>of</strong> AAV-based gene<br />

therapy products and discuss regulatory and scientiic challenges in the safety and activity assessment <strong>of</strong> these investigational<br />

products. According to 21 CFR 312.23 (a)(8), adequate information derived from pharmacology and toxicology studies is needed<br />

to support a clinical investigation that is reasonably safe and scientiically feasible. Thus, the data from preclinical studies should<br />

provide a better understanding <strong>of</strong> the activity, safety, vector biodistribution, and transgene expression proiles following product<br />

administration in appropriate animal models. These data will then be used to guide aspects <strong>of</strong> the design <strong>of</strong> early phase clinical<br />

trials <strong>of</strong> AAV-based products, including: 1) determination <strong>of</strong> a potentially safe starting dose level and dose escalation scheme; 2) an<br />

optimal route <strong>of</strong> administration/anatomic site <strong>of</strong> delivery; 3) subject eligibility criteria; and 4) an adequate clinical monitoring plan.<br />

Barry J. Byrne, MD, PhD<br />

Next <strong>Gene</strong>ration Therapies with AAV<br />

Evan Y. Snyder, MD PhD FAAP<br />

The Rationale Use <strong>of</strong> <strong>Cell</strong>-based Therapies - Viewpoint from a Scientist who Advises Regulatory Agencies<br />

Although it is true that regulatory agencies, when assessing applications for cell-based therapies, tend to focus primarily on issues<br />

<strong>of</strong> safety, they are inevitably cognizant <strong>of</strong> the rationale behind the use <strong>of</strong> particular cell type in a particular clinical context in order<br />

to determine whether the risk is justiied. In other words, they do pay attention to whether a presumed mechanism-<strong>of</strong>-action<br />

is scientiically valid and supportable by the data. Certainly the scientists and physicians who advise such regulatory agencies<br />

scrutinize such data. This talk will discuss both the rational and irrational use <strong>of</strong> cell therapy, particularly for the neurological<br />

disorders, including a number <strong>of</strong> misconceptions.<br />

Scientific Symposium 101<br />

8:00 am - 10:00 am<br />

ROOM: BALLROOM C<br />

From Blood to the Brain: <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> <strong>Gene</strong>tic Diseases and Inborn Errors <strong>of</strong><br />

Metabolism<br />

CO-CHAIRS: Randy J. Chandler, PhD, MB and Denise Sabatino, PhD<br />

SPEAKERS<br />

Ian E. Alexander, MBBS, PhD<br />

Pre-Clinical <strong>Gene</strong> <strong>Therapy</strong> for Urea Cycle Disorders<br />

A critically important function <strong>of</strong> the liver is the detoxiication <strong>of</strong> ammonia via the urea cycle. Infants with severe urea cycle<br />

enzyme deiciencies commonly present early in life with life-threatening hyperammonemia, progressing to coma and death in<br />

the absence <strong>of</strong> medical intervention. Effective management remains challenging and necessitates liver transplantation. Ornithine<br />

transcarbamylase (OTC) deiciency, the most common urea cycle defect, has long been recognized as an ideal model for livertargeted<br />

gene therapy. This presentation will explore contemporary efforts to treat OTC and other urea cycle defects, placing these<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

31


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Wednesday, May 15, 2013<br />

in historical context. Robust life-long phenotype correction has been achieved in adult mice after single dose treatment with AAVbased<br />

vectors, and the translational challenges <strong>of</strong> moving towards clinical trials involving pediatric patients are currently being<br />

addressed. These challenges include targeting the developing liver where hepatocellular proliferation leads to loss <strong>of</strong> episomal AAV<br />

vector genomes and, depending on the therapeutic context, the possible need for vector re-administration to maintain effective<br />

levels <strong>of</strong> transgene expression.<br />

Stephen C. Strom, PhD<br />

Placental Stem <strong>Cell</strong> Treatment <strong>of</strong> Liver Disease<br />

Epithelial cells isolated from human amnion (hAE) have surface marker and gene expression proiles <strong>of</strong> pluripotent stem cells.<br />

Our previous studies have shown that hAE mature liver genes when transplanted into the liver <strong>of</strong> mice. Accordingly hAE were<br />

transplanted into the liver <strong>of</strong> iMSUD –mice, a useful model <strong>of</strong> the Maple Syrup Urine Disease. While untreated animals died at<br />

weaning, treated animals survived and thrived on a normal protein diet out to adulthood and showed signiicant correction <strong>of</strong><br />

amino acid and neurotransmitter proiles. These results suggest that hAE cells could be a useful cellular therapy for metabolic liver<br />

diseases.<br />

Alessandra Bifi, MD<br />

Phase I/II Clinical Trial <strong>of</strong> Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> for the Treatment <strong>of</strong> Metachromatic<br />

Leukodystrophy<br />

Amit Nathwani, MD, PhD<br />

AAV Mediated <strong>Gene</strong> Transfer for Hemophilia A<br />

We have developed distinct approach for gene therapy <strong>of</strong> haemophilia A using adeno-associated virus (AAV) vectors which is based<br />

on our successful strategy for gene therapy <strong>of</strong> haemophilia B. Data from our preclinical evaluation will be presented together with<br />

an outline <strong>of</strong> Phase I/II trial design for Haemophilia A.<br />

Scientific Symposium 102<br />

8:00 am - 10:00 am<br />

ROOM: BALLROOM B<br />

<strong>Gene</strong> and <strong>Cell</strong> Therapies for Auditory and Olfactory Disorders<br />

CO-CHAIRS: Jodi L. McBride, PhD and Anne Messer, PhD<br />

SPEAKERS<br />

Jeffrey R. Holt, PhD<br />

<strong>Gene</strong> <strong>Therapy</strong> Strategies to Restore Sensory Function in the Inner Ear<br />

Sensory transduction in hair cells <strong>of</strong> the inner ear is the fundamental irst step that converts auditory information into electrical<br />

signals which are transmitted to the brain. Loss <strong>of</strong> sensory function in inner ear hair cells is the principle deicit in over sixty<br />

forms <strong>of</strong> genetic deafness. To investigate gene therapy as a strategy for restoration <strong>of</strong> auditory function our lab is focused on viral<br />

mediated delivery <strong>of</strong> wild-type Tmc1, mutations in which cause deafness in humans and mice. Tmc1 is expressed in hair cells and<br />

preliminary data indicated that AAV re-introduction <strong>of</strong> wild-type Tmc1 into hair cells <strong>of</strong> deaf mice can restore sensory transduction<br />

in vitro. Whether AAV-Tmc1 can restore sensory function in vivo is currently under investigation.<br />

Lawrence Lustig, MD<br />

AAV1-mediated Restoration <strong>of</strong> Hearing in the VGLUT3 Knockout Mouse<br />

Mice lacking the vesicular glutamate transporter-3 (VGLUT3) are congenitally deaf due to loss <strong>of</strong> glutamate release at the inner hair<br />

cell afferent synapse. Within two weeks <strong>of</strong> AAV1-VGLUT3 delivery, acoustic brainstem response (ABR) thresholds normalize, along<br />

with partial rescue <strong>of</strong> the startle response. Lastly, we demonstrate partial reversal <strong>of</strong> the morphologic changes seen within the<br />

afferent IHC ribbon synapse. These indings will be discussed and placed into the broader context <strong>of</strong> gene therapy for genetic forms<br />

<strong>of</strong> hearing loss.<br />

Jeffrey R. Martens, PhD<br />

<strong>Gene</strong> Therapeutic Rescue <strong>of</strong> an Olfactory Ciliopathy<br />

Olfactory dysfunction is a clinical manifestation <strong>of</strong> a growing class <strong>of</strong> human genetic diseases, termed ciliopathies. Despite<br />

substantial progress made in identifying genes that cause ciliopathies, therapies for these disorders are not yet available to patients.<br />

Here, we reported that odor detection can be restored to animals with a hypomorphic mutation in the gene encoding for the ciliary<br />

protein IFT88 that results in the loss <strong>of</strong> cilia on differentiated olfactory sensory neurons (OSNs). These studies represent the irst in<br />

vivo therapeutic treatment to reestablish cilia in a mammalian ciliopathy, and show that gene therapy is a viable curative option for<br />

functional rescue <strong>of</strong> the complex cilia organelle in established differentiated cells.<br />

32<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Marcelo N. Rivolta, MD, PhD<br />

Restoration <strong>of</strong> Auditory Evoked Responses by hESC-derived Otic Progenitors<br />

The presentation will discuss recent advances using stem cells in the search <strong>of</strong> a treatment for hearing loss. A method has been<br />

developed to generate ear sensory cells from human embryonic stem cells (hESCs). By activating FGF signalling on hESCs using<br />

ligands that induce the formation <strong>of</strong> the ear in vivo, we have generated otic progenitors that can produce sensory hair cell-like cells<br />

and auditory neurons. We have then taken the hESC-derived otic progenitor cells and explore if they could repair a deaf ear in a<br />

gerbil model <strong>of</strong> auditory neuropathy. When hESC-derived ear cells were transplanted into cochleae that have lost their auditory<br />

neurons the cells survived, engrafted and differentiated. Moreover, they sent projections making connections with the hair cells and<br />

with the brain and, more remarkably, they elicited a functional recovery represented by improved ABR thresholds. Related work,<br />

developing them as a platform for gene and drug discovery will also be reviewed.<br />

Scientific Symposium 103<br />

8:00 am - 10:00 am<br />

ROOM: 150 DEFG<br />

Novel Approaches to Cancer Immunotherapy<br />

CO-CHAIRS: Jennifer E. Adair, PhD and Elizabeth A. Mittendorf, MD, PhD<br />

SPEAKERS<br />

Wednesday, May 15, 2013<br />

Elizabeth A. Mittendorf, MD, PhD<br />

AE37: A Novel Hybrid Vaccine for Stimulating a Helper T <strong>Cell</strong> Response<br />

Our group has been leading the clinical trial efforts evaluating AE37, a novel vaccine that combines AE36, a native HER2-derived<br />

MHC class II epitope to the Ii-Key moiety. Linkage <strong>of</strong> the Ii-key moiety increases antigen presentation in vivo leading to increased<br />

potency <strong>of</strong> the vaccine. Phase I trials have demonstrated AE37 to be safe and effective in eliciting a HER2-speciic immune response.<br />

An ongoing phase II trial has shown evidence <strong>of</strong> clinical eficacy; at the time <strong>of</strong> a planned analysis at 24 month median follow-up,<br />

the disease-free survival rate was 90% in vaccinated patients versus 83% in non-vaccinated controls, a 41% relative risk reduction.<br />

This talk will focus on the preclinical and early clinical trial data available for the AE37 vaccine.<br />

John J. Nemunaitis, MD<br />

Clinical Update <strong>of</strong> bi-shRNA furin/GMCSF DNA Transfected Tumor Vaccine (FANG) in Cancer Patients<br />

Exciting the immune system to attack cancer involves 3 critical components: education <strong>of</strong> tumor antigens, enhancement <strong>of</strong> cancer<br />

targeting immune function, and blockade <strong>of</strong> pro-cancer immune inhibitors. FANG is a novel “triad” vaccine which utilizes both<br />

cellular and DNA technology to accomplish all 3 components. Speciically, autologous harvested tumor cells are transfected with a<br />

dual plasmid involving a GMCSF DNA cassette and a bifunctional RNA interference DNA cassette targeting furin, the proprotease<br />

converting enzyme <strong>of</strong> TGFß1 and TGFß2. Phase I trial involving 42 advanced cancer patients (Senzer et. al. Mol Ther 2012: 679-<br />

686) demonstrated patient safety, veriication <strong>of</strong> product mechanism and correlation <strong>of</strong> signiicant survival improvement with<br />

induction <strong>of</strong> activated T-cells as measured by ELISPOT response. Follow up results <strong>of</strong> the Phase I trial with demonstration <strong>of</strong> median<br />

survival advantage in comparison <strong>of</strong> FANG treated patients to FANG not treated patients <strong>of</strong> 562 days vs. 181 days (p


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Wednesday, May 15, 2013<br />

Scientific Symposium 104<br />

8:00 am - 10:00 am<br />

ROOM: 151 ABCG<br />

Novel Structural and Functional Assessment <strong>of</strong> the Respiratory Tract: Potential New Endpoints<br />

for <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong><br />

CO-CHAIRS: David A. Dean, PhD and Christian Mueller, PhD<br />

SPEAKERS<br />

David W. Parsons, PhD<br />

Developments in Functional X-ray Imaging: ASL, MCT and “Pinpoint Spirometry”<br />

Driven by a desire to rapidly, accurately and reliably measure the effect <strong>of</strong> airway gene therapy treatments for Cystic Fibrosis<br />

in mice, we have been developing several novel analytical options for airways using synchrotron phase contrast X-ray. The high<br />

lux and coherence <strong>of</strong> synchrotron X-rays underlie our ability to visualize mouse airway-surface anatomy and activity in-vivo, to<br />

sub-micron resolution; ultra-fast imaging <strong>of</strong> dynamic lung movement in 4-dimensions to reveal regional airlows is also enabled.<br />

Importantly, all <strong>of</strong> these new approaches are designed to be non-invasive and allow airway health and function in intact animals<br />

to be examined. Alterations in the depth <strong>of</strong> the airway surface liquid (ASL) and altered Mucociliary Transit (MCT) are the earliest<br />

physiological effects <strong>of</strong> CFTR activity that can produce visible change in airway surface structure and function, and are key markers<br />

<strong>of</strong> CF airway health to be improved by an effective gene therapy. The core methods for the image capture, analysis, and presentation<br />

<strong>of</strong> both ASL and MCT markers are rapidly developing to provide new endpoint tools. The application <strong>of</strong> velocimetry techniques to<br />

synchrotron CT data has created a powerful new tool for regional lung health assessment (”pinpoint spirometry”) that is likely to be<br />

<strong>of</strong> particular value in animal models, and is also well suited to translation into a clinically-applicable system.<br />

Cecilia Lo, PhD<br />

Respiratory Motile Cilia Dysfunction in Congenital Heart Disease Patients and Contribution to Worse<br />

Postsurgical Outcomes<br />

Steven M. Rowe, MD<br />

Functional Anatomic Imaging <strong>of</strong> the CF Airway<br />

A critical barrier causing a roadblock in our understanding <strong>of</strong> CF pathogenesis is the lack <strong>of</strong> tools available for visualizing the<br />

important microstructural, functional, and biomechanical features <strong>of</strong> the respiratory mucosa and mucus in vivo. Recently, our<br />

laboratories have developed an innovative technology, termed 1-µm resolution optical coherence tomography (µOCT), which<br />

enables real-time cross-sectional microscopy <strong>of</strong> the functional epithelial surface <strong>of</strong> living airways and can be readily combined with<br />

measures <strong>of</strong> ion transport in vivo. With µOCT, we have been able to simultaneously and quantitatively monitor airway surface liquid<br />

(ASL) and periciliary layer (PCL) depths, ciliary beating, and mucociliary transport (MCT) in situ, while also measuring mucus<br />

viscosity by native particle tracking techniques without the use <strong>of</strong> contrast dyes, exogenous microparticles, or other manipulations.<br />

Key manifestations <strong>of</strong> the underlying CF defect can readily be observed, and an in vivo probe is currently under development. In<br />

addition to answering important questions regarding CF pathophysiology, this technology provides a clear path towards the use <strong>of</strong><br />

µOCT for monitoring functional responses to novel therapeutics.<br />

Maria P. Limberis, PhD<br />

Development <strong>of</strong> an AAV-based Prophylactic Vaccine against Pandemic Inluenza<br />

We will discuss the development <strong>of</strong> an effective prophylactic vaccine against inluenza. This vaccine is based on AAV9 vector and<br />

expresses a broadly neutralizing antibody against inluenza that protects relevant animal models against challenge with H5N1 and<br />

H1N1.<br />

34<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Scientific Symposium 105<br />

8:00 am - 10:00 am<br />

ROOM: 150 ABC<br />

Polymeric <strong>Gene</strong> Delivery<br />

CHAIR: Sung Wan Kim, PhD<br />

SPEAKERS<br />

Wim E. Hennink, PhD<br />

Decationized Polyplexes: Novel Polymeric <strong>Gene</strong> Delivery System with Reduced Toxicity<br />

The clinical applicability <strong>of</strong> polymers as gene delivery systems depends not only on their eficiency, but also on their safety. The<br />

cytotoxicity <strong>of</strong> these systems remains a major issue, mainly due to their cationic nature. Therefore, it is highly preferable to have a<br />

system based on biocompatible neutral polymers, lacking polycations, without compromising the DNA condensing and protecting<br />

capacities. We introduce a concept to obtain a neutral polymeric gene delivery system, through a 3-step process to generate<br />

polyplexes with a core <strong>of</strong> disulide crosslinked poly(hydroxypropyl methacrylamide) (pHPMA) in which plasmid DNA (pDNA) is<br />

entrapped and a shell <strong>of</strong> poly(ethylene glycol) (PEG).<br />

Wednesday, May 15, 2013<br />

Ram I. Mahato, PhD<br />

Emerging Trends in Combination <strong>Therapy</strong> with RNAi<br />

Treatment strategies relying on a single small molecule drug, or silencing <strong>of</strong> a single gene <strong>of</strong>ten fail, while simultaneous targeting<br />

<strong>of</strong> multiple cellular pathways is more likely to succeed. RNA interference (RNAi) is a promising approach for treating diabetes and<br />

cancer. By pooling siRNAs targeting two different regions <strong>of</strong> the same target gene, or combining two siRNAs against two different<br />

genes, or even co-formulating small molecule drug with speciic siRNA or miRNA, we hope to improve islet transplantation and<br />

treat advanced prostate and pancreatic cancer. In this presentation, I will discuss our recent results on RNAi technologies for<br />

treating diabetes and cancer.<br />

Chae-Ok Yun, PhD<br />

Harnessing Adenovirus for Tumor Targeting by Nanocomplex<br />

A challenge to develop adenovirus (Ad)-mediated therapeutics has been issued to treat metastatic cancer via systemic<br />

administration. For effective gene therapeutics against primary and metastatic lesions, a systemically injectable tumor-targeting<br />

Ad vector system must be developed. Systemic delivery <strong>of</strong> Ad, however, is hampered by immune response against Ad, short half-life<br />

in the circulation, liver uptake, and low accumulation at target disease sites. Modiication <strong>of</strong> the Ad surface allows Ad to circulate<br />

in the bloodstream for a longer time, to be not targeted to the liver, and to passively accumulate in tumor sites via enhanced<br />

permeation and retention effects. The addition <strong>of</strong> afinity tags results in active targeting and high eficacy. Strategies including<br />

addition <strong>of</strong> polymer complexes, chemical modiications, and targeting moieties for the development <strong>of</strong> systemically injectable Ad<br />

gene therapeutic carriers will be discussed.<br />

Kazunori Kataoka, PhD<br />

Polymeric Micellar Nanocarriers for <strong>Gene</strong> and Oligonucleotide Delivery<br />

Focus <strong>of</strong> my talk will be on the use <strong>of</strong> self-assembly structures from multi-functional block copolymers, particularly polymeric<br />

micelles, for gene and oligonucleotide delivery. Importance <strong>of</strong> peptide ligands to facilitate extravasation as well as to control<br />

intracellular traficking <strong>of</strong> polymeric micelles will be discussed. Also, I will present our new strategy to delivery messenger RNA to<br />

target organ.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

35


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Wednesday, May 15, 2013<br />

Education Sessions<br />

The goal <strong>of</strong> the ASGCT Education <strong>Program</strong> is to provide participants with a broad background and introduction to topics relevant to the<br />

ield <strong>of</strong> gene and cell therapy. Education Sessions will be subdivided into two headings. “Topical Review” sessions will provide a broad<br />

perspective <strong>of</strong> an area <strong>of</strong> importance to the gene and cell therapy community such as major vector systems, speciic target organs or<br />

diseases, and funding/regulatory issues. “Emerging Field Review” sessions will provide a broad perspective <strong>of</strong> a technological or scientiic<br />

discipline that has recently become <strong>of</strong> great signiicance to ASGCT members.<br />

Education Session 110<br />

10:30 am - 12:00 pm<br />

ROOM: BALLROOM B<br />

Emerging Field Review: <strong>Gene</strong> Targeting<br />

<strong>Gene</strong> targeting, also known as genome editing, has become an increasingly feasible gene therapy strategy. In this education, three pioneers<br />

in the ield will describe different approaches to gene targeting. After this session, attendees should be able to understand the different<br />

approaches to gene targeting and which strategy might be best for their speciic gene therapy application.<br />

CHAIR: Matthew H. Porteus, MD, PhD<br />

SPEAKERS<br />

David W. Russell, MD, PhD<br />

AAV-Mediated <strong>Gene</strong> Targeting<br />

This presentation will describe the mechanism and applications <strong>of</strong> AAV-mediated gene targeting, which has been used to target<br />

over 100 genes in more than 50 different cell types. Sequence changes can be introduced at high frequencies, with up to 1% <strong>of</strong><br />

infected cells undergoing gene targeting. Insertions, deletions and substitutions can all be accurately introduced, and additional<br />

unwanted mutations are not found at targeted loci. Site-speciic nucleases are not required to obtain high targeting frequencies, so<br />

there is no risk <strong>of</strong> introducing DNA breaks at <strong>of</strong>f-target sites.<br />

J. Keith Joung, MD, PhD<br />

Engineered TALENs and CRISPR-Cas RNA-Guided Nucleases (RGNs) for Targeted Genome Editing<br />

Engineered site-speciic nucleases have emerged as a broadly applicable technology for eficiently inducing targeted alterations<br />

in the genomes <strong>of</strong> living cells and organisms. This talk will provide an introduction to two engineered nuclease platforms:<br />

transcription activator-like effector nucleases (TALENs) and CRISPR-Cas RNA-Guided Nucleases (RGNs). The strengths and<br />

limitations <strong>of</strong> each <strong>of</strong> these platforms will be discussed. In addition, publicly available methods and resources for practicing these<br />

technologies will be reviewed.<br />

Dana Carroll, PhD<br />

Nuclease-mediated <strong>Gene</strong> Targeting<br />

With new and rapidly developing technology, it is now possible to make knock-outs and knock-ins in virtually any gene in a wide<br />

range <strong>of</strong> cells and organisms. The secret is the development <strong>of</strong> nucleases that can be designed to cleave arbitrarily chosen genomic<br />

DNA sequences with high speciicity. <strong>Cell</strong>ular repair processes create localized mutations at the nuclease-induced break, or copy<br />

novel sequences from a user-provided template. This talk will cover two classes <strong>of</strong> targetable cleavage reagents, zinc-inger<br />

nucleases (ZFNs) and TALENs. The research and therapeutic potential <strong>of</strong> these reagents is enormous, and ZFNs are currently in<br />

clinical trials.<br />

Education Session 111<br />

10:30 am - 12:00 pm<br />

ROOM: BALLROOM C<br />

Emerging Field Review: Ocular <strong>Gene</strong> <strong>Therapy</strong>: Tools and <strong>Gene</strong>s<br />

Following the success <strong>of</strong> the clinical gene therapy trials for an early onset form <strong>of</strong> inherited blindness called LCA2, the momentum in the<br />

ield <strong>of</strong> ocular gene therapy is palpable. In this session, we try to capture this excitement by providing an in depth review into the genetics<br />

<strong>of</strong> vision and blindness and the technologies that are being developed to therapeutically intervene in the disease course using gene transfer.<br />

This educational session also will discuss disease gene discovery in the genomic era, genetic diagnosis for inherited forms <strong>of</strong> blindness, gene<br />

therapies for blindness under development, and AAV and nanoparticle vector systems for retinal targeting.<br />

36<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

CHAIR: Luk H. Vandenberghe, PhD<br />

SPEAKERS<br />

Eric A. Pierce, MD, PhD<br />

<strong>Gene</strong> Discovery in Inherited Retinal Blindness<br />

IRDs important causes <strong>of</strong> blindness. Pro<strong>of</strong> <strong>of</strong> concept clinical trials gene therapy for RPE65 LCA suggest that these disorders<br />

are amendable to treatment with gene therapies. The genetic heterogeneity <strong>of</strong> these disorders present challenges for genetic<br />

diagnostic testing. The use <strong>of</strong> next-generation sequencing techniques for genetic diagnostic testing and disease gene discovery<br />

research for these disorders will be discussed.<br />

Shannon E. Boye, PhD<br />

AAV <strong>Gene</strong> Transfer to the Retina<br />

Clinical trials for RPE65-LCA (LCA2) have demonstrated the ability to target a subretinally- delivered therapeutic transgene to<br />

the retinal pigment epithelium (RPE) thereby restoring retinal function and visually-evoked behavior to these patients. However,<br />

because most retinal degenerations are caused by mutations in photoreceptor (PR)- speciic genes, there is a great need to develop<br />

PR-targeted gene therapies. This presentation will review and compare known PR-targeted AAV vectors, with emphasis placed on<br />

results recently obtained in higher order species following subretinal delivery. The future development <strong>of</strong> intravitreal-delivered<br />

vectors targeted to photoreceptors will also be discussed.<br />

Wednesday, May 15, 2013<br />

Muna I. Naash, PhD<br />

Nanoparticle-mediated Ocular <strong>Gene</strong> Delivery<br />

The eye is an organ that is well-suited for the development and testing <strong>of</strong> novel therapeutic approaches. It is easily accessible and<br />

allows local application <strong>of</strong> therapeutic agents with reduced risk <strong>of</strong> systemic effects. Need exists for the development <strong>of</strong> non-viral<br />

therapeutic approaches for ocular diseases. Our lab and others have investigated the potentials <strong>of</strong> nanotechnology for ocular<br />

delivery <strong>of</strong> therapeutic genes. Investigations thus far have highlighted great potentials for nanoparticles to be a successful approach<br />

for ocular gene delivery. Our group has focused on the eficacy <strong>of</strong> compacted DNA nanoparticles for the treatment <strong>of</strong> different<br />

diseases, particularly those associated with the retina and retinal pigment epithelium. We have shown that nanoparticle treatment<br />

leads to eficient transfection <strong>of</strong> ocular cells, long term gene expression, and exerts no toxic effects on the eye even after multiple<br />

injections. These nanoparticles mediate signiicant functional rescue in models <strong>of</strong> retinitis pigmentosa, Stargardt macular dystrophy<br />

and Leber’s congenital amaurosis. They have no limitations on the size <strong>of</strong> the genetic cargo and effective gene expression has been<br />

demonstrated with vectors up to 20 kb in the lung and 14 kb in the eye, making them an ideal complement to AAVs especially for<br />

delivery <strong>of</strong> large genes. Furthermore, in a side-by-side comparison study with AAV, we recently reported that nanoparticles can<br />

drive gene expression on a comparable scale and longevity to AAV.<br />

Education Session 112<br />

10:30 am - 12:00 pm<br />

ROOM: BALLROOM D<br />

Topical Review: A Primer on Non-Viral Delivery<br />

CO-CHAIRS: Ian MacLachlan, PhD and Kevin G. Rice, PhD<br />

SPEAKERS<br />

Ian MacLachlan, PhD<br />

Liposomal and Lipid Nanoparticle Formulations for the Delivery <strong>of</strong> siRNA<br />

David H. Thompson, PhD<br />

Non-Viral Vectors: Correlations Between Structure and Performance<br />

A vast array <strong>of</strong> materials have been screened as potential non-viral vectors, including cationic lipids, hyperbranched polymers,<br />

dendrimers, cyclodextrin polymers, and nanoparticle carriers, however, few <strong>of</strong> the materials developed for this application have<br />

been systematically evaluated for their structure-property relationships. This presentation will begin by briely reviewing the<br />

various strategies used before focusing on those systems where it has been possible to correlate biological performance with the<br />

structure and/or physical properties <strong>of</strong> the non-viral vector. <strong>Final</strong>ly, new directions in non-viral vector development will be covered<br />

with an emphasis on mechanism-based studies.<br />

Kevin G. Rice, PhD<br />

Principles <strong>of</strong> DNA Polyplex Design for In Vitro and In Vivo <strong>Gene</strong> Delivery<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

37


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Wednesday, May 15, 2013<br />

Education Session 113<br />

10:30 am - 12:00 pm<br />

ROOM: 150 DEFG<br />

Topical Review: <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> Approaches to Hemoglobinopathies<br />

This session will introduce basic, translational and clinical efforts to provide therapeutic advances for the two major Hemoglobinopathies:<br />

sickle-cell anemia (SCD) and beta-thalassemia’s using gene therapy approaches. Elevation <strong>of</strong> HbF production has been a long-standing<br />

goal <strong>of</strong> therapy for ß-thalassemia and sickle cell disease (SCD) as its expression provides a potent attenuation <strong>of</strong> many <strong>of</strong> the most severe<br />

complications <strong>of</strong> disease phenotype. The central theme <strong>of</strong> this session will be improving gene transfer and gene correction in human<br />

hematopoietic stem and progenitor cells to provide more effective and safe therapies for blood cell disorders. In addition, efforts and the<br />

lessons learnt from gene therapy <strong>of</strong> Severe Combined Immunodeiciency (SCID) disease.<br />

CO-CHAIRS: Pankaj Qasba, PhD and Sonia I. Skarlatos, PhD<br />

SPEAKERS<br />

Punam Malik, MD, PhD<br />

<strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> Approaches to Hemoglobinopathies<br />

Dr. Malik will present an overview <strong>of</strong> genetic therapies for hemoglobiniopathies, a review <strong>of</strong> the literature, the current state <strong>of</strong> the<br />

ield and future promising ways <strong>of</strong> gene editing and reprogramming.<br />

John F. Tisdale, MD<br />

Stem <strong>Cell</strong>s as <strong>Gene</strong> <strong>Therapy</strong> Vehicles for the Treatment <strong>of</strong> Disorders <strong>of</strong> Globin Synthesis<br />

Sickle cell disease (SCD) is a recessive genetic disease that results from the production <strong>of</strong> an abnormal hemoglobin that is prone<br />

to polymerization upon deoxygenation causing severe morbidity and early mortality. Although palliative therapies have been<br />

developed, conventional treatment remains unsatisfactory. Signiicant advances in cellular and molecular biology have enabled<br />

the development <strong>of</strong> a mounting armamentarium <strong>of</strong> tools to allow correction at the hematopoietic stem cell (HSC) level. Allogeneic<br />

HSC transplantation, a form <strong>of</strong> genetic therapy, is an established curative approach through replacement <strong>of</strong> the defective organ<br />

with that <strong>of</strong> a donor carrying the normal genotype; however, procedural toxicities limit this approach to only severely affected<br />

children. Nonmyeloablative approaches based upon basic and preclinical studies have now allowed for the successful application<br />

<strong>of</strong> this approach in adults with severe disease, with disease reversion in the majority <strong>of</strong> patients treated through the attainment <strong>of</strong><br />

stable mixed hematopoietic chimerism. Nonetheless, this approach remains limited by donor availability, and the development <strong>of</strong><br />

gene transfer directed at autologous HSCs remains a desirable alternative. Approaches using autologous transplantation <strong>of</strong> HSCs<br />

modiied by lentiviral vectors have demonstrated expression <strong>of</strong> the human beta-globin protein at clinically signiicant levels, and<br />

this approach is now being developed for clinical application in SCD. The progress toward the goal <strong>of</strong> these HSC based therapies will<br />

be reviewed.<br />

Donald B. Kohn, MD<br />

Lessons Learned from <strong>Gene</strong> <strong>Therapy</strong> for SCID<br />

The implementation and performance <strong>of</strong> clinical trials <strong>of</strong> gene therapy using hematopoietic stem cells is a complex process. After<br />

pro<strong>of</strong>-<strong>of</strong>-principle studies demonstrate potential disease modifying activity, preclinical activity and toxicology data need to be<br />

generated, along with clinical protocol, consent documents, etc. to support regulatory applications. Subjects are treated in the<br />

high acuity setting <strong>of</strong> hematopoietic stem cell transplantation (HSCT) which may include the use <strong>of</strong> myeloreductive conditioning,<br />

although no immune suppression pre- or post-transplant is needed, due to the use <strong>of</strong> autologous cells. Ultimately, clinical<br />

acceptance <strong>of</strong> gene therapy as a standard <strong>of</strong> care will depend on demonstrating equivalent or greater eficacy and improved<br />

outcomes or reduced costs, compared to allogeneic HSCT. Experience with gene therapy for severe combined immune deiciency<br />

may inform efforts to develop similar approaches to hemoglobinopathies; persistence and patience are needed.<br />

Education Session 114<br />

10:30 am - 12:00 pm<br />

ROOM: 151 ABCG<br />

Topical Review: Vector Design<br />

CO-CHAIRS: Alberto Auricchio, MD and Dirk Grimm, PhD<br />

38<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

SPEAKERS<br />

Anja Ehrhardt, PhD<br />

Viral Hybrid-Vectors for Stable Tranduction <strong>of</strong> Mammalian <strong>Cell</strong>s: Molecular Design, Eficacy and Applications<br />

Viral hybrid-vectors combine the high transduction eficiencies <strong>of</strong> recombinant viruses with improved genetic elements for<br />

stabilized transgene expression. This tutorial provides a state-<strong>of</strong>-the-art overview <strong>of</strong> available viral hybrid-vector systems for<br />

random somatic integration (Sleeping Beauty transposase), targeted integration (designer nucleases) and episomal persistence<br />

<strong>of</strong> the transgene (plasmid replicons). Advantages but also limitations <strong>of</strong> each vector system will be discussed and safety issues<br />

addressed. Furthermore, recent in vivo applications will be mentioned.<br />

Alberto Auricchio, MD<br />

AAV - From the Genome to the Capsid<br />

Vectors based on the adeno-associated virus (AAV) are being tested in humans and the initial safety and eficacy results in several<br />

tissues, including liver, muscle, retina and central nervous system are extremely encouraging. The availability <strong>of</strong> hundreds <strong>of</strong><br />

naturally-occurring AAV serotypes, as well as <strong>of</strong> mutagenized variants with improved and different transduction proiles provide<br />

a theoretical endless source <strong>of</strong> vectors for in vivo gene therapy. Sophisticated strategies were developed to tailor transgene<br />

expression to speciic cell types within the AAV cargo capacity. In addition, efforts are being made to expand AAV cargo capacity<br />

for the expression <strong>of</strong> large transgenes. Improvements on both the outside (capsid) and inside (genome) <strong>of</strong> AAV vectors will be<br />

discussed in the context <strong>of</strong> the retina which is an excellent target tissue to challenge the versatile AAV platform.<br />

Wednesday, May 15, 2013<br />

Philip Ng, PhD<br />

Helper-dependent Adenovirus: Design, Production and Applications<br />

This education session will discuss optimal design, eficient production and novel applications <strong>of</strong> helper dependent adenovirus for<br />

gene and cell therapy.<br />

Lunch Break (On Own - Not Provided; Pre-ordered boxed lunches available for pick up at Registration Counter)<br />

12:00 pm - 1:15 pm<br />

Education Session 120<br />

1:15 pm - 2:45 pm<br />

ROOM: BALLROOM B<br />

Emerging Field Review: Therapeutic Antibody <strong>Gene</strong> Delivery<br />

Recent advances in monoclonal antibody discovery, isolation, and expression have created unprecedented opportunities to utilize this class<br />

<strong>of</strong> proteins for broad therapeutic beneit. A number <strong>of</strong> studies have highlighted several potential applications for the use <strong>of</strong> antibodies<br />

in vivo, ranging from the prevention <strong>of</strong> infectious diseases, to the treatment <strong>of</strong> drug addiction. This session will focus on several <strong>of</strong> these<br />

applications and will highlight strategies aimed at maximizing vector-based expression <strong>of</strong> antibodies in vivo.<br />

CO-CHAIRS: Alejandro B. Balazs, PhD and James M. Wilson, MD, PhD<br />

SPEAKERS<br />

James M. Wilson, MD, PhD<br />

Inluenza Antibodies and Airway Delivery<br />

Ronald G. Crystal, MD<br />

<strong>Gene</strong> Transfer Strategies to Treat Addiction<br />

Addiction to drugs is a major worldwide problem for which there is no effective therapy. Using cocaine and nicotine as examples<br />

<strong>of</strong> commonly used addictive drugs, we have developed two platform strategies to evoke high-titer antibodies speciic for the antiaddictive<br />

drug. In the irst strategy, based on the highly immunogenic nature <strong>of</strong> the adenovirus capsid, analogs <strong>of</strong> the addictive<br />

drug are bound to adenovirus capsid proteins to create active vaccines that generate high-titer anti-drug antibodies. In the second<br />

strategy, the gene coding sequences for monoclonals against the addictive drug are expressed by adeno-associated virus gene<br />

transefer vectors capable <strong>of</strong> generating, with a single administration, persistent high titers <strong>of</strong> anti-drug antibodies. In experimental<br />

animal models, both strategies are highly effective, providing new paradigms for anti-addictive molecular vaccines.<br />

Alejandro B. Balazs, PhD<br />

Expressing Antibodies in vivo via Adeno Associated Virus Vector for Vectored ImmunoProphylaxis<br />

Recent advances in vector-based antibody delivery have created the potential for engineering humoral immunity to address<br />

problems ranging from infectious disease to drug addiction. These efforts are <strong>of</strong>ten hampered by dificulties in achieving<br />

therapeutic levels <strong>of</strong> antibody expression. This presentation will focus on means <strong>of</strong> improving expression <strong>of</strong> antibodies in vivo and<br />

summarize the challenges <strong>of</strong> working with this novel application <strong>of</strong> gene transfer.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

39


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Wednesday, May 15, 2013<br />

Education Session 121<br />

1:15 pm - 2:45 pm<br />

ROOM: BALLROOM C<br />

Topical Review: Cancer <strong>Gene</strong> <strong>Therapy</strong><br />

The ield <strong>of</strong> Cancer <strong>Gene</strong> <strong>Therapy</strong> has seen many recent developments concerning applications to treat different tumors using a variety<br />

<strong>of</strong> novel vector systems that are now being exploited in human clinical trials. This session will deal with pre-clinical accomplishments<br />

concerning the use <strong>of</strong> chimeric antigen receptor (CAR) modiied T-cells directed against tumor associated antigens, the use <strong>of</strong> novel tumorselective<br />

replication-competent retroviruses expressing prodrugs, and the use <strong>of</strong> bifunctional shRNAi nanoplex technology for advanced<br />

methods <strong>of</strong> killing tumors using gene/cell therapies. Recent signiicant progress in clinical trials resulting from these approaches will also be<br />

presented.<br />

CHAIR: William F. Goins, PhD<br />

SPEAKERS<br />

John J. Nemunaitis, MD<br />

Clinical Update <strong>of</strong> bifunctional (bi)-shRNAi Nanoplex Technology in Cancer<br />

Several RNAi approaches (miRNA, siRNA, shRNA, bi-shRNA) are being explored to exquisitely disrupt post transcriptional gene<br />

silencing <strong>of</strong> cancer relevant signals. Twenty-six clinical studies involving RNAi technology have been published. bi-shRNAi (Issued<br />

Patent No. 8,252,526) utilizes a dual mechanism to knockdown sequence speciic targets by engaging both siRNA and miRNA-like<br />

RNA-inducing silence complex. The bi-shRNAi technology was initially introduced into the clinical areas to target a proprotease<br />

converting enzyme, furin, as one <strong>of</strong> 3 components involving a novel FANG vaccine (Senzer et. Al. Mol Ther 2012: 679-686) in which<br />

clinical demonstration <strong>of</strong> protein knockdown to the designed target, furin and downstream signals (TGFß1, ß2) was greater than<br />

90%, and immune response in correlation with survival advantage was demonstrated. In an effort to expand bi-shRNAi technology<br />

and to target other potentially therapeutic molecular signals, we have utilized a nanoplex approach by incorporating the bi-shRNAi<br />

plasmid into a bilamellar invaginated vesicle (BIV) (Issued Patent No. 7,037,520) which can be decorated with reversible masking<br />

lipids and targeting small molecule ligands (Issued U.S. Patient No. 8,333,988). Results <strong>of</strong> initial preclinical and clinical studies will<br />

be reviewed.<br />

Noriyuki Kasahara, MD, PhD<br />

Development <strong>of</strong> Novel Vectors and Strategies for <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Cancer<br />

Oncolytic virotherapy, engineered T cells and cancer vaccines, and stem cell-based tumor-targeting strategies are currently<br />

being evaluated in the clinic and show considerable promise. Newer approaches seek to further enhance the potency <strong>of</strong> RNA<br />

oligonucleotide-based therapeutics, replicating virus vectors, and engineered cell therapies, while maintaining tumor-selectivity<br />

and safety. An overview <strong>of</strong> recent advances showing signiicant promise for the development <strong>of</strong> clinically effective gene therapy<br />

against cancer will be presented.<br />

Gianpietro Dotti, MD<br />

Chimeric Antigen Receptor (CAR) Engineered T-cell Cancer Therapies<br />

Education Session 122<br />

1:15 pm - 2:45 pm<br />

ROOM: BALLROOM D<br />

Topical Review: <strong>Gene</strong> <strong>Therapy</strong> to the Marketplace<br />

CHAIR: H. Trent Spencer, PhD<br />

SPEAKERS<br />

H. Trent Spencer, PhD<br />

Replacing Treatments with Cures: Potential Therapeutics for Hemophilia A<br />

Hemophilia A is a monogenic bleeding disorder currently treated by protein replacement therapy. <strong>Gene</strong> therapy provides an<br />

alternative treatment that can eliminate the need for recombinant protein administration. Preclinical and clinical data show a long<br />

lasting/lifelong treatment is feasible, and various models have shown gene therapy for hemophilia A is also inancially attractive,<br />

which further justiies the development <strong>of</strong> these curative treatments. This presentation will summarize hemophilia treatment<br />

options with respect to their market potentials.<br />

R. Scott McIvor, PhD<br />

Discovery Genomics: Development <strong>of</strong> the Sleeping Beauty Transposon System for <strong>Gene</strong> <strong>Therapy</strong><br />

40<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Khursheed Anwer, PhD<br />

IL-12 <strong>Gene</strong> <strong>Therapy</strong>: From Bench to Clinic<br />

This presentation describes the clinical and preclinical development <strong>of</strong> EGEN-001, an interleukin-12 (IL-12) gene expression<br />

plasmid formulated with a biocompatible delivery lipopolymer, PEG-PEI-Cholesterol (PPC), for the treatment <strong>of</strong> peritoneally<br />

metastasized gynecological and gastrointestinal cancers. This cytokine expression <strong>of</strong> IL-12 is designed to increase the local<br />

concentration <strong>of</strong> IL-12 with minimal escape into the systemic circulation thus minimizing the systemic toxicities associated with<br />

the recombinant IL-12 therapy. Two Phase I trials <strong>of</strong> EGEN-001 administered as a single agent or in combination with standard<br />

chemotherapy agents in advanced ovarian cancer patients have been completed, a Phase II trial <strong>of</strong> EGEN-001 as a single agent in the<br />

platinum-resistant patient population is in progress, and a Phase I/II trial in combination with chemotherapy agents in metastatic<br />

colorectal cancer patients has been initiated. The manufacturing <strong>of</strong> this investigational product has been successfully advanced<br />

from bench scale to clinical scale and several cGMP lots have been successfully produced. A detailed description <strong>of</strong> EGEN-001<br />

pharmacology/toxicology and pharmaceutical properties will be presented.<br />

Wednesday, May 15, 2013<br />

Education Session 123<br />

1:15 pm - 2:45 pm<br />

ROOM: 150 DEFG<br />

Topical Review: Navigating a Dificult Funding Climate<br />

This session will present NIH training and career opportunities for investigators as well as what type <strong>of</strong> support is available from<br />

Foundations and Industry. In addition, two presentations will focus on how to write an application from the perspective <strong>of</strong> a senior and<br />

junior investigator.<br />

CO-CHAIRS: Scott Q. Harper, PhD and Sonia I. Skarlatos, PhD<br />

SPEAKERS<br />

Barry J. Byrne, MD, PhD<br />

Scott Q. Harper, PhD<br />

Startup Funds Don’t Last Forever: A Junior PI’s Path Toward Funding and Growing a New Lab<br />

Many <strong>of</strong> us spend a decade or more training to become independent scientists. When the opportunity inally arrives, walking into<br />

our own empty labs for the very irst time can be exhilarating and overwhelming. This moment also means the clock begins ticking<br />

on the next stage <strong>of</strong> our careers. Arguably the most critical part <strong>of</strong> this next stage is acquiring independent funding to sustain and<br />

grow our lab, which is no easy task in today’s economic climate. In this presentation, I will discuss my path for leveraging my lab<br />

startup package into independent funding.<br />

Drew E. Carlson, PhD<br />

Fellowships and Career Awards: Stepping Stones to Research Independence<br />

The NIH <strong>of</strong>fers a myriad <strong>of</strong> fellowships and K awards to facilitate the pursuit <strong>of</strong> a career in biomedical research. Understanding the<br />

objectives, eligibility requirements, review criteria, and process in selecting and applying for these funding opportunities is central<br />

to the submission <strong>of</strong> a competitive proposal. This presentation will focus on the general principles that apply to these mechanisms<br />

and how to navigate the intricacies <strong>of</strong> the NIH to identify the best options for your career stage and scientiic expertise.<br />

Eric A. Pierce, MD, PhD<br />

Funding from Foundations: Perspectives from the Foundation Fighting Blindness<br />

The Foundation Fighting Blindness (FFB) is the largest non-governmental supporter <strong>of</strong> research related to inherited retinal<br />

degenerations. The goal <strong>of</strong> this presentation is to describe the types <strong>of</strong> research funding available from FFB, which range from<br />

Career Development Awards to Individual Investigator Awards to Research Center grants. The grant application process and review<br />

processes will be described, with an emphasis on practical advice about preparing competitive proposals for foundations in general,<br />

using FFB as an example.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

41


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Wednesday, May 15, 2013<br />

Education Session 124<br />

1:15 pm - 2:45 pm<br />

ROOM: 150 ABC<br />

Topical Review: Synthetic <strong>Gene</strong> Delivery<br />

An overview <strong>of</strong> different philosophies <strong>of</strong> synthetic delivery systems for nucleic acids. The irst talk will address silk elastin-like proteins for<br />

gene delivery and how they can be combined with virus for an enhanced hybrid gene delivery vehicle. The second talk will focus on “smart”<br />

pH-sensitive polymeric carriers for therapeutic delivery <strong>of</strong> nucleic acids. The inal talk will examine cell-penetrating peptides for retinal gene<br />

delivery.<br />

CHAIR: James Yockman, PhD<br />

SPEAKERS<br />

Hamid Ghandehari, PhD<br />

Recombinant Polymers for <strong>Gene</strong> Delivery<br />

Polymeric systems have shown utility in gene delivery. They can form complexes with nucleic acids or be used as matrices for<br />

controlled release. Majority <strong>of</strong> polymers used for such purposes are synthesized by chemical strategies that result in limited control<br />

over polymer structure and therefore function. Recombinant polymers provide exquisite control over backbone structure. This talk<br />

will summarize the use <strong>of</strong> recombinant polymers for gene delivery applications.<br />

You Han Bae, PhD<br />

pH-Sensitive Polymeric Carrier for Nucleic Acid Delivery<br />

The journey <strong>of</strong> a gene carrier from an administration site to target individual cells encounters a series <strong>of</strong> formidable barriers in<br />

the blood compartment, when crossing vascular walls, and while penetrating extracellular matrix. <strong>Cell</strong> uptake and intracellular<br />

traficking steps then follow, which have been major foci in carrier development and in vitro tests. The carrier may require<br />

switching surface property depending on environmental conditions during the voyage for higher probability <strong>of</strong> reaching its target<br />

cell and action site. The potential roles <strong>of</strong> pH-responsive polymers, particularly weakly anionic polysulfonamide and cationic<br />

poly(L-histidine), in this challenging journey will be discussed.<br />

Rajendra Kumar-Singh, PhD<br />

Pegylated Peptide-DNA Nanoparticles Delay the Onset <strong>of</strong> Retinal Degeneration in Mouse Models <strong>of</strong> Retinitis<br />

Pigmentosa<br />

We have developed a novel peptide referred to as ‘Peptide for Ocular Delivery’ or POD that can penetrate cells and tissues in vivo<br />

within 5 minutes. When pegylated, POD can compact DNA and enable marker or therapeutic gene delivery to retina in vivo. These<br />

nanoparticles are approximately 150 nm in size and can enable therapeutic transgene expression in vivo for more than 70 days.<br />

POD-DNA nanoparticles can reduce apoptosis and delay retinal degeneration in a mouse model <strong>of</strong> retinitis pigmentosa. POD has<br />

potential therapeutic applications in ocular as well as non ocular organ systems.<br />

Education Session 125<br />

1:15 pm - 2:45 pm<br />

ROOM: 151 ABCG<br />

Topical Review: The Ins and Outs <strong>of</strong> Integration Deicient Lentiviral Vectors (IDLV’s)<br />

The Ins and Outs <strong>of</strong> Integration Deicient Lentiviral Vectors (IDLV’s)”, will focus on the development and utilization <strong>of</strong> IDLV’s in preclinical<br />

trials. The session comprises three presentations. The irst is an introductory presentation, which will concentrate on the molecular<br />

mechanisms involved in the production and regulation <strong>of</strong> gene expression from IDLV’s. The second presentation will focus on illegitimate<br />

integration <strong>of</strong> IDLV’s, and the third presentation will describe the development <strong>of</strong> a novel IDLV system for cancer immunotherapy.<br />

CHAIR: Tal Kafri, MD, PhD<br />

SPEAKERS<br />

Tal Kafri, MD, PhD<br />

The Basics <strong>of</strong> Integration Defective Lentiviral Vectors<br />

This introductory presentation will focus on the molecular mechanism involved in the generation <strong>of</strong> integration defective lentiviral<br />

vectors (IDLV’s) and the molecular assays employed to determine the eficacy and safety <strong>of</strong> the currently used IDLV gene delivery<br />

systems. In addition the presentation will outline advancement in IDLV design, which improve IDLV gene expression and reduce<br />

illegitimate integration.<br />

42<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Manfred Schmidt, PhD<br />

Clonality and Biosafety Aspects <strong>of</strong> Illegitimate Integration<br />

Integrating retroviral vectors have been used successfully in clinical applications. With the occurrence <strong>of</strong> integration associated<br />

severe side effects, enhanced efforts have been set for the clinical translation <strong>of</strong> integrase deicient viral vectors to guarantee<br />

improved biosafety. In this presentation, the focus is set on studies performed for assessing frequency, proile and mechanisms <strong>of</strong><br />

(illegitimate) integration.<br />

Scott H. Robbins, PhD<br />

Development <strong>of</strong> an ID-LV as a <strong>Gene</strong> Delivery Platform for Immunotherapy Applications<br />

One <strong>of</strong> the most fundamental challenges for the design <strong>of</strong> next generation vaccines is the generation <strong>of</strong> antigen-speciic CD8 T<br />

cell responses. The direct administration <strong>of</strong> lentivector-based vaccines genetically encoding antigen is proving to be an effective<br />

approach to elicit CD8 T cell responses in pre-clinical animal models. The ability to alter the tropism <strong>of</strong> lentiviral vectors via<br />

pseudotyping and other mechanisms makes them attractive as a platform technology on which to base product candidates for<br />

clinical applications such as antigen-directed immunotherapy and vaccines. Examples <strong>of</strong> the functionality <strong>of</strong> integration-competent<br />

and -deicient lentiviral vectors as antigen delivery vehicles in pre-clinical settings will be provided as well as an example <strong>of</strong> the<br />

design <strong>of</strong> a dendritic cell-directed integration-deicient lentiviral vector that is currently under development as an antigen-directed<br />

cancer immunotherapy (a “cancer vaccine”).<br />

Wednesday, May 15, 2013<br />

Oral Abstract Session 130<br />

3:15 pm - 5:15 pm<br />

ROOM: BALLROOM A<br />

AAV Vector Development & Application<br />

CO-CHAIRS: Mavis Agbandje-McKenna, PhD and Hiroyuki Nakai, MD, PhD<br />

(Abstracts 1 through 8; see page 87)<br />

Oral Abstract Session 131<br />

3:15 pm - 5:15 pm<br />

ROOM: BALLROOM B<br />

Cancer - Immunotherapy I<br />

CO-CHAIRS: Malcolm K. Brenner, MD, PhD and John J. Nemunaitis, MD<br />

(Abstracts 9 through 16; see pages 87-88)<br />

Oral Abstract Session 132<br />

3:15 pm - 5:15 pm<br />

ROOM: 150 DEFG<br />

Cancer - Oncolytic Viruses<br />

CO-CHAIRS: David Kirn, MD and Stephen J. Russell, MD, PhD<br />

(Abstracts 17 through 24; see page 88)<br />

Oral Abstract Session 133<br />

3:15 pm - 5:15 pm<br />

ROOM: BALLROOM C<br />

Advancing the Science <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> for Hematologic Diseases<br />

CO-CHAIRS: Arnab Ghosh, MD, PhD and Donald B. Kohn, MD<br />

(Abstracts 25 through 32; see pages 88-89)<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

43


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Wednesday, May 15, 2013<br />

Oral Abstract Session 134<br />

3:15 pm - 5:15 pm<br />

ROOM: BALLROOM D<br />

Neurological Disorders: Monogeneic Disorders<br />

CO-CHAIRS: Raymond T. Bartus, PhD and Nicholas Boulis, MD<br />

(Abstracts 33 through 40; see page 89)<br />

Oral Abstract Session 135<br />

3:15 pm - 4:15 pm<br />

ROOM: 151 ABCG<br />

Chemical and Molecular Conjugates<br />

CO-CHAIRS: Young Jik Kwon, PhD and Assem Ziady, PhD<br />

(Abstracts 41 through 44; see page 90)<br />

Oral Abstract Session 136<br />

3:15 pm - 4:15 pm<br />

ROOM: 150 ABC<br />

Infectious Diseases and Vaccines<br />

CO-CHAIRS: Renata Stripecke, PhD and Grant D. Trobridge, PhD<br />

(Abstracts 45 through 48; see page 90)<br />

Oral Abstract Session 137<br />

4:20 pm - 5:20 pm<br />

ROOM: 151 ABCG<br />

<strong>Cell</strong> Processing and Vector Production<br />

CO-CHAIRS: Adrian P. Gee, PhD and Isabelle Riviere, PhD<br />

(Abstracts 49 through 52; see page 90)<br />

Oral Abstract Session 138<br />

4:20 pm - 5:20 pm<br />

ROOM: 150 ABC<br />

Sensory (Ophthalmic & Auditory) <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

CO-CHAIRS: Alberto Auricchio, MD and Tonia S. Rex, PhD<br />

(Abstracts 53 through 56; see page 91)<br />

Exhibit Hall Welcome Reception<br />

5:15 pm - 7:15 pm<br />

ROOM: EXHIBIT HALL C/D<br />

44<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Wednesday, May 15, 2013<br />

Workshop 140<br />

7:30 pm - 9:30 pm<br />

Room: 150 DEFG<br />

Commercialization Workshop<br />

CO-CHAIRS: Estuardo Aguilar-Cordova and Brendan Lee, MD, PhD<br />

SPEAKERS<br />

Peter Kolchinsky<br />

What makes Investors want to Invest<br />

Nick Leschly<br />

Who Utilizes Early Phase Resources<br />

Wednesday, May 15, 2013<br />

Fabrizia Bignami, PhD<br />

What is Big Pharma Looking for in <strong>Gene</strong> or <strong>Cell</strong> <strong>Therapy</strong><br />

Suzannah Sundby, JD<br />

What IP Issues are Relevant for Successfully Commercializing <strong>Gene</strong> and <strong>Cell</strong> Therapies<br />

<strong>Gene</strong> and cell therapies are different from classic small molecules in that intellectual property issues can evolve and become<br />

increasingly complex as scaling up from the laboratory setting and commercialization proceeds. What effect do modiications<br />

and optimizations to vector designs and manufacturing processes, including cell isolation and culturing techniques, have on one’s<br />

right to make, use, and sell the intellectual property Do you still own the rights to the intellectual property Will the intellectual<br />

property rights <strong>of</strong> another prevent you from commercializing your own product Ms. Sundby will discuss IP in the cell and gene<br />

therapy space with particular attention paid to what questions an investigator or institution should consider prior to investing<br />

further resources in pipeline development.<br />

New Member Welcome Reception<br />

7:30 pm - 8:30 pm<br />

ROOM: 255 B<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

45


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

George Stamatoyannopoulos Lecture 200<br />

8:30 am - 9:35 am<br />

ROOM: BALLROOM E-J<br />

George Stamatoyannopoulos Lecture<br />

CHAIR<br />

SPEAKER<br />

Thursday, May 16, 2013<br />

David W. Russell, MD, PhD<br />

Mario R. Capecchi, PhD<br />

Modeling <strong>of</strong> Human Disease in the Mouse in the 21st Century: From Cancer to Neuropsychiatric Disorders<br />

<strong>Gene</strong> targeting allows the designed modiication <strong>of</strong> any gene in the mouse genome. Since genes impact all biological phenomena<br />

this methodology can be used to study any biological phenomena common to mammals in the mouse. We are using it to model<br />

human disease in the mouse. The models can be used to analyze the pathology <strong>of</strong> the disease at a level not feasible in humans and<br />

as a platform for the development <strong>of</strong> new therapeutic protocols. I will discuss modeling <strong>of</strong> a neuropsychiatric disorder, obsessive<br />

compulsive (OCD) spectrum disorder in the mouse. These studies provide the unexpected conclusion that microglia, the immune<br />

cells <strong>of</strong> the brain derived from bone marrow, are controlling behavior in the mouse.<br />

Exhibit Hall C<strong>of</strong>fee Social<br />

9:35 am - 10:30 am<br />

ROOM: EXHIBIT HALL C/D<br />

Scientific Symposium 210<br />

10:30 am - 12:30 pm<br />

ROOM: 151 ABCG<br />

50 Years <strong>of</strong> Research in Alpha-1 Antitrypsin<br />

CHAIR: Terence R. Flotte, MD<br />

SPEAKERS<br />

Robert A. Sandhaus, MD, PhD<br />

Historical Review <strong>of</strong> the Past 50 Years <strong>of</strong> Research on Alpha-1 Antitrypsin Disorder<br />

First described 50 years ago, Alpha-1 Antitrypsin Deiciency (AATD) was soon associated with the development <strong>of</strong> both lung and<br />

liver diseases. The rapidity with which the biochemical, pathophysiologic, epidemiologic, and therapeutic advances followed this<br />

initial discovery has been astounding, even by today’s standards. In spite <strong>of</strong> this, there is still much to be learned about the alpha-1<br />

antitrypsin protein and its roles in health and disease.<br />

Ronald G. Crystal, MD<br />

<strong>Gene</strong> <strong>Therapy</strong> for Alpha 1-antitrypsin Deiciency with AAV Intrapleural Administration<br />

a1-antitrypsin (a1AT) deiciency, caused by SERPINA1 gene mutations, results in low a1AT serum levels and development <strong>of</strong> earlyonset<br />

panacinar emphysema, reducing life span by 15 to 20 years. Current treatment is weekly intravenous administration <strong>of</strong> a1AT<br />

puriied from pooled human plasma. Adeno-associated (AAV)-mediated delivery <strong>of</strong> a1AT is an ideal strategy for gene therapy for<br />

the lung manifestations <strong>of</strong> a1AT deiciency because AAV vectors mediate sustained transgene expression. We have established a<br />

novel, highly eficient strategy for gene therapy for a1AT deiciency based on intrapleural administration <strong>of</strong> AAV serotype rh.10<br />

coding for human a1AT. The advantage this approach <strong>of</strong>fers is proximity <strong>of</strong> vector expression to the site <strong>of</strong> action. Pre-clinical<br />

studies comparing intrapleural administration <strong>of</strong> 25 AAV serotype vectors demonstrated that the highest a1AT levels were achieved<br />

with AAVrh.10, a serotype that is derived from a non-human primate, minimizing the challenge <strong>of</strong> pre-existing human anti-vector<br />

immunity limiting persistent gene expression. Safety studies in mice and non-human primates have shown this strategy is safe<br />

and will provide sustained expression a1AT. Our overall hypothesis is that a single intrapleural administration <strong>of</strong> an AAVrh.10<br />

gene transfer vector coding for the human a1AT cDNA will provide sustained therapeutic levels in the lung suficient to treat a1AT<br />

deiciency.<br />

46<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Christian Mueller, PhD<br />

MicroRNA’s and Alpha-1 Antitrypsin Deiciency<br />

Terence R. Flotte, MD<br />

Advances in Clinical <strong>Gene</strong> <strong>Therapy</strong> Trials for Alpha-1 Anti-trypsin Deiciency<br />

Scientific Symposium 211<br />

10:30 am - 12:30 pm<br />

ROOM: BALLROOM C<br />

Clinical Updates <strong>of</strong> Stem <strong>Cell</strong> Therapies<br />

CO-CHAIRS: Jane S. Lebkowski, PhD and Eirini P. Papapetrou, MD, PhD<br />

SPEAKERS<br />

Michele De Luca, MD<br />

Corneal Regeneration By Cultured Limbal Stem <strong>Cell</strong>s<br />

Adult stem cells are cells with a high capacity for self-renewal that can produce terminally differentiated progeny. Stem cells<br />

generate an intermediate population <strong>of</strong> committed progenitors, <strong>of</strong>ten referred to as transit amplifying (TA) cells, that terminally<br />

differentiate after a limited number <strong>of</strong> cell divisions. Human keratinocyte stem cells are clonogenic and are known as holoclones.<br />

Human corneal stem cells are segregated in the limbus while limbal-derived TA cells form the corneal epithelium. Cultivated limbal<br />

stem cells generate sheets <strong>of</strong> corneal epithelium suitable for clinical application. We report long-term (up to 15 years) clinical<br />

results obtained in an homogeneous group <strong>of</strong> patients presenting with corneal opaciication and visual loss due to chemical burndependent<br />

limbal stem cell deiciency. The corneal epithelium and the visual acuity <strong>of</strong> these patients have been restored by grafts <strong>of</strong><br />

autologous cultured limbal keratinocytes. In post hoc analyses, success was associated with the percentage <strong>of</strong> p63-bright holocloneforming<br />

stem cells in culture, but not with total number <strong>of</strong> clonogenic cells, colony size or growth rate <strong>of</strong> the cultures. Graft failure<br />

was also associated with the type <strong>of</strong> initial ocular damage and postoperative complications.<br />

Joshua Hare, MD<br />

<strong>Cell</strong> <strong>Therapy</strong> for Chronic Ischemic Heart Disease from Concept to Clinic<br />

Thursday, May 16, 2013<br />

Brian W. Bigger, PhD<br />

Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> for Neurological Diseases<br />

Haematopoietic stem cell transplantation (HSCT) has traditionally been used to treat a select group <strong>of</strong> single gene neurological<br />

diseases, with particular success in the neurodegenerative lysosomal disease Hurler syndrome. In many lysosomal diseases<br />

exogenous enzyme can be taken up by, and cross-correct affected cells, but the blood brain barrier excludes enzyme from the<br />

brain. Neurological correction after HSCT relies on monocyte/microglial donor cell traficking into the brain to deliver enzyme, and<br />

enzyme dose is thought to be one <strong>of</strong> the factors limiting HSCT to a relatively narrow range <strong>of</strong> neurological indications. Autologous<br />

haematopoietic stem cell gene therapy, using retroviral or lentiviral vectors to overexpress enzyme in ex vivo transduced and<br />

transplanted cells has been used to great effect in X-SCID and other immunodeiciencies and more recently has been adopted as a<br />

potential treatment for neurological lysosomal and related diseases. In this talk the initial clinical trial results in this ield will be<br />

discussed, together with the current challenges faced by this therapeutic approach, what is being done to address them and where<br />

the future for this exciting therapy lies.<br />

Gary K. Steinberg, MD, PhD<br />

Stem <strong>Cell</strong> <strong>Therapy</strong> for Stroke<br />

No treatment currently exists to restore lost brain function after stroke. Animal studies have demonstrated that post-ischemic<br />

intraparenchymal, intravenous and intra-arterial administration <strong>of</strong> various types <strong>of</strong> stem cells can improve neurologic outcome.<br />

Although some integration <strong>of</strong> neural stem cells into the peri-infarct brain has been shown, the main mechanisms underlying<br />

recovery <strong>of</strong> function are likely secretion <strong>of</strong> trophic factors and immunomodulation that enhance endogenous plasticity and<br />

recovery. These native repair processes include axonal sprouting, dendritic branching, neovascularization, neurogenesis,<br />

gliogenesis, synaptogenesis and decreased inlammation. To date 11 trials <strong>of</strong> cellular therapy for stroke have been completed<br />

and more than 15 additional trials are underway. This talk will briely review the experimental basis leading to the clinical trials,<br />

and focus on summarizing the clinical results <strong>of</strong> published and ongoing stroke trials using neural, bone marrow derived and<br />

other stem cells. Unresolved issues will be discussed, including the best cell source and type, optimal route <strong>of</strong> delivery, timing <strong>of</strong><br />

transplantation and patient selection.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

47


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Scientific Symposium 212<br />

10:30 am - 12:30 pm<br />

ROOM: BALLROOM D<br />

Frontiers <strong>of</strong> Cardiovascular <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong><br />

CO-CHAIRS: David A. Dichek, MD and Michael J. Passineau, PhD<br />

SPEAKERS<br />

Charles R. Bridges, MD, ScD<br />

Challenges <strong>of</strong> <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> to the Heart<br />

In this presentation I will describe the main challenges <strong>of</strong> current cardiac cell and gene therapy with an emphasis on challenges to<br />

eficient delivery. I will give a detailed comparison <strong>of</strong> available gene and cell delivery techniques. I will discuss documented and<br />

potential complications <strong>of</strong> cell injections and gene transfer such as the risk <strong>of</strong> arrhythmias, incidence <strong>of</strong> coronary restenosis and<br />

malignancy. <strong>Final</strong>ly, I will focus on the most recent results <strong>of</strong> cardiac cell and gene therapy trials and the major lessons drawn from<br />

these trials.<br />

Thursday, May 16, 2013<br />

Andrew H. Baker, PhD<br />

Vascular MiRNA and Pulmonary Hypertension<br />

MicroRNAs (miRNAs) are short non-coding RNAs which post-transcriptionally regulate gene expression. miRNAs are important<br />

in governing cell differentiation, development and disease. We have investigated the role or individual miRNAs in pathological<br />

vascular remodeling, as well as the potential therapeutic value <strong>of</strong> manipulating selected miRNA in vivo. I will discuss these<br />

indings with emphasis on vascular remodeling associated with both venous and arterial remodeling, i.e. vein graft failure and the<br />

development <strong>of</strong> pulmonary arterial hypertension.<br />

Marc Penn, MD, PhD<br />

<strong>Gene</strong> <strong>Therapy</strong> for Heart Failure<br />

The success <strong>of</strong> establishing antegrade low in patients with acute myocardial infarction has led to signiicant advancements in the<br />

survival <strong>of</strong> patients with acute ischemic events <strong>of</strong> the myocardium. Unfortunately this success had led to a signiicant increase in<br />

the prevalence <strong>of</strong> heart failure. To address this need several investigators have turned to gene therapy as a strategy to either repair,<br />

restore or optimize cardiac function. Excitingly these strategies have entered clinical trials with encouraging results. We will discuss<br />

the strategies currently under investigation as well as those that maybe entering the clinical realm in the future.<br />

Doris A. Taylor, PhD<br />

Personalizing <strong>Cell</strong> <strong>Therapy</strong>: Initial CCTN Experience<br />

Scientific Symposium 213<br />

10:30 am - 12:30 pm<br />

ROOM: BALLROOM B<br />

New Paradigms for Immune <strong>Cell</strong> Therapies<br />

CO-CHAIRS: Cynthia Dunbar, MD and Paris Margaritis, DPhil<br />

SPEAKERS<br />

David L. Porter, MD<br />

Chimeric Antigen Receptor Therapies for Lymphoid Malignancies<br />

This presentation will describe the biological activity and outcomes <strong>of</strong> patients treated with CART19 (CTL019) cells; these are<br />

autologous T cells collected by leukapheresis and transduced with a lentivirus encoding anti-CD19 scFv linked to 4-1BB and CD3-z<br />

signaling domains. <strong>Gene</strong>-modiied T cells can then target CD19+ cells. <strong>Cell</strong>s are expanded and activated ex-vivo by exposure to anti-<br />

CD3/CD28 beads prior to infusion. Patients are treated for advanced and/or refractory CLL or ALL. We previously reported marked<br />

in-vivo expansion, long-term persistence and effective anti-tumor activity <strong>of</strong> CART19 cells in 3 patients with CLL with relatively<br />

short follow up (Porter, et al NEJM 2011; Kalos et al Sci Trans Med 2011). Results from the clinical trials will be updated with longterm<br />

follow-up and include presentation <strong>of</strong> data from a larger cohort <strong>of</strong> patients. We show that these cells can undergo massive<br />

in-vivo expansion, persist for more than 2 years and remain biologically active, and can induce potent and sustained responses for<br />

patients with advanced, refractory and high risk CLL and relapsed, refractory ALL.<br />

Maria-Grazia Roncarolo, MD, PhD<br />

<strong>Cell</strong> <strong>Therapy</strong> with Regulatory T <strong>Cell</strong>s to Dampen Undesired Immune Responses<br />

48<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Nicholas Restifo, MD<br />

Curative Cancer Immunotherapy Using Stem cell-like T cells<br />

T lymphocytes play a critical role in the immune response against infectious disease and cancer. The recently identiied T memory<br />

stem cells (TSCM) are endowed with the stem cell–like attributes <strong>of</strong> self-renewal capacity and multipotency. These qualities make<br />

TSCM an attractive subset to employ in adoptive immunotherapies for cancer because they might overcome current limitations,<br />

including ineficient T-cell engraftment, poor persistence, and inability to mediate a prolonged immune attack. TSCM display robust<br />

proliferative and survival capacities and were superior to other memory T-cell subsets in causing regression <strong>of</strong> large, established<br />

tumors in preclinical models. Protocols to facilitate translation <strong>of</strong> TSCM into the clinic will be discussed.<br />

Jeffrey S. Miller, MD<br />

Educating Natural Killer <strong>Cell</strong>s to Kill Cancer<br />

Natural killer (NK) cells express a number <strong>of</strong> activating and inhibitory receptors to determine their function through a process<br />

called NK cell education. We have shown that adoptive transfer <strong>of</strong> haploidentical NK cells can induce remissions in some<br />

patients with refractory acute myeloid leukemia (AML). Limitations <strong>of</strong> this therapy include host immune rejection, how to<br />

maximize the persistence and expansion <strong>of</strong> donor NK cells and overcoming regulatory T-cell suppression. Lastly, donor Killer-cell<br />

Immunoglobulin-like Receptor (KIR) genes may inluence NK cell activity to enhance anti-tumor eficacy. Understanding the role <strong>of</strong><br />

KIR and other receptors may allow us to exploit adoptive transfer <strong>of</strong> NK cells for therapeutic use in patients with advanced cancers.<br />

Scientific Symposium 214<br />

10:30 am - 12:30 pm<br />

ROOM: 150 DEFG<br />

Recent Advancements in the Non-Viral Delivery <strong>of</strong> Nucleic Acid Based Drugs<br />

CO-CHAIRS: Ian MacLachlan, PhD and Olivia Merkel, PhD<br />

SPEAKERS<br />

Daniel G. Anderson, PhD<br />

Combinatorial Development <strong>of</strong> Synthetic Nucleic Acid Delivery Systems<br />

Thursday, May 16, 2013<br />

Jianjun Cheng, PhD<br />

a-Helical Polypeptides for Non-Viral <strong>Gene</strong> Delivery<br />

We designed a class <strong>of</strong> helical, cationic charged polypeptides via the ring-opening polymerization <strong>of</strong> vinyl benzyl glutamic acid<br />

N-carboxyanhydrides. These materials have unusual helical stability and display excellent cell penetrating property outperforming<br />

TAT peptide. By controlling the chemical, morphological and self-assembly structures <strong>of</strong> these side chain charged, helical<br />

polypeptides, we identiied a few materials that showed excellent gene/siRNA delivery eficiency in vitro and in vivo.<br />

Thomas Knotts, PhD<br />

Protein Structure and How it Changes in Association with Surfaces<br />

Proteins/surface interactions are important in a variety <strong>of</strong> existing and emerging biomedical techniques and devices. It has been<br />

known for decades that surfaces can drastically change the structure <strong>of</strong> attached or adsorbed proteins, but a priori prediction <strong>of</strong> the<br />

changes is not currently possible. In an attempt to develop some predictive capabilities with respect to protein/surface interactions,<br />

we have used advanced molecular simulation to test several theories as to how protein folding mechanisms and stabilities are<br />

affected by surfaces. This talk will present many <strong>of</strong> these results, and more importantly, design heuristics that can be used to ensure<br />

proteins <strong>of</strong> interest are stable, and functional on surfaces. Taken as a whole, the results <strong>of</strong>fer compelling evidence that the rational<br />

design <strong>of</strong> technologies involving proteins interacting with surfaces is possible.<br />

Hamid Ghandehari, PhD<br />

Silk-elastinlike Polymers for Matrix-mediated <strong>Gene</strong> Delivery<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

49


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Scientific Symposium 215<br />

10:30 am - 12:30 pm<br />

ROOM: BALLROOM A<br />

The GTRP: Perspectives <strong>of</strong> an Investigator and the <strong>Program</strong> Cores<br />

CO-CHAIRS: Cheryl L. McDonald, MD and Sonia I. Skarlatos, PhD<br />

SPEAKERS<br />

Thursday, May 16, 2013<br />

Daniel Rader, MD<br />

How the GTRP Facilitates Translational Research: An Investigator’s Perspective<br />

Atherosclerosis is a complex and heritable disease intimately inluenced by lipoprotein metabolism. Unbiased genome-wide<br />

association studies (GWAS) have identiied dozens <strong>of</strong> novel loci robustly associated with both plasma lipid traits and atherosclerotic<br />

coronary artery disease (CAD). Several <strong>of</strong> the genes at these loci could represent potential novel therapeutic targets for the<br />

treatment <strong>of</strong> inherited dyslipidemias and the prevention or treatment <strong>of</strong> CAD. Adeno-associated viral (AAV) vectors are a valuable<br />

tool for effective and stable in vivo expression <strong>of</strong> cDNAs in relevant animal models <strong>of</strong> disease. Through support from the GTRP, we<br />

have used AAV8 vectors to express a number <strong>of</strong> potential therapeutic genes at lipid/CAD GWAS loci in the livers <strong>of</strong> ‘humanized’<br />

mice. This systematic approach has not only yielded important new biological information about the effects <strong>of</strong> novel GWAS genes on<br />

lipid metabolism and atherosclerosis, but also has placed a number <strong>of</strong> new ‘therapeutic’ genes on the map. This classic translational<br />

approach moving from unbiased human genetics to mechanisms and therapeutic effects in model systems is made possible by the<br />

support <strong>of</strong> the GTRP.<br />

Sonia I. Skarlatos, PhD<br />

GTRP: Facilitating Bench to Bedside<br />

The purpose <strong>of</strong> the GTRP is to provide researchers with resources that are critical to advancing investigational gene therapy<br />

products into clinical testing. Services along the product development spectrum – ranging from production <strong>of</strong> preclinical vectors to<br />

assistance with early-phase clinical trials – are <strong>of</strong>fered through the <strong>Program</strong> at no cost to the investigator. The <strong>Program</strong> primarily<br />

supports research in heart, lung, and blood diseases.<br />

James M. Wilson, MD, PhD<br />

A Toolkit <strong>of</strong> Vectors for <strong>Gene</strong> <strong>Therapy</strong><br />

The Preclinical Vector Core provides high quality viral vectors based on adeno-associated virus (AAV), adenovirus and lentivirus<br />

as well as non-viral vectors for basic research directed toward clinical application. Also <strong>of</strong>fered are a host <strong>of</strong> other services such as<br />

consultation on vector construction and experimental design, quality control services appropriate for vectors destined for use in<br />

small or large animal models, immunology testing and preclinical biodistribution analysis. Of particular importance to NHLBI GTRP<br />

investigators has been distribution through the program <strong>of</strong> novel serotype AAV vectors which have become the gold standards in<br />

the ield for mediating gene delivery to heart, lung and liver. In addition to <strong>of</strong>fering a variety <strong>of</strong> vector platforms, the Preclinical<br />

Core rapidly transitions new technologies from key laboratories for distribution as well as develops reagents and maintains a large<br />

inventory <strong>of</strong> vectors in order to provide GTRP participants with a veritable vector toolbox for advancing preclinical studies toward<br />

clinical translation.<br />

Janet Benson, PhD, DABT<br />

From Mice to Man: IND-enabling Preclinical Studies<br />

The mission <strong>of</strong> the Pharmacology/Toxicology (Pharm/Tox) Core is to aid investigators in the design and implementation <strong>of</strong> INDenabling<br />

preclinical safety and biodistribution studies. This is <strong>of</strong>ten one <strong>of</strong> the most challenging and costly steps in the translational<br />

process. The Pharm/Tox Core scientists work closely with the Investigator(s), the GTRP Core providing the vector (if applicable),<br />

and the GTRP Clinical Coordinating Center to facilitate development <strong>of</strong> the IND packages and the pre-clinical study protocol. The<br />

GTRP Pharm/Tox Core provides dosing, endpoint evaluations including but not limited to: clinical observations, clinical pathology,<br />

histopathology, safety pharmacology, vector biodistribution (qPCR), immunology endpoints, as well as assessments <strong>of</strong> transgene<br />

expression. Upon completion <strong>of</strong> the study, the Pharm/Tox Core staff prepares an audited inal report for inclusion in the IND<br />

submission to the FDA.<br />

50<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

J. Fraser Wright, PhD<br />

AAV Vectors for Clinical Trials: Challenges, and Strategies for Success<br />

Recombinant viral vectors based on adeno-associated viruses (AAV) have shown tremendous promise for clinical therapeutic<br />

gene delivery, and an acceleration <strong>of</strong> gene-based product development programs has been catalyzed by recent clinical successes.<br />

This presentation will describe strategies for advancing AAV-based investigational product chemistry, manufacturing and<br />

controls to effectively support the translational pathway from IND-supporting pre-clinical studies through clinical studies. An<br />

important requirement for successful translational research includes well deined manufacturing processes capable <strong>of</strong> reliable and<br />

reproducible yields vector <strong>of</strong> high purity, potency and safety. Another critical requirement is the set <strong>of</strong> analytical methods required<br />

to ensure comprehensive investigational product characterization and quality control testing. In this presentation the vector<br />

manufacturing processes and characterization methods used to support AAV vector-based translational research supported by<br />

GTRP will be presented.<br />

Kenneth Cornetta, MD<br />

Lentiviral Vectors: Can We Move Past Phase I/II<br />

Lentiviral vectors have advanced into early Phase clinical trials in the setting <strong>of</strong> genetic diseases, cancer, and other applications<br />

where integration and long-term expression is required. Compared to traditional integrating vectors, the methods used in<br />

manufacturing lentiviral vectors are well suited to rapid implementation into Phase I clinical trials. Unfortunately, this property can<br />

present challenges to generating a licensed product. This talk will discuss the current status <strong>of</strong> lentiviral vectors and highlight the<br />

challenges <strong>of</strong> moving these vectors from research tools to an FDA approved agent.<br />

Susan B. Sepelak, MS, MSM<br />

Regulatory Requirements: Navigation is Easier with Assistance<br />

The GTRP Clinical Coordinating Center provides assistance to investigators in navigating the regulatory processes in translational<br />

gene therapy research. For approved requests, assistance may be provided directly to the Investigator - assistance ranging from<br />

help with scheduling pre-preIND meetings with the FDA through organization, compilation and submission <strong>of</strong> IND applications.<br />

Regulatory support with clinical site-related issues may also be requested by Investigators to help site staff and Study Coordinators<br />

prepare for study implementation and manage ongoing regulatory requirements. Investigators who receive clinical trial funding<br />

assistance through the GTRP may, additionally, apply for support with site selection, study monitoring, and preparation <strong>of</strong> NHLBIrequired<br />

study reports.<br />

Thursday, May 16, 2013<br />

Lunch Break (On Own - Not Provided; Pre-ordered boxed lunches available for pick up at Registration Counter)<br />

12:30 pm - 2:00 pm<br />

Meet-the-Investigator Lunch Session 220<br />

12:30 pm - 2:00 pm<br />

ROOM: 251 E<br />

New Frontiers – Hemoglobinopathies<br />

SPEAKERS<br />

Donald B. Kohn, MD<br />

Punam Malik, MD, PhD<br />

Meet-the-Investigator Lunch Session 221<br />

12:30 pm - 2:00 pm<br />

MEET AT THE SOUTH ENTRANCE OF THE SALT PALACE CONVENTION CENTER<br />

Huntsman Cancer Institute Tour<br />

Boxed lunches will be available at the South Entrance shortly before departure to the Huntsman Cancer Institute.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

51


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Oral Abstract Session 230<br />

2:00 pm - 4:00 pm<br />

ROOM: BALLROOM A<br />

Clinical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

CO-CHAIRS: Carl H. June, MD and Harry L. Malech, MD<br />

(Abstracts 57 through 62; see page 92)<br />

Oral Abstract Session 231<br />

2:00 pm - 4:00 pm<br />

ROOM: BALLROOM B<br />

RNA Virus Vectors<br />

CO-CHAIRS: Brian D. Brown, PhD and Jennifer E. Adair, PhD<br />

(Abstracts 63 through 70; see pages 92-93)<br />

Thursday, May 16, 2013<br />

Oral Abstract Session 232<br />

2:00 pm - 4:00 pm<br />

ROOM: BALLROOM C<br />

AAV Vector Biology<br />

CO-CHAIRS: Casey A. Maguire, PhD and David V. Schaffer, PhD<br />

(Abstracts 71 through 78; see page 93)<br />

Oral Abstract Session 233<br />

2:00 pm - 4:00 pm<br />

ROOM: BALLROOM D<br />

Stem <strong>Cell</strong> Engineering and <strong>Therapy</strong><br />

CO-CHAIRS: Hans-Peter Kiem, MD, FACP and Eirini P. Papapetrou, MD, PhD<br />

(Abstracts 80 through 86; Abstract 79 Withdrawn and Abstract 470 moved from Poster Session II; see pages 93-94)<br />

Oral Abstract Session 234<br />

2:00 pm - 4:00 pm<br />

ROOM: 150 DEFG<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

CO-CHAIRS: Charles A. Gersbach, PhD and Louise R. Rodino-Klapac, PhD<br />

(Abstracts 87 through 94; see pages 94-95)<br />

Oral Abstract Session 235<br />

2:00 pm - 3:00 pm<br />

ROOM: 150 ABC<br />

Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

CO-CHAIRS: Dongsheng Duan, PhD and Joseph E. Rabinowitz, PhD<br />

(Abstracts 95 through 98; see page 95)<br />

52<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Oral Abstract Session 236<br />

2:00 pm - 3:15 pm<br />

ROOM: 151 ABCG<br />

Physical Methods <strong>of</strong> Delivery<br />

CO-CHAIRS: King F. Kwong, MD and Kevin G. Rice, PhD<br />

(Abstracts 99 through 103; see page 95)<br />

Oral Abstract Session 237<br />

3:05 pm - 4:05 pm<br />

ROOM: 150 ABC<br />

Evolution <strong>of</strong> Pulmonary Treatments<br />

CO-CHAIRS: Uta Griesenbach, PhD and Katherine J. Exc<strong>of</strong>fon, PhD<br />

(Abstracts 104 through 107; Abstract 105 Withdrawn and Abstract 432 moved from Poster Session II; see pages 95-96)<br />

Oral Abstract Session 238<br />

3:20 pm - 4:05 pm<br />

ROOM: 151 ABCG<br />

Immunologic & Host Responses in <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

CO-CHAIRS: Antonia Follenzi, MD, PhD and Federico Mingozzi, PhD<br />

(Abstracts 108 through 110; see page 96)<br />

Thursday, May 16, 2013<br />

Exhibit Hall Open: Networking Reception & Poster Session I<br />

4:00 pm - 6:00 pm<br />

ROOM: EXHIBIT HALL C/D<br />

AAV Vectors - I<br />

(Abstracts 111-125; see pages 96-97)<br />

Adenovirus and Other DNA Virus Vectors I<br />

(Abstracts 126-138; and Abstract 561 moved from Poster Session III; see pages 97-98)<br />

Physical Methods <strong>of</strong> Delivery<br />

(Abstracts 139-154; see pages 98-99)<br />

Chemical and Molecular Conjugates<br />

(Abstracts 155-165; Abstract 165 has been withdrawn from presentation; see page 99)<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

(Abstracts 166-182; see pages 99-100)<br />

Infectious Diseases and Vaccines<br />

(Abstracts 183-195; see pages 100-101)<br />

Cancer - Immunotherapy I<br />

(Abstracts 197-209; Abstract 196 withdrawn; see pages 101-102)<br />

Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>: Viral Vector / siRNA-Mediated Therapies<br />

(Abstracts 210-221; see pages 102-103)<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

53


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Sensory (Ophthalmic and Auditory) <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

(Abstracts 222-232; see page 103)<br />

<strong>Gene</strong> Regulation<br />

(Abstracts 233-246; see page 104)<br />

Fetal and Adult Stem <strong>Cell</strong>s<br />

(Abstracts 247-258; Abstract 252 has been withdrawn from presentation; see pages 104-105)<br />

<strong>Cell</strong> Processing and Vector Production<br />

(Abstracts 259-265; see page 105)<br />

Late Breaking Abstracts I<br />

(Abstracts 677-700; Abstracts 687 and 698 Withdrawn from Presentation; see pages 105-107)<br />

Thursday, May 16, 2013<br />

Canadian Attendee Reception<br />

6:00 pm - 7:00 pm<br />

ROOM: 255 B<br />

Foundation Symposium 240<br />

6:00 pm - 8:00 pm<br />

ROOM: BALLROOM B<br />

<strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> for Cancer<br />

Supported by the Alliance for Cancer <strong>Gene</strong> <strong>Therapy</strong>.<br />

CO-CHAIRS: Xandra O. Breakeield, PhD and Savio L.C. Woo, PhD<br />

SPEAKERS<br />

Joseph C. Glorioso, III, PhD<br />

Targeted Cancer Therapies<br />

Cancer cell genetic analyses have identiied driver mutations that dysregulate cell proliferation- and differentiation-related<br />

pathways, providing focal points for targeting <strong>of</strong> cancer therapy. At least six targeting strategies have been employed: (i) the use <strong>of</strong><br />

drugs that block different steps in cancer causing signaling cascades leading to the arrest <strong>of</strong> tumor cell growth and the induction <strong>of</strong><br />

senescence, apoptosis and autophagy, (ii) application <strong>of</strong> drugs or immune mediators that attack the tumor microenvironment (iii)<br />

the use <strong>of</strong> antibodies that inhibit tumor cell growth by blocking growth factor receptors, (iv) coupling <strong>of</strong> therapeutics to antibodies,<br />

nanoparticles or other ligands that recognize tumor-associate antigens (v) immune based strategies to induce anti-tumor immunity,<br />

reduce immune down regulation or exploit engineered immune acting cells to destroy tumors, and (vi) the use <strong>of</strong> designer biologics<br />

such as viruses, bacteria or stem cells to selectively destroy tumors. Some notable successes will be highlighted for each <strong>of</strong> these<br />

approaches, however tumor heterogeneity makes it unlikely that any one strategy will succeed. Cancer virotherapy remains a<br />

very versatile strategy that takes advantage <strong>of</strong> advances in enhanced vector design to provide the most potent, highly selective<br />

tumor killers. Current methods to control vector transduction and transcription, evasion <strong>of</strong> innate immunity and enhanced vector<br />

replication and spread will be presented.<br />

Stephen J. Russell, MD, PhD<br />

Oncolytic Virotherapy<br />

Oncolytic viruses (OV) selectively destroy neoplastic tissue and it is theoretically possible to engineer or adapt any naturally<br />

occurring virus for this purpose; key engineering strategies will be reviewed. A spreading intratumoral OV infection can damage<br />

both infected and uninfected tumor cells; the mechanisms underlying both <strong>of</strong> these activities will be discussed. Oncolytic viruses<br />

can be combined with drugs or armed with transgenes to accelerate their spread, modulate their immunogenicity/potency or<br />

facilitate the noninvasive monitoring <strong>of</strong> their in vivo fate; illustrative examples will be discussed. <strong>Final</strong>ly, several oncolytic viruses<br />

are currently being tested in clinical trials and the current status <strong>of</strong> this work will be summarized.<br />

54<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Carl H. June, MD<br />

T <strong>Cell</strong> Mediated <strong>Gene</strong> Transfer for Cancer <strong>Therapy</strong><br />

The adoptive transfer <strong>of</strong> anti-tumor T cells can mediate regression <strong>of</strong> established metastatic cancers in patients. We have begun a<br />

series <strong>of</strong> clinical trials using the transduction <strong>of</strong> genes encoding chimeric antigen receptors (CARs) or anti-tumor T cell receptors<br />

(TCR) into normal peripheral lymphocytes for use in adoptive cell transfer. Anti-tumor TCRs have been identiied that recognize<br />

cancer testis antigens. Autologous cells transduced with genes encoding the anti-NY-ESO-1 TCR cancer-testes antigen mediated<br />

objective clinical responses in patients with myeloma. An afinity enhanced MAGE A3 TCR caused severe adverse events with<br />

fatal <strong>of</strong>f-target cardiac toxicity, pointing to serious concerns with the ability <strong>of</strong> pre-clinical testing to identify <strong>of</strong>f target effects <strong>of</strong><br />

TCRs. Patients with acute pre-B cell leukemia or chronic lymphocytic leukemia exhibited a high objective regression rate using<br />

T cells transduced with a CD19 CAR. The cellular and molecular mechanisms <strong>of</strong> T cell destruction <strong>of</strong> cancers are under active<br />

investigation. Ongoing studies are evaluating chimeric antibody receptors targeting mesothelin, and EGFRvIII. Together these<br />

studies demonstrate the power and potential <strong>of</strong> adoptive T cell immunotherapy to mediate the regression <strong>of</strong> established advanced<br />

cancer in humans.<br />

Lieping Chen, MD, PhD<br />

New Perspectives in the Development <strong>of</strong> Cancer Vaccines<br />

There is ample evidence that human malignancies express tumor-associated or tumor-speciic antigens. Immunization with cancer<br />

antigen-based vaccine in animal models or patients with advanced cancer induce tumor-reactive T cells in lymphoid organs and<br />

these T cells can be detected in blood. However, increased circulating tumor-reactive T cells <strong>of</strong>ten do not correlate with regression<br />

<strong>of</strong> advanced cancer. Recent studies reveal that speciic resistant mechanisms are developed in the tumor microenvironment to<br />

suppress activity <strong>of</strong> tumor-iniltrating T cells. It is thus important to understand and identify molecules underlying these resistance<br />

mechanisms. I will focus my discussion on analysis <strong>of</strong> mechanisms in the tumor microenvironment in the context <strong>of</strong> improvement<br />

<strong>of</strong> the eficacy <strong>of</strong> cancer vaccines.<br />

Thursday, May 16, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

55


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Foundation Symposium 241<br />

6:00 pm - 8:00 pm<br />

ROOM: BALLROOM A<br />

Association Francaise Contre les Myopathies/Muscular Dystrophy Association Symposium<br />

Jointly planned by the Association Francaise contre les Myopathies and the Muscular Dystrophy Association.<br />

CO-CHAIRS: Charles A. Gersbach, PhD and Kathryn R. Wagner, MD, PhD<br />

SPEAKERS<br />

Thursday, May 16, 2013<br />

Jeffrey Chamberlain, PhD<br />

Lentiviral Modiication <strong>of</strong> Myogenic Stem <strong>Cell</strong>s<br />

Over the past decade adeno-associated viral (AAV) vectors have merged as a potential therapeutic for muscle disorders. While<br />

AAV vectors can eficiently transduce post-mitotic myoibers, they display low tropism for myogenic stem cells and are rapidly lost<br />

during cell proliferation due to minimal genomic integration. In contrast, lentiviral vectors can stably transduce myogenic stem cells<br />

both in vitro and in vivo, enabling expansion and transplantation <strong>of</strong> genetically modiied cells for therapeutic interventions. This<br />

lecture will review approaches for modifying myogenic stem cells for in vivo and ex vivo gene therapy <strong>of</strong> myogenic disorders such as<br />

the muscular dystrophies.<br />

Xiao Xiao, PhD<br />

Regional Limb Vein Perfusion in Muscular Dystrophy Dogs and Human Patients<br />

Fulvio Mavilio, PhD<br />

<strong>Gene</strong>-based Therapies for Neuromuscular Disorders<br />

Most inherited neuromuscular diseases have no therapy, and collectively represent a signiicant unmet medical need. <strong>Gene</strong>thon and<br />

its collaborating clinical centers have launched an ambitious program aimed at developing gene therapy approaches for at least<br />

three <strong>of</strong> these diseases (Duchenne muscular dystrophy, myotubular myopathy and spinal muscular atrophy) based on systemic<br />

or loco-regional delivery <strong>of</strong> AAV vectors. We will provide an overview <strong>of</strong> the program and <strong>of</strong> the scientiic, regulatory and clinical<br />

challenges associated with its development.<br />

Anna Buj Bello, MD, PhD<br />

Myotubularin Deicie ncy<br />

Myotubular myopathy (XLMTM) is a very severe congenital muscle disorder due to mutations in the MTM1 gene. An overview<br />

about the disease, animal models and current experimental therapies, in particular our results on intravenous AAV-mediated gene<br />

replacement therapy, will be presented. Outstanding Achievement Award Lecture 300<br />

56<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Thursday, May 16, 2013<br />

Plenary Session 300<br />

8:00 am - 9:00 am<br />

ROOM: BALLROOM E-J<br />

Outstanding Achievement Award Lecture and Presentation <strong>of</strong> the Distinguished Service Award<br />

and Special Recognition Award<br />

CHAIR<br />

Katherine P. Ponder, MD<br />

DISTINGUISHED SERVICE AWARD RECIPIENTS<br />

SPECIAL RECOGNITION AWARD RECIPIENT<br />

Sonia I. Skarlatos, PhD Catherine McKeon, PhD John J. Rossi, PhD<br />

SPEAKER<br />

Thursday, May 16, 2013<br />

Mark A. Kay, MD, PhD<br />

Deciphering Vector and Non-coding RNA Biology: A New Frontier in Nucleic Acid based Therapies<br />

In the last decade, we have witnessed great improvements in vector biology and utilized these for novel biomedical discoveries and<br />

therapeutic applications. In addition, it is now established that over 90% <strong>of</strong> the genome is transcribed, yet the role for most <strong>of</strong> the<br />

non-coding RNAs remains unclear. I will discuss our studies aimed at both uncovering the generation and function <strong>of</strong> non-coding<br />

RNAs, as well as the mechanisms important for the development <strong>of</strong> new vector-based gene transfer approaches to manipulate gene<br />

expression. Together, these approaches have provided continued and powerful insight into gene therapy mechanisms used to treat<br />

an array <strong>of</strong> diseases.<br />

Exhibit Hall C<strong>of</strong>fee Social<br />

9:00 am - 9:45 am<br />

ROOM: EXHIBIT HALL C/D<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

57


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Scientific Symposium 310<br />

9:45 am - 11:45 am<br />

ROOM: BALLROOM D<br />

Cancer <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong>: Results from Clinical Trials<br />

CO-CHAIRS: Evanthia Galanis, MD, DSc and Juan F. Vera, MD<br />

SPEAKERS<br />

Svend O. Freytag, PhD<br />

Randomized, Controlled, Phase 2 Trial <strong>of</strong> Oncolytic Adenovirus-mediated Suicide <strong>Gene</strong> <strong>Therapy</strong> Plus IMRT<br />

Versus IMRT Alone in neWly-diagnosed, Intermediate-risk Prostate Cancer<br />

We have developed a multi-modal, gene therapy-based approach for the treatment <strong>of</strong> cancer involving an oncolytic adenovirus,<br />

suicide gene therapy and radiation therapy. We have evaluated the safety and eficacy <strong>of</strong> our approach in six clinical trials, including<br />

a randomized, controlled phase 2 trial in prostate cancer. The results <strong>of</strong> these clinical studies will be presented and the lessons<br />

learned discussed.<br />

Evanthia Galanis, MD, DSc<br />

Oncolytic Measles Virus Strains in Cancer Treatment Trials: An Update<br />

Measles virus is a negative strand RNA virus (paramyxovirus) with oncolytic properties. The signiicant preclinical activity <strong>of</strong> MV-<br />

Edmonston vaccine strains against multiple different animal tumor models, their potent bystander effect, their selectivity against<br />

tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted, makes them a promising oncolytic<br />

platform. Two trackable engineered measles virus strain derivatives are currently in clinical testing; a derivative expressing the<br />

human carcinoembryonic antigen (MV-CEA) and a strain expressing the human sodium iodine symporter (MV-NIS). Phase I/II trials<br />

are ongoing or have been completed in ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma and head and<br />

neck cancer and a phase I/II trial <strong>of</strong> mesenchymal stem cell delivery will be activated later this year. Clinical data to date, challenges<br />

in clinical applications <strong>of</strong> oncolytic measles virus strains and preclinical data supporting future translational directions will be<br />

discussed.<br />

Friday, May 17, 2013<br />

Renier J. Brentjens, MD, PhD<br />

CAR Modiied T-cells, From the Bench to the Bedside<br />

T cells may be genetically modiied to express artiicial T cell receptors, termed chimeric antigen receptors or CARs targeted to<br />

tumor associated antigens. Previous work in preclinical models has demonstrated the potential <strong>of</strong> this approach in targeting T<br />

cells to systemic tumor and in turn eradicating tumor. More recently, we and others have successfully moved this technology to the<br />

clinical setting demonstrating early very promising responses with CD19 targeted CAR modiied T cells in patients with relapsed<br />

B cell malignancies including acute lymphoblastic and chronic lymphocytic leukemias as well as indolent B cell non-Hodgkins<br />

lymphomas. However, limitations to this adoptive T cell approach need to be addressed before this approach may be successfully<br />

optimized to B cell malignancies and further expanded to other cancers targeting other tumor associated antigens. One such an<br />

approach is the design <strong>of</strong> “armored CAR” T cells additionally modiied to express cytokines or co-stimulatory ligands to enhance in<br />

vivo cytotoxicity as well as persistence <strong>of</strong> CAR modiied T cells following infusion.<br />

Stephen Gottschalk, MD<br />

<strong>Cell</strong> Therapies for Solid Tumors: Successes and Challenges<br />

The outcome for patients with advanced solid tumors has not signiicantly improved over the last 2 decades. Thus, new targeted<br />

therapies are needed to improve current outcomes, and T-cell immunotherapy has the potential to fulill this need. In my talk I will<br />

review i) the use <strong>of</strong> Epstein-Barr virus (EBV)-speciic T cells to treat patients with advanced stage EBV+ nasopharyngeal carcinoma,<br />

ii) our recent studies to target solid tumors and their supporting stroma with chimeric antigen receptor (CAR) T cells, and iii) novel<br />

approaches to render T cells speciic for solid tumor antigens.<br />

58<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Scientific Symposium 311<br />

9:45 am - 11:45 am<br />

ROOM: BALLROOM B<br />

<strong>Cell</strong> and Tissue Engineering for Musculoskeletal Disease<br />

CO-CHAIRS: Alan J. Nixon, DVM, MS and Bing Wang, MD, PhD<br />

SPEAKERS<br />

Rita Perlingeiro, PhD<br />

From iPS cells to Skeletal Muscle Precursors: Potential for <strong>Gene</strong> Correction and Therapeutic Application<br />

A major obstacle in the application <strong>of</strong> cell-based therapies for the treatment <strong>of</strong> neuromuscular disorders is obtaining the<br />

appropriate number <strong>of</strong> stem/progenitor cells to produce effective engraftment. The use <strong>of</strong> pluripotent embryonic stem (ES) or<br />

induced pluripotent stem (iPS) cells could overcome this hurdle. We have developed a method to eficiently generate skeletal<br />

myogenic progenitors from pluripotent stem cells through Pax3 or Pax7 induction. We have applied this method to mouse ES<br />

and iPS cells, and more recently to human ES and iPS cells. In each case, Pax7-induced cells engraft extensively and promote<br />

improved contractility in transplanted dystrophic muscles (using a mouse model for Duchenne Muscular Dystrophy). In addition<br />

to generating new myoibers, the transplanted cells also seeded the muscle satellite cell compartment. Accordingly, in long-term<br />

cohorts, the frequency <strong>of</strong> human-speciic dystrophin+ ibers declined only modestly at one year post-transplant, compared to one<br />

month. Based on these indings, we are now focusing on the genetic correction <strong>of</strong> iPS cells encoding mutations in the dystrophin<br />

gene. Such studies are crucial for the future therapeutic application <strong>of</strong> iPS-derived myogenic progenitors in the autologous setting<br />

for DMD. These more recent studies will also be discussed.<br />

Rocky S. Tuan, PhD<br />

Regenerative Applications <strong>of</strong> Adult Stem <strong>Cell</strong>s<br />

Farshid Guilak, PhD<br />

Engineering Functional Tissue Replacements to Treat Osteoarthritis<br />

Osteoarthritis is painful and debilitating joint disease that is characterized by pain and degenerative changes in the articular<br />

cartilage and other joint tissues. While a number <strong>of</strong> techniques have been developed over the years for the treatment <strong>of</strong> small<br />

cartilage defects, there have been few attempts at tissue-engineered therapies for end-stage osteoarthritis. Some <strong>of</strong> the major<br />

considerations for this approach include the identiication and characterization <strong>of</strong> an abundant and accessible cell source as well as<br />

the design <strong>of</strong> biologically and mechanically functional scaffolds that can withstand joint loading. Here we describe the engineering<br />

<strong>of</strong> large, anatomically-shaped cartilage constructs using different stem cell sources (adipose stem cells, mesenchymal stem cells,<br />

or induced pluripotent stem cells), combined with mechanically functional cell-instructive scaffolds based on three-dimensional<br />

weaving <strong>of</strong> biocompatible ibers. As each iber is selected individually, this textile processing technique allows site-speciic<br />

functionalization <strong>of</strong> proteins or virus to facilitate the formation <strong>of</strong> complex inhomogenous tissues from a single cell source.<br />

Brian Johnstone, PhD<br />

Stem <strong>Cell</strong>s for Cartilage Repair<br />

Scientific Symposium 312<br />

9:45 am - 11:45 am<br />

ROOM: 150 DEFG<br />

<strong>Gene</strong> <strong>Therapy</strong> and Regenerative Medicine for Ocular and Metabolic Diseases<br />

CO-CHAIRS: Alberto Auricchio, MD and Thierry C. VandenDriessche, PhD<br />

SPEAKERS<br />

Friday, May 17, 2013<br />

Ian Constable, AO<br />

Development <strong>of</strong> AAV-sFLT-1 for the Treatment <strong>of</strong> Wet Age-related Macular Degeneration<br />

The eye is an attractive organ in which to develop gene therapy. There is relative ease <strong>of</strong> access, a benign immunological response<br />

and the availability <strong>of</strong> high resolution non-invasive structural and functional tests. The safety and possible eficacy <strong>of</strong> Adenoassociated<br />

Viral (AAV) gene therapy is now well established in young humans with RPE-65 defective retinal blindness. We have<br />

adopted similar techniques to treat wet macular degeneration by subretinal injection <strong>of</strong> AAV-sFLT-1 to up-regulate production <strong>of</strong><br />

sFLT-1, a competitive analogue <strong>of</strong> the soluble Vascular Endothelial Growth Factor receptor.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

59


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Ludovic Vallier, PhD<br />

<strong>Gene</strong> Correction <strong>of</strong> AAT Deiciency Using iPS-derived Hepatic <strong>Cell</strong>s<br />

The possibility <strong>of</strong> generating human Induced Pluripotent Stem <strong>Cell</strong>s from somatic cells using epigenetic reprogramming represents<br />

a unique opportunity for personalised regenerative medicine. Indeed, these pluripotent stem cells could enable the production<br />

<strong>of</strong> patient speciic cell types which are fully immuno-compatible with the original donor thereby avoiding the need for immune<br />

suppressive treatment during cell based therapy. Here, we will present the challenges and the most recent advances toward the use<br />

<strong>of</strong> hIPSC lines for cell based therapy <strong>of</strong> inherited metabolic disorders.<br />

Daniel Gaudet, MD, PhD<br />

<strong>Gene</strong> Replacement <strong>Therapy</strong>: Lessons from Lipoprotein Lipase Deiciency<br />

Lipoprotein Lipase Deiciency (LPLD) is a rare autosomal recessive disease characterized by severe hypertriglyceridemia,<br />

chylomicronemia and risk <strong>of</strong> recurrent pancreatitis or other complications. AAV1- LPL S447X gene therapy (Glybera ®) has been<br />

developed to decrease the clinical morbidity <strong>of</strong> LPLD. The treatment is based on the rationale that by adding episomal copies<br />

<strong>of</strong> functional LPL genes into muscle cells lacking active LPL, metabolic function could be improved or restored. The clinical<br />

development program for Glybera included two observational studies, three open-label interventional studies and one case<br />

note review analysis. Based on the results <strong>of</strong> these studies, Glybera gene therapy has recently been approved by the European<br />

Commission, demonstrating that it is possible for a gene-based medication to be approved despite all the barriers, which include<br />

the rarity <strong>of</strong> the disease, the complexity <strong>of</strong> the treatment as well as a huge amount <strong>of</strong> technical, clinical, social, economical and<br />

ethical issues. Several key questions regarding the eficacy, safety, cost-effectiveness, accessibility and impact <strong>of</strong> Glybera on the<br />

treatment <strong>of</strong> LPLD will require time and long-term follow-up to be answered. These questions will be discussed with an emphasis<br />

on the clinician’s perspective and the clinician-patient relationship. Given the time and cost required to develop gene-based<br />

treatments, the approval <strong>of</strong> Glybera could have an encouraging effect on the development <strong>of</strong> gene therapy for other diseases.<br />

Alessandro Aiuti, MD, PhD<br />

Progress in <strong>Gene</strong> <strong>Therapy</strong> for Wiskott-Aldrich Syndrome<br />

Wiskott-Aldrich Syndrome (WAS) is a primary immunodeiciency associated with eczema, thrombocytopenia, and high risk <strong>of</strong><br />

developing autoimmunity and cancer. <strong>Gene</strong> therapy with ex vivo transduced hematopoietic stem cells (HSC) could represent a valid<br />

therapeutic option for patients lacking an HLA-identical donor. We designed a phase I/II clinical trial based on reduced intensity<br />

conditioning and infusion <strong>of</strong> autologous HSC transduced with a lentiviral vector expressing WAS protein under its endogenous<br />

promoter. High-throughput vector integration analyses demonstrated highly polyclonal hematopoiesis in vivo and improved safety<br />

proile over previously used retroviral technology platforms. <strong>Gene</strong> therapy resulted in unprecedented levels <strong>of</strong> progenitor cell<br />

engraftment, restored WAS expression and correction <strong>of</strong> the disease phenotype in affected children.<br />

Friday, May 17, 2013<br />

Scientific Symposium 313<br />

9:45 am - 11:45 am<br />

ROOM: BALLROOM A<br />

microRNA on <strong>Cell</strong>ular Immune Response<br />

CO-CHAIRS: Shulin Li, PhD and Denise Sabatino, PhD<br />

SPEAKERS<br />

Ryan M. O’Connell, PhD<br />

Micro-managing Inlammation<br />

MicroRNAs represent a powerful mode <strong>of</strong> posttranscriptional gene regulation, and have recently been linked to inlammatory<br />

disease in mammals. We have identiied speciic miRNAs that are expressed in immune cells during inlammatory responses, and<br />

have determined that they are central regulators <strong>of</strong> distinct types <strong>of</strong> inlammation. Our work has also unveiled direct, functionally<br />

relevant mRNA targets <strong>of</strong> these miRNAs, providing new insights into the molecular networks that govern inlammatory phenotypes.<br />

Based upon their emerging importance, miRNAs are now being targeted therapeutically in an effort to mitigate human disease.<br />

Brian D. Brown, PhD<br />

microRNA Regulation <strong>of</strong> Dendritic <strong>Cell</strong>s<br />

Plasmacytoid dendritic cells (pDC) are major interferon producing cells which are specialized at sensing the initial stages <strong>of</strong> viral<br />

infection. Because <strong>of</strong> this, pDCs are particularly relevant in the host response to vaccines and gene therapy vectors. I will discuss<br />

our work which has uncovered evidence <strong>of</strong> a microRNA that is crucial for proper pDC development and response to pathogen<br />

associated nucleic acids.<br />

Ian MacLachlan, PhD<br />

Immunological Considerations <strong>of</strong> Therapeutic siRNA<br />

60<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Judy Lieberman, MD, PhD<br />

Aptamer-siRNA Chimeras Targeting CD4 <strong>Cell</strong>s Inhibit HIV Transmission<br />

One attractive strategy for interrupting HIV transmission is a topical microbicide, but the need for application around the time <strong>of</strong><br />

sexual intercourse leads to poor patient compliance. Intravaginal application <strong>of</strong> CD4 aptamer-siRNA chimeras (CD4-AsiCs) targeting<br />

the HIV coreceptor CCR5, gag and vif protected humanized mice from sexual transmission. In nondividing cells and tissue, RNAimediated<br />

gene knockdown lasts for several weeks, providing an opportunity for infrequent dosing not temporally linked to sexual<br />

intercourse, when compliance is challenging. In follow-up studies, we investigated the durability <strong>of</strong> gene knockdown and protection,<br />

protection afforded by CCR5 or HIV gene knockdown on their own, and effectiveness <strong>of</strong> CD4-AsiCs formulated in a gel in polarized<br />

human cervicovaginal explants and in humanized mice. These data, showing persistent gene knockdown and sustained protection<br />

that was improved in a gel formulation, suggest that CD4-AsiCs are a promising approach for developing an HIV microbicide.<br />

Scientific Symposium 314<br />

9:45 am - 11:45 am<br />

ROOM: 151 ABCG<br />

Realizing the Potential: Getting to Funding, Getting to Approval and Getting to Market<br />

CO-CHAIRS: Anthony T. Cheung, PhD and Karen Kozarsky, PhD<br />

SPEAKERS<br />

Sander van Deventer, MD, PhD<br />

Development <strong>of</strong> a Commercial <strong>Gene</strong> <strong>Therapy</strong> Product<br />

The market authorization <strong>of</strong> Glybera by the EMA has given development <strong>of</strong> gene therapies a signiicant boost. In this presentation<br />

I will discuss regulatory and inancial challenges associated with the development <strong>of</strong> (future) gene therapy products, which is<br />

essential for successful transition <strong>of</strong> academic projects into commercial products.<br />

David Kirn, MD<br />

Oncolytic and Immunotherapeutic Vaccinia Viruses for Cancer: Clinical Pro<strong>of</strong>-<strong>of</strong>-concept with JX-594<br />

(Pexa-Vec)<br />

This talk will be an overview <strong>of</strong> oncolytic and immunotherapeutic vaccinia viruses for cancer, with a focus on clinical pro<strong>of</strong>-<strong>of</strong>concept<br />

data with JX-594 (Pexa-Vec). Dr. Kirn will review this emerging novel therapeutic class, including the scientiic rationale<br />

for cancer-selectivity, mechanisms-<strong>of</strong>-action, and human clinical trial data from Phase 1 and 2 studies with Pexa-Vec. Clinical trial<br />

data will include pharmacokinetics, pharmacodynamics, tumor biopsy analyses, safety, anti-cancer eficacy and survival. Data from<br />

a randomized dose-inding Phase 2 trial will be presented, demonstrating a dose-related overall survival beneit <strong>of</strong> high dose Pexa-<br />

Vec treatment in patients with advanced liver cancer (Nature Medicine 2013).<br />

Samuel C. Wadsworth, PhD<br />

Realizing the Potential: Getting to Approval and Getting to Market; Focus on Orphan Indications<br />

The successful path to approval and market for new drugs is a series <strong>of</strong> effective decisions. Basic science, clinical research and<br />

manufacturing expertise represent some <strong>of</strong> the major stepping stones on this path, although there are many others. Academic<br />

scientists, regulators, corporate scientists, regulators, patients and patient advocacy groups all play their roles on the journey. For<br />

new technologies like cell and gene therapy, the beacon that should guide us throughout this journey should be the demonstration<br />

<strong>of</strong> truly transformative beneit to patients.<br />

Friday, May 17, 2013<br />

Artur Isaev, MD, MBA<br />

Development, Clinical Trials and Registration <strong>of</strong> Neovasculgen® <strong>Gene</strong> Therapeutic Drug<br />

Presentation will cover the key steps in “Neovasculgen” VEGF165 plasmid gene therapy drug development and commercialization<br />

starting from choosing a target disease to its marketing, including assessment <strong>of</strong> key characteristics <strong>of</strong> the future drug,<br />

determination <strong>of</strong> the therapeutic approach to be used and design and performance <strong>of</strong> preclinical studies. The main focus <strong>of</strong><br />

the talk would be on “Neovasculgen” clinical trials design for chronic lower limb ischemia and their main results, which would<br />

highlight the necessity <strong>of</strong> precise deinition <strong>of</strong> the end points to obtain objective data about safety and eficacy <strong>of</strong> the drug. <strong>Final</strong>ly,<br />

the presentation would summarize speciicity <strong>of</strong> drug development in Russia, current stage <strong>of</strong> “Neovasculgen” development, and<br />

perspectives <strong>of</strong> plasmid gene therapy in general.<br />

PANEL DISCUSSION<br />

MODERATOR<br />

Estuardo Aguilar-Cordova, PhD<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

61


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

PANEL<br />

Thomas W. Chalberg, Jr., PhD<br />

Artur Isaev, MD, MBA<br />

David Kirn, MD<br />

Sander van Deventer, MD, PhD<br />

Samuel C. Wadsworth, PhD<br />

Scientific Symposium 315<br />

9:45 am - 11:45 am<br />

ROOM: BALLROOM C<br />

Target Non Coding RNAs with Oligonucleotides<br />

CO-CHAIRS: Kevin V. Morris, PhD and Marco S. Weinberg, PhD<br />

SPEAKERS<br />

Claes Wahlestedt, MD, PhD<br />

RNA-Based Strategies To Upregulate <strong>Gene</strong> Expression<br />

Recently, key roles for regulatory long noncoding RNAs (lncRNAs) in the regulation <strong>of</strong> gene expression have emerged. I will review<br />

current understanding <strong>of</strong> the mechanisms <strong>of</strong> action <strong>of</strong> lncRNAs and their roles in disease, focusing on recent work in the design<br />

<strong>of</strong> inhibitors <strong>of</strong> the natural antisense transcript (NAT) class <strong>of</strong> lncRNAs, known as AntagoNAT oligonucleotides, and the issues<br />

associated with their therapeutic application.<br />

Christine Esau, PhD<br />

Targeting microRNAs in Human Disease: miR-33 in the Treatment <strong>of</strong> Atherosclerosis<br />

microRNAs are regulators <strong>of</strong> the genome that can modulate the activity <strong>of</strong> speciic gene networks. Single stranded oligonucleotides<br />

can be designed to inhibit the activity <strong>of</strong> individual microRNAs that are overexpressed in human disease. For example, miR-<br />

33 is a microRNA that is known to be overexpressed in macrophages that may be involved in the formation <strong>of</strong> atherosclerotic<br />

plaques. Inhibition <strong>of</strong> miR-33 has been shown de-repress known target mRNAs such as ABCA1, increase cholesterol eflux<br />

from macrophages and regress atherosclerotic lesions in rodent models. Thus targeting microRNAs holds great promise for the<br />

treatment <strong>of</strong> human diseases.<br />

Friday, May 17, 2013<br />

Keith Gagnon, PhD<br />

Long Noncoding RNAs Link Transcriptional Regulation <strong>of</strong> Inlammatory Pathway <strong>Gene</strong>s<br />

Coordinated expression <strong>of</strong> the eicosanoid signaling pathway genes COX-2 and PLA2G4A are regulated by a network <strong>of</strong> non-coding<br />

RNAs and gene looping. The long non-coding RNAs overlapping the COX-2 gene promoter can be targeted by complementary<br />

endogenous and synthetic small RNAs to elicit activation <strong>of</strong> both COX-2 and PLA2G4A transcription. This activation requires RNAi<br />

factors like Argonaute 2 and GW182, recruitment <strong>of</strong> RNA Polymerase II, and chromatin modifying factors. These indings suggest<br />

that non-coding RNA has the potential to assemble related genes into functional operons for regulation and small RNAs can control<br />

this mechanism to synchronously activate transcription.<br />

Kevin V. Morris, PhD<br />

Long non-coding RNAs, Epigenetics and <strong>Gene</strong> Expression<br />

In human cells some non-coding RNAs have been found to transcriptionally modulate gene expression by targeting epigenetic<br />

complexes to particular loci. The targeted disruption <strong>of</strong> these suppressor non-coding RNAs can result in targeted activation <strong>of</strong><br />

gene expression. Examples <strong>of</strong> this form <strong>of</strong> gene activation in disease models ranging from cystic ibrosis to HIV to cancer will be<br />

discussed.<br />

62<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Scientific Symposium 316<br />

9:45 am - 11:45 am<br />

ROOM: 150 ABC<br />

Partially supported by the Juvenile Diabetes Research Foundation.<br />

<strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> for Diabetes<br />

CO-CHAIRS: Nicola Brunetti-Pierri, MD and Lawrence C. Chan, MD<br />

SPEAKERS<br />

H. Teresa Ku, PhD<br />

Pancreatic Stem and Progenitor <strong>Cell</strong>s<br />

Adult pancreatic stem and progenitor cells are potential unlimited sources <strong>of</strong> beta cells, however their existence is highly<br />

controversial. To address this issue, we report here the establishment <strong>of</strong> two in vitro pancreatic colony assays that enable<br />

quantitative measurement <strong>of</strong> self-renewal and differentiation at a single cell level, which is required to deinitively demonstrate<br />

progenitor cell activities. We ind that single pancreatic colony-forming cells are capable <strong>of</strong> self-renewal in the presence <strong>of</strong> Matrigel<br />

and a Wnt signaling agonist, and can differentiate into ductal-like cells (in the presence <strong>of</strong> Matrigel) as well as endocrine and acinar<br />

lineage cells (in the presence <strong>of</strong> an unique laminin hydrogel) in culture. These results demonstrate robust pancreatic progenitor cell<br />

activities in vitro. Our results call for further investigation <strong>of</strong> progenitor cells in the adult pancreas in vivo, a research activity that<br />

has largely ceased after a series <strong>of</strong> recent publications reporting negative indings.<br />

Lawrence C. Chan, MD<br />

<strong>Gene</strong> <strong>Therapy</strong> to Reverse Autoimmune Type 1 Diabetes<br />

Type 1 diabetes (T1D) happens when most <strong>of</strong> the body’s pancreatic beta cells are destroyed by autoimmunity. Therefore, to reverse<br />

diabetes in T1D patients, we need to [1] re-establish suficient beta cell mass, and [2] neutralize the effects <strong>of</strong> autoimmunity. Our<br />

laboratory has developed a strategy that couples gene therapy-mediated induction <strong>of</strong> new beta cell formation in the liver with an<br />

immunomodulatory regimen that protects the neo-beta cells from autoimmune destruction. This strategy successfully reverses<br />

diabetes in an autoimmune model in rodents; the concept <strong>of</strong> therapeutic hepatic islet induction may also work in nonhuman<br />

primates.<br />

Andrea Ballabio, MD<br />

Rescue <strong>of</strong> Fat Diet-induced Obesity and Diabetes by TFEB-mediated Regulation <strong>of</strong> Autophagy and Lipid<br />

Catabolism<br />

The lysosomal-autophagic pathway is activated by starvation and plays an important role in both cellular clearance and lipid<br />

catabolism. However, the transcriptional regulation <strong>of</strong> this pathway in response to metabolic cues is currently uncharacterized.<br />

Here we show that the transcription factor EB (TFEB), a master regulator <strong>of</strong> lysosomal biogenesis and autophagy, is induced by<br />

starvation through an autoregulatory feedback loop and exerts a global transcriptional control on lipid catabolism via PGC1α and<br />

PPARα. Thus, during starvation a transcriptional mechanism links the autophagic pathway to cellular energy metabolism. Viral<br />

delivery <strong>of</strong> TFEB to the liver rescued obesity, diabetes and the metabolic syndrome in both diet-induced and genetic mouse models<br />

<strong>of</strong> obesity, suggesting a novel therapeutic strategy for disorders <strong>of</strong> lipid metabolism.<br />

Friday, May 17, 2013<br />

Markus Grompe, MD<br />

Reprogramming Gall Bladder to make Insulin<br />

Lunch Break (On Own - Not Provided; Pre-ordered boxed lunches available for pick up at Registration Counter)<br />

11:45 am - 1:00 pm<br />

Oral Abstract Session 320<br />

1:00 pm - 3:00 pm<br />

ROOM: BALLROOM A<br />

DNA Vectorology & <strong>Gene</strong> Targeting<br />

CO-CHAIRS: Matthew Hirsch, PhD and Carol H. Miao, PhD<br />

(Abstracts 266 through 273; see page 108)<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

63


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Oral Abstract Session 321<br />

1:00 pm - 3:00 pm<br />

ROOM: BALLROOM B<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic and <strong>Gene</strong>tic Diseases I<br />

CO-CHAIRS: Sihong Song, PhD and Stephanie Cherqui, PhD<br />

(Abstracts 274 through 281; see pages 108-109)<br />

Oral Abstract Session 322<br />

1:00 pm - 3:00 pm<br />

ROOM: 150 ABC<br />

Neurological <strong>Therapy</strong>: Neurodegeneration and Imaging<br />

CO-CHAIRS: Kryst<strong>of</strong> Bankiewicz, MD, PhD and Brian K. Kaspar, PhD<br />

(Abstracts 282 through 289; see page 109)<br />

Oral Abstract Session 323<br />

1:00 pm - 3:00 pm<br />

ROOM: 150 DEFG<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

CO-CHAIRS: Jacques P. Tremblay, PhD and Annemieke Aartsma-Rus, PhD<br />

(Abstracts 290 through 297; see pages 109-110)<br />

Friday, May 17, 2013<br />

Oral Abstract Session 324<br />

1:00 pm - 3:00 pm<br />

ROOM: BALLROOM C<br />

Cancer - Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

CO-CHAIRS: Karen S. Aboody, MD and Janaiah Kota, PhD<br />

(Abstracts 298 through 305; see page 110)<br />

Oral Abstract Session 325<br />

1:00 pm - 3:00 pm<br />

ROOM: 151 ABCG<br />

<strong>Gene</strong> <strong>Therapy</strong> for Hematologic Diseases: From Models to Clinical Results<br />

CO-CHAIRS: Fabio Candotti, MD and Arthur W. Nienhuis, MD<br />

(Abstracts 306 through 313; see page 111)<br />

Oral Abstract Session 326<br />

1:00 pm - 3:00 pm<br />

ROOM: BALLROOM D<br />

<strong>Gene</strong> Regulation and Animal Models<br />

CO-CHAIRS: David W. Emery, PhD and David M. Spencer, PhD<br />

(Abstracts 314 through 321; see pages 111-112)<br />

64<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Presidential Symposium 330<br />

3:15 pm - 5:30 pm<br />

ROOM: BALLROOM E-J<br />

Presidential Symposium<br />

CHAIR<br />

SPEAKER<br />

Xandra O. Breakeield, PhD<br />

David Baltimore, PhD<br />

<strong>Gene</strong>-based Anti-Viral Protection<br />

Standard vaccination development methods have not provided protections against certain infectious agents, notably HIV. However,<br />

very effective monoclonal antibodies to such agents have been found. We have undertaken to use gene therapy-like methods<br />

to provide protection against HIV and other agents, using Adenovirus-Associated Virus in a methodology we termed Viral<br />

ImmunoProphylaxis (VIP). This has proved very effective in humanized mice and is being developed for human trials.<br />

PRESENTATION OF TOP ABSTRACTS:<br />

Sylvie Rival-Gervier, PhD<br />

Abstract 322: Kinetics and Epigenetics <strong>of</strong> Retroviral Silencing in Mouse Embryonic Stem <strong>Cell</strong>s Deined by<br />

Deletion <strong>of</strong> a D4Z4 Barrier Element<br />

Mahzad Akbarpour, DVM<br />

Abstract 323: Liver-Directed, Insulin-Based <strong>Gene</strong> <strong>Therapy</strong> Protects NOD Mice from Diabetes<br />

Thomas J. Cradick, PhD<br />

Abstract 324: On-Target Cleavage and Off-Target Activity <strong>of</strong> TALEN ‘Nickases’<br />

Rimas J. Orentas, PhD<br />

Abstract 325: Targeting B <strong>Cell</strong> Precursor Acute Lymphoblastic Leukemia (ALL) with Chimeric Antigen<br />

Receptors (CARs) Speciic for CD19 or CD22<br />

Exhibit Hall Open: Networking Reception & Poster Session II<br />

5:30 pm - 7:30 pm<br />

ROOM: EXHIBIT HALL C/D<br />

AAV Vectors - II<br />

(Abstracts 326-340; Abstract 329 has been withdrawn from presentation; see pages 112-113)<br />

Friday, May 17, 2013<br />

DNA Vectorology & <strong>Gene</strong> Targeting I<br />

(Abstracts 341-352; see pages 113-114)<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic and <strong>Gene</strong>tic Diseases I<br />

(Abstracts 353-365; see pages 114-115)<br />

Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

(Abstracts 366-375; see page 115)<br />

Neurologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

(Abstracts 376-391; and Abstract 590 moved from Poster Session III; see pages 115-116)<br />

Cancer - Immunotherapy II<br />

(Abstracts 392-404; see page 117)<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

65


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Cancer-Oncolytic Viruses I<br />

(Abstracts 405-417; see pages 117-118)<br />

Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

(Abstracts 418-431; see pages 118-119)<br />

<strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> for Pulmonary Diseases<br />

(Abstracts 432-440; see page 119)<br />

Immunologic & Host Responses in <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

(Abstracts 441-449; see page 120)<br />

Oligonucleotide & RNAi Therapeutics<br />

(Abstracts 450-464; see pages 120-121)<br />

Pluripotent Stem <strong>Cell</strong>s<br />

(Abstracts 465-476; Abstract 475 Withdrawn from Presentation; see pages 121-122)<br />

Late Breaking Abstracts II<br />

(Abstracts 702-724; Abstract 701 Withdrawn from Presentation; see pages 122-123)<br />

New Investigator Town Hall Gathering<br />

7:30 pm - 8:30 pm<br />

ROOM: BALLROOM B<br />

CO-CHAIRS: Jennifer E. Adair, PhD and Luk H. Vandenberghe, PhD<br />

SPEAKERS<br />

Friday, May 17, 2013<br />

David V. Schaffer, PhD<br />

The Structural Organization <strong>of</strong> ASGCT<br />

The ASGCT is a broad organization that serves many needs <strong>of</strong> its members, and there are numerous opportunities for young<br />

investigators to become actively involved in our society. This talk will discuss the overall organization <strong>of</strong> ASGCT, including our<br />

committee structures, annual meeting, and awards.<br />

Andrew H. Baker, PhD<br />

British <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong><br />

Discussion around the role <strong>of</strong> BSGCT and the opportunities for interactions for early career researchers.<br />

Luigi M. Naldini, MD, PhD<br />

Opportunity for Young Scientists to Contribute to the European <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong><br />

Kenzaburo Tani, MD, PhD<br />

Current Situation <strong>of</strong> New Investigator Support Opportunities in JSGT<br />

JSGT have been supporting new investigators by supplying several educational lectures, awards and research grants. We also have<br />

open several postdoctoral positions for foreign new investigators.<br />

Zoe Fonseca-Kelly, PhD<br />

Strategies for Career Success Beyond Academia<br />

The role and work <strong>of</strong> the National Postdoctoral Association will be presented along with data pertaining to postdoctoral issues<br />

and developments. In addition basic strategies in planning a successful career beyond ones postdoc both within and outside <strong>of</strong><br />

academia will be presented.<br />

66<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Robert M. Frederickson, PhD<br />

Molecular <strong>Therapy</strong> and the ASGCT Publishing <strong>Program</strong><br />

This presentation will provide a brief overview <strong>of</strong> the <strong>Society</strong>’s lagship journal, Molecular <strong>Therapy</strong>, as well as the new online-only,<br />

open-access sibling journals. It will also present a roadmap <strong>of</strong> the editorial processes at the journals along with suggestions on how<br />

to navigate these processes successfully. <strong>Final</strong>ly, we will outline opportunities for new investigators to get involved and contribute<br />

to the ASGCT publishing program.<br />

New Investigator Mentoring Event<br />

8:30 pm - 9:30 pm<br />

ROOM: BALLROOM D<br />

Foundation Symposium 340<br />

7:30 pm - 9:30 pm<br />

ROOM: BALLROOM A<br />

<strong>Cell</strong> and <strong>Gene</strong> <strong>Therapy</strong> in the Eye, Navigating the Road from the Lab to the Clinic<br />

Supported by the Foundation Fighting Blindness.<br />

CHAIR: Stephen M. Rose, PhD<br />

SPEAKERS<br />

Stephen M. Rose, PhD<br />

The Role <strong>of</strong> the Foundation Fighting Blindness in Bringing Treatments to the Clinic - Funding the “The Valley <strong>of</strong><br />

Death”<br />

Sue Washer, MBA<br />

Small Company Experience; Maximizing Sources <strong>of</strong> Funding and Shots on Goal<br />

Samuel C. Wadsworth, PhD<br />

Large Company Experience, Navigating Through “New Technology” Challenge in a Large Organization<br />

New technological advancements drive development <strong>of</strong> new therapeutic modalities. Newness implies risk <strong>of</strong> failure which is<br />

the norm for scientiic endeavors because out <strong>of</strong> failure <strong>of</strong>ten comes insight that propels ields to new heights <strong>of</strong> understanding.<br />

Failure is an accepted ingredient <strong>of</strong> product development as well – obviously well-managed and early failure is ideal in a corporate<br />

environment. Layering on <strong>of</strong> new technologies such as gene and cell therapies complicates the process. Navigation through this<br />

arena will be discussed.<br />

Michael Young, PhD<br />

Retinal Stem <strong>Cell</strong>s: Working with Biotech<br />

I will present my perspective on collaboration with biotech in the development <strong>of</strong> a stem cell therapy for retinal degeneration. My<br />

group has worked with Reneuron, Inc. for almost 8 years now, and we hope to translate our work into a clinical product . I will<br />

discuss the challenges one encounters when working closely with industry.<br />

Friday, May 17, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

67


<strong>Program</strong> Schedule, Friday, May 17, 2013<br />

Workshop 350<br />

7:30 pm - 9:30 pm<br />

ROOM: BALLROOM C<br />

International Consortium for <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> Workshop<br />

CHAIR: Jacques P. Tremblay, PhD<br />

SPEAKERS<br />

Jacques P. Tremblay, PhD<br />

Introduction to the Creation <strong>of</strong> an International Consortium <strong>of</strong> <strong>Gene</strong><br />

Dr. Tremblay has recently published in collaboration with 50 experts in gene therapy a letter in Molecular <strong>Therapy</strong> proposing<br />

the creation <strong>of</strong> an International Consortium <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> to accelerate the development <strong>of</strong> clinical applications. Indeed the<br />

recent progress in genomics has permitted to identify the genes responsible for 10,000 hereditary monogenic diseases. Although<br />

each one <strong>of</strong> these diseases is rare (they are thus designated as orphan diseases), this whole group <strong>of</strong> diseases affects 8% <strong>of</strong> the<br />

human population and is thus a major cost for the public health systems. On the other hand, gene therapy has recently permitted<br />

successful treatment <strong>of</strong> some <strong>of</strong> these hereditary diseases. In particular, the new AAV serotypes permit to deliver a corrective gene<br />

more eficiently because human are not pre-immunized to some <strong>of</strong> the new serotypes. There are also several new tools to correct<br />

a mutated gene: meganucleases, ZFNs, TALENs and the CRISPR system, or intervene at the level <strong>of</strong> the mRNA: oligonucleotides for<br />

exon skipping, siRNA and shRNA. Promising results have been recently obtained in several animal models <strong>of</strong> hereditary diseases.<br />

The limiting step to be able to push these discoveries to a clinical application is the high cost <strong>of</strong> producing the clinical grade vectors.<br />

The workshop during the annual meeting <strong>of</strong> the ASGCT is to set the basis <strong>of</strong> that consortium, deine its goals and elect a direction<br />

committee. Among the proposed objectives will be to lobby governments for increase funding <strong>of</strong> this type <strong>of</strong> research, establishing<br />

international patient registry, developing more GMP facilities to produce the therapeutic agents, making the regulations more<br />

uniform in various countries. A large part <strong>of</strong> the workshop will be devoted to an open discussion so that ALL the participants can<br />

make their suggestions about the objectives and the methods to reach them.<br />

Yu-Quan Wei, MD, PhD<br />

<strong>Gene</strong> <strong>Therapy</strong> for <strong>Gene</strong>tic Diseases in China<br />

Xiao Xiao, PhD<br />

Current Status <strong>of</strong> Clinical Grade AAV Vector Production<br />

Friday, May 17, 2013<br />

Annemieke Aartsma-Rus, PhD<br />

The Treat-nmd Paradigm<br />

The TREAT-NMD Alliance is a network for the neuromuscular ield that provides an infrastructure to facilitate and accelerate<br />

the clinical development <strong>of</strong> new therapies. During its EU funded period (2007-2011) the network has collaborated with the<br />

USA to develop tools such as disease registries, standard <strong>of</strong> care guidelines, a clinical trial site registry, standardized operating<br />

procedures for preclinical animal studies, has set up the TREAT-NMD advisory committee on therapeutics (TACT), has maintained<br />

a biobank with samples from neuromuscular disorder patients and has gathered a wealth <strong>of</strong> information for the neuromuscular<br />

ield (see www.treat-nmd.eu). Following the end <strong>of</strong> the EU funding, the Alliance and its tools have been maintained and the<br />

network is running with other sources <strong>of</strong> funding. Current focus is on furthering the biobanks, setting up patient registries for<br />

additional neuromuscular disorders and in more countries, optimizing the clinical trial site registry, optimizing outcome measures<br />

for ambulant and non-ambulant patients and generating standards <strong>of</strong> care for additional diseases and updating existing care<br />

guidelines. The TREAT-NMD Alliance has also given rise to new EU funded projects such as RD-Connect, Neuromics, Optimistic and<br />

SKIP-NMD. While for the TREAT-NMD infrastructure the disease area is the connecting factor, it can serve as a paradigm for the gene<br />

therapy consortium where the therapeutic tool is the connecting factor.<br />

Philip J. Brooks, PhD<br />

Activities <strong>of</strong> the Ofice <strong>of</strong> Rare Diseases Research, NCATS, NIH, in Facilitating Translational Research in Rare<br />

Diseases Around the World<br />

68<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

ASGCT Business Meeting<br />

7:30 am - 8:00 am<br />

ROOM: 150 ABC<br />

Plenary Session 400<br />

8:00 am - 10:00 am<br />

ROOM: BALLROOM E-J<br />

Outstanding New Investigator Symposium<br />

CHAIR<br />

SPEAKERS<br />

Katherine P. Ponder, MD<br />

Aravind Asokan, PhD<br />

A Sweet Side to AAV Biology<br />

Adeno-associated viruses (AAV) exploit a spectrum <strong>of</strong> glycans for cell surface attachment and transduction. Understanding the<br />

structural basis and functional implications <strong>of</strong> such virus-host interactions can guide development <strong>of</strong> recombinant AAV vectors<br />

for clinical gene therapy applications. This talk will highlight our contributions towards discovery <strong>of</strong> AAV receptors, structural<br />

determinants <strong>of</strong> AAV tissue tropism and new strategies to re-engineer AAV-glycan interactions.<br />

Paloma H. Giangrande, PhD<br />

Targeted-Image Guided RNA (TIGR) Therapies<br />

The successful application <strong>of</strong> RNAi therapeutics to humans awaits the development <strong>of</strong> robust delivery technologies. <strong>Cell</strong> conjugation<br />

<strong>of</strong> siRNAs to cell-speciic ligands provides a viable solution to this problem. Synthetic RNA ligands (aptamers) represent an<br />

emerging class <strong>of</strong> pharmaceuticals with great potential for targeted therapeutic/diagnostic applications. Here, we describe<br />

advancements in aptamer technology for enabling the development <strong>of</strong> effective image-guided RNA therapies.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

69


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

Michael A. Lalamme, MD, PhD<br />

Cardiac Repair with Human Pluripotent Stem <strong>Cell</strong>s<br />

Human pluripotent stem cells have a number <strong>of</strong> potential advantages for use in myocardial infarct repair, including tremendous<br />

capacity for expansion in the undifferentiated state and unambiguous cardiac potential. Our group irst reported what are now<br />

widely applied methods to eficiently guide the differentiation <strong>of</strong> human embryonic stem cells (hESCs) and induced pluripotent<br />

stem cells (hiPSCs) into cardiomyocytes, as well as their further differentiation to speciic cardiac subtypes (e.g. pacemaker or<br />

ventricular myocytes). In early pro<strong>of</strong>-<strong>of</strong>-concept studies using a rat infarct model, we showed that the transplantation <strong>of</strong> hESCderived<br />

cardiomyocytes results in partial remuscularization <strong>of</strong> the infarct scar and improved contractile function. More recently,<br />

we have used a guinea pig infarct model to show that hESC-derived cardiomyocyte grafts can integrate electrically and contract<br />

synchronously with host muscle; and that these grafts exert an intriguing arrhythmia-suppressive effect. Our ongoing efforts are<br />

focused on promoting the structural and functional maturation <strong>of</strong> hESC-derived cardiomyocytes, as well as their electromechanical<br />

integration in vivo.<br />

Ann M. Leen, PhD<br />

T cell <strong>Therapy</strong> for Viruses and Cancer<br />

Severe and fatal viral infections remain common after hematopoietic stem cell transplantation. Adoptive transfer <strong>of</strong> in vitro<br />

expanded cytotoxic T lymphocytes speciic for EBV, CMV and Adv antigens can treat infections that are impervious to conventional<br />

therapies. However, the time taken to prepare patient-speciic products, the limited breadth <strong>of</strong> viral speciicities that can be<br />

accommodated in a single line, and the lack <strong>of</strong> virus-speciic T-cells in cord blood and seronegative donors restricts application. In<br />

this presentation I will summarize our preclinical efforts to address these limitations and will present our clinical trial results using<br />

these products.<br />

Oral Abstract Session 410<br />

10:15 am - 12:15 pm<br />

ROOM: 150 DEFG<br />

Late Breaking Abstracts<br />

CO-CHAIRS: TO BE DETERMINED<br />

(Abstracts 725 through 732; see page 124)<br />

Saturday, May 18, 2013<br />

Oral Abstract Session 411<br />

10:15 am - 12:15 pm<br />

ROOM: 150 ABC<br />

Adenovirus and Other DNA Virus Vectors<br />

CO-CHAIRS: Prem Seth, PhD and Miguel Sena-Esteves, PhD<br />

(Abstracts 477 through 484; see pages 124-125)<br />

70<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

Oral Abstract Session 412<br />

10:15 am - 12:15 pm<br />

ROOM: BALLROOM A<br />

Nuclease Mediated Genome Editing<br />

CO-CHAIRS: Shondra M. Miller, PhD and Andy Wilber, PhD<br />

(Abstracts 485 through 492; see page 125)<br />

Oral Abstract Session 413<br />

10:15 am - 12:15 pm<br />

ROOM: BALLROOM B<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic and <strong>Gene</strong>tic Diseases II<br />

CO-CHAIRS: Gerald S. Lipshutz, PhD and Nicola Brunetti-Pierri, MD<br />

(Abstracts 494 through 500; see pages 125-126)<br />

Oral Abstract Session 414<br />

10:15 am - 12:15 pm<br />

ROOM: 151 ABCG<br />

Cancer - Immunotherapy II<br />

CO-CHAIRS: Laurence JN Cooper, MD, PhD and Richard G. Vile, PhD<br />

(Abstracts 501 through 508; see page 126)<br />

Oral Abstract Session 415<br />

10:15 am - 12:15 pm<br />

ROOM: BALLROOM C<br />

Oligonucleotide & RNAi Therapeutics<br />

CO-CHAIRS: Scott Q. Harper, PhD and M. Corinna Palanca-Wessels, MD, PhD<br />

(Abstracts 509 through 516; see page 127)<br />

Lunch Break (On Own - Not Provided; Pre-ordered boxed lunches available for pick up at Registration Counter)<br />

12:15 pm - 1:45 pm<br />

Meet-the-Investigator Lunch Session 420<br />

12:15 pm - 1:45 pm<br />

ROOM: 251 E<br />

Targeting TTR in the Liver<br />

SPEAKER<br />

Daniel G. Anderson, PhD<br />

Meet-the-Investigator Lunch Session 421<br />

12:15 pm - 1:45 pm<br />

MEET AT THE SOUTH ENTRANCE OF THE SALT PALACE CONVENTION CENTER<br />

Huntsman Cancer Institute Tour<br />

Boxed lunches will be available at the South Entrance shortly before departure to the Huntsman Cancer Institute.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

71


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

Scientific Symposium 430<br />

1:45 pm - 3:45 pm<br />

ROOM: BALLROOM B<br />

Clinical Trials<br />

CO-CHAIRS: Donald B. Kohn, MD and Miguel Sena-Esteves, PhD<br />

SPEAKERS<br />

Helen E. Heslop, MD<br />

Immunotherapy with Viral Speciic T <strong>Cell</strong>s<br />

Immunotherapy with antigen-speciic T cells has the potential to reconstitute antiviral activity post transplant without inducing<br />

GVHD and our group has performed a series <strong>of</strong> clinical studies showing that virus-speciic cytotoxic T lymphocytes (CTLs) can<br />

reconstitute immunity and treat viral reactivation and disease. To extend this approach to EBV-associated lymphoma occurring in<br />

the immunocompetent host expressing Type 2 latency, we have generated CTL lines targeting the subimmunodominant antigens<br />

LMP1 and LMP2 using antigen presenting cells genetically modiied to overexpress either LMP2 alone or LMP1 and LMP2 by<br />

transduction with an Ad5f35 vectors. 27 <strong>of</strong> 29 high-risk and/or multiply relapsed patients who received LMP-CTL as adjuvant<br />

treatment remain in remission for a median <strong>of</strong> 2.5 years after CTL while 13 <strong>of</strong> 21 patients with detectable disease had clinical<br />

responses. In conclusion, immunotherapy with CTL targeting LMP antigens is well tolerated in patients with EBV+ lymphoma and<br />

infused LMP-CTL can accumulate at tumor sites and induce complete and sustained clinical responses.<br />

Roger J. Hajjar, MD<br />

<strong>Gene</strong> <strong>Therapy</strong> for Heart Failure<br />

Congestive heart failure remains a progressive disease with a desperate need for innovative therapies to reverse the course <strong>of</strong><br />

ventricular dysfunction. One <strong>of</strong> the key abnormalities in both human and experimental HF is a defect in sarcoplasmic reticulum<br />

(SR) function, which is responsible for abnormal intracellular Ca2+ handling. Deicient SR Ca2+ uptake during relaxation has been<br />

identiied in failing hearts from both humans and animal models and has been associated with a decrease in the activity <strong>of</strong> the SR<br />

Ca2+-ATPase (SERCA2a). Over the last ten years we have undertaken a program <strong>of</strong> targeting important calcium cycling proteins<br />

in experimental models <strong>of</strong> heart by somatic gene transfer. This has led to the completion <strong>of</strong> a irst-in-man phase 1 clinical trial<br />

<strong>of</strong> gene therapy for heart failure using adeno-associated vector (AAV) type 1 carrying SERCA2a. The safety proile <strong>of</strong> AAV gene<br />

therapy along with the positive biological signals obtained from this phase 1 trial has led to the initiation and recent completion <strong>of</strong><br />

a phase 2 trial <strong>of</strong> AAV1.SERCA2a in NYHA class III/IV patients. In the phase 2 trial, gene transfer <strong>of</strong> SERCA2a was found to be safe<br />

and associated with beneit in clinical outcomes, symptoms, functional status, NT-proBNP and cardiac structure. Furthermore, the<br />

recent successful and safe completion <strong>of</strong> the CUPID trial along with the start <strong>of</strong> more recent phase 1 trials usher a new era for gene<br />

therapy for the treatment <strong>of</strong> heart failure.<br />

Andrew M. David<strong>of</strong>f, MD<br />

AAV-mediated FIX <strong>Gene</strong> Transfer for Hemophilia B<br />

We are conducting a phase I/II clinical trial <strong>of</strong> factor IX gene transfer for severe hemophilia B. In the trial we are using a serotype-8<br />

pseudotyped self-complementary adeno-associated virus (scAAV) vector expressing a codon-optimized coagulation factor IX (FIX)<br />

transgene (scAAV2/8-LP1-hFIXco). AAV-mediated FIX activity at 1-6% <strong>of</strong> normal has been established in all participants with<br />

follow-up now <strong>of</strong> between 3 months and 3 years following gene transfer.<br />

Saturday, May 18, 2013<br />

C. Frank Bennett, PhD<br />

Antisense Oligonucleotide Therapies for the Treatment <strong>of</strong> Neurodegenerative Diseases<br />

Antisense oligonucleotides are chemically modiied oligonucleotides that are designed to speciically bind to a targeted RNA<br />

through Watson-Crick base pairing, modulating the function <strong>of</strong> the RNA. Because antisense oligonucleotides target RNA, rather<br />

than protein, they can be used to target a broader range <strong>of</strong> therapeutic targets than can be approached with conventional small<br />

molecule or protein based drugs. Neurodegenerative diseases are an attractive area for antisense technology in that there a number<br />

<strong>of</strong> diseases in which the genetic basis is known and not easily approachable with small molecule drugs.<br />

Scientific Symposium 431<br />

1:45 pm - 3:45 pm<br />

ROOM: 150 ABC<br />

Do Effective <strong>Gene</strong> Therapies and Regenerative Medicine Affect Dilemmas <strong>of</strong> Resource<br />

Allocation<br />

CHAIR: TBD<br />

72<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

SPEAKERS<br />

Jeffrey Chamberlain, PhD<br />

Augmentation <strong>of</strong> Muscle Function Via <strong>Gene</strong> Transfer-The Good, The Bad and The Ugly<br />

Emerging gene and stem cell therapies for inherited muscle disorders aim to stop muscle degeneration while increasing muscle<br />

mass and strength. Interventions that regulate muscle mass are also potentially powerful approaches to slow the loss <strong>of</strong> strength<br />

that accompany aging (sarcopenia) and cancer (cachexia). However, any safe method developed to increase muscle mass or<br />

strength could also be attractive for use by individuals desiring greater strength or prowess, either due to slight build or athletic<br />

ambition. This lecture will review current approaches for enhancing muscle mass and their potential for use and abuse.<br />

Tho mas H. Murray, PhD<br />

Ethics, <strong>Gene</strong> and <strong>Cell</strong>ular Enhancements in Sport and Beyond<br />

Athletes will be quick to grasp the possible applications <strong>of</strong> gene and cell therapies for sarcopenia and other diseases for enhanced<br />

performance in sport. How should we think about the ethics <strong>of</strong> enhancement in sport and in other spheres <strong>of</strong> human life Examples<br />

from sport and from the practice <strong>of</strong> medicine demonstrate that understanding the ethics <strong>of</strong> any particular enhancement begins with<br />

appreciating the values we seek within that sphere and the meaning <strong>of</strong> that activity in people’s lives.<br />

Leonard M. Fleck, PhD<br />

Successful and Safe <strong>Gene</strong> <strong>Therapy</strong> Raises New Quandaries <strong>of</strong> Health Care Justice<br />

Our fundamental question is this: Given that any society has only limited resources to meet virtually unlimited health care needs,<br />

how high a priority, ethically speaking, ought gene therapy have in meeting those needs This leads to two subsidiary questions. (1)<br />

Who can be expected to beneit the most from emerging gene therapies, mostly younger individuals or mostly older individuals (2)<br />

What can we reasonably expect in the way <strong>of</strong> outcomes from various emerging gene therapies, cures or only halfway technologies<br />

so characteristic <strong>of</strong> medicine today If we had a form <strong>of</strong> gene therapy that could substantially address the loss <strong>of</strong> muscle function in<br />

Duchenne patients and could also address loss <strong>of</strong> muscle function in the elderly, would we argue from the perspective <strong>of</strong> health care<br />

justice in a world <strong>of</strong> limited resources with unlimited needs that both sorts <strong>of</strong> patients had an equal more right to this therapy Or<br />

would we argue instead that the younger Duchenne patients had the stronger just claim to this therapeutic intervention<br />

Scientific Symposium 432<br />

1:45 pm - 3:45 pm<br />

ROOM: 150 DEFG<br />

Exploiting Unique Attributes <strong>of</strong> Vectors for Design <strong>of</strong> Vaccines and Immunotherapies<br />

CHAIR: Eric Poeschla, MD<br />

SPEAKERS<br />

Shan Lu, MD, PhD<br />

DNA Immunization – Pro<strong>of</strong> <strong>of</strong> the Potential <strong>of</strong> <strong>Gene</strong>-based Delivery <strong>of</strong> Vaccines<br />

While gene therapy remains a challenge to treat any genetic and acquired illness, the emergence <strong>of</strong> DNA immunization has provided<br />

a unique model system to study the in vivo expression <strong>of</strong> proteins by a gene-based vector and the subsequent biological effects.<br />

Since its discovery in the early 1990s, the understanding <strong>of</strong> DNA immunization has grown substantially. New results suggest<br />

that DNA immunization is extremely effective in priming antigen-speciic B cells, establishing the stage for protective antibody<br />

responses, which are the critical components for an effective vaccine. More signiicantly, such indings are supported by clinical<br />

studies in humans, indicating a new era <strong>of</strong> gene-based vaccines.<br />

Lukas Flatz, MD<br />

Single <strong>Cell</strong> <strong>Gene</strong> Expression Proiling Reveals Qualitatively Distinct CD8 T cells Elicited by Different <strong>Gene</strong>based<br />

Vaccines<br />

Immunological techniques have dramatically advanced since the discovery <strong>of</strong> the immune system at the beginning <strong>of</strong> last<br />

century. However, to further improve immunotherapies and vaccination we have to better understand the events shaping an<br />

antigen encountering T cell on single cell base. We therefore used microluidics based single cell real-time PCR to analyze vaccine<br />

elicited antigen-speciic CD8 T cells <strong>of</strong> similar magnitude, phenotype and functionality as measured by conventional techniques.<br />

Remarkably, analysis <strong>of</strong> single cell gene expression proiles enabled the discrimination <strong>of</strong> previously unrecognized subsets <strong>of</strong><br />

central and effector memory CD8 T cells elicited by the three different gene-based vaccines. Single cell real-time PCR is a promising<br />

new technology increasing the resolution <strong>of</strong> T cell analysis.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

73


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

Aliasger K. Salem, PhD<br />

Adjuvants for Vector-Mediated Cancer Immunotherapy<br />

This presentation will cover the use <strong>of</strong> adjuvants such as biodegradable particles and oligonucleotides to enhance the magnitude <strong>of</strong><br />

antigen-speciic anti-tumor CD8+ T-cell responses generated from treatment with adenovirus based vaccines. The presentation will<br />

also discuss the use <strong>of</strong> strategies to suppress negative regulatory elements within the tumor such as myeloid derived suppressor<br />

cells (MDSCs) and regulatory T-cells (Treg) to augment the anti-tumor activity generated by treatment with adenovirus based<br />

vaccines.<br />

Andrew Geall, PhD<br />

Non-viral Delivery <strong>of</strong> Self-amplifying RNA Vaccines<br />

Novartis has developed the SAM(tm) vaccine platform. The Platform takes advantage <strong>of</strong> cell-free RNA production from a<br />

transcription reaction and delivery with a synthetic delivery system. The broad utility <strong>of</strong> this novel vaccine technology has been<br />

demonstrated with genes encoding antigens from several pathogens and found to elicit broad and potent protective immune<br />

responses. Responses are comparable to a viral delivery technology, but without the inherent limitations <strong>of</strong> viral vectors.<br />

Scientific Symposium 433<br />

1:45 pm - 3:45 pm<br />

ROOM: BALLROOM D<br />

Host <strong>Cell</strong> Responses to Viral Vectors<br />

CO-CHAIRS: John T. Gray, PhD and Dmitry M. Shayakhmetov, PhD<br />

SPEAKERS<br />

Vojo Deretic, PhD<br />

Autophagy - A Biological Paradigm for Everyone<br />

Autophagy is a homeostatic process that continuously cleanses the cytosol by removing defunct organelles, protein aggregates,<br />

microbial invaders, and endogenous sources <strong>of</strong> inlammation. It also supplies the cell with alternative sources <strong>of</strong> energy and<br />

nutrients by auto-digestion <strong>of</strong> the cytoplasm during starvation. Autophagy is <strong>of</strong> signiicance in cancer, aging, neurodegeneration,<br />

metabolic disorders, inlammatory disease such as Crohn’s disease, and infectious diseases. The presentation will cover the<br />

pathway, its connections to disease, and focus on anti-inlammatory aspects <strong>of</strong> autophagy.<br />

Roland W. Herzog, PhD<br />

Innate Immunity to AAV Vectors<br />

Rapid sensing <strong>of</strong> pathogen-associated molecular patterns by the innate immune system is a mechanism to quickly shut down<br />

a viral infection via inlammatory responses or IFN I signaling. While a major concern for other viral gene transfer vectors,<br />

innate responses to AAV are very short-lived and weak. Nonetheless, TLR9 sensing <strong>of</strong> the AAV genome has emerged as a critical<br />

component <strong>of</strong> the response, and evidence for IFN I induction, induction <strong>of</strong> NF-kB and expression <strong>of</strong> inlammatory cytokines has<br />

been obtained. Importantly, immune responses to vector and in some cases also the transgene product are impacted by innate<br />

immunity.<br />

Saturday, May 18, 2013<br />

John C. Bell, PhD<br />

Innate Immunity and Oncolytic Viruses<br />

Oncolytic Viruses have been engineered or selected to speciically replicate in and kill tumour cells. This selectivity is <strong>of</strong>ten based<br />

upon aberrant signalling pathways that are characteristic <strong>of</strong> malignant cells. However, normal cells found within the tumour<br />

microenvironment are exposed to constitutive and elevated levels <strong>of</strong> cancer cell derived growth factors leading to a disruption <strong>of</strong><br />

normal which in turn can lead to overstimulation <strong>of</strong> normal cellular regulatory pathways. We have found that both neo-vascular<br />

endothelial cells and cancer associated ibroblasts are sensitized to oncolytic virus infection and killing following exposure to<br />

tumour cell derived growth factors. The molecular and biological consequences <strong>of</strong> this sensitization will be discussed.<br />

Dmitry M. Shayakhmetov, PhD<br />

Sensing <strong>of</strong> Endosomal Rupture by the Host<br />

To achieve therapeutic beneits using gene delivery vectors, both viral and non-viral vectors must be able to eficiently<br />

penetrate through the plasma membrane <strong>of</strong> target cells and deliver the therapeutic cargo into cytosolic and/or nuclear cellular<br />

compartments. However, dedicated molecular sensors may exist that detect perturbations <strong>of</strong> the integrity <strong>of</strong> the plasma membrane<br />

and endosomal compartments within the cell. When triggered, these sensors activate innate immune defense mechanisms which<br />

can limit the eficacy <strong>of</strong> the therapy. We will review current understanding <strong>of</strong> the molecular mechanisms that are triggered within<br />

the cell upon virus entry, and present new data on molecular sensors <strong>of</strong> adenovirus-mediated endosome rupture.<br />

74<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

Scientific Symposium 434<br />

1:45 pm - 3:45 pm<br />

ROOM: 151 ABCG<br />

Lessons Learned from the Manufacture and Clinical Translation <strong>of</strong> <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong><br />

Products<br />

CO-CHAIRS: <strong>Gene</strong> Liau, PhD and Gabor Veres, PhD<br />

SPEAKERS<br />

Barrie J. Carter, PhD<br />

Overview on Product and Clinical Translation<br />

After two decades <strong>of</strong> development, the irst gene therapy in the western world that was recently approved for marketing in Europe<br />

was an rAAV, glybera. The progress over these two decades in developing and testing gene therapy products will be reviewed using<br />

rAAV as the illustrative example. Substantial progress has been made in scaled up production <strong>of</strong> rAAV vectors, at least ive different<br />

manufacturing systems have been employed to advance products into clinical testing. The puriication and quality testing <strong>of</strong> rAAV<br />

vectors has advanced signiicantly and as more products approach licensing analytics for rAAV will be further reined. Pathways<br />

for preclincal testing <strong>of</strong> rAAV for safety, toxicity and biodistribution are established. Importantly, clinical studies with rAAV have<br />

generated clear evidence that clinical beneits can be gained and have also illuminated some important considerations such as host<br />

immune responses.<br />

Harold Petry, PhD<br />

Lessons from the Glybera ® European Approval Process to Build a <strong>Gene</strong> <strong>Therapy</strong> Product Pipeline<br />

The presentation will cover the development <strong>of</strong> Glybera ® , a gene therapy product based on the use <strong>of</strong> recombinant Adenoassociated<br />

virus for gene delivery, designed for patients with Lipoprotein Lipase Deiciency. The European Medicines Agency’s<br />

Committee for Medicinal Products for Human Use (CHMP) has approved authorisation <strong>of</strong> Glybera (alipogene tiparvovec) for<br />

marketing in the European Union. It is intended to treat lipoprotein lipase (LPL) deiciency in patients with severe or multiple<br />

pancreatitis attacks, despite dietary fat restrictions. Hurdles which were recognized during the development program towards<br />

market authorization will be discussed.<br />

Bruce L. Levine, PhD<br />

<strong>Gene</strong>ration <strong>of</strong> T <strong>Cell</strong>s that Engraft, Expand and Persist<br />

Dr. Levine directs the Clinical <strong>Cell</strong> and Vaccine Production Facility and is an Associate Pr<strong>of</strong>essor in the Department <strong>of</strong> Pathology<br />

and Laboratory Medicine at the University <strong>of</strong> Pennsylvania. The CVPF develops, manufactures and tests novel cell and gene<br />

therapies in clinical trials at Penn and collaborating institutions. Critical components for generation <strong>of</strong> cells with non-homologous<br />

function include 1) source and isolation <strong>of</strong> cells, 2) method <strong>of</strong> activation, 3) method <strong>of</strong> expansion, 4) characterization and testing. T<br />

lymphocytes can be activated, cultured, and endowed with novel functions ex vivo. Ex vivo modiied cells can engraft, signiicantly<br />

expand in vivo by >1000 fold, mediate potent clinical responses, and can survive for years.<br />

Raymond T. Bartus, PhD<br />

CERE-120 (AAV-neurturin) for the Treatment <strong>of</strong> Parkinson’s Disease: Experience from 4 Clinical Trials and<br />

Human Autopsy Data<br />

CERE-120 is an AAV serotype 2 vector expressing the gene for human neurturin, a neurotrophic factor with the natural ability<br />

to protect dying dopaminergic neurons in Parkinson’s patients from cell death and stimulate their ability to produce tyrosine<br />

hydroxylase (TH), an enzyme necessary dopamine synthesis. Since CERE-120 can inhibit cell death and stimulate dopamine, it has<br />

the potential ability to provide both symptomatic improvement as well as slow the neurodegenerative process, hence be disease<br />

modifying. Ceregene has completed over 24 preclinical studies on CERE-120 in multiple animal models <strong>of</strong> Parkinson’s disease as<br />

well as multiple preclinical toxicology studies. Ceregene has completed 4 CERE-120 clinical trials including 2 Phase 1 studies and 2<br />

Phase 2/2b studies in Patients with moderately advanced Parkinson’s disease. Data from these studies as well as from the analysis<br />

<strong>of</strong> 4 brains obtained at autopsy from subjects treat with CERE-120 will be discussed.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

75


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

Scientific Symposium 435<br />

1:45 pm - 3:45 pm<br />

ROOM: BALLROOM C<br />

Technological Advances in Non-Viral <strong>Gene</strong> Transfer & Targeting<br />

CO-CHAIRS: Richard Heller, PhD and Yoichi Negishi, PhD<br />

SPEAKERS<br />

Daniel Scherman, PhD<br />

Improved Eficiency Biosafe Plasmid for Sustained Expression in Various Tissues in Non-Viral <strong>Gene</strong> <strong>Therapy</strong><br />

Nonviral gene therapy requires plasmid eukaryotic expression vectors that meet deined criteria such as biosafety and low<br />

production cost. We have designed a novel antibiotic-free selection system, the pFAR plasmids, which is based on the suppression <strong>of</strong><br />

a chromosomal amber mutation in the essential thyA gene by a plasmid-borne function. The electrotransfer <strong>of</strong> LUC-encoding pFAR<br />

into muscle led to high luciferase activities, and in skin and transplanted tumors, transgene expression levels were at least one log<br />

superior and more sustained with pFAR plasmid electrotransfer, as compared with a plasmid carrying a kanamycin resistance gene.<br />

Most importantly, pFAR plasmids hydrodynamic delivery to liver lead to more than 9 months high and stable transgene expression,<br />

thus avoiding the classically observed liver gene extinction, by a process whose mechanism will be analyzed.<br />

Harvinder Singh Gill, PhD<br />

Microneedles for <strong>Gene</strong> and Oligonucleotide Delivery<br />

Tens to hundreds <strong>of</strong> minimally invasive microneedles conigured in an array-format with controlled spacing can be used to<br />

uniformly deliver genes and oligonucleotides to tissues for therapeutic and diagnostic applications. This presentation will describe<br />

our results from the use <strong>of</strong> microneedle arrays to deliver a gene-based hepatitis C vaccine to the skin in a mouse model, and the<br />

ability <strong>of</strong> microneedles to deliver oligonucleotides into cells situated in 3-D tissues.<br />

Andrew M. Scharenberg, MD<br />

High Eficiency Genome Editing Using Endonuclease/Exonuclease Co-expression<br />

An important factor in applying gene editing technologies in translational applications is the eficiency at which a target gene can<br />

be modiied in the desired cell population. We have explored the use <strong>of</strong> exonuclease/endonuclease co-expression as a means to<br />

increase the eficiency <strong>of</strong> gene editing by several endonuclease platforms, and in both tumor and primary cell types. Results from<br />

evaluation <strong>of</strong> several different exonuclease/endonuclease platform combinations, along with mechanistic analysis <strong>of</strong> how speciic<br />

exonucleases are interacting with free DNA ends will be presented.<br />

Evan C. Unger, MD<br />

<strong>Gene</strong> Delivery with Ultrasound and Microbubbles<br />

Safe, highly eficient vectors for gene delivery should expand clinical applications <strong>of</strong> gene therapy. Ultrasound is widely used for<br />

diagnostic imaging and has therapeutic applications for heating tissues, increasing tissue and capillary permeability and other<br />

applications in drug and gene delivery. Microbubbles lower the thresh-hold <strong>of</strong> energy for cavitation by ultrasound. FDA approved<br />

ultrasound contrast agents are currently being tested as gene delivery agents, but existing agents probably do not bind the genetic<br />

materials. New microbubbles that speciically bind genetic materials are also being tested. In my presentation I will review current<br />

developments in this ield and touch upon opportunities for development <strong>of</strong> new agents.<br />

Saturday, May 18, 2013<br />

76<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


<strong>Program</strong> Schedule, Saturday, May 18, 2013<br />

Poster Session III & Reception<br />

3:45 pm - 5:45 pm<br />

ROOM: EXHIBIT HALL C/D<br />

RNA Virus Vectors<br />

(Abstracts 517-535; see pages 127-128)<br />

AAV Vectors - III<br />

(Abstracts 536-551; see pages 128-129)<br />

Adenovirus and Other DNA Virus Vectors II<br />

(Abstracts 552-564; Abstract 561 has been moved to Poster Session I after Abstract 138; see pages 129-130)<br />

DNA Vectorology & <strong>Gene</strong> Targeting II<br />

(Abstracts 565-577; see pages 130-131)<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic and <strong>Gene</strong>tic Diseases II<br />

(Abstracts 578-587; Abstract 588 has been withdrawn; see page 131)<br />

Neurologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

(Abstracts 589-604; Abstract 590 has been moved to Poster Session II after Abstract 391; see pages 131-132)<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

(Abstracts 605-620; see page 133)<br />

Cancer - Immunotherapy III<br />

(Abstracts 621-633; see pages 133-134)<br />

Cancer-Oncolytic Viruses II<br />

(Abstracts 634-647; Abstract 646 Withdrawn from Presentation; see pages 134-135)<br />

Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>: <strong>Cell</strong> <strong>Therapy</strong> / Immunotherapy / <strong>Cell</strong>ular Targets<br />

(Abstracts 648-660; see pages 135-136)<br />

Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

(Abstracts 661-674; Abstract 675 has been withdrawn from presentation; see pages 136-137)<br />

Late Breaking Abstracts III<br />

(Abstracts 733-756; Abstracts 734, 745, and 749 Withdrawn from Presentation; see pages 137-138)<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

77


ASGCT 16th Annual Meeting<br />

May 15-18, 2013<br />

Salt Palace Convention Center (Hall C/D)<br />

Salt Lake City, Utah<br />

Exhibit Hall Floor Plan<br />

78<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Exhibitor Descriptions<br />

Aldevron<br />

3233 15th Street South<br />

Fargo, ND 58104<br />

Phone: (701) 306-2675<br />

Fax: (701) 280-1642<br />

E-mail: vchambers@aldevron.com<br />

Website: www.aldevron.com<br />

Booth Number: 203<br />

Aldevron’s custom plasmid puriication service is used<br />

to support many cell and gene therapy applications. Visit<br />

with our team to learn about new options for bench scale,<br />

research grade, and clinical grade DNA production. Aldevron<br />

also provides ready-to-use plasmids including cytokine,<br />

reporter, and viral helper vectors. We can also produce<br />

recombinant proteins, mRNA, and genetic antibodies.<br />

Aldevron’s mission is to advance science and it would be a<br />

privilege to work with your group.<br />

AltheaDx<br />

3550 Dunhill Street<br />

San Diego, CA 92121<br />

Phone: (858) 224-7200<br />

Fax: (858) 224-7220<br />

E-mail: abud<strong>of</strong>f@altheadx.com<br />

Website: www.altheadx.com<br />

Booth Number: 109<br />

AltheaDx <strong>of</strong>fers comprehensive Biodistribution Studies<br />

under GLP, designed to determine the distribution and<br />

persistence <strong>of</strong> cellular and gene therapy and viral vector<br />

products at key tissue sites. Our custom designed real-time<br />

qPCR analysis provides a powerful tool for assessing the<br />

safety and eficacy <strong>of</strong> nucleic acid and cellular therapeutics.<br />

<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

555 East Wells Street<br />

Milwaukee, WI 53202<br />

Phone: (414) 278-1341<br />

Fax: (414) 276-3349<br />

E-mail: info@asgct.org<br />

Website: www.asgct.org<br />

Booth Number: 415<br />

Stop by the ASGCT membership booth to ind out where the<br />

2014 Annual Meeting will be held and to ind out more about<br />

ASGCT activities.<br />

Biomiga, Inc.<br />

10637 Roselle Street<br />

Suite C<br />

San Diego, CA 92121<br />

Phone: (858) 597-0602<br />

Fax: (858) 538-1698<br />

E-mail: info@biomiga.com<br />

Website: www.biomiga.com<br />

Booth Number: 413<br />

Featured products:<br />

- Virus Puriication Kits (Adeno virus, Adeno associate virus,<br />

Retrovirus and Lentivirus)<br />

- DNA/RNA Puriication Kits (Membrane and Magnetic<br />

beads).<br />

Contract services:<br />

- From gene to virus: gene synthesis, cloning, mutagenesis,<br />

plasmid puriication, virus production and validation.<br />

- shRNA design, gene knockdown validation, stable cell line<br />

generation and single cell cloning.<br />

BTX/Harvard Apparatus<br />

84 October Hill Road<br />

Holliston, MA 01746<br />

Phone: (800) 272-2775<br />

Fax: (508) 429-5732<br />

E-mail: support.btx@harvardapparatus.com<br />

Website: www. btxonline.com<br />

Booth Number: 404<br />

BTX Harvard Apparatus is a global manufacturer and<br />

distributor <strong>of</strong> electroporation and electr<strong>of</strong>usion systems<br />

and accessories. Our product <strong>of</strong>fering accommodates a<br />

wide range <strong>of</strong> standard applications along with specialty<br />

applications such as in vivo electroporation as well as large<br />

volume transfection and cell fusion.<br />

<strong>Cell</strong>Genix GmbH<br />

One New Hampshire Ave., Suite 125<br />

Portsmouth, NH 03801<br />

Phone: (603) 373-0408<br />

Fax: (603) 373-8104<br />

E-mail: mcdermott@cellgenix.com<br />

Website: www.cellgenix.com<br />

Booth Number: 303<br />

<strong>Cell</strong>Genix manufactures high quality cytokines and media<br />

for ex-vivo cell culture <strong>of</strong> Dendritic <strong>Cell</strong>s, T-<strong>Cell</strong>s, NK-<strong>Cell</strong>s,<br />

Hematopoietic stem cells, Chondrocytes and Mesenchymal<br />

stromal cells. Our products are manufactured in accordance<br />

with GMP guidelines and USP and are all component<br />

free providing reliability, safety and reproducible results<br />

for pre-clincal and clinical applications. <strong>Cell</strong>Genix has built<br />

strong partnerships with clinical centers world-wide in<br />

cancer and regenerative medicine.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

79


Exhibitor Descriptions<br />

Charles River<br />

251 Ballardvale Street<br />

Wilmington, MA 01887<br />

Phone: 1-877-criver1<br />

Fax: (978) 988-9236<br />

E-mail: askcharlesriver@crl.com<br />

Website: www.criver.com<br />

Booth Number: 112<br />

Charles River supports biomedical researchers with<br />

services spanning the drug development continuum. Our<br />

comprehensive preclinical <strong>of</strong>ferings include the design,<br />

execution and documentation <strong>of</strong> GLP safety tests before<br />

and after clinical trials begin. These safety programs<br />

are designed to mitigate complications <strong>of</strong> cross-species<br />

reactivity and risk factors inherent to developing novel<br />

cellular therapeutics.<br />

Children’s Hospital <strong>of</strong> Philadelphia<br />

Room 5059<br />

Colket Translational Research Building<br />

3501 Civic Center Blvd.<br />

Philadelphia, PA 19147<br />

Phone: (267) 426-5256<br />

Fax: (215) 590-3660<br />

E-mail: sunj@email.chop.edu<br />

Website: www.research.chop.edu/programs/ccmt/<br />

Booth Number: 414<br />

CCMT is dedicated to the understanding, development, and<br />

application <strong>of</strong> gene and cell therapies and the promotion <strong>of</strong><br />

pr<strong>of</strong>essional and public education in the ield. The Center<br />

fosters a multidisciplinary approach among researchers<br />

and scientists working to discover new therapies in search<br />

<strong>of</strong> cures for debilitating and life threatening childhood<br />

disorders.<br />

Cincinnati Children’s Hospital Medical Center<br />

3333 Burnet Ave. ML 7013<br />

Cincinnati, OH 45229<br />

Phone: (513) 803-1066<br />

Fax: (513) 636-1446<br />

E-mail: han.vanderloo@cchmc.org<br />

Website: https://research.cchmc.org/translationalcores/<br />

Booth Number: 103<br />

The Cincinnati Children’s Hospital Translational<br />

Laboratories were established in 2003 to eficiently move<br />

innovative ideas from the bench to the bedside. We <strong>of</strong>fer a<br />

one-stop shop approach to support research, scale-up, GMP<br />

manufacturing, testing, quality assurance, and clinical trial<br />

support <strong>of</strong> your novel cell and gene therapies.<br />

First Biotech Inc.<br />

340 West State Street<br />

Athens, OH 45701<br />

Phone: (614) 600-3341<br />

Fax: (740) 597-1548<br />

E-mail: lhallak@irstbiotech.com<br />

Website: www.FirstBiotech.com<br />

Booth Number: 211<br />

First Biotech Inc. is a DNA research reagents company. It<br />

manufactures a high idelity First Mutation site directed<br />

DNA mutagenesis kit for large plasmids up to 50 kilobase<br />

pairs. The kit is based on a new patented technology that<br />

does not require traditional sub-cloning or cloning vectors.<br />

Florida Biologix<br />

13702 Innovation Drive<br />

Alachua, FL 32615<br />

Phone: (386) 418-8199<br />

Fax: (386) 462-7838<br />

E-mail: jiannarelli@cerhb.ul.edu<br />

Website: www.loridabiologix.ul.com<br />

Booth Number: 113<br />

Florida Biologix ® is a biologics contract development,<br />

manufacturing, and testing organization staffed with 65<br />

industry-experienced personnel in a 35,000 ft 2<br />

facility<br />

<strong>of</strong>fering a variety <strong>of</strong> services, including: cell line engineering,<br />

cell banking, process development, assay development,<br />

cGMP vector/protein production in mammalian and insect<br />

cells, cell therapies, aseptic illing, product testing, and<br />

regulatory support.<br />

GE Healthcare<br />

800 Centennial Avenue<br />

Piscataway, NJ 08854<br />

Phone: (800) 526-3593<br />

Fax: (877) 295-8102<br />

E-mail: liz.pita@ge.com<br />

Website: www.gelifesciences.com<br />

Booth Number: 214<br />

GenScript USA Inc.<br />

860 Centennial Ave<br />

Piscataway, NJ 08854<br />

Phone: (732) 885-9188<br />

Fax: (732) 210-0262<br />

E-mail: info@genscript.com<br />

Website: www.GenScript.com<br />

Booth Number: 403<br />

Founded in 2002, GenScript is now the world’s leading gene<br />

synthesis company, and is particularly skillful with long and/<br />

or complex sequences. Besides, GenScript <strong>of</strong>fers a variety<br />

<strong>of</strong> services and products for preclinical drug discovery.<br />

Headquartered in USA, GenScript has currently 1,300+<br />

employees worldwide with subsidiaries in Europe, Japan and<br />

China.<br />

80<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Exhibitor Descriptions<br />

HypOxygen<br />

5111 Pegasus Ct., Ste. H<br />

Frederick, MD 21704<br />

Phone: (877) 497-6994<br />

Fax: (301) 662-8096<br />

E-mail: info@hppoxygen.us<br />

Website: www.hypoxygen.us<br />

Booth Number: 416<br />

HypOxygen is featuring the HypOxystation hypoxia<br />

incubator, designed for physiological cell culture research.<br />

Scientists have precise control <strong>of</strong> oxygen, carbon dioxide,<br />

temperature, humidity and can manipulate cells in-situ. We<br />

will also be showcasing our new INCOmed CO2 incubators,<br />

which boast Peltier technology, accurate infrared (NDIR)<br />

CO2 sensors and custom options.<br />

Lovelace Respiratory Research Institute<br />

2425 Ridgecrest Dr. SE<br />

Albuquerque, NM 87108<br />

Phone: (505) 348-9534<br />

Fax: (505) 348-4983<br />

E-mail: aholley@lrri.org<br />

Website: www.lrri.org<br />

Booth Number: 406<br />

The Lovelace Respiratory Research Institute is a private notfor-proit<br />

biomedical research organization. Lovelace <strong>of</strong>fers<br />

animal models <strong>of</strong> disease, evaluation <strong>of</strong> eficacy <strong>of</strong> potential<br />

new therapeutics, and pre-clinical assessments including<br />

evaluation <strong>of</strong> pharmacokinetics/biodistribution in large and<br />

small animal models. Studies are routinely performed under<br />

GLP guidelines.<br />

Mary Ann Liebert, Inc.<br />

140 Huguenot Street<br />

New Rochelle, NY 10801<br />

Phone: (914) 740-2100<br />

Fax: (914) 740-2101<br />

E-mail: info@liebertpub.com<br />

Website: www.liebertpub.com<br />

Booth Number: 107<br />

Mary Ann Liebert Inc. publishes the premier journal<br />

program in gene therapy, consisting <strong>of</strong> Human <strong>Gene</strong> <strong>Therapy</strong>,<br />

HGT Methods, & new in 2013, HGT Clinical Development.<br />

This expanded coverage provides unprecedented access<br />

to research and applications critical to the evolution <strong>of</strong> the<br />

ield! Visit us @ booth# 107.<br />

Miltenyi Biotec<br />

2303 Lindbergh Street<br />

Auburn, CA 95602<br />

Phone: (530) 887-5385<br />

Fax: (530) 888-8925<br />

E-mail: tausha@miltenyibiotec.com<br />

Website: www.miltenyibiotec.com<br />

Booth Number: 202<br />

Miltenyi Biotec provides MACS® Technology, the gold<br />

standard in cell separation for research and clinical scale,<br />

as well as sample preparation, cell analysis and molecular<br />

biology products and services to the biomedical research<br />

community. The company also manufactures cGMP<br />

custom reagents, antibodies, proteins, peptides, and other<br />

molecules.<br />

MPI Research<br />

54943 North Main Street<br />

Mattawan, MI 49071<br />

Phone: (269) 668-3336<br />

Fax: (269) 668-4151<br />

E-mail: info@mpiresearch.com<br />

Website: www.mpiresearch.com<br />

Booth Number: 201<br />

MPI Research is a preclinical and early clinical CRO that<br />

provides discovery, surgery, safety evaluation, bioanalytical,<br />

and analytical services. We exceed expectations<br />

through consistency and quality, with a commitment<br />

to communication and innovation, delivering beneits<br />

throughout all phases <strong>of</strong> development. Learn how we can go<br />

beyond for you at www.mpiresearch.com.<br />

NanoSight<br />

6660 N. High Street<br />

Suite 2A<br />

Worthington, OH 43085<br />

Phone: (614) 888-0023<br />

Fax: (614) 987-0045<br />

E-mail: admin@nanosight.com<br />

Website: www.nanosight.com<br />

Booth Number: 204<br />

NanoSight manufactures instruments for Counting, Sizing<br />

and Visualizing Nanoparticles from 10 nm to 2.0 µm. Size<br />

& Concentration measurements along with the ability to<br />

visualize the nanoparticles in real time and a captured video<br />

<strong>of</strong> the sample being analyzed are created for each analysis.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

81


Exhibitor Descriptions<br />

National <strong>Gene</strong> Vector Biorepository (NGVB)<br />

980 W. Walnut Street R3 C602<br />

Indianapolis, IN 46202<br />

Phone: (317) 274-4519<br />

Fax: (317) 278-3327<br />

E-mail: lrubin@iupui.edu<br />

Website: https://www.ngvbcc.org<br />

Booth Number: 412<br />

The National <strong>Gene</strong> Vector Biorepository provides support<br />

for gene therapy research by <strong>of</strong>fering several services. Check<br />

out the reagent repository comprising cell lines, plasmids,<br />

vectors and other tools used in gene therapy research. There<br />

are archiving services to meet FDA requirements. The NGVB<br />

will store clinical post-trial samples, inal product reserves,<br />

and master cell banks as well as pharmacology/toxicology<br />

samples. A pharm/tox database containing gene therapy<br />

tox studies is a valuable resource. We <strong>of</strong>fer assistance<br />

with insertional mutagenesis analysis through the SeqMap<br />

Bioinformatics Tool. Check out the <strong>Gene</strong> <strong>Therapy</strong> Data Map a<br />

tool for locating gene therapy research. Go to https://www.<br />

ngvbcc.org or come and see us in Booth 412.<br />

Nature Publishing Group<br />

75 Varick Street, 9th Floor<br />

New York, NY 10013-1917<br />

Phone: (212) 726-9200<br />

Fax: (212) 689-9711<br />

E-mail: institutions@nature.com<br />

Website: www.nature.com<br />

Booth Number: 402<br />

Nature Publishing Group brings you leading scientiic and<br />

medical research. The NPG portfolio combines the continued<br />

excellence <strong>of</strong> Nature, its associated research and review<br />

journals, and 50 leading academic and society journals in the<br />

life, physical and clinical sciences. Visit Booth 402 for free<br />

sample copies.<br />

Nature Technology Corporation<br />

4701 Innovation Drive<br />

Lincoln, NE 68521<br />

Phone: (402) 323-6289<br />

Fax: (402) 323-6292<br />

E-mail: hodgson@natx.com<br />

Website: www.natx.com<br />

Booth Number: 312<br />

Nature Technology Corporation is a biotechnology<br />

company that provides industry partners with world class<br />

technology platforms including safe and eficacious nonviral<br />

vectors (plasmids) and processes for gene therapy<br />

and DNA vaccination vector production. NTC also provides<br />

cost effective outsourcing <strong>of</strong> product development services<br />

including synthetic gene design, vector construction, plasmid<br />

DNA manufacturing and recombinant proteins.<br />

Nexcelom Bioscience<br />

360 Merrimack Street, Building 9<br />

Lawrence, MA 01843<br />

Phone: (978) 327-5340<br />

Fax: (978) 327-5341<br />

E-mail: lvavra@nexcelom.com<br />

Website: www.nexcelom.com<br />

Booth Number: 114<br />

Nexcelom’s <strong>Cell</strong>ometer line <strong>of</strong> simple-to-use cell counters<br />

automate manual cell counting procedures by obtaining<br />

accurate counts, viability, and cell sizes in less than 30<br />

seconds & only 20uL <strong>of</strong> sample. Fluorescence detection<br />

capabilities enable fast & simple determination <strong>of</strong> GFP<br />

transfection rates, PI-viability, & direct counting <strong>of</strong> WBCs<br />

without lysing.<br />

NHLBI <strong>Gene</strong> <strong>Therapy</strong> Resource <strong>Program</strong><br />

2 Rockledge Center, 6701 Rockledge Drive<br />

Bethesda, MD 20892-7940<br />

Phone: (301) 435-0477<br />

Fax: (301) 628-1929<br />

E-mail: gtrpccc@s-3.com<br />

Website: www.gtrp.org<br />

Booth Number: 408<br />

The NHLBI <strong>Gene</strong> <strong>Therapy</strong> Resource <strong>Program</strong> (GTRP)<br />

facilitates the translation <strong>of</strong> gene therapy research<br />

into clinical interventions primarily in heart, lung, and<br />

blood diseases. Services provided by the <strong>Program</strong><br />

include preclinical and clinical-grade vector production,<br />

pharmacology/toxicology testing, immunology testing,<br />

assistance with regulatory activities, and partial inancial<br />

support <strong>of</strong> clinical trials.<br />

NIH Office <strong>of</strong> Biotechnology Activities<br />

6705 Rockledge Dr.<br />

Suite 750<br />

Bethesda, MD 20892-7985<br />

Phone: (301) 496-9838<br />

Fax: (301) 496-9839<br />

E-mail: oba@od.nih.gov<br />

Website: http://oba.od.nih.gov<br />

Booth Number: 105<br />

NIH Ofice <strong>of</strong> Biotechnology Activities staff is available to<br />

answer questions about human gene transfer research<br />

under the NIH Guidelines and provide information about<br />

GeMCRIS, a web-based, information resource and analytical<br />

tool that provides information about HGT trials and enables<br />

investigators to ile adverse event and annual reports<br />

electronically.<br />

82<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Exhibitor Descriptions<br />

Panasonic Healthcare Company <strong>of</strong> North America<br />

1300 Mitchell Drive, Suite A<br />

Wood Dale, IL 60191<br />

Phone: (800) 858-8442<br />

Fax: (630) 238-0074<br />

E-mail: phc_info@us.panasonic.com<br />

Website: www.panasonic.com/biomedical<br />

Booth Number: 411<br />

Panasonic Healthcare Company is a global, leading provider<br />

<strong>of</strong> energy, environment, and lifestyle applications with<br />

laboratory equipment for pharmaceutical, life science and<br />

biotechnology applications. Product lines include spaceeficient<br />

VIP ® ultra-low temperature freezers, cryogenic<br />

freezers, pharmaceutical and medical refrigerators, cell<br />

culture incubators, plant growth chambers, and portable<br />

autoclaves.<br />

Penn Vector Core<br />

125 South 31st Street, Suite 2000<br />

University <strong>of</strong> Pennsylvania<br />

<strong>Gene</strong> <strong>Therapy</strong> <strong>Program</strong><br />

Perelman School <strong>of</strong> Medicine<br />

Philadelphia, PA 19104<br />

Phone: (215) 573-0633<br />

Fax: (215) 261-2442<br />

E-mail: aksandhu@mail.med.upenn.edu<br />

Website: http://www.med.upenn.edu/gtp/vector_core.shtml<br />

Booth Number: 410<br />

Penn Vector Core is a state-<strong>of</strong>-the-art viral vector production<br />

facility for investigators both within and external to the<br />

University <strong>of</strong> Pennsylvania. The main objective <strong>of</strong> the Core is<br />

to make various types <strong>of</strong> high quality viral vectors for gene<br />

transfer/Vaccine studies at the preclinical and basic research<br />

level.<br />

PerkinElmer<br />

68 Elm Street<br />

Hopkinton, MA 01748<br />

Phone: (781) 663-6900<br />

E-mail: CustomerCareUS@perkinelmer.com<br />

Website: www.perkinelmer.com<br />

Booth Number: 101<br />

Biological complexity raises questions requiring<br />

translational research from the well, to the cell, to the animal<br />

and back again. PerkinElmer enables you to approach<br />

your target from multiple perspectives: locate, detect and<br />

quantitate your biology <strong>of</strong> interest; analyze and understand<br />

it in wider physiological contexts.<br />

PolyPlus-Transfection<br />

Bioparc BP 90018<br />

Illkirch SA 67401<br />

France<br />

Phone: 33-(0)3-90-40-61-80<br />

Fax: 33-(0)3-90-40-61-81<br />

E-mail: info@polyplus-transfection.com<br />

Website: www.polyplus-transfection.com<br />

Booth Number: 104<br />

Polyplus transfection provides state-<strong>of</strong>-the-art quality<br />

transfection reagents for in vitro and in vivo DNA and<br />

siRNA delivery. Polyplus also <strong>of</strong>fers qualiied reagents for<br />

bioproduction including virus production for the clinic and<br />

supplies GMP grade reagents for human gene therapy and<br />

cell therapy clinical trials.<br />

REGENX Biosciences, LLC<br />

750 17th Street NW<br />

Suite 1100<br />

Washington, DC 20006<br />

Phone: (202) 778-2365<br />

Fax: (202) 785-7439<br />

E-mail: jbrown@regenxbio.com<br />

Website: www.regenxbio.com<br />

Booth Number: 401<br />

REGENX BioSciences is leading the effort to translate<br />

promising gene delivery applications into a pipeline <strong>of</strong><br />

next generation personalized therapies for a range <strong>of</strong><br />

severe diseases with serious unmet needs. We believe that<br />

the NAV technology, to which we have exclusive rights,<br />

represents the potential promise <strong>of</strong> curing the root cause <strong>of</strong><br />

disease rather than the symptoms, and we are committed to<br />

establishing best in class standards for our NAV vectors.<br />

SAFC<br />

BioReliance by SAFC<br />

Glasgow G20 0XA<br />

UNITED KINGDOM<br />

Phone: +44(0)141 576 2462<br />

Fax: +44(0)141 948 0000<br />

E-mail: susan.livingston@bioreliance.com<br />

Website: www.safcglobal.com<br />

Booth Number: 115<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

83


Exhibitor Descriptions<br />

St. Jude Children’s Research Hospital<br />

262 Danny Thomas Place<br />

Memphis, TN 38015<br />

Phone: (901) 595-2750<br />

Fax: (901) 595-5376<br />

E-mail: postdoc@stjude.org<br />

Website: www.stjude.org/research<br />

Booth Number: 215<br />

At St Jude Children ’s Research Hospital, a non-proit<br />

biomedical research institution in Memphis, TN, 190 basic<br />

science and clinical researchers investigate the molecular<br />

basis <strong>of</strong> normal cellular and diseased processes. Visit our<br />

booth to discuss and apply for Postdoctoral Fellowship<br />

positions.<br />

Contact Information:<br />

St. Jude Children’s Research Hospital<br />

Ofice <strong>of</strong> Academic <strong>Program</strong>s<br />

262 Danny Thomas Place, MS 276<br />

Memphis, TN 38105<br />

Email: postdoc@stjude.org<br />

http://www.stjude.org/research<br />

The Baker Company<br />

P. O. Drawer E<br />

Sanford, ME 04073<br />

Phone: (800) 992-2537<br />

Fax: (207) 324-3869<br />

E-mail: bakerco@bakerco.com<br />

Website: www.bakerco.com<br />

Booth Number: 302 & 304<br />

For 60 years, The Baker Company has delivered high quality<br />

contamination control products to meet the unique and<br />

evolving needs <strong>of</strong> laboratory pr<strong>of</strong>essionals. Learn about<br />

our new generation <strong>of</strong> high-performance, precision-crafted<br />

biomedical refrigeration, controlled atmosphere and<br />

Ruskinn hypoxia workstations on our website at www.<br />

bakerco.com.<br />

TriLink BioTechnologies, Inc.<br />

9955 Mesa Rim Road<br />

San Diego, CA 92121<br />

Phone: (858) 546-0004<br />

Fax: (858) 546-0020<br />

E-mail: info@trilinkbiotech.com<br />

Website: www.trilinkbiotech.com<br />

Booth Number: 301<br />

TriLink manufactures custom oligonucleotides, modiied<br />

nucleoside triphosphates and CleanAmp PCR products<br />

for the diagnostic and OEM markets. In addition, custom<br />

chemistry, long RNA transcript synthesis and contract<br />

research services and ISO/QSR compliant cGMP production<br />

facilities are <strong>of</strong>fered. TriLink’s solutions help advance drug<br />

discovery and biomedical research.<br />

UAB Vector Production Facility<br />

550 11th Street South<br />

Birmingham, AL 35294-4558<br />

Phone: (205) 975-9871<br />

Fax: (205) 934-9511<br />

E-mail: tvstrong@uab.edu<br />

Website: www.uab.edu/vector/<br />

Booth Number: 316<br />

The goal <strong>of</strong> the UAB Vector Production Facility (VPF) is to<br />

accelerate the translation <strong>of</strong> novel biological therapies into<br />

Phase I human clinical trials. The UAB VPF produces largescale,<br />

high quality viral vectors, cell banks and recombinant<br />

proteins for research and clinical applications, in accordance<br />

with current Good Manufacturing Practices.<br />

UNC <strong>Gene</strong> <strong>Therapy</strong> Vector Core<br />

7119 Thurston Bowles<br />

Chapel Hill, NC 27599<br />

Phone: (919) 962-3285<br />

Fax: (919) 843-9410<br />

E-mail: vectorcore@unc.edu<br />

Website: http://genetherapy.unc.edu/jvl.htm<br />

Booth Number: 102<br />

University <strong>of</strong> Iowa/<strong>Gene</strong> Transfer Vector Core<br />

<strong>Gene</strong> Transfer Vector Core<br />

500 Newton Road<br />

221 EMRB<br />

Iowa City, IA 52242<br />

Phone: (319) 335-6726<br />

Fax: (319) 335-6895<br />

E-mail: maria-scheel@uiowa.edu<br />

Website: www.uiowa.edu/~gene/<br />

Booth Number: 313<br />

The GTVC’s objective is to support investigators in the<br />

use <strong>of</strong> gene transfer technologies. The Core utilizes<br />

molecular biology techniques to engineer and develop viral<br />

vectors based on multiple vector systems. Core staff and<br />

investigators work together allowing for cross fertilization<br />

<strong>of</strong> ideas, technical advancements, and innovations in vector<br />

design.<br />

84<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Exhibitor Descriptions<br />

University <strong>of</strong> Utah Blood & Marrow Transplant<br />

<strong>Program</strong> - <strong>Cell</strong> <strong>Therapy</strong> & Regenerative Medicine<br />

Facility<br />

675 Arapeen Dr., Suite 300<br />

Salt Lake City, UT 84108<br />

Phone: (801) 585-6262<br />

Fax: (801) 585-3222<br />

E-mail: joanna.reems@hsc.utah.edu<br />

Website: http://medicine.utah.edu/cell/<br />

Booth Number: 314<br />

The <strong>Cell</strong> <strong>Therapy</strong> and Regenerative Medicine <strong>Program</strong> at<br />

the University <strong>of</strong> Utah supports Hematopoietic stem cell<br />

transplants and delivers innovative cellular and tissue<br />

engineered products to patients by providing comprehensive<br />

“bench to bedside” services that coordinate the efforts <strong>of</strong><br />

clinicians, researchers, and bioengineers.<br />

VGXI, Inc.<br />

2700 Research Forest Drive<br />

Suite 180<br />

The Woodlands, TX 77381<br />

Phone: (281) 296-7300<br />

Fax: (281) 296-7333<br />

E-mail: info@vgxii.com<br />

Website: www.vgxii.com<br />

Booth Number: 116<br />

VGXI Inc. is a leading provider <strong>of</strong> DNA plasmid<br />

manufacturing and development services for DNA vaccine<br />

and gene therapy clinical research. The Company has an<br />

outstanding track record <strong>of</strong> success manufacturing plasmid<br />

products under GMP for clients in the US, Europe, and<br />

Australia.<br />

Waisman Biomanufacturing<br />

1500 Highland Avenue<br />

Madison, WI 53705<br />

Phone: (608) 263-8940<br />

E-mail: info@gmpbio.org<br />

Website: www.gmpbio.org<br />

Booth Number: 213<br />

Waisman Biomanufacturing has in-depth experience<br />

manufacturing a wide range <strong>of</strong> biotherapeutics for human<br />

Phase I/II clinical trials including gene therapeutics, cell<br />

therapeutics, vaccines, and recombinant proteins. Services<br />

include process development through cGMP production<br />

and ill/inish capabilities— all with full quality system<br />

support—and comprehensive support for your IND iling.<br />

Wilson Wolf Corporation<br />

33 5th Avenue, NW<br />

New Brighton, MN 55112<br />

Phone: (651) 628-9259<br />

Fax: (651) 628-9259<br />

E-mail: info@wilsonwolf.com<br />

Website: www.wilsonwolf.com<br />

Booth Number: 111<br />

Wilson Wolf created “G-Rex” technology to simplify and<br />

reduce the cost cell production for Adoptive <strong>Cell</strong> <strong>Therapy</strong>.<br />

<strong>Cell</strong> production in G-Rex devices saves material and labor<br />

while simultaneously shortening production time, allowing<br />

the most practical and cost effective process for research and<br />

clinical work. Stop by our booth for details.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

85


Exhibitor Information<br />

<strong>Gene</strong>ral Information<br />

The Exhibit Hall is located in Hall C/D <strong>of</strong> the Salt Palace<br />

Convention Center. All participants are urged to allow<br />

adequate time to visit the exhibits. The companies,<br />

organizations and institutions exhibiting at the ASGCT<br />

16th Annual Meeting will be providing you with the latest<br />

information on products and services directly related to<br />

your pr<strong>of</strong>essional needs, as well as recruiting for open<br />

positions.<br />

Exhibit Dates<br />

Exhibits will be open Wednesday, May 15 through Friday,<br />

May 17, 2013.<br />

Exhibitor Registration<br />

The Exhibitor Registration Desk is located at the East<br />

Registration Area – by the East Entrance on the 2nd loor <strong>of</strong><br />

the Salt Palace Convention Center<br />

Exhibitor Registration Desk Hours<br />

Tuesday, May 14 5:00 pm – 7:00 pm<br />

Wednesday, May 15 7:00 am – 7:30 pm<br />

Thursday, May 16 7:00 am – 6:30 pm<br />

Friday, May 17<br />

7:30 am – 7:30 pm<br />

Exhibit Move In<br />

Wednesday, May 15 9:00 am – 5:00 pm<br />

Exhibit Hall Hours<br />

Wednesday, May 15 5:15 pm – 7:15 pm<br />

Thursday, May 16 9:35 am – 10:30 am<br />

Thursday, May 16 4:00 pm – 6:00 pm<br />

Friday, May 17<br />

9:00 am – 9:45 am<br />

Friday, May 17<br />

5:30 pm – 7:30 pm<br />

Exhibit Move Out<br />

Friday, May 17<br />

7:30 pm – 9:30 pm<br />

Note: All exhibit booths must be staffed during hall hours.<br />

Packing <strong>of</strong> equipment/literature and the dismantling <strong>of</strong><br />

exhibits will not be permitted until after 7:30 pm on Friday,<br />

May 17, 2013.<br />

Exhibitor Badge Policy<br />

Admission to the Exhibit Hall will be by name badge only.<br />

Security guards will monitor exhibit hall entrances for<br />

proper I.D. Exhibit booth personnel must show an <strong>of</strong>icial<br />

ASGCT exhibitor name badge in order to gain access to the<br />

exhibit hall during installation, show, or dismantlement<br />

hours. Independent contractor personnel, hired by<br />

an exhibitor to install and dismantle their display, do<br />

not need to show exhibitor badges, but should possess<br />

identiication that they are employed by the independent<br />

contractor. If independent contractors do not possess proper<br />

identiication, they should obtain a name badge at the onsite<br />

exhibitor registration desk.<br />

Endorsement Disclaimer<br />

Products and services displayed in the Exhibit Hall or<br />

advertised in this program occur by contractual business<br />

arrangements between the ASGCT and participating<br />

companies and organizations. These arrangements do not<br />

constitute or imply an endorsement by the ASGCT <strong>of</strong> these<br />

products and services.<br />

86<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Wednesday, May 15, 2013<br />

Oral Abstract Session 130<br />

AAV Vector Development & Application<br />

3:15 PM - 5:15 PM<br />

Room: Ballroom A<br />

1 3:15 PM<br />

Identiication <strong>of</strong> Novel Vectors Capable <strong>of</strong> CNS<br />

Transduction in Adult Mice after Single Round<br />

Selection Using DNA Shufled AAV Capsid Library<br />

Sourav Choudhury, Stacy Maitland, Jennifer Ferreira, Miguel<br />

Sena-Esteves.<br />

2 3:30 PM<br />

Re-Engineering Capsid-Glycan Interactions Expands the<br />

CNS Transduction Proile <strong>of</strong> AAV Serotype 4<br />

Giridhar Murlidharan, Laura Sommerville, Troy Ghashghaei,<br />

Aravind Asokan.<br />

3 3:45 PM<br />

Directed Evolution <strong>of</strong> Adeno-Associated Virus for<br />

Enhanced <strong>Gene</strong> Delivery to Neural Stem <strong>Cell</strong>s In Vitro<br />

and In Vivo<br />

David V. Schaffer, Melissa A. Bartel, Jae-Hyung Jang, Tandis Vazin.<br />

4 4:00 PM<br />

A Rationally Engineered Novel Capsid Variant <strong>of</strong> AAV9<br />

for Pripheral Tissue-Detargeted and CNS-Directed<br />

Systemic <strong>Gene</strong> Delivery<br />

Li Zhong, Shaoyong Li, Kim Van Vliet, Mengxin Li, Jun Xie, Jia<br />

Li, Qin Su, Ran He, Yu Zhang, Huapeng Li, Dan Wang, Jason<br />

Goetzmann, Terence R. Flotte, Mavis Agbandje-McKenna,<br />

Guangping Gao.<br />

5 4:15 PM<br />

In Vivo Directed Evolution <strong>of</strong> a Novel Adeno-Associated<br />

Virus for Therapeutic Outer Retinal <strong>Gene</strong> Delivery from<br />

the Vitreous<br />

Leah C. Byrne, Deniz Dalkara, Ryan R. Klimczak, Meike Visel, Lu<br />

Yin, William H. Merigan, John G. Flannery, David V. Schaffer.<br />

6 4:30 PM<br />

Adeno-Associated Virus Capsid Motif That Inluences<br />

Tissue Speciic Vector Transduction In Vivo<br />

Jayme K. Warischalk, Richard J. Samulski.<br />

7 4:45 PM<br />

A Species Restricted rAAV Vector Obtained from Viral<br />

Capsid Shufling<br />

Leszek Lisowski, Kirk Chu, Mark A. Kay.<br />

8 5:00 PM<br />

Solving the T-<strong>Cell</strong> Problem: <strong>Gene</strong>ration <strong>of</strong> Immune<br />

Stealth AAV<br />

Thierry VandenDriessche, Frederico Mingozzi, Nisha Nair, Jessica<br />

Willems, Hanneke Evens, Omid Ghandeharian, Kathy High,<br />

Marinee K. Chuah.<br />

Oral Abstract Session 131<br />

Cancer Immunotherapy I<br />

3:15 PM - 5:15 PM<br />

Room: Ballroom B<br />

9 3:15 PM<br />

Enhanced DNA Vaccination Against a Tyrosinase (Tyr)<br />

Mediates Protection and Targets Myeloid-Derived<br />

Suppressor <strong>Cell</strong>s in a Syngeneic Murine Model<br />

Taron C. Gorham, Lavanya Mahadevan, Colleen Lucke, Randolph<br />

Lyde, Kenneth E. Ugen, Niranjan Y. Sardesai, Joseph J. Kim,<br />

Karuppiah Muthumani, David B. Weiner.<br />

10 3:30 PM<br />

First-in-Human Application <strong>of</strong> Sleeping Beauty System<br />

for <strong>Gene</strong> <strong>Therapy</strong><br />

Partow Kebriaei, Helen Huls, Harjeet Singh, Simon Olivares,<br />

Matthew J. Figliola, Margaret Dawson, Bipulendu Jena, Rineka<br />

Jackson, Doyle Bosque, Ian McNiece, Gabriela Rondon, Perry B.<br />

Hackett, Elizabeth J. Shpall, Richard E. Champlin, Laurence J. N.<br />

Cooper.<br />

11 3:45 PM<br />

AAV-Mediated CNS <strong>Gene</strong> Transfer <strong>of</strong> Bevacizumab<br />

Reduces Human Glioblastoma Growth and Increases<br />

Survival in Mice<br />

Martin J. Hicks, Kosuke Funato, Lan Wang, Eric Aronowitz,<br />

Jonathan P. Dyke, Douglas J. Ballon, Vivianne S. Tabar, David F.<br />

Havlicek, Esther Z. Frenk, Bishnu P. De, Maria J. Chiuchiolo, Dolan<br />

Sondhi, Neil R. Hackett, Stephen M. Kaminsky, Ronald G. Crystal.<br />

12 4:00 PM<br />

NKT <strong>Cell</strong>s as a Novel Platform for Cancer<br />

Immunotherapy with Chimeric Antigen Receptors<br />

Andras Heczey, Da<strong>of</strong>eng Liu, Amy Courtney, Ekaterina Marinova,<br />

Gengwen Tian, Eric Yvon, Jie Wei, Gianpietro Dotti, Leonid<br />

Metelitsa.<br />

13 4:15 PM<br />

Removal <strong>of</strong> Physical Barriers inside the Tumor<br />

Improves T-<strong>Cell</strong> <strong>Therapy</strong><br />

Hua Cao, Ines Beyer, Vy Phan-Lai, Nora Disis, Andre Lieber.<br />

14 4:30 PM<br />

Administration <strong>of</strong> GD2 Chimeric Antigen<br />

Receptor Modiied, Tri-Virus Speciic Cytotoxic T<br />

Lymphocytes after HLA Mismatched Allogeneic<br />

Stem <strong>Cell</strong> Transplantation for Relapsed, Refractory<br />

Neuroblastoma<br />

Doug Myers, Jiali Sun, Cliona M. Rooney, Natalia Lapteva, Adrian<br />

P. Gee, Gianpietro Dotti, Bambi Grilley, Malcolm K. Brenner, Robin<br />

Ryan.<br />

15 4:45 PM<br />

Nonclinical and Phase I Clinical Studies with a<br />

Regulated Adenoviral <strong>Gene</strong> Delivery <strong>of</strong> IL-12 Shows<br />

Promising Clinical Activity in Unresectable Stage III/IV<br />

Melanoma<br />

A. Vergara-Silva, J. Barrett, A. Marsh, R. Khosravi-Far, L. A. Martell,<br />

O. Hamid, T. Chan, T. D. Reed, H. Youssouian, J. Nemunaitis.<br />

Wednesday, May 15, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

87


Wednesday, May 15, 2013<br />

Abstract Directory, Wednesday, May 15, 2013<br />

Oral Abstract Session 131, continued<br />

Cancer Immunotherapy I<br />

3:15 PM - 5:15 PM<br />

Room: Ballroom B<br />

16 5:00 PM<br />

Effective and Safe <strong>Gene</strong>-Modiied T <strong>Cell</strong>s Expressing<br />

High Afinity NYESO-1 Speciic TCR Variants with<br />

Silencing Endogenous TCRs<br />

Sachiko Okamoto, Yasunori Amaishi, Hiroaki Ikeda, Hiroshi Shiku,<br />

Junichi Mineno.<br />

Oral Abstract Session 132<br />

Cancer-Oncolytic Viruses<br />

3:15 PM - 5:15 PM<br />

Room: 150 DEFG<br />

17 3:15 PM<br />

Intraperitoneal (IP) Administration <strong>of</strong> an Oncolytic<br />

Measles Virus (MV) Strain Expressing the Sodium<br />

Iodine Symporter <strong>Gene</strong> in Patients (pts) with Advanced<br />

Ovarian Cancer (OvCa)<br />

Evanthia Galanis, Pamela Atherton, Sean Dowdy, William Cliby,<br />

Paul Haluska, Jr, Harry Long, Ileana Aderca, Keith Knutson,<br />

Matthew Block, Mark Federspiel, Stephen Russell, Kah Whye Peng,<br />

Lynn Hartmann.<br />

18 3:30 PM<br />

In Vivo Expansion <strong>of</strong> a Recipient Population <strong>of</strong> <strong>Cell</strong><br />

Carriers Allows for Highly Effective Systemic Delivery <strong>of</strong><br />

Oncolytic Reovirus Even in the Presence <strong>of</strong> Neutralizing<br />

Antibody<br />

Timothy Kottke, Oliver Donnelly, Elizabeth Ilett, Jill Thompson,<br />

Rosa Diaz, Matt C<strong>of</strong>fey, Peter Selby, Hardev Pandha, Kevin<br />

Harrington, Alan Melcher, Richard Vile.<br />

19 3:45 PM<br />

Baseline Neutralizing Antibody Status Does Not Affect<br />

Intravenous Delivery <strong>of</strong> Oncolytic Vaccinia Pexa-Vec (JX-<br />

594) in Liver Cancer Patients<br />

Caroline J. Breitbach, Jeong Heo, Mong Cho, Anne Moon, Chang<br />

Won Kim, James Burke, Theresa Hickman, Kara Dubois, Yeon<br />

Sook Lee, Manijeh Daneshmand, John C. Bell, Richard Patt, Tae-Ho<br />

Hwang, David H. Kirn.<br />

20 4:00 PM<br />

Induction <strong>of</strong> Antiviral <strong>Gene</strong>s by the Tumor<br />

Microenvironment Confers Resistance to Virotherapy<br />

Yu-Ping Liu, Lukkana Suksanpaisan, Stephen J. Russell, Kah-Whye<br />

Peng.<br />

21 4:15 PM<br />

Superior Antitumoral Activity Induced by a Novel<br />

Oncolytic Adenovirus Armed with an EGFR-Targeted<br />

ImmunoRNase<br />

Ines Fernandez-Ulibarri, Michaela A. E. Arndt, Dominik E. Dorer,<br />

Sarah Engelhardt, Jürgen Krauss, Dirk M. Nettelbeck.<br />

22 4:30 PM<br />

The Oncolytic and Immunotherapeutic Vaccinia<br />

Virus Pexa-Vec (JX-594) Induces Antibody-Mediated<br />

Complement-Dependent Cancer <strong>Cell</strong> Cytolysis<br />

Mi Kyung Kim, Caroline H. Breitbach, Anne Moon, Jeong Heo, Yu<br />

Kyung Lee, Mong Cho, Jun Woo Lee, Seung Geun Kim, Dae Hwang<br />

Kang, Byung Ho Park, John C. Bell, David H. Kirn, Tae-Ho Hwang.<br />

23 4:45 PM<br />

Modulation <strong>of</strong> Innate Immunity with the Anti-CTLA4<br />

Antibody Ipilimumab (Ipi) in Measles Virotherapy for<br />

Glioblastoma<br />

Jayson J. Hardcastle, Hirosha Geekiyanage, Evidio Domingo<br />

Musibay, Cory Allen, Jin Fang, Aaron Johnson, Evanthia Galanis.<br />

24 5:00 PM<br />

Human Bone Marrow-Derived Mesenchymal<br />

Stromal <strong>Cell</strong>s Permit Delivery, and Enhance Eficacy<br />

<strong>of</strong> Systemically Administered Oncolytic Measles<br />

Virotherapy to Disseminated Human Pre-B ALL Murine<br />

Xenograft Models in the Presence <strong>of</strong> Humoral Immunity<br />

Anna Castleton, Aditi Dey, Bella Patel, Brendan Beaton, Anne<br />

Aucher, Daniel Davis, Adele Fielding.<br />

Oral Abstract Session 133<br />

Advancing the Science <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> for<br />

Hematologic Diseases<br />

3:15 PM - 5:15 PM<br />

Room: Ballroom C<br />

25 3:15 PM<br />

Improved Chemotherapy Eficacy after MGMT(P140K)<br />

Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> in Poor-<br />

Prognosis Glioblastoma by Patient-Speciic<br />

Mathematical Modeling<br />

Jennifer E. Adair, Brian C. Beard, Sandra K. Johnston, Maciej M.<br />

Mrugala, Russell C. Rockne, Kristin R. Swanson, Hans-Peter Kiem.<br />

26 3:30 PM<br />

Therapeutic Levels <strong>of</strong> Anti-Sickling Hemoglobin<br />

Production in Erythroid Progeny <strong>of</strong> Sickle <strong>Cell</strong> Disease<br />

CD34+ <strong>Cell</strong>s Following Lentivirus Vector-Mediated <strong>Gene</strong><br />

Delivery<br />

Fabrizia Urbinati, Phillip W. Hargrove, Sabine Geiger, Zulema<br />

Romero, Jennifer Wherley, Michael L. Kaufman, Roger P. Hollis,<br />

Christopher B. Chambers, Derek A. Persons, Donald B. Kohn,<br />

Andrew Wilber.<br />

27 3:45 PM<br />

Superior Stem <strong>Cell</strong> Mobilization by a Combination <strong>of</strong><br />

Plerixafor+G-CSF in Patients with Thalassemia<br />

Evangelia Yannaki, Achilles Anagnostopoulos, Garyfalia<br />

Karponi, Fani Zervou, Varnavas Constantinou, Nikoleta Psatha,<br />

Asimina Bouinta, Erica Jonlin, Thalia Papayannopoulou, George<br />

Stamatoyannopoulos.<br />

88<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Wednesday, May 15, 2013<br />

Oral Abstract Session 133, continued<br />

Advancing the Science <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> for<br />

Hematologic Diseases<br />

3:15 PM - 5:15 PM<br />

Room: Ballroom C<br />

28 4:00 PM<br />

Tracking Fate and Plasticity <strong>of</strong> T <strong>Cell</strong>s in Humans by<br />

Retroviral Tagging<br />

Luca Biasco, Serena Scala, Cristina Baricordi, Nicoletta Cieri,<br />

Andrea Calabria, Eugenio Montini, Chiara Bonini, Alessandro Aiuti.<br />

29 4:15 PM<br />

Quantitative Tracking <strong>of</strong> the Output <strong>of</strong> Individual<br />

Hematopoietic Stem/Progenitor <strong>Cell</strong>s in a Non-Human<br />

Primate Model<br />

Chuanfeng Wu, Brian Li, Rong Lu, Alexander Jares, Robert<br />

Donahue, Irving Weissman, Cynthia Dunbar.<br />

30 4:30 PM<br />

Evaluation <strong>of</strong> Transduced CD34+ <strong>Cell</strong>s To Predict <strong>Gene</strong><br />

Marking Levels In Vivo in Rhesus <strong>Gene</strong> <strong>Therapy</strong> Model<br />

Naoya Uchida, Molly Evans, Aylin Bonifacino, Sandra Price, Allen<br />

Krouse, Mark Metzge, Matthew Hsieh, Robert Donahue, John<br />

Tisdale.<br />

31 4:45 PM<br />

Unimolecular Microchimerism Achieved through<br />

Hematopoietic Stem <strong>Cell</strong> Transplantation <strong>Gene</strong> <strong>Therapy</strong><br />

Facilitates Adjunctive <strong>Therapy</strong> with <strong>Gene</strong>tically-<br />

Modiied Mesenchymal Stem <strong>Cell</strong>s in Hemophilia A<br />

Allison M. Abuin, H. Trent Spencer, Christopher B. Doering.<br />

32 5:00 PM<br />

Rapamycin Treatment <strong>of</strong> Hematopoietic Stem <strong>Cell</strong>s<br />

Enhances Lentiviral Transduction through Autophagy<br />

Xueqian Wang**, Blythe D. Sather**, Iram Khan, Swati Singha,<br />

Gabrielle Curinga, David J. Rawlings, Bruce Torbett.<br />

Oral Abstract Session 134<br />

Neurological <strong>Therapy</strong>: Monogeneic Disorders<br />

3:15 PM - 5:15 PM<br />

Room: Ballroom D<br />

33 3:15 PM<br />

Intravenous AAV8-MTM1 Prolongs Life and<br />

Ameliorates Severe Muscle Pathology in Mouse and Dog<br />

Models <strong>of</strong> X-Linked Myotubular Myopathy<br />

Martin K. Childers, Romain Joubert, Melanie N. Holder, Robert<br />

W. Grange, Jon Doering, Michael W. Lawlor, Christelle Moal,<br />

Thibaud Jamet, Nathalie Daniele, Samia Martin, Christel Riviere,<br />

Kimberly Poppante, Thomas Soker, Caroline Hammer, Laetitia Van<br />

Wittenberghe, Melissa Goddard, Erin Mitchell, Jane Barber, Mark<br />

E. Furth, Alban Vignaud, Carole Masurier, Philippe Moullier, Alan<br />

H. Beggs, Alan H. Beggs, Anna Buj-Bello.<br />

34 3:30 PM<br />

Augmenting CNS Glucocerebrosidase Activity as a<br />

Therapeutic Strategy for Parkinsonism and Other<br />

Gaucher-Related Synucleinopathies<br />

Pablo S. Sardi, Lamya S. Shihabuddin, Richard L. Sidman, Seng H.<br />

Cheng.<br />

35 3:45 PM<br />

Eficacious and Sustained Canavan <strong>Gene</strong> <strong>Therapy</strong> by<br />

Single rAAV Injections Via IV at Postnatal Day 21 or ICV<br />

at a 100 Fold Lower Dose<br />

Seemin S. Ahmed, Reuben Matalon, Guangping Gao.<br />

36 4:00 PM<br />

Dramatic Phenotypic Improvement after Adeno-<br />

Associated Virus <strong>Gene</strong> <strong>Therapy</strong> in a Feline Model <strong>of</strong><br />

Sandh<strong>of</strong>f Disease<br />

Victoria J. McCurdy, Heather L. Gray-Edwards, Ashley N. Randle,<br />

Allison M. Bradbury, Aime K. Johnson, Patricia M. Beadlescomb,<br />

Nancy Morrison, Misako Hwang, Miguel Sena-Esteves, Douglas R.<br />

Martin.<br />

37 4:15 PM<br />

Preclinical Safety and Eficacy <strong>of</strong> Human CD34+ <strong>Cell</strong>s<br />

Transduced with Lentiviral Vector for the Treatment <strong>of</strong><br />

Adrenoleukodystrophy<br />

Lauryn Christiansen, Maria Denaro, John Pierciey, Anne Moser,<br />

Cynthia Bartholoma, Michael Rothe, Robert Kutner, Christopher<br />

Baum, Byoung Ryu, Manfred Schmidt, Garrett Heffner, Mitchell<br />

Finer, Gabor Veres.<br />

38 4:30 PM<br />

Preclinical Evaluation <strong>of</strong> Systemic Delivery <strong>of</strong> Blood-<br />

Brain Barrier-Targeted IDUA in Treating CNS Deicits <strong>of</strong><br />

Mice with Hurler Syndrome after Long Term Stem <strong>Cell</strong><br />

<strong>Gene</strong> <strong>Therapy</strong><br />

Salim S. El-Amouri, Mei Dai, Dao Pan.<br />

39 4:45 PM<br />

Broad Correction <strong>of</strong> Molecular Impairments by a<br />

Single Systemic rAAVrh74-hSGSH <strong>Gene</strong> Delivery in a<br />

Mouse Model <strong>of</strong> MPS IIIA: Links between the Brain and<br />

Peripheral Blood<br />

F. Jason Duncan, Bartholomew J. Naughton, Kimberly Zaraspe,<br />

Darren Murrey, Tierra Ware, Aaron Meadows, Haiyan Fu, Douglas<br />

McCarty.<br />

40 5:00 PM<br />

Amelioration <strong>of</strong> Neurologic Disease after AAV-<strong>Gene</strong><br />

<strong>Therapy</strong> in a Sheep Model <strong>of</strong> Tay-Sachs Disease<br />

H. L. Gray-Edwards, S. M. Hubbard, A. E. Randle, M. Hwang, A. M.<br />

Bradbury, V. J. McCurdy, D. U. Wilson, J. A. Hudson, B. K. Whitlock,<br />

J. L. Sartin, N. Salibi, R. J. Beyers, T. S. Denney, J. A. Johnson, K. P.<br />

Riddell, N. R. Cox, M. Sena-Estevez, D. R. Martin.<br />

Wednesday, May 15, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

89


Wednesday, May 15, 2013<br />

Abstract Directory, Wednesday, May 15, 2013<br />

Oral Abstract Session 135<br />

Chemical and Molecular Conjugates<br />

3:15 PM - 4:15 PM<br />

Room: 151 ABCG<br />

41 3:15 PM<br />

Optimized Polyplexes That Avoid Liver Uptake and<br />

Maintain Eficient <strong>Gene</strong> Transfer In Vivo<br />

Sanjib Khargharia, Koby Kizzire, Mark E. Ericson, Nick J.<br />

Baumhover, Kevin G. Rice.<br />

42 3:30 PM<br />

Synergistic Cancer <strong>Therapy</strong> by Simultaneous<br />

Expression and Silencing <strong>of</strong> Pro-Apoptotic and Pro-<br />

Survival <strong>Gene</strong>s Using Chimeric Nanoparticles<br />

Soo Kyung Cho, Jane Kim, Young Jik Kwon.<br />

43 3:45 PM<br />

Examining <strong>Cell</strong>-Penetrating Homochiral Cyclic Peptides<br />

as siRNA Non-Viral Transfection Agents<br />

Christiaan D. King, Ria L. Swanekamp, Bradley L. Nilsson, David A.<br />

Dean.<br />

44 4:00 PM<br />

Structure and Silencing Activity <strong>of</strong> Imidazole-<br />

Containing Peptide siRNA Polyplexes Are Dependent on<br />

Hydrogen Bonding<br />

Szu-Ting Chou, Kellie Hom, Lucas Tricoli, Jason Hustedt, Amy<br />

Lee, Joonil Seog, Jason Kahn, Qixin Leng, Daoning Zhang, Michael<br />

Shapiro, Archibald J. Mixson.<br />

Oral Abstract Session 136<br />

Infectious Diseases and Vaccines<br />

3:15 PM - 4:15 PM<br />

Room: 150 ABC<br />

45 3:15 PM<br />

Inducing Humoral and <strong>Cell</strong>ular Responses to Multiple<br />

Sporozoite and Liver-Stage Malaria Antigens Using<br />

pDNA<br />

Bernadette Ferraro, Kendra T. Talbot, Amritha Balakrishnan,<br />

Matthew P Morrow, Natalie A. Hutnick, Devin J. Myles, Devon J.<br />

Shedlock, Nyamekye Obeng-Adjei, Jian Yan, Rachel Shiver, Amir<br />

S. Khan, Maria Yang, Ami S. Brown, Ulrike Wille-Reece, Ashley<br />

Birkett, Niranjan Y. Sardesai, David B. Weiner.<br />

46 3:30 PM<br />

T-<strong>Cell</strong>s Edited To Express the C34 Peptide from gp41<br />

Heptad Repeat-2 Fused to CCR5 or CXCR4 Exhibit<br />

Robust Protection from Diverse HIV-1 Isolates<br />

Jianbin Wang, George J. Leslie, Jennifer Duong, Kevin L. Hua, Jenny<br />

J. Yan, Beth Haggarty, Andrea P. Jordon, Josephine Romano, Lei<br />

Zhang, Edward J. Rebar, Philip D. Gregory, James A. Hoxie, Michael<br />

C. Holmes.<br />

47 3:45 PM<br />

Integrase-Defective Lentiviral Vector-Induced Dendritic<br />

<strong>Cell</strong>s: Clinical Development and Validation <strong>of</strong> CD4+/<br />

CD8+ T <strong>Cell</strong> Responses for Combination with Adoptive<br />

CMV-Speciic T-<strong>Cell</strong> <strong>Therapy</strong><br />

Anusara Daenthanasanmak, Constanca Figueiredo, Eliana<br />

Ruggiero, Manfred Schmidt, Arnold Ganser, Renata Stripecke.<br />

48 4:00 PM<br />

Engineering Resistance to HIV-1 Infection with a Dual<br />

Therapeutic Lentiviral Vector<br />

Bryan P. Burke, Maureen P. Boyd, Michelle L. Millington, Helen<br />

Impey, Jane Zhang, Maria V. Carroll, Joanna Camba-Colon, Naomi<br />

Keech, Frederic Delebecque, Orit Wolstein, Annett Howe, Rachel<br />

Koldej, Tamara Nicolson, Bernard R. Levin, Valerie Rezek,<br />

Dimitrios N. Vatakis, Scott G. Kitchen, Louis R. Breton, Jeffrey S.<br />

Bartlett, Ge<strong>of</strong>f P. Symonds.<br />

Oral Abstract Session 137<br />

<strong>Cell</strong> Processing and Vector Production<br />

4:20 PM - 5:20 PM<br />

Room: 151 ABCG<br />

49 4:20 PM<br />

gc Cytokines IL7 and IL15 Expanded Chimeric Antigen<br />

Receptor-Redirected T <strong>Cell</strong>s (CAR-T) with Superior<br />

Antitumor Activity In Vivo<br />

Yang Xu, Ming Zhang, Aruna Mahendravada, Barbara Savoldo,<br />

Gianpietro Dotti.<br />

50 4:35 PM<br />

Large-Scale Clinical-Grade Retroviral Vector Production<br />

in iCELLis Nano Bioreactor<br />

Xiuyan Wang, Malgorzata Olzzewska, Jinrong Qu, Teresa<br />

Wasielewska, Shirley Bartido, Gregory Hermetet, Michel Sadelain,<br />

Isabelle Riviere.<br />

51 4:50 PM<br />

Large Scale Production <strong>of</strong> Lentiviral Vectors Using<br />

Serum Free Suspension <strong>Cell</strong> Culture System<br />

Amelia H. Thomas, Kevin Brown, Francis H. Pierciey, Jr, Gabor<br />

Veres, Byoung Y. Ryu.<br />

52 5:05 PM<br />

A Single Baculovirus for the Production <strong>of</strong> rAAV8 Viral<br />

Vectors<br />

Lionel Galibert, Aurélien Jacob, Bérangère Langlet-Bertin,<br />

Marjorie Boutin Fontaine, Delphine Bonnin, Christophe Lecomte,<br />

Christel Rivière, Otto W. Merten.<br />

90<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Wednesday, May 15, 2013<br />

Oral Abstract Session 138<br />

Sensory (Ophthalmic and Auditory) <strong>Gene</strong> &<br />

<strong>Cell</strong> <strong>Therapy</strong><br />

4:20 PM - 5:20 PM<br />

Room: 150 ABC<br />

53 4:20 PM<br />

Retinal <strong>Gene</strong> <strong>Therapy</strong> May Alter Connectivity <strong>of</strong> Visual<br />

Pathways<br />

M. Ashtari, L. Cyckowski, G. Zhang, P. Cook, K. Marshall, J. Wellman,<br />

J. Gee, A. Vossough, K. Shindler, A. Maguire, J. Bennett.<br />

Wednesday, May 15, 2013<br />

54 4:35 PM<br />

<strong>Gene</strong> <strong>Therapy</strong> for Wet-AMD: Progress Report on a<br />

Phase I/II Clinical Trial<br />

Elizabeth P. Rakoczy, May C. Lai, Cora Pierce, Aaron L. Magno,<br />

Richard J. Samulski, David J. Dismuke, Joshua C. Grieger, Thomas<br />

W. Chalberg, Mark S. Blumenkrnz, Martyn French, Ian J. Constable.<br />

55 4:50 PM<br />

Preclinical Safety Studies for AAV2-MerTK <strong>Gene</strong><br />

<strong>Therapy</strong> Vector for Retinitis Pigmentosa<br />

Thomas J. Conlon, Wen-Tao Deng, Renee C. Ryals, Kirsten E. Erger,<br />

Travis L. Cossette, Shannon E. Boye, Isaam McDoom, Nathalie<br />

Clemente, Brian Cleaver, Mark Potter, Corinne Abernathy, Sanford<br />

L. Boye, William H. Hauswirth.<br />

56 5:05 PM<br />

Glaucoma-GT, a Novel <strong>Gene</strong> <strong>Therapy</strong> Treatment for<br />

Primary Open-Angle Glaucoma<br />

Katie Binley, Scott Ellis, Vicky Scripps, Sharifah Iqball, Stuart<br />

Naylor, Kyriacos Mitrophanous.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

91


Thursday, May 16, 2013<br />

Abstract Directory, Thursday, May 16, 2013<br />

Oral Abstract Session 230<br />

Clinical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Oral Abstract<br />

Session<br />

2:00 PM - 4:00 PM<br />

Room: Ballroom A<br />

57 2:00 PM<br />

Acid alpha-Glucosidase <strong>Gene</strong> Replacement <strong>Therapy</strong><br />

to the Diaphragm in Ventilator-Dependent Pompe<br />

Disease: One-Year Respiratory Motor Outcomes<br />

Barbara K. Smith, Daniel Martin, Lee Ann Lawson, Cathryn S. Mah,<br />

Saleem Islam, Thomas Conlon J. Conlon, Dawn Phillips, Shelley<br />

Collins, Barry J. Byrne.<br />

58 2:15 PM<br />

Long Term CD4 Reconstitution in HIV Subjects<br />

Receiving ZFN CCR5 Modiied CD4 T-<strong>Cell</strong>s (SB-728-T)<br />

May Be Attributed to the Sustained Durability <strong>of</strong> the<br />

Central Memory T-<strong>Cell</strong> Subset<br />

Gary K. Lee, Joumana Zeidan, Jay Lalezari, Ronald Mitsuyasu,<br />

Shelley Wang, Marty Giedlin, Ge<strong>of</strong>f Nichol, Winson Tang, Dale<br />

Ando, Raick-Pierre Sekaly.<br />

59 2:30 PM<br />

Cardiovascular Toxicity and Titin Cross-Reactivity <strong>of</strong><br />

Afinity-Enhanced TCR-Engineered T <strong>Cell</strong>s Against<br />

HLA-A1 Restricted MAGE-A3 Antigen<br />

Marcela V. Maus, Gerald P. Linette, Edward A. Stadtmauer, Aaron<br />

P. Rapoport, Bruce L. Levine, Lyndsey A. Emery, Leslie Litzky,<br />

Gwendolyn K. Binder-Scholl, Dominic P. Smethurst, Andrew B.<br />

Gerry, Nick J. Pumphrey, Alan Bennet, Joanna Brewer, Jane Harper,<br />

Namir Hassan, Bent K. Jakobsen, Michael Kalos, Carl H. June.<br />

60 2:45 PM<br />

<strong>Gene</strong> <strong>Therapy</strong> for Aromatic L-Amino Acid<br />

Decarboxylase Deiciency: Report <strong>of</strong> Treatment for 8<br />

Patients<br />

Wuh-Liang Hwu, Shin-ichi Muramatsu, Sheng-Hong Tseng, Kai-<br />

Yuan Tzen, Ni-Chung Lee, Yin-Hsiu Chien, Richard O. Snyder, Barry<br />

Byrne, Chun-Hwei Tai, Ruey-Meei Wu.<br />

61 3:00 PM<br />

Safe G-CSF Mobilization <strong>of</strong> Thalassemia Patient CD34+<br />

<strong>Cell</strong>s and Effective Globin <strong>Gene</strong> Transduction for<br />

Therapeutic Infusion<br />

Farid Boulad, Xiuyan Wang, Clare Taylor, Jinrong Qu, Leda Ferro,<br />

Garie Karponi, Shirley Bartido, Patricia Giardina, Glenn Heller,<br />

Susan E. Prockop, Aurelio Maggio, Michel Sadelain, Isabelle<br />

Riviere.<br />

62 3:15 PM<br />

Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> with<br />

Lentiviral Vector in 4 Patients with Cerebral X-Linked<br />

Adrenoleukodystrophy: Long-Term Outcome and<br />

Comparison <strong>of</strong> Eficacy with Allogeneic Hematopoietic<br />

Stem <strong>Cell</strong> Transplantation<br />

Paul Orchard, Nathalie Cartier, Salima Hacein-Bey-Abina,<br />

Joanne Kurtzberg, Maria Escolar, Jakub Tolar, André Baruchel,<br />

Jean-Hughes Dalle, Gérard Michel, Stéphane Blanche, Cynthia<br />

Bartholomä, Manfred Schmidt, Pierre Bougnères, Christ<strong>of</strong> van<br />

Kalle, Marina Cavazzana-Calvo, Alain Fischer, Patrick Aubourg.<br />

676 3:30 PM<br />

Update on Toca 511 - a retroviral replicating vector in<br />

clinical trials for High Grade Glioma<br />

Douglas J Jolly, Joan M. Robbins, Derek Ostertag, Amy Lin, Carlos<br />

Ibanez, Harry E. Gruber, Noriyuki Kasahara, Timothy F. Cloughesy,<br />

Manish K. Aghi, Susan M. Chang, Michael A. Vogelbaum, Santosh<br />

Kesari, Tom Mikkelsen, Joseph Landoli, E. Antonio Chiocca, James<br />

Elder, Greg Foltz, Dan Pertschuk<br />

299 3:45 PM<br />

Clinical Responses in Patients Infused with<br />

T Lymphocytes Redirected To Target -Light<br />

Immunoglobulin Chain<br />

Carlos A. Ramos, Barbara Savoldo, Enli Liu, Adrian P. Gee, Zhuyong<br />

Mei, Bambi Grilley, Cliona M. Rooney, Helen E. Heslop, Malcolm K.<br />

Brenner, Gianpietro Dotti.<br />

Oral Abstract Session 231<br />

RNA Virus Vectors<br />

2:00 PM - 4:00 PM<br />

Room: Ballroom B<br />

63 2:00 PM<br />

Comprehensive Study <strong>of</strong> Lentiviral “Integrome” in WAS<br />

<strong>Gene</strong> <strong>Therapy</strong> Patients<br />

Luca Biasco, Cristina Baricordi, Francesca Dionisio, Andrea<br />

Calabria, Samantha Scaramuzza, Danilo Pellin, Clelia Di Serio,<br />

Christ<strong>of</strong> Von Kalle, Manfred Schmidt, Eugenio Montini, Luigi<br />

Naldini, Alessandro Aiuti.<br />

64 2:15 PM<br />

In Vivo Safety Evaluation <strong>of</strong> a Novel Insulated SIN LV<br />

Reveals Genotoxicity Escape-Mechanisms<br />

Monica Volpin, Daniela Cesana, Alexandre Artus, Caroline Duros,<br />

Fabrizio Benedicenti, Lucia Sergi Sergi, Luigi Naldini, Odile Cohen-<br />

Haguenauer, Eugenio Montini.<br />

65 2:30 PM<br />

No Impact <strong>of</strong> Lentiviral Transduction on Hematopoietic<br />

Stem and Progenitor <strong>Cell</strong> Telomere Length or <strong>Gene</strong><br />

Expression Proile in the Rhesus Macaque<br />

Stephanie E. Sellers, Bogden Dumitriu, Mary Morgan, Colin O. Wu,<br />

Nalini Raghavarchari, Yanqin Yang, Naoya Uchida, John F. Tisdale,<br />

Robert E. Donahue, Andre Larochelle, Cynthia E. Dunbar.<br />

92<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Oral Abstract Session 231, continued<br />

RNA Virus Vectors<br />

2:00 PM - 4:00 PM<br />

Room: Ballroom B<br />

66 2:45 PM<br />

Rescue <strong>of</strong> the X-CGD Phenotype by an Alpharetroviral<br />

Vector without Concomitant Induction <strong>of</strong> Aberrant<br />

Splicing<br />

Kerstin B. Kaufmann, Christian Brendel, Julia D. Suerth, Uta<br />

Müller-Kuller, Linping Chen-Wichmann, Joachim Schwäble,<br />

Shweta Pahujani, Hana Kunkel, Axel Schambach, Christopher<br />

Baum, Manuel Grez.<br />

67 3:00 PM<br />

<strong>Gene</strong> Transfer to Motor Neurons with Novel Targeted<br />

Lentiviral Vectors<br />

Ioanna Eleftheriadou, Antonio Trabalza, Stuart M. Ellison, Nicholas<br />

D. Mazarakis.<br />

68 3:15 PM<br />

NXF1 Controls Nuclear Export <strong>of</strong> Spliced and Unspliced<br />

Gammaretroviral Transcripts<br />

Toshie Sakuma, Yasuhiro Ikeda.<br />

69 3:30 PM<br />

Dual microRNA-Regulated Oncolytic Coxsackievirus B3<br />

Infection Displays Antitumor Activity with Attenuated<br />

Pathogenicity in Mice<br />

Shohei Miyamoto, Hiroyuki Inoue, Miyako Sagara, Beibei Wang,<br />

Koichi Takayama, Hiroyuki Shimizu, Yoichi Nakanishi, Kenzaburo<br />

Tani.<br />

70 3:45 PM<br />

Retroviral Replicating Vector (RRV)-Mediated Prodrug-<br />

Activator <strong>Gene</strong> <strong>Therapy</strong> Transcriptionally Targeted to<br />

Prostate Cancer<br />

Shuichi Kamijima, Takahiro Kimura, Kazunori Haga, Kei Hiraoka,<br />

Akihito Inagaki, Masamichi Takahashi, Christopher R. Logg,<br />

Chinghai Kao, Bernard H. Bochner, Noriyuki Kasahara.<br />

Oral Abstract Session 232<br />

AAV Vector Biology<br />

2:00 PM - 4:00 PM<br />

Room: Ballroom C<br />

71 2:00 PM<br />

The Structure <strong>of</strong> AAVrh32.33, a Novel <strong>Gene</strong> Delivery<br />

Vector<br />

Kyle Mikals, Hyun-Joo Nam, Kim Van Vliet, Luk H. Vandenberghe,<br />

Lauren E. Mays, Robert McKenna, James M. Wilson, Mavis<br />

Agbandje-McKenna.<br />

72 2:15 PM<br />

Identiication <strong>of</strong> Nucleolar Localization Sequences in<br />

the C-Terminal Region <strong>of</strong> Assembly-Activating Protein<br />

Lauriel F. Earley, Xiao-Xin Sun, Kei Adachi, Mushui Dai, Hiroyuki<br />

Nakai.<br />

73 2:30 PM<br />

Integrins Play a Pivotal Role in Transvascular<br />

Transport and Tissue Uptake <strong>of</strong> AAV9 In Vivo<br />

Shen Shen, Aravind Asokan.<br />

74 2:45 PM<br />

Adeno-Associated Virus Utilizes Host <strong>Cell</strong> Nuclear<br />

Import Machinery to Enter the Nucleus<br />

Sarah C. Nicolson, Richard J. Samulski.<br />

75 3:00 PM<br />

Functional Roles <strong>of</strong> the AAV2 Inverted Terminal Repeat<br />

in Messenger RNA Transport and Transgene Expression<br />

Yuan Wang, Yuan Lu, Lina Wang, Joon-Hyung Kim, George V.<br />

Aslanidi, Changquan Ling, Arun Srivastava, Chen Ling.<br />

76 3:15 PM<br />

Epigenetic Alterations in the Dystrophic Muscle<br />

Environment Down-Regulate rAAV-Mediated Transgene<br />

Expression<br />

Jean Baptiste Dupont, Benoit Tournaire, Christophe Georger,<br />

Laetitia Van Wittenberghe, Beatrice Marolleau, Laurence Dubreil,<br />

Emilie Lecomte, Fulvio Mavilio, Richard O. Snyder, Philippe<br />

Moullier, Adrien Leger.<br />

77 3:30 PM<br />

Sialic Acids and Erythrocyte Interactions Are Critical<br />

Determinants <strong>of</strong> Cardiopulmonary Tropism Displayed<br />

by AAV Serotype 4<br />

Shen Shen, Andrew Troupes, Nagesh Pulicherla, Aravind Asokan.<br />

78 3:45 PM<br />

Simultaneous Pharmacokinetic Proiling <strong>of</strong> Multiple<br />

AAV Serotypes and Mutants in a Non-Human Primate<br />

by AAV Barcode-Seq<br />

Kei Adachi, Yasuhiro Kawano, Gregory A. Dissen, Sergio R. Ojeda,<br />

Hiroyuki Nakai.<br />

Oral Abstract Session 233<br />

Stem <strong>Cell</strong> Engineering and <strong>Therapy</strong><br />

2:00 PM - 4:00 PM<br />

Room: Ballroom D<br />

79 Abstract Withdrawn from Presentation<br />

470 2:00 PM (Moved from Poster Session II)<br />

Human Parthenogenetic Stem <strong>Cell</strong>-Derived Hepatocytes<br />

for Liver Repopulation: <strong>Cell</strong> <strong>Therapy</strong> Demonstrated in a<br />

Pilot Study with Gunn Rats<br />

Larisa Agapova, Alina Ostrowska, Trudy Christiansen-Weber,<br />

Tiffany Chu, Ruslan Semechkin.<br />

80 2:15 PM<br />

Transplanted Mesenchymal Stem <strong>Cell</strong>s Provide Type<br />

VII Collagen in the Skin <strong>of</strong> Recessive Dystrophic<br />

Epidermolysis Bullosa<br />

Katsuto Tamai, Shin Iinuma, Eriko Ikawa, Yasuhi Kikuchi, Ryo<br />

Fujita, Masaru Ishii, John McGrath, Jouni Uitto, Yasuhumi Kaneda.<br />

Thursday, May 16, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

93


Abstract Directory, Thursday, May 16, 2013<br />

Oral Abstract Session 233, continued<br />

Stem <strong>Cell</strong> Engineering and <strong>Therapy</strong><br />

2:00 PM - 4:00 PM<br />

Room: Ballroom D<br />

Oral Abstract Session 234<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

2:00 PM - 4:00 PM<br />

Room: 150 DEFG<br />

Thursday, May 16, 2013<br />

81 2:30 PM<br />

“Semi-Universal Donor Stem <strong>Cell</strong>s” That Express a<br />

Single Class I Human Leukocyte Antigen (HLA) A*0201<br />

Can Present Peptides to Allorestricted CD8+ T-<strong>Cell</strong>s<br />

German Gornalusse, Marvin Festag, Roli Hirata, Laura Riolobos,<br />

Cameron Turtle, Stan Riddell, David W. Russell.<br />

82 2:45 PM<br />

Targeted Correction <strong>of</strong> X-CGD iPSCs by TALEN-Mediated<br />

<strong>Gene</strong> Transfer to the CYBB Locus<br />

Colin L. Sweeney, Uimook Choi, Jizhong Zou, Suk See DeRavin,<br />

Harry L. Malech.<br />

83 3:00 PM<br />

<strong>Gene</strong>tically Corrected Myoblasts Derived from<br />

Dystrophic hIPSCs Fused with Existing Muscle Fibers<br />

in Immunodeicient mdx Mice and Led to Expression <strong>of</strong><br />

Micro-Dystrophin and a-Sarcoglycan<br />

Chantale Maltais, Carl Lebel, Joël Rousseau, Jacques P. Tremblay.<br />

84 3:15 PM<br />

<strong>Gene</strong>ration <strong>of</strong> Functional Monocyte/Macrophages<br />

by <strong>Gene</strong>tic Correction <strong>of</strong> Patient-Speciic iPSC in<br />

Congenital Pulmonary Alveolar Proteinosis<br />

Nico Lachmann, Christine Happle, Doreen Lüttge, Mania<br />

Ackermann, Adele Mucci, Nicolaus Schwerk, Martin Wetzke, Sylvia<br />

Merkert, Axel Schambach, Gesine Hansen, Thomas Moritz.<br />

85 3:30 PM<br />

Clonogenic Hepatocyte Progenitors from the Liver,<br />

Pancreas and Gall Bladder<br />

Craig Dorrell, Meritxell Huch, Yuhan Wang, Hans Clevers, Markus<br />

Grompe.<br />

86 3:45 PM<br />

The Activation <strong>of</strong> the Wnt3a/b-Catenin Pathway<br />

Induced Maturation <strong>of</strong> Impaired Neutrophils as Well<br />

as the Endoplasmic Reticulum Stress in Induced<br />

Pluripotent Stem <strong>Cell</strong> Derived from a Severe Congenital<br />

Neutropenia Patient with ELANE Mutation<br />

Takafumi Hiramoto, Yasuhiro Ebihara, Yoko Mizoguchi, Kazuhiro<br />

Nakamura, Kiyoshi Yamaguchi, Kazuko Ueno, Naoki Nariai, Shinji<br />

Mochizuki, Shohei Yamamoto, Masao Nagasaki, Yoichi Furukawa,<br />

Kenzaburo Tani, Hiromitsu Nakauchi, Masao Kobayashi, Kohichiro<br />

Tsuji.<br />

87 2:00 PM<br />

The Effect <strong>of</strong> Neonatal <strong>Gene</strong> <strong>Therapy</strong> on Dysostosis<br />

Multiplex in Mucopolysaccaridosis VII Dogs after a<br />

Decade<br />

Katherine P. Ponder, Elizabeth M. Xing, Van W. Knox, Patricia A.<br />

O’Donnell, Yuli Liu, Susan Wu, Mark E. Haskins.<br />

88 2:15 PM<br />

scAAV Provides Sustained Expression <strong>of</strong> a Homologous<br />

Therapeutic Transgene in Large Mammalian Joints,<br />

with Enhanced Expression in Osteoarthritis<br />

Rachael S. Watson, Ted Broome, Andrew Smith, Patrick Colahan,<br />

Steven Ghivizzani.<br />

89 2:30 PM<br />

Dual Axis <strong>Gene</strong>-<strong>Therapy</strong> Using Stem <strong>Cell</strong>s<br />

Overexpressing TGF-b3 in Combination with IL-1b and<br />

TNF-a RNA Silencing for Osteoarthritis Control in a<br />

Large Animal Osteochondral Chip Fracture Model<br />

Alan J. Nixon, Ashlee E. Watts, Laila Begum.<br />

90 2:45 PM<br />

Respiratory Function in a Canine Model <strong>of</strong> X-Linked<br />

Myotubular Myopathy Following Regional Limb<br />

Infusion with Recombinant AAV8-MTM1<br />

Melissa Goddard, Romain Joubert, Karine Poulard, Robert Grange,<br />

Michael Lawlor, Christelle Moal, Thibaud Jamet, Nathalie Danièle,<br />

Samia Martin, Christel Rivière, Caroline Hammer, Laetitia Van<br />

Wittenberghe, Erin Mitchell, Alban Vignaud, Carole Masurier,<br />

Philippe Moullier, Alan Beggs, Anna Buj-Bello, Barbara Smith,<br />

Barry Byrne, Martin Childers.<br />

91 3:00 PM<br />

Vascular Delivery <strong>of</strong> AAV.Micro-Dystrophin Using<br />

Whole Limb Re-Circulation in the Non-Human Primate<br />

as a <strong>Therapy</strong> for DMD<br />

Louis G. Chicoine, Chrystal L. Montgomery, Danielle A. Grifin,<br />

Kristin N. Heller, Kim Shontz, Thomas J. Preston, William G.<br />

Bremer, Christopher M. Walker, K. R. Clark, Jerry R. Mendell,<br />

Louise R. Rodino-Klapac.<br />

92 3:15 PM<br />

Safety and Histological Signs <strong>of</strong> Eficacy Following<br />

Systemic AAV9-CMV-Microutrophin <strong>Gene</strong> <strong>Therapy</strong> in a<br />

Canine Model for Duchenne Muscular Dystrophy<br />

Alock Malik, Andrew Mead, Mike Petrov, Marilyn Mitchell, Leonard<br />

Su, Frederick Balzer, Jacqueline Farag, Janet Bogan, Dan Bogan, Joe<br />

Kornegay, Hansell Stedman.<br />

93 3:30 PM<br />

A Xenograft Model <strong>of</strong> Skeletal Muscle for Preclinical<br />

<strong>Gene</strong> <strong>Therapy</strong> Studies<br />

Kathryn R. Wagner, Tracy Y. Zhang, Terence A. Partridge, Takako<br />

Jone, Oliver King, Fedik Rahimov, Qin Su, Guangpin Gao, Louis M.<br />

Kunkel, Robert H. Brown, Jr, Miguel Sena-Esteves.<br />

94<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Oral Abstract Session 234, continued<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

2:00 PM - 4:00 PM<br />

Room: 150 DEFG<br />

94 3:45 PM<br />

Kidney Toxicity Caused by NEMO-Binding Domain<br />

(NBD) Peptide <strong>Therapy</strong> in a Murine Model <strong>of</strong> Muscular<br />

Dystrophy<br />

Paula R. Clemens, Daniel P. Reay, Katy Wack, Donna B. Stolz, Paul<br />

D. Robbins.<br />

Oral Abstract Session 235<br />

Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

2:00 PM - 3:00 PM<br />

Room: 150 ABC<br />

95 2:00 PM<br />

FunSel: <strong>Gene</strong>ration <strong>of</strong> AAV-Based, Arrayed Libraries for<br />

In Vivo Functional Selection <strong>of</strong> Secreted Factors and<br />

miRNAs Against Degenerative Disorders<br />

Giulia Ruozi, Francesca Bortolotti, Luca Braga, Antonella Falcione,<br />

Matteo Dal Ferro, Serena Zacchigna, Lorena Zentilin, Mauro<br />

Giacca.<br />

96 2:15 PM<br />

Intra-Infarct Delivery <strong>of</strong> Microparticles Containing<br />

MAP4K4 siRNA Reduce Acute Post-Infarct<br />

Inlammatory Responses<br />

Matthew S. Weaver, Jun Luo, James E. Dennis, Myriam Aouadi,<br />

Timothy P. Fitzgibbons, Shinya U. Amano, Michael P. Czech,<br />

Margaret D. Allen.<br />

97 2:30 PM<br />

<strong>Gene</strong> Transfer Using a Snake Venom Derived<br />

Vascular Endothelial Growth Factor Induces Robust<br />

Angiogenesis and Improves Ventricular Function in<br />

Ischemic Porcine Myocardium<br />

Paavo J. Halonen, Jussi Nurro, Antti Kuivanen, Tuomas T. Rissanen,<br />

Seppo Ylä-Herttuala.<br />

98 2:45 PM<br />

Long-Term Robust Myocardial Transduction <strong>of</strong> the Dog<br />

Heart from Peripheral Vein by Adeno-Associated Virus<br />

Serotype-8 (AAV-8)<br />

Xiufang Pan, Yongping Yue, Keqing Zhang, William Lostal, Jin-Hong<br />

Shin, Dongsheng Duan.<br />

Oral Abstract Session 236<br />

Physical Methods <strong>of</strong> Delivery<br />

2:00 PM - 3:15 PM<br />

Room: 151 ABCG<br />

99 2:00 PM<br />

Effective <strong>Gene</strong> Electrotransfer Is Dependent on the<br />

Pulse Parameters <strong>of</strong> the Applied Electric Field<br />

Richard Heller, Cathryn Lundberg, Fanying Li, Niculina Burcus,<br />

Shawna Shirley.<br />

100 2:15 PM<br />

Targeted Modulation <strong>of</strong> BACE1 Expression and<br />

Electrical Activity in Neuronal Cultures Using Voltage<br />

Pre-Conditioning<br />

Arati M. Sridharan, Jit Muthuswamy.<br />

101 2:30 PM<br />

Ultrasound and Microbubbles Mediated Factor VIII<br />

Plasmid <strong>Gene</strong> <strong>Therapy</strong> in Hemophilia A Mice<br />

Shuxian Song, Misty L. Noble, Ryan Sun, Luping Fan, Carol H. Miao.<br />

102 2:45 PM<br />

Gadolinium Chloride Extends the Duration <strong>of</strong> <strong>Gene</strong><br />

Expression in Dogs Hydrodynamically Infused with<br />

Sleeping Beauty Transposons<br />

R. Scott McIvor, Myra C. Rusten, Erik R. Olson, Jason B. Bell, Elena<br />

L. Aronovich, Kendra A. Hyland, John R. Lake, Roland Gunther,<br />

Bryan M. Ladd, David W. Hunter, Perry B. Hackett.<br />

103 3:00 PM<br />

Non-Invasive In Vivo Imaging, Biodistribution and<br />

Clearance Analyses <strong>of</strong> Intravenously Administered<br />

Extracellular Vesicles<br />

Charles P. Lai, Osama Mardini, Casey A. Maguire, Bakhos T.<br />

Tannous, Xandra O. Breakeield.<br />

Oral Abstract Session 237<br />

Evolution <strong>of</strong> Pulmonary Treatments<br />

3:05 PM - 4:05 PM<br />

Room: 150 ABC<br />

104 3:05 PM<br />

Maternal Immunization with Chimpanzee Adenovirus<br />

Expressing RSV Fusion Protein Protects Against<br />

Neonatal RSV Pulmonary Infection<br />

Anurag Sharma, Rebecca Wendland, Biin Sung, Wendy Wu, Stefan<br />

Worgall.<br />

Thursday, May 16, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

95


Abstract Directory, Thursday, May 16, 2013<br />

Oral Abstract Session 237, continued<br />

Evolution <strong>of</strong> Pulmonary Treatments<br />

3:05 PM - 4:05 PM<br />

Room: 150 ABC<br />

Poster Session I<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

AAV Vectors I<br />

Thursday, May 16, 2013<br />

105 Abstract Withdrawn from Presentation<br />

432 3:20 PM Moved from Poster Session II<br />

A Novel Cancer <strong>Cell</strong> Vaccine Using Induced Pluripotent<br />

Stem <strong>Cell</strong>s <strong>Gene</strong>tically Engineered To Produce GM-CSF<br />

Elicits Substantial Antitumor Immunity in a Syngeneic<br />

Mouse Model<br />

Hiroyuki Inoue, Ayumi Wanatabe, Chika Sakamoto, Megumi<br />

Narusawa, Shohei Miyamoto, Makoto Inoue, Koichi Takayama,<br />

Mamoru Hasegawa, Yoichi Nakanishi, Kenzaburo Tani.<br />

106 3:35 PM<br />

Safety, Toxicology and Eficacy <strong>of</strong> a Lung-Directed AAV-<br />

Based <strong>Gene</strong> <strong>Therapy</strong> for a1-Antitrypsin Deiciency<br />

Maria J. Chiuchiolo, Neil R. Hackett, Esther Z. Frenk, Yihharn<br />

Hwang, Jianping Qiu, Janet Benson, Gensheng Wang, Stephen M.<br />

Kaminsky, Ronald G. Crystal.<br />

107 3:50 PM<br />

Allele-Preferred Targeted Correction <strong>of</strong> CFTR <strong>Gene</strong> in<br />

Cystic Fibrosis Induced Pluripotent Stem <strong>Cell</strong>s<br />

Jacquelin H. Bui, Ana M. Crane, Xuan S. Li, Philipp Kramer, Manuel<br />

Gonzalez-Garay, Wei Liao, Jianbin Wang, Helena C. Sun, David E.<br />

Paschon, Dmitry Y. Guschin, Philip D. Gregory, Darrell N. Kotton,<br />

Michael C. Holmes, Brian R. Davis.<br />

Oral Abstract Session 238<br />

Immunologic & Host Responses in <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong><br />

3:20 PM - 4:05 PM<br />

Room: 151 ABCG<br />

108 3:20 PM<br />

Escaping Immune Activation through the Use <strong>of</strong> CpG-<br />

Depleted AAV Vectors<br />

Susan Faust, Peter Bell, Benjamin Cutler, Scott Ashley, Joseph<br />

Rabinowitz, James Wilson.<br />

109 3:35 PM<br />

Ex Vivo Expanded Treg Suppress Inhibitor Formation in<br />

Protein and <strong>Gene</strong> Therapies for Hemophilia<br />

Debalina Sarkar, David M. Markusic, Todd M. Brusko, Roland W.<br />

Herzog.<br />

110 3:50 PM<br />

Overcoming Pre-Existing Humoral Immunity to AAV<br />

Using Capsid Decoys<br />

Federico Mingozzi, Xavier M. Anguela, Giulia Pavani, Yifeng Chen,<br />

Robert H. Davidson, Daniel H. Hui, Mustafa Yazicioglu, Liron<br />

Elkouby, Christian J. Hinderer, Armida Faella, Carolann Howard,<br />

Alex Tai, Gregory M. Podsak<strong>of</strong>f, Margaret C. Ragni, Shangzhen<br />

Zhou, Etiena Basner-Tschakarjan, Fraser J. Wright, Katherine A.<br />

High.<br />

111<br />

Locoregional Intravenous Delivery <strong>of</strong> AAV Vector in<br />

Macaque Results in Persistent Transgene Expression<br />

Despite a Dedicated Humoral and <strong>Cell</strong>ular Immune<br />

Responses<br />

Gwladys Gernoux, Marie Devaux, Laurence Dubreil, Nicolas Jaulin,<br />

Mickaël Guilbaud, Jack-Yves Deschamps, Thibaut Larcher, Guigand<br />

Lydie, Maeva Dutilleul, Caroline Le Guiner, Yan Chérel, Philippe<br />

Moullier, Oumeya Adjali.<br />

112<br />

Global CNS <strong>Gene</strong> Delivery in Non-Human Primates<br />

by Intra-CSF Administration: Evasion <strong>of</strong> Anti-AAV<br />

Neutralizing Antibodies but Not a Transgene-Speciic<br />

CTL Response<br />

Steven J. Gray, Sahana Nagabhushan Kalburgi, Thomas J. McCown,<br />

R. Jude Samulski.<br />

113<br />

Increased Occurrence <strong>of</strong> Hepatocellular Carcinoma<br />

(HCC) in Mice after Neonatal Adeno-Associated Virus<br />

(AAV8) <strong>Gene</strong> Delivery Exhibits Dose-Dependent<br />

Tumorigenesis<br />

Randy J. Chandler, Charles P. Venditti.<br />

114<br />

A Novel Adeno-Associated Virus Serotype (AAV)-8<br />

Capsid Mutant Improves Human Coagulation Factor IX<br />

Expression In Vivo<br />

Dwaipayan Sen, Rupali A. Gadkari, Govindarajan Sudha, Nishanth<br />

Gabriel, V. Ramya, Sukesh C. Nair, N. Srinivasan, Alok Srivastava,<br />

Giridhara R Jayandharan.<br />

115<br />

New MiniPromoters with Restricted-Retinal Expression<br />

When Docked in the Mouse Genome Show the Same<br />

Expression When Delivered in AAV<br />

Elizabeth M. Simpson, Charles N. de Leeuw, Frank M. Dyka,<br />

Sanford L. Boye, Stephanie Laprise, Michelle Zhou, Alice Y. Chou,<br />

Lisa Borretta, Simone C. McInerny, Elodie Portales-Casamar,<br />

Magdalena I. Swanson, Steven J. M. Jones, Robert A. Holt, Daniel<br />

Goldowitz, William W. Hauswirth, Wyeth W. Wasserman.<br />

116<br />

AAV Serotypes 1, 8, and 9 Share a Conserved<br />

Mechanism for Axonal Transport but Exhibit<br />

Differences in Distal <strong>Gene</strong> Transfer In Vivo<br />

Michael J. Castle, April Giles, Erika L. F. Holzbaur, John H. Wolfe.<br />

117<br />

AAV6 Captron Vectors Facilitate Persistent Expression<br />

<strong>of</strong> Therapeutic Levels <strong>of</strong> Human a1-Antitrypsin in<br />

Canine Lungs<br />

Christine L. Halbert, David K. Madtes, A. D. Miller.<br />

96<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

AAV Vectors I<br />

118<br />

Productive Life Cycle <strong>of</strong> the AAV2 in the Complete<br />

Absence <strong>of</strong> a Conventional Polyadenylation Signal<br />

Lina Wang, Yuan Wang, Yuan Lu, George V. Aslanidi, Arun<br />

Srivastava, Changquan Ling, Chen Ling.<br />

119<br />

A Unique Biological Property <strong>of</strong> an AAV9 Mutant<br />

Showing Increased <strong>Cell</strong> Attachment in the Presence and<br />

Absence <strong>of</strong> AAV5<br />

Kei Adachi, Alex Summers, Hiroyuki Nakai.<br />

120<br />

Effective Transduction <strong>of</strong> Common Marmoset with rAAV<br />

1 and 9 To <strong>Gene</strong>rate NHP Model <strong>of</strong> Muscular Dystrophy<br />

Hironori Okada, Hidetoshi Ishibashi, Hiromi Hayashita-Kinoh,<br />

Tomoko Chiyo, Yuko Nitahara-Kasahara, Takashi Okada, Shin’ichi<br />

Takeda.<br />

121<br />

Precise Evaluation <strong>of</strong> NAb Status Against Adeno-<br />

Associated Viral Vectors and an Approach toward<br />

Managing Its Inhibitory Effect<br />

Hiroaki Mizukami, Jun Mimuro, Shuji Hishikawa, Tomokazu<br />

Ikemoto, Ryosuke Uchibori, Tomonori Tsukahara, Masashi Urabe,<br />

Akihiro Kume, Asuka Sakata, Tsukasa Ohmori, Seiji Madoiwa,<br />

Yoichi Sakata, Keiya Ozawa.<br />

122<br />

Dissection <strong>of</strong> Key Parameters Inluencing Ex Vivo AAV<br />

Library Selections<br />

Eike Kienle, Dirk Grimm.<br />

123<br />

Peptide-Mediated Retargeting <strong>of</strong> 12 AAV Serotypes<br />

Anna Sacher, Kathleen Börner, Eike Kienle, Hans-Georg<br />

Kraeusslich, Martin Mueller, Dirk Grimm.<br />

124<br />

Creation <strong>of</strong> Liver-Detargeting AAV2-Derived Mutants<br />

Based on the Knowledge <strong>of</strong> AAV9 Capsid Functions<br />

Kei Adachi, Michael Verga, Hiroyuki Nakai.<br />

125<br />

Cruciform Hairpin Structure <strong>of</strong> AAV Genome Is<br />

Speciically Subject to ATM-Dependent Silencing <strong>of</strong><br />

<strong>Gene</strong> Expression<br />

Marcela P. Cataldi, Kim Zaraspe, Haiyan Fu, Douglas M. McCarty.<br />

Adenovirus and Other DNA Virus Vectors I<br />

126<br />

Shielding the Hexon Hyper Variable Region 1 <strong>of</strong><br />

Ad5-Based <strong>Gene</strong> Transfer Vectors by PEGylation<br />

Decreases Sequestration by Erythrocytes and Increases<br />

Blood Coagulation Factor XMediated Hepatocyte<br />

Transduction<br />

Lea Krutzke, Jan-Michael Prill, Tatjana Engler, Stefan Kochanek,<br />

Florian Kreppel.<br />

127<br />

Therapeutic Eficacy in a Breast Cancer Model <strong>of</strong> Novel<br />

Conditionally Replicative Adenovirus (CRAd) Based<br />

upon the Deletion <strong>of</strong> Minor Core Protein <strong>Gene</strong> V<br />

Hideyo Ugai, George C. Dobbins, Minghui Wang, David T. Curiel.<br />

128<br />

No Recombinant Vector Sequences Detected in<br />

Tumor Tissues from Two Research Subjects Received<br />

Adenovirus Ornithine Transcarbamylase <strong>Gene</strong> <strong>Therapy</strong><br />

Li Zhong, Shaoyong Li, Mengxin Li, Yu Zhang, Brendan Lee, Mark L.<br />

Batshaw, James M. Wilson, Guangping Gao.<br />

129<br />

Oncolytic Adenovirus Expressing IL-23 and p35<br />

Elicits IFN-g- and TNF-a-Co-Producing T <strong>Cell</strong>-Mediated<br />

Antitumor Immunity<br />

Il-Kyu Choi, Yan Li, Eonju Oh, Chae-Ok Yun.<br />

130<br />

Wnt Decoy Receptor (sLRP6E1E2) Induces Antiibrotic<br />

Effect Via Inhibition <strong>of</strong> Wnt Signaling in Keloid Scars<br />

Jung-Sun Lee, Won Jai Lee, Chae-Ok Yun.<br />

131<br />

Versican Stimulates Adenoviral Transgene Expression<br />

in a JAK Dependent Manner<br />

Patricia Y. Akinfenwa, Wesley S. Bond, Mary Y. Hurwitz, Richard L.<br />

Hurwitz.<br />

132<br />

Replication <strong>of</strong> Human Adenoviruses in Non-Human<br />

<strong>Cell</strong>s In Vitro and In Vivo<br />

Catherine M. Crosby, Mallory A. Turner, Michael A. Barry.<br />

133<br />

Adenovirus Serotypes Differ in Their Susceptibility to<br />

Neutralization by Mouse Serum: Role <strong>of</strong> Coagulation<br />

Factor X<br />

Jie Tian, Zhili Xu, Andrew P. Byrnes.<br />

134<br />

Non-Covalent Coating <strong>of</strong> Adenoviral Vectors with<br />

PAMAM Dendrimer Conjugates Allows for CAR<br />

Independent Virus Uptake and Targeting to the EGF<br />

Receptor<br />

Alexandra Vetter, Kulpreet S. Virdi, Sigrid Espenlaub, Wolfgang<br />

Rödl, Ernst Wagner, Florian Kreppel, Christine Spitzweg, Manfred<br />

Ogris.<br />

Thursday, May 16, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

97


Abstract Directory, Thursday, May 16, 2013<br />

Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Adenovirus and Other DNA Virus Vectors I<br />

135<br />

A <strong>Cell</strong> Line for Large-Scale Production <strong>of</strong><br />

Nondisseminative Adenoviral Vectors (Deleted<br />

<strong>of</strong> Protease [PS] <strong>Gene</strong>) for Cancer <strong>Therapy</strong> and<br />

Vaccination<br />

Rénald Gilbert, Claire Guilbault, Mélanie Simoneau, Seyyed Mehdy<br />

Elahi, Bernard Massie.<br />

136<br />

Inhibition <strong>of</strong> Breast Cancer Malignant Progression by<br />

Neutralizing Hypoxia-Induced <strong>Cell</strong> Motility<br />

Yi Lu, Liyuan Li, Jun Zhang.<br />

137<br />

HATHFUN: A Protein-Based Alternative to Viral<br />

Reprogramming<br />

Trudy Christiansen-Weber, Rodolfo Gonzalez, Alexa Dillberger,<br />

Tiffany Chu, Larisa Agapova, Alina Ostrowska, Ruslan Semechkin.<br />

138<br />

hChonJb#7 <strong>Cell</strong>s (Chondrocytes Expressing TGF-b1)<br />

Reduced Pain in a Rat Osteoarthritis Model<br />

Kyoung Baek Choi, Hyeon Youl Lee, Dae Wook Kim, Su Jeong Kim.<br />

561 (Moved from Poster Session III)<br />

Lister Strain Vaccinia Virus Demonstrates Favourable<br />

Anti-Tumor Eficacy and Tumor-Selectivity Compared<br />

to Western Reserve Strain<br />

Jonathan Hughes, Pengju Wang, Ghassan Alusi, Vipul Bhakta,<br />

Yongchao Chu, Hailiang Shi, Iain McNeish, Andrea McCart, Istvan<br />

Fodor, Nicholas Lemoine, Yaohe Wang.<br />

Physical Methods <strong>of</strong> Delivery<br />

139<br />

Electro-Chemo-<strong>Gene</strong> <strong>Therapy</strong> for Long-Term<br />

Management <strong>of</strong> Cancer in Canines<br />

Jeffry Cutrera, Xueqing Xia, Glenn King, Pamela Jones, Kristin<br />

Kicenuik, Shulin Li.<br />

140<br />

Engineering Novel Transducers for Effective<br />

Ultrasound-Mediated <strong>Gene</strong> <strong>Therapy</strong><br />

Misty L. Noble, Shuxian Song, Ryan R. Sun, Kyle P. Morrison,<br />

George W. Keilman, Luping Fan, Marla Paun, Keith R. Loeb, Carol<br />

H. Miao.<br />

141<br />

<strong>Gene</strong> Transfer Mediated by First-<strong>Gene</strong>ration Plasmids<br />

Induce Large Scale Proteomic Changes to <strong>Cell</strong>ular<br />

<strong>Program</strong>ming That Are Minimized by Elimination <strong>of</strong><br />

Prokaryotic Sequences<br />

Ramaz Geguchadze, Zhimin Wang, Lee Zourelias, Laurie Machen,<br />

Michael J. Passineau.<br />

142<br />

Development <strong>of</strong> pDNA-Loaded Bubble Liposomes for<br />

a Potential Theranostic Approach: Nano-Sized Agents<br />

Containing Cationic Lipid for Ultrasound Imaging and<br />

<strong>Gene</strong> Delivery<br />

Yoichi Negishi, Yoko Endo-Takahashi, Daichi Suzuki, Ukai Saori,<br />

Norio Takagi, Ryo Suzuki, Kazuo Maruyama, Yukihiko Aramaki.<br />

143<br />

Intracarotid Injection <strong>of</strong> Adipose Tissue-Derived<br />

Platelet-Derived Growth Factor Receptor b-Positive<br />

<strong>Cell</strong>s in Rat and Canine Model: Feasibility <strong>of</strong> <strong>Cell</strong><br />

Delivery under Mannitol-Induced Blood-Brain Barrier<br />

Opening<br />

Jung-Ick Byun, Keun-Hwa Jung, Kon Chu, Sung Won Yoon, Jong<br />

Young Lee, Soon-Tae Lee, Jeong-Min Kim, Manho Kim, Sang Kun<br />

Lee, Moon-Hee Han, Jae-Kyu Roh.<br />

144<br />

Measuring Intracellular Degradation <strong>of</strong> Polylactide-<br />

Based Magnetic Nanoparticles Using FRET<br />

Jillian E. Tengood, Alferiev S. Ivan, Fishbein Ilia, Robert J. Levy,<br />

Michael Chorny.<br />

145<br />

<strong>Gene</strong> Delivery System for Liver by Sonoporation with<br />

Nanobubble<br />

Ryo Suzuki, Yusuke Oda, Daiki Omata, Yoshikazu Sawaguchi, Yoichi<br />

Negishi, Kazuo Maruyama.<br />

146<br />

Exploring Therapeutic Applications <strong>of</strong> Pseudouridine-<br />

Containing mRNA<br />

Katalin Karikó, Hiromi Muramatsu, Norbert Pardi, Drew<br />

Weissman.<br />

147<br />

Transfection <strong>of</strong> Pseudouridine-Containing mRNA<br />

Encoding CPD-Photolyase into UVB-Irradiated Human<br />

Keratinocytes Results in Rapid Repair <strong>of</strong> DNA Damage<br />

Gábor Boros, Edit Miko, Eszter Emri, Gijsbertus T. J. van der Horst,<br />

Iren Horkay, Gabriella Emri, Eva Remenyik, Hiromi Muramatsu,<br />

Drew Weissman, Katalin Karikó.<br />

148<br />

Improvement <strong>of</strong> Both <strong>Cell</strong> Survival and Eficacy for<br />

Large Plasmids Electrotransfer in MSC<br />

Léa L. Lesueur, Lluis M. Mir, Franck M. Andre.<br />

149<br />

Minicircles Mediate Superior Ultrasound-Assisted<br />

<strong>Gene</strong> Transfer Relative to First-<strong>Gene</strong>ration Plasmids at<br />

Eqimolar Concentrations<br />

Zhimin Wang, Ramaz Geguchadze, Lee Zourelias, Laurie Machen,<br />

Michael J. Passineau.<br />

98<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Physical Methods <strong>of</strong> Delivery<br />

150<br />

Multifunctional Cationic Lipid-Based Magnetic<br />

Nanoparticles for Enhanced <strong>Gene</strong> Transfection and<br />

Magnetic Resonance Imaging Applications<br />

Srinath Govindarajan, Kumiko Kitaura, Makoto Takafuji, Hirotaka<br />

Ihara, K. S. Varadarajan, Anant B. Patel, Vijaya Gopal.<br />

158<br />

Anionic, Self-Assembling Nanocomplexes for Improved<br />

Receptor-Targeted Transfection In Vitro and In Vivo<br />

Aristides D. Tagalakis, Gavin D. Kenny, Alison S. Bienemann, John<br />

A. T. Pugh, Mark F. Lythgoe, Cameron W. McLeod, Edward A. White,<br />

Stephen L. Hart.<br />

159<br />

Prostate Cancer <strong>Cell</strong>-Speciic siRNA and Drug Co-<br />

Delivery with Aptamer-Functionalized Liposomes<br />

(Aptamosomes)<br />

Gwang-Hyun Lee, Hwa Yeon Jeong, Yong Serk Park, Dong-Eun Kim,<br />

Keun-Sik Kim.<br />

151<br />

Non-Viral Enteral Hormone Gastrin <strong>Gene</strong> <strong>Therapy</strong><br />

Improves the Function and Stimulates the Proliferation<br />

<strong>of</strong> Pancreatic beta <strong>Cell</strong>s<br />

Jeonghyun Park, Hyesook Jung, Na Han, Taekyun Kim, Minjung<br />

Kwon, Soonhee Lee, Byungdoo Rhee, Mikyung Kim.<br />

152<br />

Initial Toxicology <strong>of</strong> High Dose GNE Plasmid in Rodent<br />

and Canine Animal Species<br />

Yadira Valles-Ayoub, Rosangela Carbajo, Lucia Sandoval, Zeshan<br />

Khokher, Jorge Garcia-Figueroa, Sarah Stein, Daniel No, Babak<br />

Darvish, Daniel Darvish.<br />

153<br />

Elucidating the Expression Kinetics and Iniltration<br />

Resulting from <strong>Gene</strong> Delivery Enhanced by Dermal<br />

Electroporation<br />

Janess M. Mendoza, Gleb Kichaev, Dinah Amante, Christine Knott,<br />

Trevor R. F. Smith, Niranjan Y. Sardesai, Kate E. Broderick.<br />

154<br />

The Optimization <strong>of</strong> Electroporation Parameters To<br />

Enhance the Eficiency <strong>of</strong> Plasmid <strong>Gene</strong> Delivery in<br />

Muscle<br />

Ningqing Wang, Yong Diao.<br />

160<br />

Large <strong>Gene</strong> Non-Viral Transfer Mediated by Chitosan<br />

Nanoparticles and Integrase<br />

Daniel C. Chung, Anna V. Oliviera, Hadassah Janumala, Gabriela<br />

Silva.<br />

161<br />

Co-Delivery <strong>of</strong> siRNA and pDNA for Increased<br />

Transfection Eficiency<br />

Laura Rose, Michael Hogarth, Hasan Uludag.<br />

162<br />

Stability <strong>of</strong> Polymer/Plasmid DNA Complexes In Vitro<br />

and In Vivo<br />

Laura Rose, Jeremy Fife, Cezary Kucharski, Hasan Uludag.<br />

163<br />

When Nucleic Acids Meet Cationic Polymers: Effects <strong>of</strong><br />

Mixing Sequence on Complexation and Transfection<br />

Eficiencies<br />

Soo Kyung Cho, Xi Wang, Regina Ragan, Young Jik Kwon.<br />

164<br />

Bioreducible and Acid-Labile Poly(Amido Amine)s for<br />

Eficient <strong>Gene</strong> Delivery<br />

Qinghui Zhou, Yezhi You, Zhiqiang Yu, Junjie Yan.w<br />

Thursday, May 16, 2013<br />

Chemical and Molecular Conjugates<br />

155<br />

A High Throughput Screening Approach To Identify<br />

<strong>Gene</strong> Transfer Peptides In Vitro<br />

Jing Li, Jason Duskey, Kevin G. Rice.<br />

156<br />

Targeted Delivery <strong>of</strong> Short Interfering RNA by Human<br />

TAR RNA-Binding Protein-Afibody Chimera<br />

Gulam H. Dar, Erica Nathan, Nalam M. Rao, Vijaya Gopal.<br />

157<br />

Oligopeptide Comb Architectures for Controlled DNA<br />

Binding and Non-Viral Transfection<br />

Sangram S. Parelkar, Rachel Letteri, Delphine Chan-Seng, Todd<br />

Emrick.<br />

165 Abstract Withdrawn from Presentation<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

166<br />

Micro-Dystrophin Ameliorates Muscular Dystrophy in<br />

the Canine Model <strong>of</strong> Duchenne Muscular Dystrophy<br />

Jin-Hong Shin, Xiufang Pan, Chady H. Hakim, Hsiao T. Yang,<br />

Yougping Yue, Keqing Zhang, Ronald L. Terjung, Dongsheng Duan.<br />

167<br />

Expression <strong>of</strong> Minidystrophin from the Dystrophin<br />

Locus by TALEN Mediated <strong>Gene</strong> Targeting<br />

David G. Ousterout, Pablo Perez-Pinera, Pratiksha I. Thakore, Xiao<br />

Xiao, Charles A. Gersbach.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

99


Abstract Directory, Thursday, May 16, 2013<br />

Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

168<br />

Activation, Expansion, and In Vivo Regenerative<br />

Potential <strong>of</strong> Pax3-Transduced Satellite <strong>Cell</strong>s: A Potential<br />

<strong>Cell</strong>-Based <strong>Therapy</strong> for Duchenne Muscular Dystrophy<br />

Antonio Filareto, Robert W. Arpke, Darko Bosnakovski, Radbod<br />

Darabi, Fabrizio Rinaldi, Auston Miller, Michael Kyba, Rita C. R.<br />

Perlingeiro.<br />

169<br />

<strong>Gene</strong>tic Correction <strong>of</strong> Facioscapulohumeral Dystrophy<br />

Using Telomere Insertion: Potential for Therapeutic<br />

Application<br />

Fabrizio Rinaldi, Linn Hartweck, Darko Bosnakovski, Erik<br />

Toso, Abhijit Dandapat, Radbod Darabi, Thomas Zwaka, Simon<br />

Nargarkhan, Rita Perlingeiro, Michael Kyba.<br />

170<br />

Enhanced Myogenic Differentiation Induced by<br />

Engineered MyoD Transcription Factors<br />

Ami M. Kabadi, Pratiksha I. Thakore, Charles A. Gersbach.<br />

171<br />

Viral Mediated Acute Mouse Model for Myotonic<br />

Dystrophy Type1<br />

Syed-Rehan A. Hussain, Lindsay Wallace, Danielle Grifin, Chrystal<br />

Montgomery, Scott Q. Harper, Zarife Sahenk, K. Reed Clark.<br />

172<br />

Pre-Clinical Eficacy Study <strong>of</strong> Beta-Sarcoglycan <strong>Gene</strong><br />

Transfer<br />

Eric R. Pozsgai, William E. Grose, Danielle A. Grifin, Kristin N.<br />

Heller, Jerry R. Mendell, Louise R. Rodino-Klapac.<br />

173<br />

The Cardiac Alkali Myosin Light Chain Can Restore<br />

Skeletal Muscle Function in a Mouse Model <strong>of</strong> Nemaline<br />

Myopathy<br />

Johan M. Lindqvist, Julien Ochala.<br />

176<br />

Engraftment <strong>of</strong> Mesenchymal Stromal <strong>Cell</strong>s That Can<br />

Differentiate To Form Myogenic <strong>Cell</strong>s Is Enhanced<br />

by Expressing IL-10 in Dog with Duchenne Muscular<br />

Dystrophy<br />

Yuko N. Kasahara, Hiromi H. Kinoh, Tomoko Chiyo, Hironori<br />

Okada, Takashi Okada, Shin’ichi Takeda.<br />

177<br />

Modulating <strong>Cell</strong> Cycle Inhibitor Expression To Enhance<br />

Skeletal Myoblast Engraftment<br />

Pratiksha I. Thakore, David G. Ousterout, Charles A. Gersbach.<br />

178<br />

Human Muscle Derived Stem <strong>Cell</strong>s Exhibit Bone<br />

Regeneration Capacity Similar to Bone Marrow<br />

Mesenchymal Stem <strong>Cell</strong>s When <strong>Gene</strong>tically Modiied To<br />

Express BMP2 Both In Vitro and In Vivo<br />

Xueqin Gao, Arvydas Usas, Ying Tang, Aiping Lu, Jian Tan, Johannes<br />

Schneppendahl, Nick Oyster, Bing Wang, Rocky Tuan, Johnny<br />

Huard.<br />

179<br />

Rapid Progression <strong>of</strong> Muscular Dystrophy in<br />

Dystrophin/Utrophin-/- Mice Is Associated with Muscle<br />

Progenitor <strong>Cell</strong> Exhaustion<br />

Aiping Lu, Minakshi Poddar, Ying Tang, Jonathan D. Proto,<br />

Xiaodong Mu, Bing Wang, Johnny Huard.<br />

180<br />

A New Mouse Model <strong>of</strong> DMD: A Tool for Therapeutic<br />

Development Directed at Exon Duplications<br />

Adeline Vulin, Nicolas Wein, Yuuki J. Kaminoh, Andrew R. Findlay,<br />

Kevin M. Flanigan.<br />

181<br />

Investigation <strong>of</strong> Dystromirs in the mdx Mouse<br />

Thomas C. Roberts.<br />

182<br />

Dose-Dependent Toxicity <strong>of</strong> Humanized Renilla<br />

Reniformis GFP (hrGFP) Limits Its Utility as a Reporter<br />

<strong>Gene</strong> in Mouse Muscle<br />

Lindsay M. Wallace, Andrew Moreo, K. Reed Clark, Scott Q. Harper.<br />

174<br />

<strong>Gene</strong>rating Dystrophin+ Myogenic <strong>Cell</strong>s from mdx<br />

Fibroblasts by Using a Triple-Recombinase iPS <strong>Cell</strong>-<br />

Based Strategy<br />

Jonathan M. Geisinger, Chunli Zhao, Alfonso P. Farrugio,<br />

Christopher L. Chavez, Christopher R. Bjornson, Tawny L. Neal,<br />

Michele P. Calos.<br />

175<br />

Alpha7 Integrin Partially Preserves the Mechanical<br />

Function <strong>of</strong> the Extensor Digitorum Longus Muscle in<br />

Dystrophin-Deicient Mice<br />

Chady H. Hakim, Dean J. Burkin, Dongsheng Duan.<br />

Infectious Diseases and Vaccines<br />

183<br />

Electroporation <strong>of</strong> ZFN mRNA Enables Eficient CCR5<br />

<strong>Gene</strong> Disruption in Mobilized Blood Hematopoietic<br />

Stem <strong>Cell</strong>s at Clinical Scale<br />

Paula M. Cannon, Jill E. Henley, Travis Wood, Lynn Truong, Jianbin<br />

Wang, Kenneth Kim, Jenny Yan, Philip D. Gregory, Gary Lee,<br />

Michael C. Holmes.<br />

100<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Infectious Diseases and Vaccines<br />

184<br />

Next <strong>Gene</strong>ration TALENs Mediate Eficient Disruption <strong>of</strong><br />

the CCR5 <strong>Gene</strong> in Human HSCs<br />

Nick Llewellyn, Jeffrey C. Miller, John Campo, Colin Exline, Orla<br />

Mulhern, Jill Henley, Jianbin Wang, Dmitry Guschin, Danny Xia,<br />

Irina Ankoudinova, Philip D. Gregory, Lei Zhang, Edward J. Rebar,<br />

Michael C. Holmes, Paula M. Cannon.<br />

185<br />

Enhanced Neutralising Antibody Response to Bovine<br />

Viral Diarrhoea Virus (BVDV) Induced by BVDV DNA<br />

Vaccine Co-Expressing RIG-I Agonist in Cattle<br />

Laila M. El-Attar, Olivia Anstaett, Carole Thomas, Jeremy Luke,<br />

James Williams, Joe Brownlie.<br />

186<br />

Preclinical Safety Evaluation <strong>of</strong> an Antibiotic-Free<br />

LAMP-1 Plasmid Allergy Immunotherapy<br />

Teri L. Heiland, James A. Williams, William G. Hearl.<br />

187<br />

Inhibition <strong>of</strong> HBV Replication through ZFN-Mediated<br />

Disruption <strong>of</strong> cccDNA<br />

Daniel Stone, Nick Weber, Harshana De Silva Feelixge, Keith R.<br />

Jerome.<br />

188<br />

Development <strong>of</strong> Designer Homing Endonucleases for<br />

Inactivation <strong>of</strong> the HIV Provirus<br />

Esther Mintzer, Jordan Jarjour, Andy Scharenberg, Barry Stoddard,<br />

David Baker, Nick Weber, Daniel Stone, Keith R. Jerome.<br />

189<br />

Whole <strong>Cell</strong>-SELEX Derived Anti-CD7 Aptamers for the<br />

Delivery <strong>of</strong> Anti-CCR5 siRNA: A Prohylactic Approach to<br />

HIV <strong>Therapy</strong><br />

Laura Millroy, Daniel Lazar, Makobetsa Khati, Marc S. Weinberg.<br />

190<br />

Capsid Modiied AAV2 Vectors Are Capable <strong>of</strong><br />

<strong>Gene</strong>rating Functional Cytotoxic T <strong>Cell</strong>s in a Prime-<br />

Boost Vaccine Protocol<br />

Brad E. H<strong>of</strong>fman, Irene Zolotukhin, Roland W. Herzog, Ou Cao.<br />

191<br />

The Anti-Genomic (Negative) Strand <strong>of</strong> Hepatitis C<br />

Virus Is Not Targetable by shRNA<br />

Leszek Lisowski, Menashe Elazar, Kirk Chu, Jeffrey S. Glenn, Mark<br />

A. Kay.<br />

192<br />

Development <strong>of</strong> the Oral Universal Type A Inluenza<br />

Vaccine Using Biidobacterium Displaying Inluenza-<br />

M2e Protein<br />

Naoya Morishita, Suzuka Ozaki, Koichi Kitagawa, Chihiro<br />

Shirosaki, Hiroki Saito, Katsumi Shigemura, Masato Fujisawa,<br />

Masato Kawabata, Toshiro Shirakawa.<br />

193<br />

Enzyme Engineering <strong>of</strong> Homing Endonucleases To<br />

Target HBV cccDNA<br />

Nicholas D. Weber, Ryo Takeuchi, Jordan Jarjour, Daniel Stone,<br />

Barry L. Stoddard, Keith R. Jerome.<br />

194<br />

In Vivo Electroporation <strong>of</strong> Minicircle DNA as a Noval<br />

Method <strong>of</strong> Vaccine Delivery<br />

Wenlin Huang, Qingtao Wang, Changchuan Pan, Shijuan Gao, Wei<br />

Jiang.<br />

195<br />

The Potential Therapeutic Role <strong>of</strong> Secreted Antiviral<br />

Entry Inhibitory (SAVE) Peptides Expressed by<br />

Transduced MSCs To Block Viral Replication<br />

Narae Lee, Edith Walker, Wenpeng Li, Lisa Egerer, Dorothee von<br />

Laer, Bruce A. Bunnell, Stephen E. Braun.<br />

Cancer Immunotherapy I<br />

196 Abstract Withdrawn<br />

197<br />

Dual Transgenesis <strong>of</strong> T <strong>Cell</strong>s with a CD44v6-Speciic<br />

CAR and a Suicide <strong>Gene</strong> for the Safe Eradication <strong>of</strong><br />

Myeloid Leukemia and Myeloma<br />

Monica Casucci, Benedetta Nicolis di Robilant, Laura Falcone,<br />

Barbara Camisa, Pietro Genovese, Bernhard Gentner, Claudio<br />

Bordignon, Barbara Savoldo, Fabio Cicieri, Luigi Naldini,<br />

Gianpietro Dotti, Chiara Bonini, Attilio Bondanza.<br />

198<br />

Capitalizing on Epitope Escape To Avoid T <strong>Cell</strong><br />

Fratricide without Compromising Targeting <strong>of</strong> CD56+<br />

Tumors<br />

Denise L. Crossland, Sonny Ang, Simon Olivares, Kirsten Switzer,<br />

Tiejuan Mi, Helen Huls, Laurence J. N. Cooper.<br />

199<br />

Phase II Study <strong>of</strong> FANG (Autologous Tumor <strong>Cell</strong><br />

– GMCSF/pbi-shRNA Furin DNA Plasmid) Vaccine in<br />

Advanced Melanoma<br />

John Nemunaitis, Neil Senzer, Minal Barve, Padmasini Kumar,<br />

Donald D. Rao, Gladice Wallraven, Beena O. Pappen, Jospeh Kuhn,<br />

Peter Beitsch, Robert Steckler, Brian M. Gogel, Walton Taylor,<br />

Phillip B. Maples.<br />

200<br />

Renal <strong>Cell</strong> Tumor-Mediated Reprogramming <strong>of</strong> Natural<br />

Killer <strong>Cell</strong>s by Soluble Immune Modulators<br />

Yue Guan, Purba Singh, Trenae Mann, Christopher B. Chambers,<br />

Donald S. Torry, Andrew Wilber.<br />

Thursday, May 16, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

101


Abstract Directory, Thursday, May 16, 2013<br />

Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Cancer Immunotherapy I<br />

201<br />

A New Epithelial Junction Opener for Cancer <strong>Therapy</strong><br />

Ines Beyer, Hua Cao, Jonas Persson, Roma Yumul, Andre Lieber.<br />

202<br />

A Chemotherapy-Selective Method for Expansion <strong>of</strong><br />

Transgenic T <strong>Cell</strong>s<br />

David Rushworth, Laurence Cooper.<br />

203<br />

Phase I Study <strong>of</strong> the “Triad” Autologous (FANG)<br />

Vaccine, Incorporating Bifunctional shRNAfurin and<br />

GMCSF Transgene Expression, in Advanced Ewing’s<br />

Sarcoma: Preliminary Data in Pediatrics Patients<br />

Maurizio Ghisoli, Carl Lenarsky, Gladice Wallraven, Padmasini<br />

Kumar, Phillip B. Maples, John Nemunaitis.<br />

204<br />

Dissecting the Human T <strong>Cell</strong> Receptor Repertoire<br />

in Different Immunological Conditions by Deep<br />

Sequencing<br />

Eliana Ruggiero, Jan P. Nicolay, Anne Arens, Raffaele Fronza, Anna<br />

Paruzynski, Ali Nowrouzi, Gökçe Ürenden, Sergij Goerdt, Hanno<br />

Glimm, Peter H. Krammer, Manfred Schmidt, Christ<strong>of</strong> von Kalle.<br />

205<br />

Aptamer Targeted Antigen Delivery<br />

Matthew Levy, Brian C. Wengerter, Debborah Palliser, Joseph<br />

Katakowski.<br />

206<br />

FANG Cytokine Expression Analyses Update<br />

Padmasini Kumar, Connor Phalon, Beena O. Pappen, Gladice<br />

Wallraven, Yang Yu, Fabienne Norvell, Christopher M. Jay, Zhaohui<br />

Wang, Donald D. Rao, John Nemunaitis, Neil Senzer, Phillip B.<br />

Maples.<br />

207<br />

Effect <strong>of</strong> Interleukin-15 and Dendritic <strong>Cell</strong>s on the<br />

Phenotype and Cytotoxicity <strong>of</strong> Cytokine-Induced Killer<br />

<strong>Cell</strong>s<br />

Xianghui He, Zhaohui Lai, Na Zhao, Liwei Zhu.<br />

208<br />

Investigating Macrophage Induction <strong>of</strong> Metastasis: A<br />

Precursor To Identify Therapeutic Targets<br />

Trevor Memmott, Evita Weagel, Justin Livingston, Pingguo Liu, Atif<br />

Elnaggar, Richard Robison, Kim O’Neill.<br />

209 Abstract Withdrawn from Presentation<br />

Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>: Viral<br />

Vector / siRNA-Mediated Therapies<br />

210<br />

Modelling Viral Insertion Sites Via Network Based<br />

Frameworks<br />

Raffaele Fronza, Cynthia Bartholomae, Annette Deichmann,<br />

Stephanie Laufs, Christ<strong>of</strong> von Kalle, Manfred Schmidt.<br />

211<br />

rAAV Mediated Modulation <strong>of</strong> miR-1 Inluences the<br />

Progression <strong>of</strong> Hepatocellular Carcinoma in a Mouse<br />

Model <strong>of</strong> Alpha-1 Antitrypsin<br />

Florie Borel, Qiushi Tang, Nancy Marcus, Jeffery Teckman, Terence<br />

Flotte, Christian Mueller.<br />

212<br />

AAV Mediated IFNb <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Orthotopic<br />

Xenograft Mouse Model <strong>of</strong> Invasive Glioblastoma<br />

multiforme<br />

Dwijit GuhaSarkar, James Neiswender, Miguel Sena-Esteves.<br />

213<br />

Response <strong>of</strong> Drug Sensitive and Resistant Breast Cancer<br />

<strong>Cell</strong>s to Combinatorial siRNA <strong>Therapy</strong><br />

Hamidreza Montazeri Aliabadi, Parvin Mahdipoor, Hasan Uludag.<br />

214<br />

Combination <strong>Therapy</strong> with Novel Nanoparticle,<br />

SNS01-T, and Bortezomib Results in Synergistic<br />

Cytotoxicity In Vitro and In Vivo in Multiple Myeloma<br />

Catherine Taylor, Qifa Zheng, Zhongda Liu, Terence Tang, Sarah<br />

Francis, Richard Dondero, John Thompson.<br />

215<br />

Rapamycin Enhances Adenovirus-Mediated Cancer<br />

Diagnosis in Naive and Pre-Immunized Hosts<br />

Ziyue Karen Jiang, Mai Johnson, Diana Moughon, Jennifer Kuo,<br />

Makoto Sato, Lily Wu.<br />

216<br />

Anti-Tumor Effects <strong>of</strong> Ad-p53 on INK4A/ARF-Defective<br />

Mesothelioma Are Inluenced Positively by Small G<br />

Protein Inhibitors but Negatively by Heat Shock Protein<br />

90 Inhibitors<br />

Masatoshi Tagawa, Kuan Chai, Yuanyuan Jiang, Kiyoko Kawamura,<br />

Shan Yang, Atsushi Ogino, Naoto Yamaguchi, Kazunori Kato, Yuji<br />

Tada, Yuichi Takiguchi, Koichiro Tatsumi, Hideaki Shimada, Kenzo<br />

Hiroshima, Shuji Kubo.<br />

217<br />

Lentiviral shRNA Targeting NANOG/NANOGP8<br />

Enhances Topotecan Chemotherapy in Human<br />

Colorectal Carcinomas<br />

John M. Jessup, Jingyu Zhang, Luis A. Espinoza, Abid Mattoo,<br />

Snorri S. Thorgeirsson.<br />

102<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>: Viral<br />

Vector / siRNA-Mediated Therapies<br />

218<br />

Comparative Evaluation <strong>of</strong> the Antitumor Activity<br />

<strong>of</strong> Anti-Angiogenic Proteins Delivered by Lentivirus<br />

Vector in Human Malignant Mesothelioma Model<br />

Misato Takagi-Kimura, Tomoko Hashimoto-Tamaoki, Noriyuki<br />

Kasahara, Shuji Kubo.<br />

219<br />

Clinical Development <strong>of</strong> “Bifunctional” shRNA<br />

Knockdown <strong>of</strong> Acid Ceramidase<br />

James Norris, Xiang Liu, Donald D. Rao, Zhaohui Wang, Neil Senzer,<br />

John Nemunaitis.<br />

220<br />

Photochemical Internalization (PCI)-Enhanced<br />

Nonviral <strong>Gene</strong>-Directed Enzyme Prodrug Cancer<br />

<strong>Therapy</strong><br />

Henry Hirschberg, Young Jik Kwon.<br />

221<br />

TRAIL-R2 and HRK Mediate Angiotensin Type 2<br />

Receptor-Induced Apoptosis <strong>of</strong> Human Prostate Cancer<br />

<strong>Cell</strong>s<br />

Nana Pei, Yanling Zhang, Feilong Jie, Jie Luo, Xinglu Chen, Jinlong<br />

Li, Hongwei Li.<br />

225<br />

In Vitro Repair <strong>of</strong> Rhodopsin Mutation by Spliceosome-<br />

Mediated RNA Trans-Splicing<br />

Adeline Berger, Stéphanie Lorain, Charlène Joséphine, Mélissa<br />

Desrosiers, Peggy Fabre, Cecile Peccate, Thomas Voit, Luis Garcia,<br />

José-Alain Sahel, Alexis-Pierre Bemelmans.<br />

226<br />

Muller <strong>Cell</strong> Reactivity Despite Neuronal Preservation<br />

after Systemic <strong>Gene</strong> <strong>Therapy</strong><br />

Tonia S. Rex.<br />

227<br />

<strong>Gene</strong> Replacement <strong>Therapy</strong> for Choroideremia<br />

Aaron D. Black, Vidyullatha Vasireddy, Rajashekhar Gaddameedi,<br />

Daniel C. Chung, Albert M. Maguire, Jeannette L. Bennicelli, Tanya<br />

Tolmachova, Miguel C. Seabra, Jean Bennett.<br />

228<br />

Adeno-Associated Vector (Type 8)-Mediated Expression<br />

<strong>of</strong> siRNA Targeting Vascular Endothelial Growth Factor<br />

Eficiently Inhibits Neovascularization in a Murine<br />

Choroidal Neovascularization Model<br />

Tsutomu Igarashi, Koichi Miyake, Noriko Miyake, Osamu Iijima,<br />

Chiemi Yaguchi, Takashi Shimada, Hiroshi Takahashi.<br />

229<br />

AAV-Mediated Expression <strong>of</strong> Secreted Human Ciliary<br />

Neurotropic Factor (hCNTF) Leads to Long-Term<br />

Preservation <strong>of</strong> Cone Photoreceptors in an Autosomal<br />

Recessive Model <strong>of</strong> Retinitis Pigmentosa<br />

Daniel M. Lipinski, Alun R. Barnard, Mandeep S. Singh, Edward<br />

Lee, Robert E. MacLaren.<br />

Thursday, May 16, 2013<br />

Sensory (Ophthalmic and Auditory) <strong>Gene</strong> &<br />

<strong>Cell</strong> <strong>Therapy</strong><br />

222<br />

CEP290 Directly Anchors Microtubules to the<br />

Membrane and Its N- and C- Termini Inhibit Protein<br />

Function and Ciliogenesis<br />

Theodore G. Drivas, Jean Bennett.<br />

223<br />

Dual Adeno-Associated Virus Vectors for Delivery <strong>of</strong><br />

Large <strong>Gene</strong>s to the Retina<br />

Frank M. Dyka, Sanford L. Boye, Shannon E. Boye, William W.<br />

Hauswirth.<br />

224<br />

Induced Pluripotent Stem <strong>Cell</strong>s as a Model To Test <strong>Gene</strong><br />

Augmentation <strong>Therapy</strong> for Choroideremia<br />

Vidyullatha Vasireddy, Jason A. Mills, Rajashekhar Gaddameedi,<br />

Etiena Basner-Tschakarjan, Monica Kohnke, Aaron H. Black, Krill<br />

Alexandrov, Albert M. Maguire, Daniel Chung, Helen Mac, Lisa<br />

Sullivan, Paul Gadue, Jeannette L. Bennicelli, Deborah L. French,<br />

Jean Bennett.<br />

230<br />

The Anti-Angiogenic Capacity <strong>of</strong> POMC <strong>Gene</strong> Delivery:<br />

From Cancer to Blindness<br />

Guei-Sheung Liu, Ming-Hong Tai, Gregory J. Dusting.<br />

231<br />

Genotype to Phenotype Relationship in CEP290<br />

Mutations: Improving <strong>Gene</strong> <strong>Therapy</strong> Strategies for the<br />

Most Common Form <strong>of</strong> Leber’s Congenital Amaurosis<br />

Adam P. Wojno, Theodore G. Drivas, Jean Bennett.<br />

232<br />

The LentiVector® <strong>Gene</strong> <strong>Therapy</strong> Platform for Ocular<br />

Disease: A Clinical Update<br />

Yatish Lad, Kyriacos Mitrophanous, Scott Ellis, James Miskin, Katie<br />

Binley, Michelle Kelleher, Cherry Lucas, Stuart Naylor.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

103


Abstract Directory, Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

<strong>Gene</strong> Regulation<br />

233<br />

Lentiviral Vector-Based Insertional Mutagenesis<br />

Identiies New Oncogenes and Molecular Networks<br />

That Control Hepatocyte Transformation and<br />

Metabolism<br />

Marco Ranzani, Daniela Cesana, Cynthia Bartholomae, Francesca<br />

Sanvito, Stefano Annunziato, Michela Riba, Fabrizio Benedicenti,<br />

Pierangela Gallina, Claudio Doglioni, Christ<strong>of</strong> von Kalle, Yoon Jun<br />

Kim, Elia Stupka, Manfred Schmidt, Giovanni Tonon, Luigi Naldini,<br />

Eugenio Montini.<br />

240<br />

Spacio-Temporal Mutagenesis in Muscle by Using AAV-<br />

Cre Vectors: The Example <strong>of</strong> the Mtm1 <strong>Gene</strong><br />

Romain Joubert, Alban Vignaud, Mickaël Le, Christelle Moal, Nadia<br />

Messaddeq, Anna Buj-Bello.<br />

241<br />

Synergistic and Tunable <strong>Gene</strong> Activation by<br />

Combinations <strong>of</strong> Synthetic Transcription Factors<br />

Pablo Perez-Pinera, David G. Ousterout, Jonathan M. Brunger,<br />

Alicia M. Farin, Katherine A. Glass, Farshid Guilak, Gregory E.<br />

Crawford, Alexander J. Hartemink, Charles A. Gersbach.<br />

242<br />

A Novel Enhancer Increases the Level and Duration <strong>of</strong><br />

Transgene Expression in Mice<br />

Chunbo Zhang, Leping Li, Dexi Liu.<br />

Thursday, May 16, 2013<br />

234<br />

Detection <strong>of</strong> RNA Interference (RNAi) Mediated mRNA<br />

Cleavage in Fresh Injected Tumor Tissue from Patients<br />

a Phase I Trial <strong>of</strong> an Intratumoral pbi-shRNA Lipoplex<br />

Targeting Stathmin-1<br />

Zhaohui Wang, Donald D. Rao, Phillip B. Maples, Neil Senzer, John<br />

Nemunaitis.<br />

235<br />

LncRNA Saf Interacts with SPF45 To Promote Fas<br />

Receptor Alternative Splicing in Maturing Erythroid<br />

<strong>Cell</strong>s<br />

Olga Villamizar, Christopher B. Chambers, Janice M. Riberdy, Derek<br />

A. Persons, Andrew Wilber.<br />

236<br />

Stable and Selective Production <strong>of</strong> Therapeutic Protein<br />

in the Breastmilk <strong>of</strong> Non-Transgenic Mice Via Early<br />

Gestational Intra-Amniotic <strong>Gene</strong> Transfer<br />

Jesse D. Vrecenak, Miroslaw Kozlowski, Carlyn A. Todorow,<br />

Antoneta Radu, Alan W. Flake.<br />

237<br />

Improved Engraftment <strong>of</strong> Lentivirally Transduced<br />

Adipose Tissue-Derived Stem <strong>Cell</strong>s for Hemophilia B<br />

<strong>Therapy</strong> Using Bioengineered <strong>Cell</strong> Sheet Technology<br />

Inkyong Shim, Kazuo Ohashi, Kohei Tatsumi, Natsumi Watanabe,<br />

Yuji Kashiwakura, Tsukasa Ohmori, Yoichi Sakata, Makoto Inoue,<br />

Mamoru Hasegawa, Teruo Okano.<br />

238<br />

Targeted PLGA Nanoparticles Encapsulating Histone<br />

Deacetylase Inhibitor, Panobinostat Effectively Control<br />

T <strong>Cell</strong> Leukemia<br />

Boyoung Choi, Jangwook Lee, Jeong-A. Shin, Dahye Lee, Kuen Yong<br />

Lee, Priti Kumar, Sang-Kyung Lee.<br />

239<br />

Radiosensitivity <strong>of</strong> Human Induced Pluripotent Stem<br />

<strong>Cell</strong>s (hiPSC) Detectable by <strong>Cell</strong> Cycle Analysis<br />

Frank Houghton, Michael W. Epperly, Xichen Zhang, Vishwajit<br />

Nimgaonkar, Joel S. Greenberger.<br />

243<br />

Design and Screening <strong>of</strong> Custom Zinc Finger<br />

Transcription Factors To Modulate Expression <strong>of</strong> <strong>Gene</strong>s<br />

Controlling <strong>Cell</strong> Fate<br />

Ashley L. Fischer, Qingzhou Ji, Erik R. Eastlund, Mark A. Gerber,<br />

Carol A. Kreader, Scott W. Knight.<br />

244<br />

TaqMan® Assays for Assessment <strong>of</strong> Genome,<br />

Epigenome and Quality <strong>of</strong> Pluripotent Stem <strong>Cell</strong>s<br />

Andrew Fontes, Rene H. Quintanilla, Jeffrey Fergus, Uma<br />

Lakshmipathy.<br />

245<br />

An ‘Open-Source’ Approach to Simple and Precise<br />

Genome Editing with rAAV<br />

Rob Howes, Alex Rieck, Eric Rhodes.<br />

246<br />

UV Light Modulates Transcriptional Activity <strong>of</strong> Egr-1<br />

Promoter on Human Primary Tenocytes<br />

Francisco Martinez-F, Araceli Barrera-Lopez, Hugo Sandoval-<br />

Zamora, David T. Curiel, Juan A. Madinaveitia-V, Rebecca E.<br />

Franco-Bourland.<br />

Fetal and Adult Stem <strong>Cell</strong>s<br />

247<br />

Embryonic Renal Progenitor <strong>Cell</strong>s Activate the<br />

b-Catenin/TCF Signaling Pathway during Integration<br />

into Damaged Adult Renal Tubules<br />

Paul Goodyer, Zhao Zhang, Diana Iglesias.<br />

248<br />

Preclinical Investigations <strong>of</strong> Therapeutic Beneits and<br />

Biodistribution from Stress Erythropoiesis on Minimal<br />

Dose <strong>of</strong> Lysosomal Enzyme Required for Phenotypic<br />

Correction in Mice with Hurler Syndrome<br />

Jingfen Han, Mei Dai, Salim S. Elamouri, Phuong Cao, Dao Pan.<br />

104<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Fetal and Adult Stem <strong>Cell</strong>s<br />

249<br />

Evidence <strong>of</strong> a Functional Role <strong>of</strong> Co-Culture in Delta-<br />

Mediated Expansion<br />

Korashon L. Watts, Colleen Delaney, Hans-Peter Kiem.<br />

250<br />

Rapidly Adhering <strong>Cell</strong>s (RACs) Residing in Skeletal<br />

Muscle Contribute to Ectopic Adipose <strong>Cell</strong> Formation/<br />

Accumulation in Skeletal Muscle <strong>of</strong> Dystrophin/<br />

Utrophin-/- Mice<br />

Jihee Sohn, Aiping Lu, Ying Tang, Bing Wang, Johnny Huard.<br />

251<br />

PGE2 Increases Lentiviral Vector Transduction<br />

Eficiency <strong>of</strong> Human HSC<br />

Garrett C. Heffner, Lauryn Christiansen, Francis J. Pierciey, Jr,<br />

Robert Kutner, Mitchell Finer, Gabor Veres.<br />

252 Abstract Withdrawn from Presentation<br />

253<br />

Amniotic Fluid Stem <strong>Cell</strong>s for the Treatment <strong>of</strong><br />

Hemophilia A<br />

Chung-Jung Kuo, Saloomeh Mokhtari, Melisa Soland, Shay Soker,<br />

James Yoo, John Owen, Mary Ann Knovich, Anthony Atala, Graca<br />

Almeida-Porada, Christopher Porada.<br />

254<br />

Characterization <strong>of</strong> Tumor Suppressive Effect Mediated<br />

by Human Bone Marrow-Derived Mesenchymal Stem<br />

<strong>Cell</strong>s<br />

Yulyana Yulyana, Ivy A. W. Ho, Jerry K. Y. Chan, Paula YP Lam.<br />

255<br />

Non-Invasive High-Resolution Imaging <strong>of</strong> Muscle<br />

Regeneration with a New Red-Absorbing Fluorescent<br />

Protein<br />

Jun Chu, Russell D. Haynes, Stephane Y. Corbel, Pengpeng Li,<br />

Emilio Gonzalez-Gonzalez, Palula J. Cranill, Michelle Baird,<br />

Michael W. Davidson, Christopher H. Contag, Kang Shen, Helen M.<br />

Blau, Michael Z. Lin.<br />

256<br />

Effects <strong>of</strong> Nano-Pillar Arrays on Differentiation <strong>of</strong><br />

Human Mesenchymal Stem <strong>Cell</strong>s<br />

Hyuk Sang Yoo, Hyesung Kim.<br />

257<br />

Integrating Non-Viral Sleeping Beauty Vector<br />

Delivery <strong>of</strong> Sox Transcription Factors Enhances MSC<br />

Chondrogenesis<br />

Laila Begum, Alan J. Nixon.<br />

258<br />

Variables That Affect Transduction <strong>of</strong> CD34+<br />

Hematopoietic Stem <strong>Cell</strong>s<br />

Francis J. Pierciey, Jr, Lauryn M. Christiansen, Robert Kutner,<br />

Garrett C. Heffner, Gabor Veres.<br />

<strong>Cell</strong> Processing and Vector Production<br />

259<br />

Assembly-Activating Protein Is Highly Tolerant To Point<br />

Mutations without Loss <strong>of</strong> Function: A High-Throughput<br />

Mutagenesis Screen Utilizing DNA Barcoding<br />

Lauriel Earley, Kei Adachi, Hiroyuki Nakai.<br />

260<br />

Development <strong>of</strong> a Validated Method Offering a<br />

Potentially Standardized Biological Assay for the<br />

Titration <strong>of</strong> HIV-1 Based Lentiviral Vectors<br />

Christian Skorik, Wesley Gorman, Mitch Finer, Mark D. Angelino,<br />

Robert H. Kutner.<br />

261<br />

Technology Transfer <strong>of</strong> a High Yield Fermentation<br />

Process and cGMP Production <strong>of</strong> Antibiotic-Free<br />

Plasmid DNA Vaccines<br />

Philippe Ledent, Olivier Geurten, Laurent Jost, Marc Daukandt,<br />

James A. Williams, Aaron Carnes.<br />

262<br />

Development <strong>of</strong> a Scale-Down Manufacturing Model for<br />

<strong>Gene</strong>ration <strong>of</strong> HIV-1 Based Lentiviral Vectors<br />

Wesley C. Gorman, Christian Skorik, Mitch Finer, Mark D. Angelino,<br />

Robert H. Kutner.<br />

263<br />

Antibiotic-Free Production <strong>of</strong> a Herpes Simplex Virus 2<br />

DNA Vaccine in a High Yield cGMP Process<br />

Jared Nelson, Ying Cai, Stephen Rodriguez, Neil Finlayson, James<br />

A. Williams, Aaron E. Carnes.<br />

264<br />

Characterization Technique for Drug and <strong>Gene</strong> Delivery<br />

Nanoparticles in Complex/Biological Media<br />

Sonja Capracotta, Duncan Grifiths, Phil Vincent, William Bernt,<br />

Patrick Hole.<br />

265<br />

Molecular and <strong>Cell</strong>ular Analyses <strong>of</strong> Platelet-Rich<br />

Plasma Preparations<br />

Roberta S. Stilhano, Priscila M. A. Denapoli, Sheila J. M. Ingham,<br />

Renne J. Abdalla, Sang W. Han.<br />

Late Breaking Abstracts I<br />

677<br />

RNA-guided Genome Editing Using CRISPR-Cas Systems<br />

Feng Zhang<br />

Thursday, May 16, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

105


Abstract Directory, Thursday, May 16, 2013<br />

Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Late Breaking Abstracts I<br />

678<br />

Rescue <strong>of</strong> T-cell deiciency in Prkdc scid mice by<br />

transplantation <strong>of</strong> gene-repaired haematopoietic stem<br />

cells<br />

Hayder H Abdul-Razak, Céline Rocca, Steven J Howe, María<br />

Eugenia Alonso-Ferrero, Richard Gabriel, Cynthia C Bartholomae,<br />

Chih Hao V Gan, Marina I Garín, Francisco Javier Molina Estévez,<br />

Alison Roberts, Michael Blundell, Guillermo Güenechea, Jianbin<br />

Wang, Michael C Holmes, Philip D Gregory, Christine Kinnon,<br />

Christ<strong>of</strong> von Kalle, Manfred Schmidt, Juan Antonio Bueren, Adrian<br />

J Thrasher and Rafael J Yáñez-Muñoz<br />

679<br />

A microRNA-based system for selective gene expression<br />

in tumor-associated macrophages after adenovirus<br />

mediated gene transfer<br />

Michelle Giovani, Kamola Saydaminova, Hongjie Wang, Jonas<br />

Persson, Hua Cao, Erini Papapetrou, Il-Kyu Choi, Chae-Ok Yun,<br />

Andre Lieber<br />

680<br />

Overcoming problems in the generation <strong>of</strong> adenovirus<br />

vectors for genome editing in human hematopoietic<br />

stem cells<br />

Kamola Saydaminova, Xun Ye, Hongjie Wang, Akseli Hemminki,<br />

Eirini Papapetrou, Andre Lieber<br />

681<br />

Scalable contaminant-free production <strong>of</strong> adenoassociated<br />

virus vectors utilizing cytoplasmic helper<br />

carrier<br />

Biao Dong, Andrea R. Moore, Jihong Dai, Sean Roberts, Kirk Chu,<br />

Philipp Kapranov, Bernard Moss, Weidong Xiao<br />

682<br />

A novel RNA oligonucleotide improves liver function<br />

and inhibits liver carcinogenesis in vivo<br />

V. Reebye, P. Sætrom, P.J. Mintz, K.W. Huang, P. Swiderski, L. Peng,<br />

C. Liu, X.X. Liu, S. Jensen, D. Zacharoulis, N. Kostomitsopoulos, N.<br />

Kasahara, J.P. Nicholls, L.R. Jiao, M. Pai, M. Mizandari, T. Chikovani,<br />

M.M. Emara, A. Haoudi, D.A. Tomalia, J.J. Rossi, N.A. Habib<br />

683<br />

Pre-T cell receptor for improved expansion <strong>of</strong> T cells in<br />

the absence <strong>of</strong> TCR alpha<br />

Roman Galetto, Céline Lebuhotel, Laurent Poirot, Cécile Schiffer<br />

Mannioui, Julianne Smith, Andrew Scharenberg<br />

685<br />

Human Erythropoietin <strong>Gene</strong> Delivery for Cardiac<br />

Remodeling <strong>of</strong> Myocardial Infarction in Rats<br />

Youngsook Lee, Arlo N. McGinn, Curtis D. Olsen, Kihoon Nam,<br />

Minhyung Lee, Sug Kyun Shin, Sung Wan Kim<br />

686<br />

MGN1703 – structure <strong>of</strong> agonist determines cellular<br />

responses to TLR9 activation<br />

Kerstin Kapp, Christiane Kleuss, Manuel Schmidt, Matthias<br />

Schr<strong>of</strong>f, Burghardt Wittig<br />

687 Abstract Withdrawn from Presentation<br />

688<br />

Mini-LCC DNA Vector: The Gold Standard <strong>of</strong> <strong>Gene</strong><br />

Delivery in Molecular Medicine<br />

Naiseh Naissi, Roderick Slavcev<br />

689<br />

Overcoming physical barriers in oncolytic virotherapy<br />

using a serotype 3-based oncolytic adenovirus<br />

expressing relaxin<br />

Joung-Woo Choi, Il-Kyu Choi, Andre Lieber, Chae-Ok Yun<br />

690<br />

Design <strong>of</strong> oncolytic HSV1 that express cellular gene<br />

moieties that improve antiglioma eficacy and normal<br />

cell safety<br />

Hiroshi Nakashima, Tran T. Nguyen, William F. Goins, Ennio A.<br />

Chiocca<br />

691<br />

Polymeric Carriers for the Delivery <strong>of</strong> Neurotrophins to<br />

the Brain<br />

Lei Miao, Devika S-Manickam, Zhijian He,Yuhang Jiang, Alexander<br />

V. Kabanov<br />

692<br />

A Lentiviral System for Analysis <strong>of</strong> Signaling Pathways<br />

Involved in Reprogramming <strong>of</strong> Induced Pluripotent<br />

Stem <strong>Cell</strong>s<br />

Ashley Fritz, Sunnie Mao, David Schaffer<br />

693<br />

Pluronic block copolymers for gene delivery<br />

Vivek Mahajan, Alexander Kabanov<br />

694<br />

Gold nanoparticles assisted laser optoporation <strong>of</strong> cells:<br />

a novel physical method for eficient, safe and versatile<br />

gene delivery<br />

W. Ding, E. Bergeron, J. Baumgart, M-O. Lapointe, L. Humbert, J-J.<br />

Lebrun, M. Meunier<br />

684<br />

An inducible Caspase-9 delivery-system using<br />

Mesenchymal Stromal <strong>Cell</strong>s for lung cancer treatment<br />

Miki Ando, Valentina Hoyos, Shigeki Yagyu, Carlos Ramos, Antonio<br />

Di Stasi, Gianpietro Dotti, Lisa Bouchier-Hayes, Malcolm Brenner<br />

695<br />

A potential therapeutic role for survivin in mitigating<br />

the harmful effects <strong>of</strong> ionizing radiation<br />

G Metzger, E Choi, K Carruthers, E Kocak<br />

106<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Thursday, May 16, 2013<br />

Poster Session I, continued<br />

4:00 PM - 6:00 PM<br />

Room: Exhibit Hall C/D<br />

Late Breaking Abstracts I<br />

696<br />

HIV Latency: Activating Virus Expression with<br />

Combined <strong>Gene</strong>tic and Chemical Tools<br />

Suresh K. Arya, PhD, Agnes Holczbauer, MD<br />

697<br />

Sensitisation <strong>of</strong> neuroblastoma cells for TRAIL-induced<br />

apoptosis by downregulated XIAP<br />

Ahmet Cingoz, Yavuz Taga, Betul Catalgol<br />

698 Abstract Withdrawn from Presentation<br />

699<br />

Culture and cryopreservation <strong>of</strong> human epidermal<br />

melanocytes (MC) for preclinical trials<br />

Kim Jin Tac, Pak Seoung Hoon, Shin Back Soo, Han Su-Youne, Lee<br />

Hyeon Kyeong, Lee Hyun Woo, Kim Ji Hyang, Lee Ai-Young, Do<br />

Byung-Rok<br />

700<br />

Universal Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> Platform: Upgrading<br />

the Long-Term <strong>Gene</strong> <strong>Therapy</strong> Arm by shifting from<br />

Analogic to Breakthrough Digital Endonuclease-<br />

Boosted <strong>Gene</strong> Targeting and Focussing on Next<br />

<strong>Gene</strong>ration Ex Vivo Protocols<br />

Roger Bertolotti<br />

Thursday, May 16, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

107


Friday, May 17, 2013<br />

Abstract Directory, Friday, May 17, 2013<br />

Oral Abstract Session 320<br />

DNA Vectorology & <strong>Gene</strong> Targeting<br />

1:00 PM - 3:00 PM<br />

Room: Ballroom A<br />

266 1:00 PM<br />

<strong>Gene</strong> Targeting at Silent Loci with Adeno-Associated<br />

Virus Vectors<br />

Li B. Li, David R. Deyle, David W. Russell.<br />

267 1:15 PM<br />

Development <strong>of</strong> Novel Adeno-Associated Virus Variants<br />

Targeting HIV-Infected T <strong>Cell</strong>s<br />

Dawn P. Wooley, John Weinstein, Poornima K. L. Narayan, Priyanka<br />

Sharma, David V. Schaffer, Katherine J. D. A. Exc<strong>of</strong>fon.<br />

268 1:30 PM<br />

DNA Hairpins Stimulate Eficient <strong>Gene</strong> Correction Via<br />

Double Strand Break Repair<br />

Matthew L. Hirsch, Richard H. Samulski.<br />

269 1:45 PM<br />

A Transposon-Based Inducible System for Improved<br />

Expression In Vivo<br />

Joseph E. Doherty, Lauren E. Woodard, Adham S. Bear, Aaron<br />

Foster, Matthew H. Wilson.<br />

270 2:00 PM<br />

Minicircle DNA Is Superior to Plasmid DNA in Eliciting<br />

Antigen-Speciic CD8+ T <strong>Cell</strong> Responses and <strong>Gene</strong>rating<br />

Protective Immunity<br />

Nicole E. B. Skinner, Wynette M. Dietz, Sara E. Hamilton, Michelle<br />

D. Jund, Suzanne Heitfeld, Adam J. Litterman, Patrick Hwu, Zhi-<br />

Ying Chen, Andres M. Salazar, John R. Ohlfest, Bruce R. Blazar,<br />

Christopher A. Pennell, Mark J. Osborn.<br />

271 2:15 PM<br />

A Mini-Intronic Plasmid (MIP): A Novel Robust<br />

Transgene Expression Vector In Vivo and In Vitro<br />

Jiamiao Lu, Feijie Zhang, Mark A. Kay.<br />

272 2:30 PM<br />

Vertically-Integrated Translational Studies <strong>of</strong> PDX1 as<br />

a Therapeutic Target for Pancreatic Cancer Via a Novel<br />

Bifunctional RNAi Platform<br />

F. Charles Brunicardi, Juehua Yu, Shi-he Liu, Guisheng Zhou, Robbi<br />

Sanchez, Christopher M. Jay, Padmasini Kumar, Phillip B. Maples,<br />

Donald D. Rao, Neil Senzer, John Nemunaitis.<br />

273 2:45 PM<br />

Phase I Trial <strong>of</strong> Escalating Doses <strong>of</strong> SGT-53 Infusion in<br />

Combination with Docetaxel in Advanced Solid Tumor<br />

Patients<br />

John Nemunaitis, Neil Senzer, Cynthia Bedell, Derek Nemunaitis,<br />

Meghan Degele, Gerald Edelman, Minal Barve, Robert Nunan,<br />

Kathleen F. Pirollo, Antonina Rait, Esther H. Chang.<br />

Oral Abstract Session 321<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic<br />

and <strong>Gene</strong>tic Diseases I<br />

1:00 PM - 3:00 PM<br />

Room: Ballroom B<br />

274 1:00 PM<br />

AAV Integrates Randomly into the Nuclear and<br />

Mitochondrial Genome after LPLD <strong>Gene</strong> <strong>Therapy</strong><br />

Christine Kaeppel, Stuart Beattie, Raffaele Fronza, Richard van<br />

Logtenstein, Florence Salmon, Sabine Schmidt, Stephan Wolf, Ali<br />

Nowrouzi, Hanno Glimm, Christ<strong>of</strong> von Kalle, Harald Petry, Daniel<br />

Gaudet, Manfred Schmidt.<br />

275 1:15 PM<br />

Ex Vivo Lentiviral <strong>Gene</strong> <strong>Therapy</strong> as a Cure for Murine<br />

Pompe Disease<br />

Merel Stok, Helen de Boer, Marshall W. Huston, Edwin H. Jacobs,<br />

Onno Roovers, Holger Jahr, Dirk J. Duncker, Trudi P. Visser,<br />

Ans T. van der Ploeg, Arnold J. J. Reuser, Nico P. van Til, Gerard<br />

Wagemaker.<br />

276 1:30 PM<br />

Pathogenesis <strong>of</strong> Growth Failure in Murine and Canine<br />

Glycogen Storage Disease-Ia and Partial Reversal <strong>of</strong><br />

Growth Failure Using Adeno-Associated Viral Vector<br />

<strong>Therapy</strong><br />

Elizabeth J. Brooks, Dianne Little, Ramamani Arumugam, Baodong<br />

Sun, Sarah Curtis, Amanda DeMaster, Michael Maranzano, Mark W.<br />

Jackson, Priya Kishnani, Michael S. Freemark, Dwight D. Koeberl.<br />

277 1:45 PM<br />

AAV-Mediated Direct Somatic <strong>Gene</strong>tic Correction <strong>of</strong><br />

Epidermolysis Bullosa<br />

Sandra Melo, Leszek Lisowski, Lisa Bashkirova, Mark A. Kay,<br />

Anthony E. Oro.<br />

278 2:00 PM<br />

Correction <strong>of</strong> Mitochondrial Cardiomyopathy<br />

Associated with Friedreich Ataxia in a Transgenic<br />

Model by <strong>Gene</strong> <strong>Therapy</strong><br />

Brahim Belbellaa, Morgane Perdomini, Laurent Monassier,<br />

Laurence Reutenauer, Nadia Messaddeq, Ronald G. Crystal, Patrick<br />

Aubourg, Hélène Puccio.<br />

279 2:15 PM<br />

Integration Proile <strong>of</strong> Lentiviral Vectors in <strong>Gene</strong><br />

<strong>Therapy</strong> for X-Adrenoleukodystrophy<br />

Cynthia C. Bartholomae, Nathalie Cartier, Salima Hacein-Bey-<br />

Abina, Ina Kutschera, Alain Fischer, Marina Cavazzana-Calvo,<br />

Patrick Aubourg, Manfred Schmidt, Christ<strong>of</strong> von Kalle.<br />

280 2:30 PM<br />

A Partial Deiciency Model <strong>of</strong> MUT Methylmalonic<br />

Acidemia (MMA) Displays Diet Inducible Disease and<br />

Sensitivity to Acetaminophen (APAP)<br />

Julien S. Senac, Vijay H. Aswani, Justin R. Sysol, Irini Manoli,<br />

Charles P. Venditti.<br />

108<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Oral Abstract Session 321, continued<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic<br />

and <strong>Gene</strong>tic Diseases I<br />

1:00 PM - 3:00 PM<br />

Room: Ballroom B<br />

281 2:45 PM<br />

AAV-Based over Expression <strong>of</strong> PEPCK-C Re-Patterns<br />

Mouse Muscle Energy Metabolism and Prevents High-<br />

Fat Diet Induced Obesity<br />

Daibang Nie, Sheri Wang, Ying Tang, Dong Wei, William Witt, Allan<br />

Zhao, Yifan Dai, Freddie Fu, Johnny Huard, Bing Wang.<br />

Oral Abstract Session 322<br />

Neurological <strong>Therapy</strong>: Neurodegeneration<br />

and Imaging<br />

1:00 PM - 3:00 PM<br />

Room: 150 ABC<br />

287 2:15 PM<br />

Fusion <strong>of</strong> Either Gap-43 or Tau to the Clostridial<br />

Tetanus Toxin Light Chain Improves Synaptic Inhibition<br />

in the Rat Spinal Cord Following Adenoviral Vector<br />

<strong>Gene</strong> Delivery<br />

Eleanor M. Donnelly, Chalonda R. Handy, Marie Kim, Jeremiah<br />

Huang, Thais Federici, Nicholas M. Boulis.<br />

288 2:30 PM<br />

MR-Guided Delivery <strong>of</strong> AAV2-hAADC into the Midbrain<br />

<strong>of</strong> Macaques Results in a Safe and Eficient Axonal<br />

Transport <strong>of</strong> AADC into the Striatum<br />

Kryst<strong>of</strong> S. Bankiewicz, Adrian P. Kells, Lluis Samaranch, Waldy San<br />

Sebastian, Nitasha Sharma, John Bringas, Phillip Pivirotto, John<br />

Forsayeth.<br />

289 2:45 PM<br />

Noninvasive, Quantitative PET Imaging <strong>of</strong> AAV-<br />

Mediated D2R80A Reporter <strong>Gene</strong> Expression in Live<br />

Animal Brains<br />

Sea Young Yoon, Datta Ponde, Harish Poptani, Jessica Bagel,<br />

Patricia A. O’Donnell, Charles H. Vite, John H. Wolfe.<br />

282 1:00 PM<br />

Silencing Mutant Htt by AAV-Mediated Expression <strong>of</strong><br />

RNAi Ameliorates Disease Manifestations in the YAC128<br />

Mouse Model <strong>of</strong> Huntington’s Disease<br />

Lisa M. Stanek, Lamya S. Shihabuddin, Seng H. Cheng.<br />

283 1:15 PM<br />

<strong>Gene</strong> Transfer <strong>of</strong> Human Apoe e2 Alleviate the<br />

Progression <strong>of</strong> Amyloid Deposition In Vivo<br />

Eloise Hudry, Jonathan Dashk<strong>of</strong>f, Allyson Lee, Shuko Takeda,<br />

Robert M. K<strong>of</strong>ie, Tadafumi Hashimoto, Maria Scheel, Tara Spires-<br />

Jones, Michal Arbel-Ornath, Rebecca A. Betensky, Beverly L.<br />

Davidson, Bradley T. Hyman.<br />

284 1:30 PM<br />

Vascular Delivery <strong>of</strong> AAV9-RNAi as a Potential <strong>Therapy</strong><br />

for Huntington’s Disease<br />

Brett Dufour, Catherine Smith, Randall Clark, Timothy Walker, Jodi<br />

McBride.<br />

285 1:45 PM<br />

Transcriptional Targeting <strong>of</strong> HSV Vector-Mediated<br />

Transgene Expression to Speciic Sensory Neuron<br />

Subtypes<br />

Mark F. Doyal, Mingdi Zhang, George Huang, Justus Cohen, Nicole<br />

Scheff, Michael Gold, William F. Goins, Joseph C. Glorioso.<br />

Oral Abstract Session 323<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

1:00 PM - 3:00 PM<br />

Room: 150 DEFG<br />

290 1:00 PM<br />

<strong>Gene</strong> <strong>Therapy</strong> Combined with NF-kappaB Inhibition for<br />

Duchenne Muscular Dystrophy<br />

Ying Tang, Robert Kang, Kara Imbrogno, Arvydas Usas, Qing Yang,<br />

Aiping Lu, Freddie Fu, Johnny Huard, Bing Wang.<br />

291 1:15 PM<br />

AAV Mediated Overexpression <strong>of</strong> Human a7 Integrin<br />

Leads to Histological and Functional Improvement in<br />

Dystrophic Mice<br />

Kristin N. Heller, Chrystal L. Montgomery, Kimberly M. Shontz,<br />

Paul M. L. Janssen, K. Reed Clark, Jerry R. Mendell, Louise R.<br />

Rodino-Klapac.<br />

292 1:30 PM<br />

<strong>Gene</strong>tic Correction <strong>of</strong> Duchenne Muscular Dystrophy<br />

Using Zinc Finger Nucleases<br />

David G. Ousterout, Pablo Perez-Pinera, Pratiksha I. Thakore,<br />

Matthew T. Brown, Charles A. Gersbach.<br />

Friday, May 17, 2013<br />

286 2:00 PM<br />

Mechanisms <strong>of</strong> Caspase-1 Mediated Schwannoma<br />

Regression<br />

Mehran Taherian, Shilpa Prabhakar, Giulia Fulci, Miguel Sena-<br />

Esteves, Xandra O. Breakeield, Gary J. Brenner.<br />

293 1:45 PM<br />

New TALENs To Correct the Reading Frame <strong>of</strong> Exon 54<br />

<strong>of</strong> the Dystrophin <strong>Gene</strong><br />

Joel Rousseau, Jean-Paul Iyombe, Charles A. Gersbach, Jacques P.<br />

Tremblay.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

109


Friday, May 17, 2013<br />

Abstract Directory, Friday, May 17, 2013<br />

Oral Abstract Session 323, continued<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

1:00 PM - 3:00 PM<br />

Room: 150 DEFG<br />

294 2:00 PM<br />

Restriction <strong>of</strong> Calpain3 Expression to the Skeletal<br />

Muscle Prevents Cardiac Toxicity and Corrects<br />

Pathology in a Murine Model <strong>of</strong> Limb-Girdle Muscular<br />

Dystrophy<br />

Carinne Roudaut, Florence Le Roy, Laurence Suel, Isabelle Richard.<br />

295 2:15 PM<br />

RNAi <strong>Therapy</strong> for Limb Girdle Muscular Dystrophy<br />

Type 1A<br />

Jian Liu, Lindsay Wallace, Sara Garwick-Coppens, Carol Davis,<br />

Chady Hakim, Susan Guckes, Michael Hauser, Jerry Mendell, Susan<br />

Brooks, Scott Harper.<br />

296 2:30 PM<br />

Expression <strong>of</strong> FKRP Consequently Restored Functional<br />

Glycosylation <strong>of</strong> a-DG in the Skeletal and Cardiac<br />

Muscles in FKRP Mutant Mice<br />

Qi Long Lu, Lei Xu, Pei Juan Lu, Chi-Hsien Wang, Elizabeth<br />

Keramaris, Chunping Qiao, Bin Xiao, Derek J. Blake, Xiao Xiao.<br />

297 2:45 PM<br />

Minimally Invasive Implantation <strong>of</strong> Autologous<br />

Chondrocytes Transduced with rAAV5-IGF-I Improves<br />

Longterm Cartilage Repair in Full-Thickness Chondral<br />

Defects in the Equine Model<br />

Kyla Ortved, Alan J. Nixon.<br />

Oral Abstract Session 324<br />

Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

1:00 PM - 3:00 PM<br />

Room: Ballroom C<br />

298 1:00 PM<br />

Safety and Correlates <strong>of</strong> Clinical Response in an Early<br />

Phase Clinical Trial in Multiple Myeloma Patients<br />

Post Auto-SCT and Adoptive Immunotherapy with<br />

Engineered T <strong>Cell</strong>s Expressing an HLA-A2 Restricted<br />

Afinity-Enhanced TCR for LAGE-1 and NY-ESO-1<br />

Bruce L. Levine, Aaron P. Rapoport, Edward A. Stadtmauer, Dan<br />

T. Vogl, Brendan Weiss, Gwendolyn K. Binder-Scholl, Dominic P.<br />

Smethurst, Jeffrey Finkelstein, Irina Kulikovskaya, Minnal Gupta,<br />

Erica Suppa, Joanna E. Brewer, Alan D. Bennett, Andrew B. Gerry,<br />

Nick J. Pumphrey, Helen K. Tayton-Martin, Daniel Williams,<br />

Zhaohui Zheng, Ashraf Z. Badros, Saul Yanovich, Gorgon Akpek,<br />

Michael Kalos, Bent K. Jakobsen, Carl H. June.<br />

299 Abstract Moved to Oral Abstract Session 230<br />

648 1:15 PM<br />

Neural Stem <strong>Cell</strong>s Expressing a Modiied Human<br />

Carboxylesterase Potentiate Anti-Cancer Activity <strong>of</strong><br />

Irinotecan in Murine Glioma Model<br />

Karen S. Aboody, Lucy Y. Ghoda, Margarita Gutova, Megan<br />

Gilchrist, Christine Brown, Vazgen Kankaldyyan, Elizabth Garcia,<br />

Lauren H<strong>of</strong>fman, Rex A. Moats, Phil Potter, Timothy W. Synold,<br />

Michael Barish.<br />

300 1:30 PM<br />

Virus-Speciic Cytotoxic T Lymphocytes (CTLs)<br />

Redirected with a Chimeric Antigen Receptor (CAR)<br />

and Engineered To Respond to IL7 Resist Regulatory T<br />

<strong>Cell</strong> (Treg) Inhibition<br />

Serena K. Perna, Daria Pagliara, Aruna Mahendravada, Hao Liu,<br />

Malcolm K. Brenner, Barbara Savoldo, Gianpietro Dotti.<br />

301 1:45 PM<br />

Engineering Hematopoiesis for Tumor-Targeted<br />

Delivery <strong>of</strong> IFNa by Tumor-Iniltrating Macrophages<br />

Achieves Safe and Effective Inhibition <strong>of</strong> Breast<br />

Cancer and Its Metastases in Both Murine and Human<br />

Hematochimeric Models<br />

Giulia Escobar, Davide Moi, Anna Ranghetti, Mario L. Squadrito,<br />

Michele De Palma, Roberta Mazzieri, Luigi Naldini.<br />

302 2:00 PM<br />

Myeloid Suppressor <strong>Cell</strong> Blockade Potentiates Anti-<br />

Tumor Responses <strong>of</strong> Adoptive T <strong>Cell</strong> Transfer <strong>Therapy</strong><br />

Steven Mok, Christopher Tsui, Thinle Chodon, Antoni Ribas,<br />

Richard C. Koya.<br />

303 2:15 PM<br />

Afinity-Enhanced Epithelial Junction Openers Improve<br />

Cancer Chemotherapy<br />

Roma Yumul, Hua Cao, Maximillian Richter, Julie Gralow, Andre<br />

Lieber.<br />

304 2:30 PM<br />

Glioblastoma Transfer miRNAs into Microglial <strong>Cell</strong>s<br />

through Extracellular Vesicles<br />

Erik R. Abels, Kristan E. van der Vos, Johan Skog, Suzanne E.<br />

Hickman, Joseph El Khoury, Xandra O. Breakeield.<br />

305 2:45 PM<br />

ab-T <strong>Cell</strong> Receptor-Based <strong>Gene</strong> <strong>Therapy</strong> Targeting<br />

the Common Tumor-Antigen Survivin for <strong>Therapy</strong> <strong>of</strong><br />

Hematological Malignancies<br />

Caroline Arber, Harshal Abhyankar, Helen E. Heslop, Gianpietro<br />

Dotti, Barbara Savoldo.<br />

110<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Oral Abstract Session 325<br />

<strong>Gene</strong> <strong>Therapy</strong> for Hematologic Diseases: From<br />

Models to Clinical Results<br />

1:00 PM - 3:00 PM<br />

Room: 151 ABCG<br />

306 1:00 PM<br />

Lentiviral Vector-Based <strong>Gene</strong> <strong>Therapy</strong> for Wiskott-<br />

Aldrich Syndrome: Preliminary Results from the<br />

French Center<br />

Salima Hacein-Bey-Abina, Johanna Blondeau, Laure Caccavelli,<br />

Sabine Charrier, Capucine Picard, Liliane Dal-Cortivo, Guillem<br />

Cross, Stephane Blanche, Frederic Bushman, Nirav Malani, Alain<br />

Fischer, Adrian Thrasher, Anne Galy, Marina Cavazzana-Calvo.<br />

307 1:15 PM<br />

Phase II Clinical <strong>Gene</strong> <strong>Therapy</strong> Trial for Adenosine<br />

Deaminase-Deicient Severe Combined Immune<br />

Deiciency (ADA-SCID)<br />

Kit L. Shaw, Robert Sokolic, Suparna Mishra, Satiro de Oliveira,<br />

Christopher Silvin, Geiger-Schredelseker Sabine, Brown<br />

Berkley, Garabedian Elizabeth, Monika Smogorzewska, Denise<br />

A. Carbonaro, Pei-yu Fu, Alejandra Davila, Jayashree Jagadeesh,<br />

Michael Hershield, Alan Wayne, Neena Kapoor, Theodore Moore,<br />

Fabio Candotti, Donald B. Kohn.<br />

311 2:15 PM<br />

Expansion <strong>of</strong> <strong>Gene</strong>-Modiied T <strong>Cell</strong>s Following<br />

Direct Intravenous Injection <strong>of</strong> Therapeutic Foamy<br />

Virus Vector in a Canine Model <strong>of</strong> Severe Combined<br />

Immunodeiciency<br />

Christopher R. Burtner, Brian C. Beard, Douglas R. Kennedy, Troy<br />

R. Torgerson, Andrew M. Scharenberg, David J. Rawlings, Grant D.<br />

Trobridge, Peter J. Felsburg, Hans-Peter Kiem.<br />

312 2:30 PM<br />

Adeno-Associated Virus-Mediated Expression <strong>of</strong> a<br />

C-Terminal Truncated ADAMTS13 Variant Prevents<br />

Shigatoxin-Induced Thrombotic Thrombocytopenic<br />

Purpura<br />

Sheng-Yu Jin, Juan Xiao, Jialing Bao, Shangzhen Zhou, Fraser J.<br />

Wright, X. Long Zheng.<br />

313 2:45 PM<br />

Self-Inactivating Lentiviral Vectors for Correction <strong>of</strong><br />

Rag1 Severe Combined Immunodeiciency<br />

Karin Pike-Overzet, Anna-Sophia Wiekmeijer, Miranda R. M. Baert,<br />

Chantal Lagresle-Peyrou, Axel Schambach, Fang Zhang, Rob C.<br />

Hoeben, Salima Hacein-Bey-Abina, Arjen C. Lankester, Robbert G.<br />

M. Bredius, Gertjan J. A. Driessen, Adrian J. Thrasher, Christopher<br />

Baum, Marina Cavazzana-Calvo, Jacques J. M. van Dongen, Frank J.<br />

T. Staal.<br />

308 1:30 PM<br />

Lentiviral <strong>Gene</strong> Transfer for Treatment <strong>of</strong> Children<br />

>2 Years Old with X-Linked Severe Combined<br />

Immunodeiciency<br />

Suk See De Ravin, Uimook Choi, Narda Theobald, Janet Lee,<br />

Hongmei Wang, Xiaolin Wu, Geraldine O’Connor, Daniel W.<br />

McVicar, Elizabeth Kang, John T. Gray, Brian P. Sorrentino, Harry L.<br />

Malech.<br />

309 1:45 PM<br />

Integration Site Analysis in a Clinical Trial <strong>of</strong> Lentiviral<br />

Vector Based Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong><br />

for Metachromatic Leukodystrophy. An 18 Months<br />

Follow-Up<br />

Eugenio Montini, Alessandra Bifi, Andrea Calabria, Luca Biasco,<br />

Martina Cesani, Fabrizio Benedicenti, Tiziana Plati, Simone Leo,<br />

Victor Neduva, Gianluigi Zanetti, Alessandro Aiuti, David Dow,<br />

Christ<strong>of</strong> von Kalle, Manfred Schmidt, Maria Sessa, Luigi Naldini.<br />

310 2:00 PM<br />

Comparison <strong>of</strong> Integration Site Proiles between<br />

SCID-X1 <strong>Gene</strong> <strong>Therapy</strong> Trials Using Gammaretroviral<br />

Vectors with Intact or Deleted (SIN) LTRs<br />

Salima Hacein-Bey-Abina, Laure Caccavelli, Nirav Malani, Charles<br />

Berry, Frances Male, Frederic Bushman, Alain Fischer, Marina<br />

Cavazzana-Calvo.<br />

Oral Abstract Session 326<br />

<strong>Gene</strong> Regulation and Animal Models<br />

1:00 PM - 3:00 PM<br />

Room: Ballroom D<br />

314 1:00 PM<br />

Pristimerin Enhances Recombinant Adeno-Associated<br />

Virus Serotype 2 Vector-Mediated Transgene<br />

Expression Both In Vitro and In Vivo<br />

Lina Wang, Yuan Wang, George V. Aslanidi, Arun Srivastava,<br />

Changquan Ling, Chen Ling.<br />

315 1:15 PM<br />

Transcriptional and Post-Transcriptional Regulation To<br />

Overcome Immunological Responses to <strong>Gene</strong> <strong>Therapy</strong><br />

for Hemophilia A<br />

Stefania E. Cannizzo, Simone Merlin, Antonia Follenzi.<br />

316 1:30 PM<br />

Selective Expansion <strong>of</strong> Transduced Hepatocytes: A<br />

Mechanism for Modulating Transgene Levels In Vivo<br />

Sean C. Nygaard, Annelise Haft, Milton Finegold, Markus Grompe.<br />

317 1:45 PM<br />

Multiplex Bi-Functional Short-Hairpin RNA (shRNA)<br />

Targeting Single-Nucleotide KRAS Mutations in<br />

Pancreatic Cancer<br />

Donald D. Rao, Zhaohui Wang, Padmasini Kumar, Neil Senzer, John<br />

Nemnaitis.<br />

Friday, May 17, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

111


Abstract Directory, Friday, May 17, 2013<br />

Oral Abstract Session 326, continued<br />

<strong>Gene</strong> Regulation and Animal Models<br />

1:00 PM - 3:00 PM<br />

Room: Ballroom D<br />

318 2:00 PM<br />

Engineering an XID-Site Speciic I-AniI Homing<br />

Endonuclease through Combination <strong>of</strong> Rational Design<br />

and Directed Evolution<br />

Yupeng Wang, Jordan Jarjour, Sandrine Boissel, Summer Thyme,<br />

Iram Khan, Joseph Pangallo, David Baker, Barry Stoddard, Andrew<br />

M. Scharenberg, David J. Rawlings.<br />

319 2:15 PM<br />

LMO2 Perturbs Human T <strong>Cell</strong> Development In Vivo by<br />

Two Different Mechanisms<br />

Anna-Sophia Wiekmeijer, Karin Pike-Overzet, Martijn H. Brugman,<br />

Willem E. Fibbe, Frank J. T. Staal.<br />

325 5:10 PM<br />

Targeting B <strong>Cell</strong> Precursor Acute Lymphoblastic<br />

Leukemia (ALL) with Chimeric Antigen Receptors<br />

(CARs) Speciic for CD19 or CD22<br />

Rimas J. Orentas, Waleed Haso, Daniel W. Lee, Terry J. Fry, Alan S.<br />

Wayne, Crystal L. Mackall.<br />

Poster Session II<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

AAV Vectors II<br />

326<br />

Retro-Orbital Injection <strong>of</strong> RAAVs to Neonatal Mice<br />

Dramtically Enhances <strong>Gene</strong> Delivery to the CNS<br />

Jia Li, Li Zhong, Shaoyong Li, Mengxin Li, Su Qin, Ran He, Flotte R.<br />

Terence, Guangping Gao.<br />

Friday, May 17, 2013<br />

320 2:30 PM<br />

Tightly Regulated Doxycycline (Dox)-Inducible<br />

Lentiviral Vectors for Human Myeloprotective <strong>Gene</strong><br />

<strong>Therapy</strong>: In Vitro and CD34+Xenotransplant Studies<br />

Nico Lachmann, Roman Hilje, Sebastian Brennig, Julia Dahlmann,<br />

Niels Heinz, Ina Gruh, Bernd Schiedlmeier, Christopher Baum,<br />

Thomas Moritz.<br />

321 2:45 PM<br />

Transcription Factor Activity Analysis Using a<br />

Functional Multiplex Gaussia Luciferase-Based<br />

Reporter Assay<br />

Sjoerd van Rijn, Jonas Nilsson, David P. Noske, W. Peter Vandertop,<br />

Bakhos A. Tannous, Thomas Würdinger.<br />

Presidential Symposium 330<br />

Presidential Symposium<br />

3:15 PM - 5:30 PM<br />

Room: Ballroom E-J<br />

322 4:10 PM<br />

Kinetics and Epigenetics <strong>of</strong> Retroviral Silencing in<br />

Mouse Embryonic Stem <strong>Cell</strong>s Deined by Deletion <strong>of</strong> a<br />

D4Z4 Barrier Element<br />

Sylvie Rival-Gervier, Mandy Lo, Shahryar Khattak, Peter Pasceri,<br />

Matthew Lorincz, James Ellis.<br />

323 4:30 PM<br />

Liver-Directed, Insulin-Based <strong>Gene</strong> <strong>Therapy</strong> Protects<br />

NOD Mice from Diabetes<br />

Mahzad Akbarpour, Kevin S. Goudy, Andrea Annoni, Francesca<br />

Sanvito, Luigi Naldini, Maria Grazia Roncarolo.<br />

324 4:50 PM<br />

On-Target Cleavage and Off-Target Activity <strong>of</strong> TALEN<br />

‘Nickases’<br />

Thomas J. Cradick, Christopher J. Antico, Eli J. Fine, Cory R.<br />

Lindsay, Eric Kildebeck, David B. Roth, Matthew H. Porteus.<br />

327<br />

AAV2H22, a Vector Selected by Directed Evolution,<br />

Transduces More Eficiently from the Basolateral<br />

Surface Despite Apical Selective Pressure<br />

Benjamin R. Steines, David D. Dickey, Katherine J. Exc<strong>of</strong>fon, David<br />

V. Schaffer, Joseph Zabner.<br />

328<br />

High-Eficiency Transduction <strong>of</strong> Primary Human<br />

Hematopoietic Stem <strong>Cell</strong>s and Erythroid Lineage-<br />

Restricted Expression by Optimized scAAV6 Serotype<br />

Vectors In Vitro and in a Murine Xenograft Model In<br />

Vivo<br />

Liujiang Song, Xiaomiao Li, Giridhara R. Jayandharan, Yuan Wang,<br />

George V. Aslanidi, Chen Ling, Li Zhong, Guangping Gao, Mervin C.<br />

Yoder, Changquan Ling, Mengqun Tan, Arun Srivastava.<br />

329 Abstract Withdrawn from Presentation<br />

330<br />

Comparing Dual AAV Vector Strategy Eficiencies for<br />

<strong>Gene</strong> <strong>Therapy</strong> In Vitro and In Vivo<br />

Heikki T. Turunen, María Victoria Luna Velez, Rajani Shelke, Ru<br />

Xiao, Jean Bennett, Luk H. Vandenberghe.<br />

331<br />

Regulation <strong>of</strong> Host <strong>Cell</strong>ular DNA Binding Proteins<br />

Augment the <strong>Gene</strong> Transfer Eficiency <strong>of</strong> Adeno-<br />

Associated Virus (AAV) Vectors<br />

Akshaya Krishnagopal, Sangeetha Hareendran, Dwaipayan Sen,<br />

Arun Srivastava, Alok Srivastava, Giridhara R Jayandharan.<br />

332<br />

Differences in AAV Serotype Dependent Distribution<br />

and Tropism Exist within the CNS <strong>of</strong> Wild Type and<br />

Mutant Mice in the MPSIIIB Mouse Model<br />

Janine A. Gilkes, Matthew D. Bloom, Andrew R. Kolarich, Coy D.<br />

Heldermon.<br />

112<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

AAV Vectors II<br />

333<br />

High-Eficiency Transduction <strong>of</strong> Primary Human<br />

Monocyte-Derived Dendritic <strong>Cell</strong>s by Recombinant<br />

AAV6 Vectors Containing Mutations in Surface-Exposed<br />

Serine and Threonine Residues<br />

George Aslanidi, Angela Rivers, Luis Ortiz, Jhell Pandya, Chen Ling,<br />

Kim Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava.<br />

334<br />

Optimization <strong>of</strong> the Capsid <strong>of</strong> Recombinant Adeno-<br />

Associated Virus 2 Vectors: The <strong>Final</strong> Threshold<br />

George Aslanidi, Angela Rivers, Luis Ortiz, Chen Ling, Kim Van<br />

Vliet, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun<br />

Srivastava.<br />

335<br />

Directed Evolution <strong>of</strong> AAV Capsid for Targeted Cancer<br />

<strong>Therapy</strong><br />

Damien Marsic, Yuan Lu, Chunxia Cao, Dane Phelan, Lakshmanan<br />

Govindasamy, Frederic J. Kaye, Mavis Agbandje-McKenna, Steve<br />

Ghivizzani, Sergei Zolotukhin.<br />

336<br />

Structures <strong>of</strong> the Retargeted AAV-DJ Vector in the<br />

Presence and Not <strong>of</strong> Receptor-Analog Sucrose<br />

Octasulfate<br />

Qing Xie, Nancy Meyer, Thomas F. Lerch, Dustin McCraw, Michael<br />

Spillman, Scott Stagg, Michael S. Chapman.<br />

337<br />

Improved AAV1 and AAV9 Vectors for <strong>Gene</strong> Delivery<br />

Balaji Balakrishnan, Akshaya Krishnagopal, Dwaipayan Sen, Alok<br />

Srivastava, Giridhara r Jayandharan.<br />

338<br />

Plasmid Integration within AAVS1 in AAV Producer <strong>Cell</strong><br />

Lines<br />

Amy Frederick, Yuxia Luo, John Martin, Jeffery Ardinger, Donna<br />

Armentano, Sam Wadsworth, Karen Vincent.<br />

339<br />

Short Hairpin RNA Delivered by Adeno-Associated<br />

Virus Vector Eficiently Reduced Target <strong>Gene</strong><br />

Expression in Mouse Primary Cortical Neurons<br />

Yun Lin, Holly Carlisle, Tom Wolfe, Danny Ortuno, Trish Amarante,<br />

Huiren Zhao, Steve Wood, Cherylene Plewa, Mike Wyszynski, Paul<br />

Kassner, Ki Jeong Lee.<br />

340<br />

AAV Vectors Puriied from Culture Medium with a<br />

Simple and Rapid Protocol Transduce Eficiently<br />

Murine Liver, Muscle and Retina<br />

Monica Doria, Antonella Ferrara, Alberto Auricchio.<br />

DNA Vectorology & <strong>Gene</strong> Targeting I<br />

341<br />

Minimally Invasive Electroporation <strong>of</strong> Synthetic DNA<br />

Vaccines for the Induction CTL and Functional Humoral<br />

Immune Responses Against HIV<br />

Megan Wise, Karuppiah Muthumani, Kate E. Broderick, Amir S.<br />

Khan, Janess Mendoza, Maria Yang, Jian Yan, Natalie Hutnick,<br />

Niranjan Y. Sardesai, David B. Weiner.<br />

342<br />

An E3-14.7K Peptide That Promotes Microtubules-<br />

Mediated Transport <strong>of</strong> Plasmid DNA Increases<br />

Polyplexes Transfection Eficiency<br />

Lucie Pigeon, Cristine Gonçalves, David Gosset, Chantal Pichon,<br />

Patrick Midoux.<br />

343<br />

Benchtop DNA Synthesizer: Oligo-Templated<br />

Polymerization (OTP)<br />

Adi Barzel, Mark A. Kay.<br />

344<br />

Nanoparticle-Mediated <strong>Gene</strong> Delivery for Rhodopsin-<br />

Associated Retinitis Pigmentosa<br />

Zongchao Han, Rasha Makkia, Junjing Guo, Miles J. Merwin, Mark J.<br />

Cooper, Muna I. Naash.<br />

345<br />

Hybrid Flp-TALE and Cre-TALE Recombinases with<br />

Designed Target Speciicity as Genome Engineering<br />

Tools<br />

Feng Li, Riddhi Shah, Eugenia Voziyanova, Yuri Voziyanov.<br />

346<br />

Permanent <strong>Gene</strong>tic Modiication <strong>of</strong> Dividing <strong>Cell</strong>s Using<br />

Episomally Maintained S/MAR DNA Vectors and the<br />

Correction <strong>of</strong> a Cancer Phenotype in Renal Tumour<br />

<strong>Cell</strong>s<br />

Suet Ping Wong, Richard P. Harbottle.<br />

347<br />

Collagen VII <strong>Gene</strong> Delivery Via Sleeping Beauty<br />

Transposon in COL7A1-Deicient Keratinocytes from<br />

Epidermolysis Bullosa Patients<br />

Maria Carmela Latella, Fabienne Cocchiarella, Giandomenico<br />

Turchiano, Zsuzsanna Izsvak, Zoltan Ivics, Manuel Gonçalves,<br />

Fulvio Mavilio, Fernando Larcher, Alessandra Recchia.<br />

348<br />

DNAJB4, a Heat Shock Rotein hsp40 Homolog, Activates<br />

Dendritic <strong>Cell</strong>s and Functions as a Molecular Adjuvant<br />

When Incorporated into Cancer DNA Vaccine<br />

Hsing-Yu Chen, Jeremy. J.W. Chen, Chi-Chen Lin.<br />

349<br />

Surface-Stabilized Calcium Phosphate Nano-Crystals<br />

for Eficient <strong>Gene</strong> Delivery<br />

Min Sang Lee, Kyuri Lee, Nak Won Kim, Ji Hoon Jeong.<br />

Friday, May 17, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

113


Abstract Directory, Friday, May 17, 2013<br />

Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

DNA Vectorology & <strong>Gene</strong> Targeting I<br />

350<br />

Polymeric Micellar Nanocarriers for <strong>Gene</strong> and<br />

Oligonucleotide Delivery<br />

Kazunori Kataoka.<br />

351<br />

Methods <strong>of</strong> Facilitating Patient Participation in DNA<br />

Based Experimental Therapeutic Phase I Cancer<br />

Studies<br />

Wanda Strange, Cynthia Bedell, Shannon Cagnina, Jeanne Jones,<br />

Patricia Brown, Gladice Wallraven, John Nemunaitis.<br />

352<br />

Manufacturing Developments for Scale-Up <strong>of</strong><br />

Autologous Phase II Ovarian Tumor Tissue FANG<br />

Vaccine<br />

Nicolas Taquet, John Nemunaitis, Phillip B. Maples.<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic<br />

and <strong>Gene</strong>tic Diseases I<br />

353<br />

Ultrasound-Guided Hepatic Injections <strong>of</strong> HDAd Vector<br />

Are More Eficient and Safer Than Systemic Intravenous<br />

Injections for Liver-Directed <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Crigler-<br />

Najjar Syndrome Type I<br />

Nunzia Pastore, Edoardo Nusco, Pasquale Piccolo, Sigismondo<br />

Castaldo, Francesco Vetrini, Donna Palmer, Libor Vitek, Philip Ng,<br />

Nicola Brunetti-Pierri.<br />

354<br />

<strong>Gene</strong> <strong>Therapy</strong> for Liver Diseases Using Non-Viral<br />

Minicircle-DNA Vector<br />

Hiu Man Viecelli, Richard P. Harbottle, Suet Ping Wong, Marinne<br />

Chuah, Thierry VandenDriessche, Cary O. Harding, Beat Thony.<br />

355<br />

Hepatic Delivery <strong>of</strong> <strong>Gene</strong>s Encoding Therapeutic<br />

Proteins or Mirnas Using Hyperactive Transposons: A<br />

Platform Technology for <strong>Gene</strong> <strong>Therapy</strong> and Functional<br />

Genomics In Vivo<br />

Mario Di Matteo, Pieter De Bleser, Ermira Samara-Kuko, Marinee<br />

Chuah, Thierry VandenDriessche.<br />

356<br />

Liver Progenitor <strong>Cell</strong>s Isolated from Adult Mice Fed a<br />

Choline-Deicient, Ethionine-Supplemented Diet Can<br />

Engraft, Expand and Mature in the Injured Liver <strong>of</strong> the<br />

FRG Mouse Model<br />

Gustavo de Alencastro, Grant J. Logan, Allison P. Dane, Sophia H. Y.<br />

Liao, George C. T. Yeoh, Ian E. Alexander.<br />

357<br />

Long-Term Phenotypic Correction <strong>of</strong> Hemophilia A by<br />

Non-Viral PiggyBac Transposon Vector<br />

Hideto Matsui, Mitsuhiko Sugimoto, Midori Shima, Naoko<br />

Fujimoto, Akitsu Hotta.<br />

358<br />

Long-Term Secretion <strong>of</strong> Arylsulfatase A without<br />

Antibody Formation after AAV Mediated Neonatal <strong>Gene</strong><br />

Transfer into MLD Model Mice<br />

Noriko Miyake, Koichi Miyake, Motoko Yamamoto, Takashi<br />

Shimada.<br />

359<br />

In Vitro and In Vivo Characterization <strong>of</strong> an Engineered<br />

Arylsulfatase B for <strong>Therapy</strong> <strong>of</strong> Mucopolysaccharidosis<br />

VI<br />

Rita Ferla, Pamela Claudiani, Gabriella Cotugno, Aaron Petrey,<br />

Richard Steet, Alberto Auricchio.<br />

360<br />

<strong>Gene</strong> <strong>Therapy</strong> for MPS VI Is Effective in Cats without<br />

Pre-Existing Immunity to AAV8<br />

Rita Ferla, Thomas O’Malley, Roberto Calcedo, Patricia O’Donnell,<br />

Ping Wang, Gabriella Cotugno, Pamela Claudiani, James M. Wilson,<br />

Mark Haskins, Alberto Auricchio.<br />

361<br />

Correlation <strong>of</strong> <strong>Gene</strong> Transfer and Transduction to<br />

Chloride Current Defect from rAAV2/5 Vector Derived<br />

Transgene DCFTR in Murine CF Nasal Airway<br />

Gang Shi, Kelvin D. MacDonald, Christian Mueller, Terence R.<br />

Flotte, Anne C. Fischer.<br />

362<br />

Helper-Dependent Adenoviral Vectors for Liver-<br />

Directed <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Primary Hyperoxaluria Type<br />

1<br />

Raffaele Castello, Stefania D”Aria, Roberta Borzone, Pasquale<br />

Piccolo, Patrizia Annunziata, Nicola Brunetti-Pierri.<br />

363<br />

Fetal <strong>Gene</strong> <strong>Therapy</strong> at 0.4G with AAV-hFIX or AAV-hFX<br />

Mediates Therapeutic Transgene Expression Despite<br />

Growth and a Positive Immune Response in a Non-<br />

Human Primate Model<br />

Citra Mattar, Cecilia Rosales, Rowell Fragata, Nuryanti Johana,<br />

Simon Waddington, Arijit Biswas, Mahesh Choolani, Amit<br />

Nathwani, Jerry Chan.<br />

364<br />

AAV Vector-Mediated Iduronidase <strong>Gene</strong> Delivery in<br />

a Murine Model <strong>of</strong> Mucopolysaccharidosis Type I:<br />

Comparing Different Routes <strong>of</strong> Delivery to the CNS<br />

Lalitha Belur, Zhenhong Nan, Kelly M. Podetz-Pedersen, Carolyn<br />

A. Fairbanks, Leah R. Hanson, William H. Frey, Karen Kozarsky,<br />

Walter C. Low, R. Scott McIvor.<br />

114<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic<br />

and <strong>Gene</strong>tic Diseases I<br />

365<br />

Enzyme Replacement <strong>Therapy</strong> Enhanced a Therapeutic<br />

Eficacy <strong>of</strong> Bone Marrow Transplantation in MPS II<br />

Mouse<br />

Kazumasa Akiyama, Yohta Shimada, Takashi Higuchi, Sayoko<br />

Iizuka, Makoto Otsu, Hiromitsu Nakauchi, Jillian R. Brown, Brett<br />

E. Crawford, Takahiro Fukuda, Hiroshi Kobayashi, Yoshikatsu Eto,<br />

Hiroyuki Ida, Toya Ohashi.<br />

Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />

366<br />

Ex-Vivo Transduced Monocytes as <strong>Gene</strong> Delivery<br />

Vehicles to Restenotic Arteries<br />

Ilia Fishbein, Richard F. Adamo, Jeanne M. Connolly, Shira Redlich,<br />

Katherine A. Clark, Ricardo A. Corrales, Michael Chorny, Scott P.<br />

Forbes, Robert J. Levy.<br />

367<br />

AAV9-Mediated miR-499 Expression Is Suficient To<br />

Induce Progressive Heart Failure in Mice<br />

Ru-Hang Tang, Bin Xiao, Zhenhua Yuan, Chunping Qiao, Jianbin Li,<br />

Bo He, Juan Li, Xiao Xiao.<br />

368<br />

Eficacy <strong>of</strong> Various Populations <strong>of</strong> Murine Mesenchymal<br />

Stem <strong>Cell</strong>s for the Treatment <strong>of</strong> Critical Limb Ischemia<br />

Francesca Bortolotti, Laura Ukovich, Vahid Razban, Valentina<br />

Martinelli, Giulia Ruozi, Franca Dore, Mauro Giacca, Serena<br />

Zacchigna.<br />

369<br />

Functional Impairment <strong>of</strong> Circulating Angiogenic <strong>Cell</strong>s<br />

for Treatment <strong>of</strong> Myocardial Infarction Is Differentially<br />

Driven by Both Advanced Age and Coronary Artery<br />

Disease, and Is Improved or Further Impaired by<br />

Modulating Nitric Oxide Synthase Expression<br />

Qiumei Chen, Monika Varga, Xiaoyin Wang, Daniel J. Haddad,<br />

Songtao An, Lejla Medzikovic, Yan Zhang, Brian T. Clifford, Wenhui<br />

Gong, Jeffrey R. Fineman, Christian Heiss, Kirstin A. Aschbacher,<br />

Yerem Yeghiazarians, Matthew L. Springer.<br />

370<br />

Dobutamine Stress Enhances Echocardiography<br />

Detection in mdx Mouse Heart and Reveals Therapeutic<br />

Beneits by Minidystrophin <strong>Gene</strong> <strong>Therapy</strong><br />

Chunping Qiao, Chunxia Zhao, Chi-Hsien Wang, Zhenhua Yuan,<br />

Jianbin Li, Juan Li, Xiao Xiao.<br />

371<br />

Ixmyelocel T: A <strong>Cell</strong>ular <strong>Therapy</strong> for the Treatment <strong>of</strong><br />

Severe, Chronic Cardiovascular Disease<br />

Ronnda L. Bartel.<br />

372<br />

Prevention <strong>of</strong> Restenosis through Ad-iNOS <strong>Gene</strong><br />

<strong>Therapy</strong> Combined with Supplementation <strong>of</strong><br />

Tetrahydrobiopterin and Arginine<br />

Scott P. Forbes, Ivan Alferiev, Richard F. Adamo, Michael Chorny,<br />

Robert J. Levy, Ilia Fishbein.<br />

373<br />

Safety <strong>of</strong> Direct Administration <strong>of</strong> AdVEGF-All6A+, an<br />

Adenovirus Vector Expressing a cDNA/Genomic Hybrid<br />

<strong>of</strong> Human Vascular Endothelial Growth Factors, to the<br />

Ischemic Myocardium <strong>of</strong> Rats<br />

Stephen M. Kaminsky, Lucy Quach, Stacey Chen, Lorraine Pierre-<br />

Destine, Benjamin Van de Graaf, Sébastien Monette, Jonathan B.<br />

Rosenberg, Dolan Sondhi, Neil R. Hackett, Ronald G. Crystal.<br />

374<br />

A Novel Anti-Inlammatory Formulation Approach<br />

To Enhance Myocardial <strong>Gene</strong> Transfer: An In-Vitro<br />

Assessment <strong>of</strong> Aspirin Loaded Poly-Lactic Glycolic Acid<br />

Nanoparticles<br />

Anthony S. Fargnoli, Anbin Mu, Michael G. Katz, Richard D.<br />

Williams, Marina V. Sumaroka, Robert Levy, David B. Weiner, Scott<br />

L. Diamond, Kenneth B. Margulies, Shu Yang, Charles R. Bridges.<br />

375<br />

Development <strong>of</strong> In Vitro and In Vivo Evaluation<br />

Methods for <strong>Gene</strong> <strong>Therapy</strong> Products<br />

Il Ung Oh, Ki Dae Park, Soyeong Kang, Ju Hyun Choi, Sung Yeol<br />

Han, Min Jeong Choi, Sun-Young Baek.<br />

Neurologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

376<br />

Restoration <strong>of</strong> the Motor and Behavior Phenotype<br />

with AAV9 in Aromatic L-Amino Acid Decarboxylase<br />

Deiciency Mice<br />

Ni-Chung Lee, Yin-Hsiu Chien, Shin-ichi Muramatsu, Barry J.<br />

Byrne, Wuh-Liang Hwu.<br />

377<br />

Signiicant Therapeutic Beneit after Post-Symptomatic<br />

<strong>Gene</strong> <strong>Therapy</strong> in a Feline Model <strong>of</strong> GM2 Gangliosidosis<br />

Victoria J. McCurdy, Ashley N. Randle, Heather L. Gray-Edwards,<br />

Allison M. Bradbury, Aime K. Johnson, Patricia M. Beadlescomb,<br />

Miguel Sena-Esteves, Douglas R. Martin.<br />

378<br />

Tight Regulation <strong>of</strong> Transgene Expression by<br />

Mifepristone-Inducible System after In Vitro Delivery<br />

by Lentiviral Vectors to Neural Progenitor <strong>Cell</strong>s<br />

Christopher Grunseich, Yijun Shi, Michael Mooney, Kenneth H.<br />

Fischbeck, Tyler M. Pierson.<br />

Friday, May 17, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

115


Abstract Directory, Friday, May 17, 2013<br />

Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Neurologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />

379<br />

Intravenous AAV9 Based <strong>Gene</strong> <strong>Therapy</strong> Corrects a<br />

Mouse Model <strong>of</strong> Sandh<strong>of</strong>f Disease<br />

Jagdeep S. Walia, Alexander Bello, Naderah Altaleb, Christa Kruck,<br />

Richard Hemming, Gary P. Kobinger, Barbara Triggs-Raine.<br />

380<br />

A Speciic Cleavage <strong>of</strong> Amyloid-b by a Viral Protease<br />

NIa Prevents the Amyloid-b-Mediated Mitochondrial<br />

Dysfunction<br />

Woo Jin Park, Bae-Hyun Shin, Hye-Eun Han, Sang Min Park.<br />

381<br />

Viral Vector Mediated Overexpression <strong>of</strong> Pleiotrophin<br />

for Disease Modiication in Parkinson’s Disease<br />

S. E. Gombash, F. P. Manfredsson, C. J. Kemp, S. L. Wohlgenant, N. C<br />

Kuhn, S. M. Fleming, R. J. Mandel, T. H. Collier, C. E. Sortwell.<br />

382<br />

Infrared Fluorescent Protein (iRFP) as a Reporter for<br />

Monitoring and Modulating Neurons<br />

Christopher T. Richie, Lowella V. Fortuno, Douglas B. Howard,<br />

Leslie R. Whitaker, Bruce T. Hope, Brandon K. Harvey.<br />

383<br />

Fetal Brain-Directed AAV5 and AAV9 <strong>Gene</strong> <strong>Therapy</strong><br />

Results in Rapid, Robust, and Persistent Transgene<br />

Expression in Mouse Choroid Plexus Epithelia<br />

Marie Reine Haddad, Eun-Young Choi, Anthony Donsante, Patricia<br />

M. Zerfas, Stephen G. Kaler.<br />

384<br />

Intravenous Administration <strong>of</strong> AAV9-mbgal in a GM1<br />

Gangliosidosis Mouse Model Expresses Enzyme in the<br />

CNS and Delays Disease Onset with Gender Differences<br />

Cara M. Weismann, Jennifer Ferreira, Stacy Maitland, Quin Su,<br />

Guangping Gao, Miguel Sena-Esteves.<br />

385<br />

<strong>Gene</strong> Delivery <strong>of</strong> ATP6 by a Mitochondrial Targeting<br />

Sequence Modiication <strong>of</strong> AAV9 Capsid VP2 Rescues<br />

<strong>Cell</strong>s with Mutated T8993G MtDNA Responsible for<br />

Neuropathy Ataxia and Retinitis Pigmentosa and<br />

Expresses in the Mouse CNS<br />

John Guy, Huijan Yuan.<br />

386<br />

rAAV2/5-Mediated <strong>Gene</strong> Transfer Is Less Eficient<br />

in the Aged Rat Brain: Examination <strong>of</strong> a-Synuclein-<br />

Mediated Neurodegeneration in the Nigrostriatal<br />

System<br />

Sara E. Gombash, Fredric P. Manfredsson, Christopher H. Kemp,<br />

David L. Fischer, Nathan C. Kuhn, Allyson Cole-Strauss, Ronald J.<br />

Mandel, Sheila M. Fleminig, Timothy J. Collier, Jack W. Lipton, Caryl<br />

E. Sortwell.<br />

387<br />

Safety Study <strong>of</strong> Intracranial AAVrh8-Mediated <strong>Gene</strong><br />

Transfer <strong>of</strong> beta-Hexosaminidase in Non-Human<br />

Primates<br />

Diane Golebiowski, Imramsjah M. J. van der Bom, Churl-Su Kwon,<br />

Stacy Maitland, Anna Luisa Kühn, Nina Bishop, Elizabeth Curren,<br />

Nilsa Silva, Andrew Miller, Susan Westmoreland, Matthew Gounis,<br />

Douglas R. Martin, Wael Asaad, Miguel Sena-Esteves.<br />

388<br />

Targeting Human SOD1 Using AAV Mediated RNAi in a<br />

Mouse Model <strong>of</strong> Amyotrophic Lateral Sclerosis<br />

Lorelei I. Stoica, Gabriella Toro, Robert Brown, Christian Mueller,<br />

Miguel Sena-Esteves.<br />

389<br />

TALEFrat#8–VP64 Increases Frataxin <strong>Gene</strong> and Protein<br />

Expression in Fibroblasts <strong>of</strong> Friedreich Patients and <strong>of</strong><br />

Mouse Model<br />

Jacques P. Tremblay, Pierre Chapdelaine, Jean-Paul Iyombe, Joël<br />

Rousseau, Zoé Coulombe.<br />

390<br />

Transduction <strong>of</strong> the Central Nervous System Following<br />

Intra-Cerebroventricular Administration <strong>of</strong> Adeno-<br />

Associated Viral Vectors to Neonatal and Juvenile Mice<br />

Shervin Gholizadeh, Sujeenthar Tharmalingam, Margarita E.<br />

MacAldaz, David R. Hampson.<br />

391<br />

Serial and Endpoint Biomarkers for Cardiorespiratory<br />

Function in a Canine Model <strong>of</strong> DMD Provide an<br />

Integrative View <strong>of</strong> Disease Pathogenesis and Response<br />

to <strong>Therapy</strong><br />

Andrew Mead, Alock Malik, Mihail Petrov, Martin Childers, Janet<br />

Bogan, Benjamin Kozyak, Hansell Stedman.<br />

590 (Moved from Poster Session III)<br />

Intracranial AAV <strong>Gene</strong> <strong>Therapy</strong> Extends the Life Span<br />

<strong>of</strong> GM2 Gangliosidosis Cats >Four-Fold with No Clinical<br />

Evidence <strong>of</strong> Vector Toxicity<br />

Allison M. Bradbury, Victoria J. McCurdy, Aime K. Johnson, Heather<br />

Gray-Edwards, Brandon L. Brunson, Ashley N. Randle, Nancy R.<br />

Cox, Miguel Sena-Esteves, Douglas R. Martin.<br />

116<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Cancer Immunotherapy II<br />

392<br />

Restored Expression <strong>of</strong> Heparanase in Tumor<br />

Speciic T <strong>Cell</strong>s Enhances Their Antitumor Effects in<br />

Neuroblastoma<br />

Ignazio Caruana, Valentina Hoyos, Gerrit Weber, Barbara Savoldo,<br />

Dario Marchetti, Gianpietro Dotti.<br />

393<br />

Single-<strong>Cell</strong> Imaging Reveals That Subsets <strong>of</strong> T <strong>Cell</strong>s<br />

Expressing a CD19-Speciic Chimeric Antigen Receptor<br />

Differ in Effector Function<br />

Harjeet Singh, Ivan Liadi, Gabrielle Romain, Navin Varadarajan,<br />

Laurence J. N. Cooper.<br />

394<br />

MCSP-Chimeric Antigen Receptor (CAR)-Redirected T<br />

<strong>Cell</strong>s Target Multiple Solid Tumors<br />

Claudia Arambula, Barbara Savoldo, Valentina Hoyos, Eric Yvon,<br />

Michele Del Vecchio, Soldano Ferrone, Gianpietro Dotti.<br />

395<br />

Tumor Recurrences Share Immunogenic Antigens<br />

across Both Tumor Types and Primary Treatments<br />

Which Can Be Therapeutically Targeted with VSV-cDNA<br />

Libraries<br />

Nicolas Boisgerault, Jose Pulido, Timothy Kottke, Oliver Donnelly,<br />

Esteban Celis, Jill Thompson, Rosa Diaz, Kevin Harrington, Hardev<br />

Pandha, Peter Selby, Alan Melcher, Richard Vile.<br />

396<br />

BARF1-Speciic T <strong>Cell</strong>s for the Adoptive Immunotherapy<br />

<strong>of</strong> EBV-Positive Nasopharyngeal Carcinoma<br />

Mamta Kalra, Minhtran C. Ngo, Ulrike Gerdemann, Ann Leen,<br />

Chrystal Louis, Cliona M. Rooney, Stephen Gottschalk.<br />

397<br />

IL-12 Increases Immune Responses Induced by a Novel<br />

pDNA Prostate Cancer Immunotherapy Approach in<br />

Non-Human Primates<br />

Bernadette Ferraro, Amritha Balakrishnan, Jewell N. Walters,<br />

Devin J. Myles, Jian Yan, Amir S. Khan, Niranjan Y. Sardesai, David<br />

B. Weiner.<br />

398<br />

Transgenic Expression <strong>of</strong> a Novel Immunosuppressive<br />

Signal Converter on T <strong>Cell</strong>s<br />

Norihiro Watanabe, Usanarat Anurathapan, Malcolm K. Brenner,<br />

Helen E. Heslop, Ann M. Leen, Cliona M. Rooney, Juan F. Vera.<br />

399<br />

Hypomethylating Agent 5-aza Cytidine Exposure To<br />

Improve AP1903 Treatment for Apoptosis Induction <strong>of</strong><br />

iCasp9/DCD19 <strong>Gene</strong> Modiied T <strong>Cell</strong>s<br />

Elodie Bole-Richard, Jean-Marie Certoux, Idir Idirene, Laurent<br />

Jossot, Eric Deconinck, Fabrice Larosa, Etienne Daguindau,<br />

Christophe Borg, Pierre Tiberghien, Christophe Ferrand, Marina<br />

Deschamps.<br />

400<br />

Adapting the Spontaneous Canine Osteosarcoma Model<br />

for T-<strong>Cell</strong> <strong>Therapy</strong><br />

Melinda Mata, Sunitha Kakarla, Juan Vera, Lisa Wang, Cliona<br />

Rooney, Heather Wilson, Stephen Gottschalk.<br />

401<br />

T-<strong>Cell</strong> Engineering for Adoptive Immunotherapy Using<br />

TAL-Effector Nucleases (TALENTM)<br />

Laurent Poirot Poirot, Cécile Schiffer-Mannioui, Agnes Gouble,<br />

Roman Galetto, Stephanie Grosse, Isabelle Chion-Sotinel, Diane Le<br />

Clerre, Laetitia Lemaire, Céline Lebuhotel, Justin Eyquem, Sylvain<br />

Arnould, Julianne Smith, Andrew Scharenberg, Sophie Derniame.<br />

402<br />

Randomized Phase II Trial <strong>of</strong> Post-Operative Adjuvant<br />

Chemotherapy ±FANG Autologous Tumor <strong>Cell</strong> Vaccine<br />

in Colorectal Carcinoma with Liver Metastases<br />

Joseph Kuhn, Neil Senzer, Minal Barve, G. Thomas Shires,<br />

Padmasini Kumar, Donald D. Rao, Gladice Wallraven, Beena O.<br />

Pappen, Phillip B. Maples, John Nemunaitis.<br />

403<br />

The Potential <strong>of</strong> Pro-Apoptotic PAC-1 Treatment<br />

for Augmentation <strong>of</strong> IL-2 Mediated Breast Cancer<br />

Immunotherapy<br />

Shyambabu Chaurasiya, Paggy Hew, Paul J. Hergenrother, David<br />

Sharon, Mary Hitt.<br />

404<br />

Effect <strong>of</strong> IL-15 <strong>Gene</strong> <strong>Therapy</strong> and mTOR Inhibitor<br />

Everolimus on Experimental Metastatic Breast Cancer<br />

Growth<br />

Na Zhao, Xiaodan Li, Feng Qi, Yujie Qiu, Xianghui He, Liwei Zhu.<br />

Cancer-Oncolytic Viruses I<br />

405<br />

Measles Virus for Immunovirotherapy <strong>of</strong> Cancer<br />

Christian Grossardt, Christine E. Engeland, Sascha Bossow, Silke<br />

Hamzaoui-Nord, Niels Halama, Dirk Jäger, Christ<strong>of</strong> von Kalle, Guy<br />

Ungerechts.<br />

406<br />

Oncolytic Herpes Simplex Viruses Encoding an<br />

Antibody Retargeted C5a Complement Protein for<br />

Multiple Myeloma <strong>Therapy</strong><br />

Hongtao Li, Stephen J. Russell.<br />

Friday, May 17, 2013<br />

407<br />

Mengovirus <strong>Therapy</strong> for Multiple Myeloma<br />

Autumn Ruiz, Elizabeth M. Hadac, Stephen J. Russell.<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

117


Abstract Directory, Friday, May 17, 2013<br />

Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Cancer-Oncolytic Viruses I<br />

408<br />

Systemic Administration <strong>of</strong> Fiber Redesigned<br />

Infectivity-Selective Oncolytic Adenovirus for Cancer<br />

Treatment<br />

Yoshiaki Miura, Joohee Han, Julia Davydova, Masato Yamamoto.<br />

409<br />

Therapeutic Eficacy <strong>of</strong> Oncolytic Herpes Virus and<br />

Chemotherapy for Treatment <strong>of</strong> Late-Stage Ovarian<br />

Cancer<br />

Chelsea M. Bolyard, Balveen Kaur.<br />

410<br />

T-<strong>Cell</strong> Engager-Armed Oncolytic Vaccinia Virus<br />

Signiicantly Enhances Antitumor <strong>Therapy</strong><br />

Feng Yu, Stephen M. Gottschalk, Xiao-Tong Song.<br />

411<br />

Improving the Oncolytic Activity <strong>of</strong> Measles Virus<br />

by Enhancing the Neutrophil-Mediated Response to<br />

Infected Tumor <strong>Cell</strong>s<br />

Aditi Dey, Yu Zhang, Anna Z. Castleton, Bella Patel.<br />

412<br />

Directed Evolution <strong>of</strong> Oncolytic HSV To Overcome<br />

Resistance to Virotherapy Due to Low Entry Receptor<br />

Expression<br />

Pin-Yi Wang, Pearlly Yan, Ralf Bundschuh, Hok-Hei Tam, Timothy<br />

P. Cripe.<br />

413<br />

VSV Pseudotyped with Maraba Virus G Glycoprotein<br />

Escapes Serum Neutralization<br />

Mulu Z. Tesfay, Arun Ammayappan, Mark J. Federspiel, Glen N.<br />

Barber, David F. Stojdl, Kah-Whye Peng, Stephen J. Russell.<br />

414<br />

Oncolytic Adenovirus-Mediated Interferon<br />

Expression Augments Chemoradiation <strong>Therapy</strong> in<br />

Immunocompetent Pancreatic Cancer Model<br />

Joohee Han, Yoshi Miura, Ryan Shanley, Xianghua Luo, Kazunori<br />

Aoki, Selwyn M. Vickers, Masato Yamamoto, Julia Davydova.<br />

415<br />

High-Resolution SPECT/CT Imaging Elucidates<br />

Molecular Determinants <strong>of</strong> Viral Oncolysis in Primary<br />

and Metastatic Lymphoma<br />

Tanner S. Miest, Marie Frenzke, Roberto Cattaneo.<br />

416<br />

Enhanced GBM <strong>Therapy</strong> Using a New Class <strong>of</strong> HSV<br />

Oncolytic Vector<br />

Lucia Mazzacurati, Marco Marzulli, Bonnie Reinhart, Justus B.<br />

Cohen, Glorioso C. Joseph, Grandi Paola.<br />

417<br />

<strong>Gene</strong> Expression Proiling Identiies Predictive Markers<br />

<strong>of</strong> Response to Oncolytic Measles Virus <strong>Therapy</strong><br />

Ianko Iankov, Cory Allen, Ian Parney, Caterina Giannini, Evanthia<br />

Galanis.<br />

Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong> I<br />

418<br />

Enhanced Engraftment <strong>of</strong> Hematopoietic Stem<br />

<strong>Cell</strong>s (HSCs) by Inhibition <strong>of</strong> Mammalian Target <strong>of</strong><br />

Rapamycin<br />

Emily A. Partridge, Jesse Vrecenak, Merek Kozlowski, Alan W.<br />

Flake.<br />

419<br />

Improved Expansion <strong>of</strong> Primitive Erythroid/<br />

Megakaryocyte Precursors from Cord Blood CD34+<br />

<strong>Cell</strong>s with Hyperactive Variants <strong>of</strong> Pharmacologically-<br />

Regulated Mpl<br />

Eyayu Belay, Christophre P. Miller, Amanda Kortum, Beverly Torok-<br />

Storb, C. Anthony Blau, David W. Emery.<br />

420<br />

The Challenge <strong>of</strong> HSCs Procurement for <strong>Gene</strong><br />

<strong>Therapy</strong> <strong>of</strong> beta-Thalassemia: Exploring Plerixafor as<br />

Mobilization Agent<br />

Maria Rosa Lidonnici, Annamaria Aprile, Marta Frittoli, Giacomo<br />

Mandelli, Bernhard Gentner, Laura Bellio, Elena Cassinerio, Laura<br />

Zanaboni, Silvano Rossini, Maria Domenica Cappellini, Fabio<br />

Ciceri, Sarah Marktel, Giuliana Ferrari.<br />

421<br />

Leukocyte Telomere Maintenance after Transplant and<br />

In Vivo Chemoselection <strong>of</strong> Mutant MGMTP140K <strong>Gene</strong>-<br />

Modiied Hematopoietic <strong>Cell</strong>s<br />

Christopher R. Burtner, Devikha Chandrasekaran, Brian C. Beard,<br />

Hans-Peter Kiem, Jennifer E. Adair.<br />

422<br />

Assessing Clonal Composition <strong>of</strong> Human Hematopoiesis<br />

in an NSG Transplantation Model after In Vitro<br />

Expansion <strong>of</strong> Transduced Cord Blood CD34 <strong>Cell</strong>s<br />

Reinhard Haemmerle, Ruhi Phaltane, Michael Rothe, Thomas<br />

Moritz, Ute Modlich.<br />

423<br />

Targeted Expansion <strong>of</strong> Individual Hematopoietic<br />

Lineages by Regulated Mpl Signaling<br />

David W. Emery, Eyayu Belay, Christopher P. Miller, Beverly Torok-<br />

Storb, C. Anthony Blau.<br />

424<br />

Correction <strong>of</strong> Murine Sickle <strong>Cell</strong> Disease Using Non-<br />

Ablative Conditioning and Autologous Bone Marrow<br />

<strong>Cell</strong>s Transduced with a Gamma Globin Lentiviral<br />

Vector<br />

Tamara I. Pestina, Phillip W. Hargrove, Hui Fen Zhao, Derek A.<br />

Persons.<br />

118<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong> I<br />

425<br />

Evaluating a LM-PCR and Pyrosequencing Method<br />

for the Detection <strong>of</strong> Clonal Contribution in Polyclonal<br />

Retrovirally Transduced Samples<br />

Martijn H. Brugman, Julia D. Suerth, Michael Rothe, Sebastian<br />

Suerbaum, Axel Schambach, Ute Modlich, Olga S. Kustikova,<br />

Christopher Baum.<br />

426<br />

Disease Modeling Using Induced Pluripotent Stem <strong>Cell</strong>s<br />

Derived from Severe Congenital Neutropenia Patients<br />

Lisa Trump, Ramesh Nayak, Jose Cancelas, Carolyn Lutzko.<br />

427<br />

Enhanced Engraftment <strong>of</strong> Murine and Human<br />

Hematopoietic Stem <strong>Cell</strong>s Mobilized Using the<br />

Plerixafor+G-CSF Combination<br />

Nikoleta Psatha, Garyfalia Karponi, Eleni Sgouramali, Athanasios<br />

Siametis, Panayotis Baliakas, Isabelle Riviere, Michel Sadelain,<br />

Achilles Anagnostopoulos, George Stamatoyannopoulos, Thalia<br />

Papayannopoulou, Evangelia Yannaki.<br />

428<br />

Evaluation <strong>of</strong> Engraftment and Tolerance Induction<br />

after Reduced Intensity Conditioning for Hematopoietic<br />

Stem <strong>Cell</strong> Transplantation in the Rhesus <strong>Gene</strong> <strong>Therapy</strong><br />

Model<br />

Naoya Uchida, Molly Evans, Richard Weitzel, Aylin Bonifacino,<br />

Sandra Price, Allen Krouse, Mark Metzger, Matthew Hsieh, Robert<br />

Donahue, John Tisdale.<br />

429<br />

Myeloprotective Properties <strong>of</strong> Inducible (shRNA-<br />

Mediated) Knock-Down <strong>of</strong> Deoxycytidine-Kinase (dCK)<br />

in Human Hematopoietic In Vitro Models<br />

Nico Lachmann, Kevin Czarnecki, Miriam Hetzel, Sebastian<br />

Brennig, Niels Heinz, Bernd Schiedlmeier, Thomas Moritz.<br />

430<br />

Comparision <strong>of</strong> In-Utero <strong>Gene</strong> <strong>Therapy</strong> and In-Utero<br />

Hemopoietic Stem <strong>Cell</strong> <strong>Therapy</strong> Approaches in Severe<br />

Models <strong>of</strong> Murine beta Thalassemia<br />

Niraja Dighe, Citra Mattar, Lay Geok Tan, Daren Sandikin, Simon<br />

Waddington, Michael Antoniou, Mahesh Choolani, Jerry Chan.<br />

431<br />

Regulatory T <strong>Cell</strong>s Suitable for Clinical Use Can Be<br />

Propagated on Artiicial Antigen Presenting <strong>Cell</strong>s<br />

Pappanaicken Kumaresan, Chetan Dhamne, Sourindra Maiti,<br />

Janani Krishnamoorthy, Radhika Thokala, Helen Huls, Champlin<br />

Richard, Dean Lee, Dat Tran, Laurence Cooper.<br />

<strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> for Pulmonary<br />

Diseases<br />

432 Abstract Moved to Oral Abstract Session 237<br />

433<br />

Eficient <strong>Gene</strong> Delivery to Pig Airway Epithelia<br />

and Submucosal Glands Using Helper-Dependent<br />

Adenoviral Vectors<br />

Huibi Cao, Tiago N. Machuca, Jonathan Yeung, Jing Wu, Kai Du,<br />

Cathleen Duan, Riccardo Bonato, Allan L. Coates, Kitty Leung,<br />

Herman Yeger, Ernest Cutz, Mingyao Liu, Shaf Keshavjee, Jim Hu.<br />

434<br />

Minicircle Plasmids Result in Enhanced and Prolonged<br />

Transgene Expression <strong>of</strong> Airway Epithelial <strong>Cell</strong>s Both In<br />

Vitro and In Vivo<br />

Mustafa M. Munye, Rachel E. Brown, Aristides D. Tagalakis,<br />

Josephine L. Barnes, Rupinder K. Ghatrora, Martin Pule, Mark F.<br />

Lythgoe, Robin J. McAnulty, Steven J. Howe, Stephen L. Hart.<br />

435<br />

Novel Human Bronchial Epithelial <strong>Cell</strong> Lines for the<br />

Study <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> Approaches To Treat Primary<br />

Ciliary Dyskinesia<br />

Mustafa M. Munye, Claire M. Smith, Rob A. Hirst, Amelia Shoemark,<br />

Juliette M. Delhove, Tristan R. Mckay, Claire Hogg, Christopher<br />

O’Callaghan, Steven J. Howe, Stephen L. Hart.<br />

436<br />

Upregulation <strong>of</strong> a Cluster <strong>of</strong> microRNAs on Mouse<br />

Chromosome 12qF1 in a Kras Mutant Mouse Model <strong>of</strong><br />

Lung Adenocarcinoma<br />

Paul N. Valdmanis, Biswajoy Roy-Chaudhuri, Hak Kyun Kim,<br />

Leanne C. Sayles, Yanyan Zheng, Chen-Hua Chuang, Debbie<br />

Caswell, Monte Winslow, E. A. Sweet-Cordero, Mark A. Kay.<br />

437<br />

Lentiviral-Mediated Functional Correction <strong>of</strong><br />

Hermansky-Pudlak Syndrome Type 1 Melanocytes<br />

Yasuhiro Ikawa, Richard Hess, Heidi Dorward, Bernadette<br />

Gochuico, William A. Gahl, Fabio Candotti.<br />

438<br />

Development <strong>of</strong> a Myeloid <strong>Cell</strong>-Binding Adenovirus for<br />

the Potential <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Alpha-1 Anti-Trypsin<br />

Deiciency<br />

Maurizio Buggio, Christopher Towe, Michael O. Alberti, Justin C.<br />

Roth, Anand C. Annan, David T. Curiel.<br />

439<br />

MicroRNAs as Potential Targets for <strong>Therapy</strong> <strong>of</strong><br />

Pulmonary Hypertension<br />

Igor B. Gubrij, Amanda K. Pangle, Li Pang, Larry G. Johnson.<br />

440<br />

CVB3 Infection Elicits Potent Oncolytic Activity Against<br />

Lung Cancer Stem <strong>Cell</strong>s<br />

Miyako Sagara, Hiroyuki Inoue, Shohei Miyamoto, Chika Sakamoto,<br />

Yuki Nakano, Koichi Takayama, Hiroyuki Shimizu, Yoichi<br />

Nakanishi, Kenzaburo Tani.<br />

Friday, May 17, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

119


Abstract Directory, Friday, May 17, 2013<br />

Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Immunologic & Host Responses in <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong><br />

441<br />

Liver-Directed <strong>Gene</strong> <strong>Therapy</strong> with Lentiviral Vector<br />

Reverts Pre-Existing Immunity to Coagulation Factor IX<br />

and Rescues Hemophilia B Mice from the Disease<br />

Andrea Annoni, Alessio Cantore, Kevin Goudy, Mahzad Akbarpour,<br />

Fabio Russo, Sara Bartolaccini, Luigi Naldini, Maria Grazia<br />

Roncarolo.<br />

442<br />

Combination Use <strong>of</strong> TLR7 Ligand with GM-CSF <strong>Gene</strong>-<br />

Transduced Tumor Vaccines Provides Substantial<br />

Antitumor Immunity Against Poorly Immunogenic<br />

Mouse Lung Cancer <strong>Cell</strong>s<br />

Megumi Narusawa, Hiroyuki Inoue, Chika Sakamoto, Tomoko<br />

Inoue, Shohei Miyamoto, Makoto Inoue, Koichi Takayama, Mamoru<br />

Hasegawa, Yoichi Nakanishi, Kenzaburo Tani.<br />

443<br />

Elimination <strong>of</strong> Contaminating Capsid-Expressing <strong>Gene</strong>s<br />

in AAV Vectors Reduces Immune Responses to Vector<br />

Administration in a Canine <strong>Gene</strong> <strong>Therapy</strong> Model<br />

Zejing Wang, Christine L. Halbert, Donghoon Lee, Tiffany Butts,<br />

Rainer Storb, Stephen H. Tapscott, Dusty Miller.<br />

444<br />

Immune Activation and Transgene Stability Following<br />

AAV9 <strong>Gene</strong> Transfer to an Acute Myocardial Infarct<br />

Mouse Model<br />

Susan Faust, Ehre Gao, Rebecca Tenney, Jason Ohlstein, Peter Bell,<br />

Walter Koch, James Wilson, Joseph Rabinowitz.<br />

445<br />

Blood Proteins Affecting rAAV Eficiency<br />

Jerome Denard, Hans Jörg Fehling, Philippe Moullier, Tomas Voit,<br />

Fedor Svinartchouk.<br />

446<br />

B & T <strong>Cell</strong> Immunomodulation Attenuates Anaphylaxis<br />

in a Novel Mouse Model <strong>of</strong> Pompe Disease<br />

Phillip A. Doerler, Sushrusha Nayak, Roland W. Herzog, Barry J.<br />

Byrne.<br />

447<br />

Quantiication <strong>of</strong> Alpha-L-Iduronidase Expression<br />

Outcomes in Mice Following Sleeping Beauty<br />

Transposon-Mediated <strong>Gene</strong> <strong>Therapy</strong><br />

Elena L. Aronovich, Bryan C. Hall, Jason B. Bell, R. Scott McIvor,<br />

Perry B. Hackett.<br />

449<br />

Over-Expression <strong>of</strong> Interleukin-6 Alone Induces<br />

Dexamethasone-Relieved Multiple-Organ Lesion in<br />

Mice<br />

Tao Bian, Zhenhua Yuan, Chunxia Zhao, Ting Zhang, Juan Li, Xiao<br />

Xiao.<br />

Oligonucleotide & RNAi Therapeutics<br />

450<br />

AAV6-Mediated Systemic Administration <strong>of</strong> miR30-<br />

Based RNAi Hairpins Impacts Muscle Disease in the<br />

HSALR Myotonic Dystrophy Mouse Model<br />

Darren R. Bisset, Maja Zavaljevski, Carrie Stoltzman, Joel R.<br />

Chamberlain.<br />

451<br />

Peptide-Conjugated Morpholino Rescues Utrophin-<br />

Dystrophin-Deicient Mice by Restoring Dystrophin<br />

Expression and Improvement in Muscle Pathology and<br />

Function<br />

Bo Wu, Caryn Cloer, Stephanie Milazi, Mona Shaban, Sapana N.<br />

Shah, Peijuan Lu, Hong M. Moulton, Qi Long Lu.<br />

452<br />

Co-Delivery <strong>of</strong> VEGF siRNA and IL-4 into Chitosan<br />

Nanoparticles in Breast Tumor Model <strong>of</strong> Rat<br />

Emine Salva, Suna Özbas-Turan, Levent Kabasakal, Fatih Eren,<br />

Saadet Alan, Naziye Özkan, Jülide Akbuga.<br />

453<br />

Systemic Delivery <strong>of</strong> a Peptide-Linked Morpholino<br />

Oligonucleotide Neutralizes Mutant RNA Toxicity in a<br />

Mouse Model <strong>of</strong> Myotonic Dystrophy<br />

Andrew J. Leger, Leocadia M. Mosquea, Nicholas P. Clayton,<br />

I.-Huan Wu, Timothy Weeden, Carol A. Nelson, Lucy Phillips,<br />

Errin Roberts, Peter A. Piepenhagen, Seng H. Cheng, Bruce M.<br />

Wentworth.<br />

454<br />

<strong>Gene</strong> Expression from Pseudouridine and<br />

5-Methylcytidine Modiied Messenger RNAs<br />

Jiehua Zhou, Maggie L. Bobbin, Julie Escamilla-Powers, Eric<br />

Arnold, Anthony Lauer, Laura Juckem, Karl-Dimiter Bissig, Anton<br />

P. McCaffrey, John J. Rossi.<br />

455<br />

Integrin-Targeted Nanoparticle Delivery <strong>of</strong> miRNA for<br />

Anti-Tumor <strong>Therapy</strong><br />

Puthupparampil Scaria, Yijia Liu, Betty Zhou, Martin Woodle.<br />

456<br />

Multi-Subtype Targeting, Escape-Reducing (MuSTER)<br />

Anti-HIV shRNA <strong>Gene</strong> <strong>Therapy</strong><br />

Ulrike Jung, John J. Rossi.<br />

448<br />

Hepatocyte Heparan Sulfate Is Dispensable for<br />

Adenovirus Liver Transduction In Vivo<br />

Anne K. Zaiss, Erin Foley, Ding Xu, Roger Lawrence, Jeffrey D. Esko,<br />

Harvey R. Herschman.<br />

120<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Oligonucleotide & RNAi Therapeutics<br />

457<br />

RNA Interference-Based <strong>Gene</strong> <strong>Therapy</strong> for Parkinson’s<br />

Disease Using shRNA That Speciically Targeting the<br />

LRRK2 G2019S Allele<br />

Liang Huang, Xiaomin Su, Juan Wang, Kathleen Maguire-Zeiss,<br />

Howard J. Feder<strong>of</strong>f.<br />

458<br />

An RNAi Screening Platform To Identify Modulators <strong>of</strong><br />

Glioma Stem <strong>Cell</strong>s Viability and Differentiation<br />

Christian E. Badr, Romain Amante, Stephanie Van Hoppe, Bakhos<br />

A. Tannous.<br />

459<br />

Short Hairpin RNAs (shRNA) Against Steroid Receptor<br />

Coactivator-3/Ampliied in Breast Cancer 1 (SRC-3)<br />

and Steroid Receptor Coactivator-1 (SRC-1) as Breast<br />

Cancer Therapeutic Agents<br />

David M. Lonard, Donald Rao, John J. Nemunaitis, Neil N. Senzer,<br />

Bert W. O’Malley.<br />

460<br />

Lentiviral-Mediated ENaCa Knockdown, as a Treatment<br />

for Cystic Fibrosis Lung Disease<br />

Rebekka E. Harding-Smith, Deborah R. Gill, Stephen C. Hyde.<br />

461<br />

Engineering Mammalian <strong>Cell</strong>s To Secrete RNA to the<br />

Extracellular Space<br />

Kevin J. Polach, Leslie Wilkinson, Elaine Brunhoeber, Amy<br />

Pettigrew, Kirby Wallace, Jeff Sparks, Angela Rea-Ramsey, Casey<br />

Pence, Majed Matar, Diane McClure, Jennifer Rice, Khursheed<br />

Anwer, Jason G. Fewell.<br />

462<br />

Lipid-Polymer Mediated siRNA <strong>Therapy</strong> for Silencing<br />

CXCR4 in Acute Myeloid Leukemia<br />

Breanne Landry, Hilal Gül-Uludag, Hasan Uludag.<br />

463<br />

Messenger RNA as a Novel Therapeutic Approach<br />

Antonin de Fougerolles.<br />

464<br />

Development <strong>of</strong> Post-Column Process <strong>of</strong> Immobilized<br />

Colanic Acid Degrading Enzyme Reactor<br />

Chromatography in SuperClean Therapeutic Plasmid<br />

DNA Production<br />

Li Chen, Christopher M. Jay, Nancy S. Templeton, John Nemunaitis,<br />

Nicolas Taquet, Phillip B. Maples.<br />

Pluripotent Stem <strong>Cell</strong>s<br />

465<br />

<strong>Cell</strong> Replacement <strong>Therapy</strong> for Parkinson’s Disease with<br />

Neuronal <strong>Cell</strong>s Derived from Human Parthernogenetic<br />

Stem <strong>Cell</strong><br />

Ibon Garitaonandia, Rodolfo Gonzalez, Alina Ostrowska, Tatiana<br />

Abramihina, Gerald Wambua, Alexander Noskov, Francesca<br />

Boscolo, Louise Laurent, Eugene Redmond, Evan Snyder, Ruslan<br />

Semechkin.<br />

466<br />

<strong>Gene</strong>ration <strong>of</strong> Isogenic Pairs <strong>of</strong> Mutant and<br />

Complemented Fanconi Anemia Human Induced<br />

Pluripotent Stem <strong>Cell</strong>s<br />

Laura I. Marquez, Kathryn Schubert, Feorillo Galivo, Milton<br />

Finegold, Susan Olson, Markus Grompe.<br />

467<br />

Engineering <strong>of</strong> Safety Control Switches for Human<br />

Induced Pluripotent Stem <strong>Cell</strong>s<br />

Wu Ou, Pingjuan Li, Jakob Reiser.<br />

468<br />

Eficient <strong>Gene</strong>ration <strong>of</strong> Integration-Free iPS <strong>Cell</strong>s from<br />

Human Adult Peripheral Blood<br />

Rui-Jun Su, David J. Baylink, Amanda Nieses, Xianmei Meng, Jason<br />

B. Kiroyan, Kimberly J. Payne, Yuyou Duan, Benjamin Tschudy-<br />

Seney, Mary Kearns-Jonker, K.-H William Lau, Xiao-Bing Zhang.<br />

469<br />

iPSC-Based Strategy To Correct the Bleeding Phenotype<br />

in Hemophilia A Targeting FVIII Expression to<br />

Endothelial <strong>Cell</strong>s<br />

Maria Talmon, Gabriella Ranaldo, Chantal Grosso, Angelo<br />

Lombardo, Simone Merlin, Stefania E. Cannizzo, Angel Raya, Luigi<br />

Naldini, Piercarla Schinco, Antonia Follenzi.<br />

470 Abstract Moved to Oral Abstract Session 233<br />

471<br />

Correction <strong>of</strong> DF508 CFTR in Patient-Derived iPS <strong>Cell</strong>s<br />

Using Small Frgement Homologous Replacement<br />

(SFHR) and Transcription Activator-Like Effector<br />

Nucleases (TALENs)<br />

Shingo Suzuki, Thomas J. Cradick, Roy G. Sargent, Lee Albert,<br />

Matthew Porteus, Gang Bao, Dieter C. Gruenert.<br />

472<br />

Directed Differentiation <strong>of</strong> Human Induced Pluripotent<br />

Stem (hiPS) <strong>Cell</strong>s into Functional Parathyroid Tissue<br />

for <strong>Cell</strong> <strong>Therapy</strong><br />

Alaleh Esmaeili Shandiz, Albert Lee, Shingo Suzuki, R. G. Sargent,<br />

Michael H. Yezzi, Lisa A. Orl<strong>of</strong>f, Dieter C. Gruenert.<br />

473<br />

iPSC-Derived Cardiomyocytes from the Urine <strong>of</strong> a<br />

Patient with Duchenne Muscular Dystrophy<br />

Xuan Guan, David Mack, Yingai Shi, Chad Markert, Guihua Liu,<br />

Michael Lawlor, Emily Mooreield, Tara Jones, Mark Furth,<br />

Yuanyuan Zhang, Martin K. Childers.<br />

Friday, May 17, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

121


Abstract Directory, Friday, May 17, 2013<br />

Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Pluripotent Stem <strong>Cell</strong>s<br />

474<br />

Process Development for Scalable Manufacturing <strong>of</strong><br />

hESC-Derived Cardiomyocytes<br />

Vincent C. Chen, Jingjing Ye, Giau Hua, Ziguang Lin, Dalin Chen,<br />

Aparna Roy, Patricia Huang, Wei Dang, Josh Tompkins, Arthur<br />

Riggs, Wenyi Chen, Joseph Wu, David Hsu, Larry Couture.<br />

475 Abstract Withdrawn from Presentation<br />

476<br />

Development and Qualiication <strong>of</strong> Assays To<br />

Characterize Human Embryonic Stem <strong>Cell</strong>s (hESC) and<br />

hESC-Derived Products at the Center <strong>of</strong> Biomedicine<br />

and <strong>Gene</strong>tics (CBG)<br />

Patricia Huang, Aparna Krishnan, Wei Dang, Vincent Chen, Jing<br />

Jing Ye, Aparna Roy, Patricia Lopez, Jing Chai, Ruilin Wu, Tania<br />

Aguilar, David Hsu, Larry Couture.<br />

Late Breaking Abstracts II<br />

701 Abstract Withdrawn from Presentation<br />

702<br />

Preclinical study <strong>of</strong> a scAAV2/8-Lp1-huPPCA vector in<br />

the treatment <strong>of</strong> the galactosialidosis mouse model<br />

Huimin Hu, Elida Gomero, Erik Bonten, John T Gray, Arthur<br />

Nienhuis, Alessandra d’Azzo<br />

703<br />

Improved Retroviral Replicating Vectors for Prodrug-<br />

Activator <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Cancer<br />

Noriyuki Kasahara, Christopher Logg, Omar Perez, Oscar Diago,<br />

Ryan Burnett, Aki Inagaki, Amy Lin, Cindy Burrascano, Mitchel<br />

Berger, Kryst<strong>of</strong> Bankiewicz, Weijun Wang, Hyun Kim, Walter Wolf,<br />

Thomas Chen, Kenneth Cornetta, Carlos Ibañez, Joan Robbins,<br />

Harry Gruber, Douglas J. Jolly<br />

704<br />

The recombinant tight junction opener JO-1* decreases<br />

hypoxia in tumors<br />

Kamola Saydaminova, Roma Yumul, Christine Wang, Akseli<br />

Hemminki, Andre Lieber<br />

705<br />

Development <strong>of</strong> a Clinical AAV-Based Vector Encoding<br />

a Microdystrophin Transgene for the Treatment <strong>of</strong><br />

Duchenne Muscular Dystrophy<br />

Yoshiaki Miura, Joohee Han, Julia Davydova, Masato Yamamoto<br />

706<br />

Novel therapeutic nanoparticles for in vivo delivery <strong>of</strong><br />

low dose siRNA in liver cells and for the treatment <strong>of</strong><br />

liver ibrosis associated nonalcoholic steatohepatitis<br />

Xavier de Mollerat du Jeu, Akiko Eguchi, Andronikou Nektaria,<br />

Ariel E. Feldsteinand, Peter Welch<br />

707<br />

Directed evolution <strong>of</strong> artiicial viruses<br />

Ir. Erik Teunissen, Dr. Enrico Mastrobattista Pr<strong>of</strong>. Dr. Peter Rottier,<br />

Pr<strong>of</strong>. Dr. Daan Crommelin<br />

708<br />

The NanoAssemblr Platform: Microluidics-based<br />

Manufacture <strong>of</strong> Limit Size Lipid Nanoparticles for<br />

Nucleic Acid Delivery<br />

J. Taylor, C. Walsh, N. Belliveau, P. Lin, R. Rungta, H. Choi, J. Lee, E.<br />

Ramsay, T. Leaver, A. Wild, K. Ou, A. Leung, Y. Tam, I. Hafez, S. Chen,<br />

B. MacVicar, C. Hansen, P. Cullis<br />

709<br />

Preclinical development <strong>of</strong> an AAV vector for the<br />

treatment <strong>of</strong> X-linked retinitis pigmentosa due to<br />

RPGRorf15 mutation<br />

Zhijian Wu, Suja Hiriyanna, Haohua Qian, Suddhasil Mookherjee,<br />

Kayleigh Kaneshiro, Maria Campos, Chun Gao, Robert Fariss,<br />

Anand Swaroop, Tiansen Li, Peter Colosi<br />

710<br />

Cytotoxic T-cell Surface Engineering with Chemically<br />

Self-Assembled Antibody Nanorings (CSANS)<br />

C. R. Wagner, Kari Gabrielse, Dr. Jae Chul Lee<br />

711<br />

Speciic siRNA delivery to primary activated T cells for<br />

anti-inlammatory therapy<br />

Na Hyung Kim, Yuran Xie, Archana Thakur, Lawrence Lum, Olivia<br />

Merkel<br />

712<br />

MicroRNA-155 confers encephalogenic potential to<br />

Th17 cells by promoting effector gene expression<br />

Ruozhen Hu, Thomas B. Huffaker, Dominique A. Kagele, Marah C.<br />

Runtsch, Erin Bake, Aadel A. Chaudhuri, June L. Round, Ryan M.<br />

O’Connell<br />

713<br />

DNA Mini Strings: The Gold Standard for Transgene<br />

Delivery<br />

Naiseh Naissi, Roderick Slavcev<br />

714<br />

Restoring a minimal motor unit potential and<br />

peripheral motor conductivity in lower extremities in<br />

a 15 years old girl with complete loss <strong>of</strong> spinal cord<br />

continuity at Th2-Th3 after combine autologous bone<br />

marrow derived cells and mesenchymal stem cells tr<br />

Jarocha Danuta, Milczarek Olga, Kwiatkowski Stanislaw, Majka<br />

Marcin<br />

715<br />

Genomic correction <strong>of</strong> Duchenne Muscular Dystrophy<br />

patient-derived iPSCs using TALENs<br />

Hongmei Li, Naoko Fujimoto, Noriko Sasakawa, Takashi<br />

Yamamoto, Knut Woltjen, Hidetoshi Sakurai, Shinya Yamanaka,<br />

Akitsu Hotta<br />

122<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Friday, May 17, 2013<br />

Poster Session II, continued<br />

5:30 PM - 7:30 PM<br />

Room: Exhibit Hall C/D<br />

Late Breaking Abstracts II<br />

716<br />

A versatile method for titration <strong>of</strong> chimeric antigen<br />

receptor-expressing retroviral vectors based on<br />

translocation <strong>of</strong> CD3-epsilon<br />

Daniel Abate-Daga, Steve A. Feldman, Rachel E. Beard, Steven A.<br />

Rosenberg, Richard A. Morgan<br />

717<br />

Dual Speciic Suicide <strong>Gene</strong> Expression plasmid Delivery<br />

Using Bio-reducible Polymer for Hepatocellular<br />

Carcinoma <strong>Gene</strong> <strong>Therapy</strong><br />

Hyun Ah Kim, Kihoon Nam, Minhyung Lee, Sung Wan Kim<br />

723<br />

Attenuation <strong>of</strong> TGF-β induced liver ibrosis by bone<br />

morphogenetic protein 2.<br />

Mu-Rou Tsai, Pao-Rong Chen, Yu-Lin Yang,, Ming-Chuan Hung,<br />

Tao-Chen Lee, Tsuing-Jeu Hung, Chien-Ya Hung, Wen-Teng Chang,<br />

Pei-fang Hsieh Shu-Fen Liu<br />

724<br />

Subpopulation <strong>of</strong> T-lymphocytes in leukoconcentrates<br />

obtained from bone marrow donors in the setting <strong>of</strong><br />

stable hematopoiesis<br />

R. Bogdanov, L. Mendeleeva, I. Galtseva, L. Kuzmina, T. Gaponova,<br />

N. Kalinin, E. Parovichnikova, V. Savchenko<br />

718<br />

Expression <strong>of</strong> the immunomodulatory cytokines<br />

interleukin-10 and interleukin-6 are increased in<br />

equine MSCs cultured in an inlammatory environment<br />

in vitro<br />

KO Ortved, J Witten, AJ Nixon<br />

719<br />

<strong>Gene</strong> Delivery Using Therapeutic Ultrasound To<br />

Mesenchymal Stem <strong>Cell</strong>s: Targeted Antiangiogenic<br />

Tumor <strong>Therapy</strong><br />

Tom Haber, Marcelle Machluf<br />

720<br />

The role <strong>of</strong> S100A4 in glioblastoma and cancer stem<br />

cell<br />

Shih-Hwa Chiou, Jun-Ming Han, Hsin-I Ma<br />

721<br />

Biodistribution and toxicology studies <strong>of</strong> AAV2/rh8-<br />

CBA-β-hexosaminidase after intracranial delivery in<br />

C57/Bl6 mice<br />

Kirsten Erger, Ronald Mandel, William Castleman, Martha<br />

Campbell-Thompson, Corinne Abernathy, Matthew Getz, Travis<br />

Cossette, Lynda Schneider, Ryan Brown, Miguel Sena-Esteves,<br />

Thomas Conlon<br />

Friday, May 17, 2013<br />

722<br />

Qualiication for human umbilical cord derived<br />

mesenchymal stem cells (hUC-MSCs) for regenerative<br />

medicine<br />

Hyun Woo Lee, Su-Youne Han, Hyeon Kyeong Lee, Seung Hoon Pak,<br />

Jin Tac Kim, Ji Hyang Kim, Byung-Rok Do<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

123


Abstract Directory, Saturday, May 18, 2013<br />

Oral Abstract Session 410<br />

Late Breaking Abstracts<br />

10:15 am - 12:15 pm<br />

Room: 150 DEFG<br />

Oral Abstract Session 411<br />

Adenovirus and Other DNA Virus Vectors<br />

10:15 AM - 12:15 PM<br />

Room: 150 ABC<br />

Saturday, May 18, 2013<br />

725 10:15 AM<br />

AAV/RNAi-mediated improvement <strong>of</strong> anti-malaria<br />

vaccination strategies<br />

Christiane Hammerschmidt-Kamper, Franziska Hentzschel,<br />

Kirsten Heiss, Kathleen Boerner, Ann-Kristin Mueller, Dirk Grimm<br />

726 10:30 AM<br />

Post-entry Restriction <strong>of</strong> AAV Vectors by A PHD Finger<br />

Protein<br />

Claire A. Shreiber, Toshie Sakuma, Yasuhiro Ikeda<br />

727 10:45 AM<br />

AAV-mediated Bevacizumab Maintenance <strong>Therapy</strong><br />

Inhibits Ovarian Cancer In Vivo<br />

Yi Xie, PhD, Martin J. Hicks, PhD, Stephen M. Kaminsky, PhD,<br />

Malcolm A.S. Moore, PhD, Ronald G. Crystal, MD, Arash Raii, MD,<br />

PhD<br />

728 11:00 AM<br />

Human iPS-derived antigen-targeted T cells are<br />

functional innate-like cytotoxic effectors and lyse<br />

CD19-positive tumor cells<br />

Maria Themeli, Christopher C. Kloss, Giovanni Ciriello, Michel<br />

Sadelain<br />

729 11:15 AM<br />

Penton-dodecahedral particles trigger opening <strong>of</strong><br />

intercellular junctions and facilitate viral spread<br />

during adenovirus serotype 3 infection <strong>of</strong> epithelial<br />

cells.<br />

Zhuo-Zhuang Lu, Hongjie Wang, YiYi Zhang, Zongyi Li, Pascal<br />

Fender, Andre Lieber<br />

730 11:30 AM<br />

An oncolytic adenovirus able to express a full-length<br />

functional anti-Her2 monoclonal antibody from tumor<br />

cells<br />

Paula Savola, Ilkka Liikanen, Theresia Gutmann, Kilian Guse and<br />

Akseli Hemminki<br />

731 11:45 AM<br />

Non-toxic and highly eficient targeting <strong>of</strong> a human<br />

chromosomal locus with a lentiviral vector-associated<br />

meganuclease<br />

Chenxia He, Agnès Gouble, Alix Bourdel, Laurent Poirot, Frédéric<br />

Pâques, Philippe Duchateau, Aleksander Edelman, Olivier Danos<br />

732 12:00 PM<br />

Non-viral gene delivery to human embryonic stem cellderived<br />

retinal pigment epithelium<br />

A Subrizi, T Ilmarinen, M Yliperttula, H Tenhu, H Skottman, A Urtti<br />

477 10:15 AM<br />

Molecular Modeling <strong>of</strong> Coagulation FVII Binding to<br />

Adenovirus Hexon Revealed a Binding Pocket for<br />

Coagulation Factor GLA Domain That Deines the<br />

Infectivity <strong>of</strong> Adenovirus-Coagulation Factor Complexes<br />

Eric E. Irons, Justin W. Flatt, Konstantin Doronin, Tara L. Fox,<br />

Mauro Acchione, Phoebe L. Stewart, Dmitry M. Shayakhmetov.<br />

478 10:30 AM<br />

Identiication <strong>of</strong> a Negative Regulator <strong>of</strong> TRPV1 Via an<br />

HSV Based cDNA Library Screen<br />

Bonnie L. Reinhart, Asaff Harel, MingDi Zhang, James R. Goss,<br />

William F. Goins, Justus B. Cohen, Joseph C. Glorioso.<br />

479 10:45 AM<br />

Long Term Follow Up <strong>of</strong> Phase II Clinical Trial <strong>of</strong> a<br />

Granulocyte-Macrophage Colony-Stimulating Factor-<br />

Encoding, Second-<strong>Gene</strong>ration Oncolytic Herpes Virus<br />

(Talimogene Laherparepvec, T-VEC) in Patients with<br />

Unresectable Metastatic Melanoma<br />

John Nemunaitis, Cynthia Bedell, Beena O. Pappen, Staci Horvath,<br />

Neil Senzer.<br />

480 11:00 AM<br />

Combined Therapies with Oncolytic Adenovirus<br />

Suppress Tumor Growth in Hamsters<br />

Brittany A. Young, Karoly Toth, Jacqueline F. Spencer, William S. M.<br />

Wold.<br />

481 11:15 AM<br />

Analysis <strong>of</strong> Host <strong>Cell</strong> and Viral Transcriptomes during<br />

Infection by Wild-Type Species C Ad6 and Species D<br />

Ad26<br />

Mallory A. Turner, Sean E. Hoherr, Michael A. Barry.<br />

482 11:30 AM<br />

Suppression <strong>of</strong> the Leaky Expression <strong>of</strong> Adenovirus<br />

<strong>Gene</strong>s Following Transduction with a Replication-<br />

Incompetent Adenovirus Vector by Incorporating<br />

microRNA-Targeted Sequences into the 3’-Untranslated<br />

Region <strong>of</strong> the E2A, E4, or pIX <strong>Gene</strong><br />

Kahori Shimizu, Fuminori Sakurai, Shin-ichiro Nakamura, Yasuhito<br />

Nagamoto, Kyoko Tomita, Masashi Tachibana, Hiroyuki Mizuguchi.<br />

483 11:45 AM<br />

Biodistribution <strong>of</strong> Fiber-Chimeric Ad5/3 Vectors in<br />

DSG2-Transgenic Mice<br />

Maximillian Richter, Roma Yumul, Hongjie Wang, Dirk Nettelbeck,<br />

Andre Lieber.<br />

124<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Saturday, May 18, 2013<br />

Oral Abstract Session 411, continued<br />

Adenovirus and Other DNA Virus Vectors<br />

10:15 AM - 12:15 PM<br />

Room: 150 ABC<br />

484 12:00 PM<br />

Ad5-Based Vectors Can Transduce Hepatocytes with<br />

High Eficiency Independent <strong>of</strong> FX<br />

Jan-Michael Prill, Lea Krutzke, Tatjana Engler, Stefan Kochanek,<br />

Florian Kreppel.<br />

Oral Abstract Session 412<br />

Nuclease Mediated Genome Editing<br />

10:15 AM - 12:15 PM<br />

Room: Ballroom A<br />

485 10:15 AM<br />

Cross Your Fingers: A Comprehensive Survey <strong>of</strong> the<br />

Cys2His2 Zinc Finger Domain Hints toward Codes <strong>of</strong><br />

Speciicity and Assembly<br />

Elizabeth F. Rowland, Anton V. Persikov, Benjamin L. Oakes, Mona<br />

Singh, Marcus B. Noyes.<br />

486 10:30 AM<br />

Eficient Site-Speciic Integration and In Situ <strong>Gene</strong><br />

Correction <strong>of</strong> Human Long-Term Repopulating<br />

Hematopoietic Stem <strong>Cell</strong>s by Zinc Finger Nucleases<br />

Pietro Genovese, Angelo Lombardo, Giulia Schiroli, Giulia Escobar,<br />

Tiziano Di Tomaso, Claudia Firrito, Davide Moi, Lucia Sergi Sergi,<br />

Philip D. Gregory, Michael C. Holmes, Luigi Naldini.<br />

487 10:45 AM<br />

Optimizing Plasmid DNA Templates for Homologous<br />

Recombination-Mediated <strong>Gene</strong> Modiication Following<br />

Zinc Finger Nuclease Treatment <strong>of</strong> Hematopoietic Stem<br />

<strong>Cell</strong>s<br />

Colin M. Exline, Orla L. Mulhern, Nick Llewellyn, Jill Henley, Jianbin<br />

Wang, Kenneth Kim, Jenny Yan, Philip D. Gregory, Michael C.<br />

Holmes, Paula M. Cannon.<br />

488 11:00 AM<br />

In Vivo ZFN Mediated Targeting <strong>of</strong> Albumin as a<br />

Platform for Expression <strong>of</strong> Multiple Therapeutic <strong>Gene</strong>s<br />

Rajiv Sharma, Xavier M. Anguela, Yannick Doyon, Sunnie Y. Wong,<br />

David E. Paschon, Hojun Li, Virginia Haurigot, Robert J. Davidson,<br />

Shangzhen Zhou, Philip D. Gregory, Michael C. Holmes, Edward J.<br />

Rebar, Katherine A. High.<br />

489 11:15 AM<br />

Quantifying Rates <strong>of</strong> <strong>Gene</strong> Targeting and Off-Target<br />

Cleavage <strong>of</strong> Engineered Nucleases Using SMRT<br />

Sequencing<br />

Eli J. Fine, Eric Kildebeck, Yanni Lin, Matthew H. Porteus, Thomas<br />

J. Cradick, Gang Bao.<br />

490 11:30 AM<br />

Precise Modiication <strong>of</strong> Human <strong>Gene</strong>s Directed by<br />

Single-Stranded DNA Oligonucleotides and TALENs<br />

Shengdar Q. Tsai, Deepak Reyon, Cyd Khayter, J. Keith Joung.<br />

491 11:45 AM<br />

Eficient Template-Free <strong>Gene</strong>tic Correction with TALE<br />

Nucleases<br />

David G. Ousterout, Pablo Perez-Pinera, Pratiksha I. Thakore,<br />

Ami M. Kabadi, Matthew T. Brown, Kamel Mamchaoui, Jacques P.<br />

Tremblay, Charles A. Gersbach.<br />

492 12:00 PM<br />

Enhancing the Eficiency <strong>of</strong> Zinc Finger Nuclease<br />

Delivery by Integrase-Defective Lentiviral Vectors Using<br />

Valproic Acid<br />

Alok V. Joglekar, Michelle Ho, Libby Stein, Sara Sanadiki, Roger P.<br />

Hollis, Donald B. Kohn.<br />

Oral Abstract Session 413<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic<br />

and <strong>Gene</strong>tic Diseases II<br />

10:15 AM - 12:15 PM<br />

Room: Ballroom B<br />

494 10:15 AM<br />

Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> for Cystinosis<br />

Sarah Ur, Celine J. Rocca, Jay Sharma, Donald B. Kohn, Stephanie<br />

Cherqui.<br />

493 10:30 AM<br />

Mechanism <strong>of</strong> Hematopoietic Stem <strong>Cell</strong>-Mediated<br />

<strong>Therapy</strong> in Cystinosis<br />

Brian A. Yeagy, Jay Sharma, Celine J. Rocca, Sarah Ur, Thomas<br />

Whisenant, Daniel R. Salomon, Stephanie Cherqui.<br />

495 10:45 AM<br />

Prevention <strong>of</strong> Neurocognitive Deicit by Ex Vivo<br />

Lentiviral Transduction <strong>of</strong> Hematopoietic Stem <strong>Cell</strong>s in<br />

a Murine Model <strong>of</strong> Mucopolysaccharidosis Type II<br />

Kelly M. Podetz-Pedersen, Andrea D. Karlen, Megan P. Buckvold,<br />

Zenhong Nan, Vladimir Slepushkin, Andre Roy, Galina Yakovief,<br />

Zi Gong, Joseph Muenzer, Boro Dropulic, Walter C. Low, R. Scott<br />

McIvor.<br />

496 11:00 AM<br />

Hyper-Functional Synthetic Transgenes Improve the<br />

Eficiency <strong>of</strong> Lentiviral and AAV-Based Liver-Directed<br />

<strong>Gene</strong> <strong>Therapy</strong> and Induce Immune Tolerance<br />

Nisha Nair, Alessio Cantore, Mario Di Matteo, Patrizia Della Valle,<br />

Jessica Willems, Hanneke Evens, Armando D’Angelo, Janka Matrai,<br />

Luigi Naldini, Marinee Chuah, Thierry VandenDriessche.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

125


Saturday, May 18, 2013<br />

Abstract Directory, Saturday, May 18, 2013<br />

Oral Abstract Session 413, continued<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic<br />

and <strong>Gene</strong>tic Diseases II<br />

10:15 AM - 12:15 PM<br />

Room: Ballroom B<br />

497 11:15 AM<br />

Prevention <strong>of</strong> Neuropathology and Normal Cognitive<br />

Development in the Hyperargininemic Mouse with AAV<br />

<strong>Gene</strong> Transfer<br />

Ellen K. Lee, Chuhong Hu, Ragini Bhargava, Ravi Ponnusamy, Hana<br />

Park, Sarah Novic<strong>of</strong>f, Nora Rozengurt, Bart Marescau, Peter De<br />

Deyn, David Stout, Lisa Schlichting, Wayne W. Grody, Stephen D.<br />

Cederbaum, Gerald S. Lipshutz.<br />

498 11:30 AM<br />

Assessing the Safety <strong>of</strong> AAV Liver <strong>Gene</strong> Transfer <strong>of</strong><br />

Hyperfunctional FIX Padua in Inhibitor-Prone Dogs and<br />

Mice<br />

Julie M. Crudele, Jonathan D. Finn, Joshua I. Siner, Yifeng Chen,<br />

Shangzhen Zhou, Glenn P. Niemeyer, Clinton D. Lothrop Jr, Federico<br />

Mingozzi, Katherine A. High, Valder R. Arruda.<br />

499 11:45 AM<br />

Development <strong>of</strong> AAV2/8-Mediated <strong>Gene</strong> <strong>Therapy</strong><br />

Clinical Trial for Crigler-Najjar Syndrome Type I:<br />

Optimization <strong>of</strong> Liver-Speciic Expression Cassette<br />

Nunzia Pastore, Alberto Auricchio, Nicola Brunetti-Pierri.<br />

500 12:00 PM<br />

Stromal <strong>Cell</strong>-Derived Factor-1 Non-Viral DNA <strong>Therapy</strong><br />

Accelerates Wound Healing and Decreases Scar<br />

Formation in Porcine Surgical Incisions<br />

Timothy J. Miller, Karissa Henson, Rahul Aras, Evan Facher, Marc<br />

S. Penn.<br />

Oral Abstract Session 414<br />

Cancer Immunotherapy II<br />

10:15 AM - 12:15 PM<br />

Room: 151 ABCG<br />

501 10:15 AM<br />

DAI-Armed Double Deleted Oncolytic Vaccinia Virus<br />

Displays Enhanced Anti-Tumor Activity by Eliciting a<br />

More Robust Anti-Tumor Immune Response<br />

Mari Hirvinen, Kilian Guse, Marko Ahonen, Eerika Karli, Dario<br />

Greco, Markus Vähä-Koskela, Akseli Hemminki, Vincenzo Cerullo.<br />

502 10:30 AM<br />

Clinical Implications <strong>of</strong> ROR1-Speciic T <strong>Cell</strong>s That<br />

Target B-<strong>Cell</strong> Leukemia<br />

Drew C. Deniger, Thomas H. Kipps, Simon Olivares, Harjeet Singh,<br />

Sourindra Maiti, Lenka V. Hurton, Kirsten C. Switzer, Tiejuan Mi,<br />

Radhika Thokala, Helen Huls, William G. Wierda, Laurence J. N.<br />

Cooper.<br />

503 10:45 AM<br />

Randomized Phase II Trial <strong>of</strong> Adjuvant Autologous<br />

Tumor <strong>Cell</strong> Vaccine (FANG) for High Risk Stage III/IV<br />

Ovarian Cancer: Preliminary Results<br />

Neil Senzer, Minal Barve, Cynthia Bedell, Jonathan Oh, Joseph<br />

Kuhn, Bruce Fine, Thomas P. Heffernan, Carolyn M. Matthews, C.<br />

Allen Stringer, E. Colin Koon, Samuel Lifshitz, Beena O. Pappen,<br />

Padmasini Kumar, Phillip B. Maples, John Nemunaitis.<br />

504 11:00 AM<br />

TCR <strong>Gene</strong> Editing To Treat Acute Leukemia and<br />

Multiple Myeloma<br />

Sara Mastaglio, Pietro Genovese, Zulma Magnani, Elena Provasi,<br />

Angelo Lombardo, Andreas Reik, Nicoletta Cieri, Aurora Brambilla,<br />

Fabio Ciceri, Claudio Bordignon, Michael C. Holmes, Philip D.<br />

Gregory, Luigi Naldini, Chiara Bonini.<br />

505 11:15 AM<br />

Novel VSV-Based Immunotherapy for Brain Tumors<br />

Rosa Diaz, Diana Rommelfanger-Konkol, Timothy Kottke, Jill<br />

Thompson, Oliver Donnelly, Addie Embry, Alan Melcher, Richard<br />

Vile.<br />

506 11:30 AM<br />

CD19-Targeted T <strong>Cell</strong>s Rapidly Induce Molecular<br />

Remissions in Adults with Chemotherapy Refractory<br />

Acute Leukemia<br />

Renier Brentjens, Marco L. Davila, Isabelle Riviere, Jae Park,<br />

Xiuyan Wang, Shirley Bartido, Jolanta Stefankski, Oriana Borquez-<br />

Ojeda, Yvette Bernal, Michel Sadelain.<br />

507 11:45 AM<br />

A Vaccinia Virus Armed with Interleukin-10 That<br />

Dampens Host Immunity to the Vctor but Not to Tumor<br />

Is a Promising Therapeutic Agent for Pancreatic Cancer<br />

Louisa S. Chard, Eleni Maniati, Pengju Wang, Jonathan Hughes,<br />

Jiwei Wang, Bela Denes, Istvan Fodor, Thorsten Hagemann,<br />

Nicholas R. Lemoine, Yaohe Wang.<br />

508 12:00 PM<br />

Identiication <strong>of</strong> an Alternative Speciicity for<br />

Engineered T <strong>Cell</strong>s Expressing an Enhanced Afinity<br />

MAGE A3 TCR<br />

Namir J. Hassan, Brian Cameron, Andrew Gerry, Joseph Dukes,<br />

Jane Harper, Vivekanandan Kannan, Frayne Bianchi, Francis<br />

Grand, Giovanna Bossi, Joanna Brewer, Debbie Sutton, Annelise<br />

Vuidepot, Alex Powlesland, Alison Legg, Katherine Adams, Alan<br />

Bennett, Nick Pumphrey, Gwen Binder-Scholl, Irina Kulikovskaya,<br />

Minnal Gupta, Gabriela Plesa, Michael Kalos, Bruce L. Levine,<br />

James L. Riley, Angel Varela-Rohena, Edward A. Stadtmauer, Aaron<br />

P. Rapoport, Gerald P. Linette, Carl H. June, Bent Jakobsen.<br />

126<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Saturday, May 18, 2013<br />

Oral Abstract Session 415<br />

Oligonucleotide & RNAi Therapeutics<br />

10:15 AM - 12:15 PM<br />

Room: Ballroom C<br />

509 10:15 AM<br />

Targeted, Multifunctional RNA Therapies for Advanced<br />

Cancers <strong>of</strong> the Prostate<br />

Luiza I. Hernandez, William M. Rockey, Craig A. Howell, Justin P.<br />

Dassie, Frank J. Hernandez, Xiu Y. Liu, Paloma H. Giangrande.<br />

510 10:30 AM<br />

Circulating Plasmid Detection in a Phase I Clinical Trial<br />

<strong>of</strong> Intratumoral Injection <strong>of</strong> pbi-shRNA Nanoplex<br />

Christopher M. Jay, Donald D. Rao, Zhaohui Wang, Neil Senzer,<br />

Phillip B. Maples, John Nemunaitis.<br />

511 10:45 AM<br />

Smooth Muscle <strong>Cell</strong> Targeted RNA Aptamers for the<br />

Treatment <strong>of</strong> Vascular Disease<br />

William H. Thiel, Maysam Takapoo, Shuxia Jiang, Jennifer<br />

Streeter, Bojana Stanic, Xiuying Liu, Francis J. Miller, Jr, Paloma H.<br />

Giangrande.<br />

512 11:00 AM<br />

Long-Term Inhibition <strong>of</strong> miR-122 Signiicantly<br />

Increases Hepatocellular Carcinoma in Multiple Adult<br />

Mouse Models<br />

Jun Xie, Qin Mao, Jia Li, Xia<strong>of</strong>ang Yang, Qin Su, Ran He, Zhong Jiang,<br />

Xia<strong>of</strong>ei Wang, Phillip D. Zamore, Guangping Gao.<br />

513 11:15 AM<br />

In Vitro and In Vivo Effects <strong>of</strong> Composite Calcium<br />

Phosphate and Poly(Lactic-Co-Glycolic Acid) (PLGA)<br />

Nanoparticles Engineered for Enhanced Cancer <strong>Cell</strong><br />

Internalization and Sustained siRNA Release<br />

Lisa A. Tobin, Yili Xie, Su I. Chung, King F. Kwong.<br />

514 11:30 AM<br />

Robust RNAi Enhancement Via Human Argonaute-2<br />

Overexpression from Plasmids, Viral Vectors or <strong>Cell</strong><br />

Lines<br />

Kathleen Boerner, Dominik Niopek, Daniel Gilbert, Konrad Streetz,<br />

Hans-Georg Kraeusslich, Dirk Grimm.<br />

515 11:45 AM<br />

Ultra-Stable Trivalent RNA Nanoparticles for Targeting<br />

to Cancers and HIV-1<br />

Kato Shum, Peixuan Guo, John J. Rossi.<br />

516 12:00 PM<br />

Directed Evolution-Based Dissection <strong>of</strong> the Four Human<br />

Argonaute Proteins<br />

Nina Schuermann, Leonardo Trabucco, Christian Bender, Rob<br />

Russell, Dirk Grimm.<br />

Poster Session III<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

RNA Virus Vectors<br />

517<br />

Data Mining Methods for Integration Site Analysis in<br />

Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> Trials<br />

Andrea Calabria, Luca Biasco, Fabrizio Benedicenti, Simone Leo,<br />

Martina Cesani, Gianluigi Zanetti, Elia Stupka, Alessandra Bifi,<br />

Alessandro Aiuti, Luigi Naldini, Eugenio Montini.<br />

518<br />

Mutually Dependent Barcode Strategy for Accurate<br />

Deep Sequencing <strong>of</strong> Vector Integration Sites<br />

Richard Gabriel, Cynthia C. Bartholomae, Frank Giordano, Raffaele<br />

Fronza, Stephanie Laufs, Christ<strong>of</strong> von Kalle, Manfred Schmidt.<br />

519<br />

Sequencing <strong>of</strong> a <strong>Gene</strong>tic Barcode Reveals Altered<br />

Population Dynamics in a Mouse Model <strong>of</strong> Transplanted<br />

Hematopoietic Stem <strong>Cell</strong>s Transduced with a Lentivirus<br />

Encoding LMO2<br />

Bryan E. Strauss, Daniela B. Zanatta, Rodrigo Aguiar, Maristela<br />

Tsujita, Primavera Borelli.<br />

520<br />

A New Strategy for Retroviral Vector Puriication Based<br />

on LNGR-Ab Immunomagnetic Selection<br />

Stornaiuolo Anna, Corna Stefano, Bossi Sergio, Bordignon Claudio,<br />

Rizzardi Gian Paolo, Bovolenta Chiara.<br />

521<br />

Lentiviral <strong>Gene</strong> <strong>Therapy</strong> in a SCID-X1 Mouse Model<br />

after Treatment with Granulocyte Colony Stimulating<br />

Factor<br />

Marshall W. Huston, Niek P. van Til, Rana Yadak, Yvette van<br />

Helsdingen, Gerard Wagemaker.<br />

522<br />

Development <strong>of</strong> Human Mesenchymal Stem <strong>Cell</strong>-Based<br />

Tumor-Homing Producer <strong>Cell</strong>s for Eficient Delivery <strong>of</strong><br />

Retroviral Replicating Vectors to Brain Tumors<br />

Shuichi Kamijima, Akihito Inagaki, Kei Hiraoka, Masamichi<br />

Takahashi, Quincy Tam, Emmanuelle Faure-Kumar, Janet Treger,<br />

Brooke Bogan, Christopher R. Logg, Noriyuki Kasahara.<br />

523<br />

Reducing In Vivo Clearance <strong>of</strong> Lentiviral Vectors by<br />

Immune <strong>Cell</strong>s in order To Improve Eficacy and Safety<br />

<strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong><br />

Nisha G. Sosale, Irena I. Ivanovska, Richard K. Tsai, Philip K.<br />

Zoltick, Yale Goldman, Dennis E. Discher.<br />

524<br />

A Novel Retroviral Envelope as a Candidate for<br />

Pseudotyping Retroviral and Lentiviral Vectors<br />

Wenqin Xu, Jill Russ, Kristen Gorman, Kyle Delaney, Maribeth V.<br />

Eiden.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

127


Abstract Directory, Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

RNA Virus Vectors<br />

525<br />

A Novel Shuttle Vector Approach To Identify <strong>Gene</strong>s<br />

Involved in Hematopoietic Stem <strong>Cell</strong> Disorders Using<br />

Vector-Mediated Genotoxicity<br />

Dustin T. Rae, Ryan Maynard, H. Joachim Deeg, Grant D. Trobridge.<br />

526<br />

A Systematic Approach to the Establishment and<br />

Characterisation <strong>of</strong> Endothelial Progenitor <strong>Cell</strong>s for<br />

<strong>Gene</strong> <strong>Therapy</strong><br />

Yuan Zhao, Natalie Werling, Robin Thorpe.<br />

527<br />

Lentiviral Vector Transduction <strong>of</strong> Human CD34+ <strong>Cell</strong>s<br />

Requires a Wash/Rest Phase between Vector Exposures<br />

To Produce Additional Beneit but Does Not Require<br />

High Dose Cytokines<br />

Michael R. Greene, Brian P. Sorrentino.<br />

528<br />

Phorbol 12-Myristate 13-Acetate Enhances Lentiviral<br />

Transduction <strong>of</strong> Human Hematopoietic <strong>Cell</strong>s through<br />

Activation PKC<br />

Jennifer M. Johnston, Gabriela Denning, Christopher B. Doering, H.<br />

Trent Spencer.<br />

529<br />

Production <strong>of</strong> Recombinant Lentiviral Vectors<br />

in Serum-Free Suspension Culture and Column<br />

Chromatography Puriication<br />

Yonghai Li, Bernd Hauck, Tiffany Kincaid, Fraser J. Wright,<br />

Katherine A. High, Guang Qu.<br />

533<br />

Lentiviral Vectors-Mediated Long-Term and High<br />

Eficiency Expression <strong>of</strong> Foreign <strong>Gene</strong> in HEK 293T <strong>Cell</strong>s<br />

Renhe Yan, Yingying Mao, Zhibing Liang, Yi Feng, Tianbai Li,<br />

Maomin Lu, Weiwang Gu, Jingang Zhang, Hongwei Li.<br />

534<br />

Tumorigenic Effect <strong>of</strong> Transplanted Myoblasts<br />

Overexpressing Bcl-2 Based on Retroviral Vector<br />

Francisco Martinez-F, Maria Ustoa, Araceli Barrera-L, Hugo<br />

E. Sandoval-Zamora, Bruno Guevara, Pablo Vizcaino-Dorado,<br />

Alejandro Zentella-Dehesa, Catalina Machuca-R.<br />

535<br />

Transduction <strong>of</strong> Ferret Airways with Avian Inluenza<br />

Virus Hemagglutinin Pseudotyped Equine Infectious<br />

Anemia Virus Vector<br />

Ziying Yan, Manij Patel, Xingshen Sun, Diana CM - Lei-butters,<br />

Hongshu Sui, John C. Olsen, John F. Engelhardt.<br />

AAV Vectors III<br />

536<br />

Multiple Molecular Alterations in Phosphodegrons 1-3<br />

within AAV2 Capsid Demonstrates Higher Hepatic <strong>Gene</strong><br />

Transfer Eficiency<br />

Dwaipayan Sen, V. Kalaivani, Rupali Gadkari, G. Sudha, N.<br />

Srinivasan, Alok Srivastava, Giridhara R Jayandharan.<br />

537<br />

Improved Adeno-Associated Virus Serotype (AAV)5<br />

Vectors for Hepatic <strong>Gene</strong> <strong>Therapy</strong><br />

Dwaipayan Sen, Prachi Agarwal, V. Kalaivani, Alok Srivastava,<br />

Giridhara R Jayandharan.<br />

538<br />

Adeno Associated Virus Puriication Independent <strong>of</strong><br />

Gradient Centrifugation and Chromatography<br />

Erik Arden, Joseph M. Metzger.<br />

Saturday, May 18, 2013<br />

530<br />

Eficient Selection <strong>of</strong> <strong>Gene</strong>tically Engineered HIV<br />

Resistant <strong>Cell</strong>s by Short Hairpin RNA Mediated HPRT<br />

and CCR5 Knockdown<br />

Munetoshi Narukawa, Saki Shimizu, Katrin Hacke, Janet Treger,<br />

Ruth Cortado, Erica Egger, Noriyuki Kasahara, Dong Sung An.<br />

531<br />

Designing Trans-Regulated Lentiviral Vectors for <strong>Gene</strong><br />

Transfer in Functional Genomics and <strong>Gene</strong> <strong>Therapy</strong><br />

Agnes Holczbauer, Adriana Zingone, Suresh Arya.<br />

532<br />

Application <strong>of</strong> VSV-G Induced Nanovesicles (Gesicles)<br />

for the Delivery <strong>of</strong> Active Protein To Target <strong>Cell</strong>s<br />

Thomas P. Quinn, Lily Lee, Mei Fong, Michael Haugwitz, Hiroaki<br />

Sagawa, Andrew Farmer.<br />

539<br />

Transcriptional Repression with Zinc-Finger and Tale<br />

Protein Scaffold<br />

Salvatore Botta, Elena Marrocco, Nicola de Prisco, Toni Cathomen,<br />

Claudio Mussolino, Enrico Maria Surace.<br />

540<br />

Mouse Gender Inluences Brain Expression <strong>of</strong> a<br />

Reporter <strong>Gene</strong> by Intravascularly-Administered AAV9<br />

Casey A. Maguire, Matheus H. W. Crommentuijn, Dakai Mu, Eloise<br />

Hudry, Alberto Serrano-Pozo, Bradley Hyman, Bakhos A. Tannous.<br />

541<br />

Site-Directed Mutagenesis <strong>of</strong> Surface-Exposed<br />

Lysine Residues Leads to Improved Transduction<br />

by Recombinant AAV2 and AAV8 Vectors in Murine<br />

Hepatocytes In Vivo<br />

Baozheng Li, Wenqin Ma, George Aslanidi, Chen Ling, Kim Van<br />

Vliet, Mavis Agbandje-McKenna, Arun Srivastava.<br />

128<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

AAV Vectors III<br />

542<br />

Transduction <strong>of</strong> Murine, Nonhuman Primate,<br />

and Human Hematopoietic Stem <strong>Cell</strong>s (HSCs) by<br />

Recombinant AAV Serotype Vectors: Identiication <strong>of</strong><br />

AAV6 as the Most Eficient Serotype for Human HSCs,<br />

and Further Augmentation in Transduction Eficiency<br />

In Vitro and In Vivo with Point-Mutations <strong>of</strong> Tyrosine<br />

Residues in the Viral Capsid<br />

Liujiang Song, M. Ariel Kauss, Etana Kopin, Manasa Chandra,<br />

Tahira Ul-Hasan, Erin Miller, Giridhara R. Jayandharan, Angela<br />

E. Rivers, George V. Aslanidi, Chen Ling, Baozheng Li, Wenqin<br />

Ma, Xiaomiao Li, Lourdes M. Andino, Li Zhong, Alice F. Tarantal,<br />

Mervin C. Yoder, Kamehameha K. Wong, Jr, Menqun Tan, Saswati<br />

Chatterjee, Arun Srivastava.<br />

543<br />

Eficient Transduction <strong>of</strong> Canine Muscle Using rAAV6<br />

Jane T. Seto, Julian N. Ramos, James M. Allen, Eric Finn, Guy L.<br />

Odom, Jeffrey S. Chamberlain.<br />

544<br />

Integrated Transcriptional and Post Transcriptional<br />

Targeting Results in Cardiac Biased Transgene<br />

Expression<br />

Jinhui Wang, Joshua Gorsky, Jonathan Peterson, Joseph<br />

Rabinowitz.<br />

545<br />

Reprogramming Adipose Tissue Derived Mesenchymal<br />

Stem <strong>Cell</strong>s (AT-MSC) into Pluripotent Stem <strong>Cell</strong>s by a<br />

Mutant AAV Vector<br />

Mong-Jen Chen, Yuanqing Lu, Takashi Hamazaki, Hsin-Yin Tsai,<br />

Kirsten Erger, Thomas Conlon, Arun Srivastava, Mark Brantly,<br />

Vince Chiodo, William Huaswirth, Naohiro Terada, Sihong Song.<br />

546<br />

Optimized Kidney-Targeted <strong>Gene</strong> Delivery Using AAV in<br />

a Mouse Model <strong>of</strong> Cystinosis<br />

Celine J. Rocca, Sarah M. Ur, Corinne Antignac, Jude R. Samulski,<br />

Stephanie Cherqui.<br />

547<br />

Concentration <strong>of</strong> AAV8 and 9 Vector to Titers Ranging<br />

from 1-6 x1014 vg/mL: Feasibility Assessment for<br />

Volume-Limited Dosing<br />

J. Fraser Wright, Bernd Hauck, Shang-Zhen Zhou, Olga Zelenaia,<br />

Marina Sumaroka, Katherine A. High.<br />

548<br />

Enhanced Fracture Healing Utilizing Directed Evolution<br />

<strong>of</strong> Adeno-Associated Virus<br />

Seth G. Levy, Damien Marsic, Shawn Gilbert, Sergei Zolotukhin,<br />

Selvarangan Ponnazhagan.<br />

549<br />

Targeted Bio-Engineering <strong>of</strong> Adeno Associated Virus<br />

Serotype rh.10 Capsid Improves Its <strong>Gene</strong> Delivery In<br />

Vitro and In Vivo<br />

Ruchita Selot, Nishanth Gabriel, Monika Kumari, Giridhara R<br />

Jayandharan.<br />

550<br />

Adeno-Associated Virus Vectors Containing Either<br />

Elongation Factor 1 alpha or Human Synapsin 1<br />

Promoters Eficiently Drive Expression in Rodent<br />

Primary Cortical Neurons<br />

Thomas G. Wolfe, Yun Lin, Holly Carlisle, Danny Ortuno, Huiren<br />

Zhao, Yun Hu, Yu Sun, Cherylene Plewa, Paul Kassner, Ki Jeong Lee.<br />

551<br />

Highly Flexible, Precise and Eficient <strong>Gene</strong> Editing <strong>of</strong><br />

Diverse Human Tissue Types Using rAAV-Mediated<br />

Homologous Recombination<br />

Ramu Mangena, Tom Henley, Christine Schoield, Chris Torrance,<br />

Eric Rhodes.<br />

Adenovirus and Other DNA Virus Vectors II<br />

552<br />

Structural Studies on the Interaction <strong>of</strong> Adenovirus<br />

Serotype 3 Fiber Knob and Desmoglein 2<br />

Hongjie Wang, Roma Yumul, Maximillian Richter, Pascal Fender,<br />

Andre Lieber.<br />

553<br />

Blocking <strong>of</strong> Scavenger-Receptor A Results in Increased<br />

HDAd-Mediated Hepatocyte Transduction through<br />

Inhibition <strong>of</strong> Vector Particle Uptake by Kupffer <strong>Cell</strong>s<br />

and Liver Sinusoidal Endothelial <strong>Cell</strong>s<br />

Pasquale Piccolo, Pratibha Mithbaokar, Nicola Brunetti-Pierri.<br />

554<br />

Artiicial Riboswitches for External Regulation <strong>of</strong><br />

Oncolytic Viruses<br />

Patrick Ketzer, Johanna K. Kaufmann, Sarah Engelhardt, Sascha<br />

Bossow, Jörg S. Hartig, Guy Ungerechts, Dirk M. Nettelbeck.<br />

555<br />

Liver-Detargeted Ad5/48 Chimaeric Hexon Based<br />

Oncolytic Adenoviruses Targeting TGFb Signaling:<br />

A Safe and Effective Approach for the Treatment <strong>of</strong><br />

Prostate Cancer Bone Metastases<br />

Weidong Xu, Zhenwei Zhang, Zebin Hu, Stuart Stock, Charles<br />

Brendler, Prem Seth.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

129


Abstract Directory, Saturday, May 18, 2013<br />

Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Adenovirus and Other DNA Virus Vectors II<br />

556<br />

Enhanced Anti-Tumor Eficacy by Oncolytic Adenovirus<br />

Using a Stimuli Responsive Block Copolymer<br />

mPEG-b-Poly(His)<br />

Joung-Woo Choi, You Han Bae, Chae-Ok Yun.<br />

557<br />

Distinct Integration Proiles after Sleeping Beauty<br />

Transposase-Mediated Somatic Integration from AAV<br />

and Adenoviral Vectors<br />

Wenli Zhang, Christina Rauschhuber, Martin Haeusl, Nadine<br />

Muether, Anja Ehrhardt.<br />

558<br />

Screening and Characterization <strong>of</strong> Alternative<br />

Adenovirus Serotypes with Enhanced Virus-<br />

Lateralization Ability In Vitro for Improved Antitumor<br />

Eficacy<br />

Junji Uchino, David T. Curiel, Hideyo Ugai.<br />

559<br />

Improved Animal Models for Testing <strong>Gene</strong> or <strong>Cell</strong><br />

Therapies for Atherosclerosis<br />

Liang Du, Jingwan Zhang, David Dichek.<br />

560<br />

Liver Retargeting <strong>of</strong> Adenovirus Using Robo4 Promoter<br />

and Hexon Substitution<br />

Sergey A. Kaliberov, Lyudmila N. Kaliberova, Zhi Hong Lu,<br />

Meredith A. Preuss, Justin A. Barnes, Cecil R. Stockard, William E.<br />

Grizzle, Jeffrey M. Arbeit, David T. Curiel.<br />

561 (Moved to Poster Session I after Abstract 138)<br />

Lister Strain Vaccinia Virus Demonstrates Favourable<br />

Anti-Tumor Eficacy and Tumor-Selectivity Compared<br />

to Western Reserve Strain<br />

Jonathan Hughes, Pengju Wang, Ghassan Alusi, Vipul Bhakta,<br />

Yongchao Chu, Hailiang Shi, Iain McNeish, Andrea McCart, Istvan<br />

Fodor, Nicholas Lemoine, Yaohe Wang.<br />

562<br />

Development <strong>of</strong> a Novel Vaccine Vector Based on<br />

Synthesized Adenovirus Genome<br />

Yong Yang, Chao Zhang, Xiang Wang, Yudan Chi, Dongming Zhou.<br />

563<br />

Construction <strong>of</strong> a Novel Bicistronic Adenoviral Vector<br />

Feilong Jie, Shengyao Wang, Jie Luo, Na Zhang, Jingang Zhang,<br />

Hongwei Li.<br />

564<br />

Ciproloxacin Regulates Negatively Egr-1<br />

Transcriptional Activity in Human Primary Tenocytes<br />

Transduced with Ad-Egr-1/Luc<br />

Francisco Martinez-F, Araceli Barrera-Lopez, Hugo Sandoval-<br />

Zamora, Karina Guzman-M, Alejandro Jimenez-Orozco, Christian Y.<br />

Lomeli-R, David T. Curiel, Rebecca E. Franco-Bourland.<br />

DNA Vectorology & <strong>Gene</strong> Targeting II<br />

565<br />

A Placebo Controlled Phase IIb Clinical Study<strong>of</strong><br />

Tissue<strong>Gene</strong>-C (TG-C) in Patients with Osteoarthritis<br />

Jung Jong Cho, Tae Won Kim, Yeo Myeong Park, Eu <strong>Gene</strong> Jeong,<br />

Moon Jong Noh, Kwan Hee Lee, Bum Sup Lee.<br />

566<br />

A Novel Oncolytic HSV Design Based on the Common<br />

Over-Expression <strong>of</strong> miR-21 in Tumors<br />

Marco Marzulli, Lucia Mazzacurati, Bonnie Reinhart, Mark E.<br />

Hatley, Joseph C. Glorioso, Paola Grandi, Justus B. Cohen.<br />

567<br />

Comparing the Activity <strong>of</strong> TALENs Constructed with<br />

Different Guanine-Targeting RVDs<br />

Yanni Lin, Thomas J. Cradick, Eli J. Fine, Gang Bao.<br />

568<br />

In Vivo Cleavage <strong>of</strong> Transgene Donors Promotes<br />

Nuclease-Mediated Targeted Integration<br />

Sandra Cristea, Yevgeniy Freyvert, Yolanda Santiago, Michael C.<br />

Holmes, Fyodor D. Urnov, Philip D. Gregory, Gregory J. Cost.<br />

569<br />

Helper Independent Self-Inactivating Chimeric<br />

PiggyBac Transposases for Genomic Targeting in<br />

Human <strong>Cell</strong>s<br />

Jesse B. Owens, Johann Urschitz, Ilko Stoytchev, Stefan Moisyadi.<br />

570<br />

Eficacy with Extremely Low Doses <strong>of</strong> Plasmid DNA<br />

Using Small Molecule Targeted Delivery <strong>of</strong> Bilamellar<br />

Invaginated Vesicles (BIVs) to Melanoma Tumor<br />

Xenografts<br />

Nancy S. Templeton, Li Chen, Connor Phalon, Phillip B. Maples,<br />

Neil Senzer, John Nemunaitis.<br />

571<br />

Zinc Finger Nuclease-Based <strong>Gene</strong> <strong>Therapy</strong> for Arginase<br />

I Deiciency as a Model for Curing Single-Enzyme Urea<br />

Cycle Disorders<br />

Ragini Bhargava, Hana Park, Sarah Novic<strong>of</strong>f, Alok V. Joglekar,<br />

Donald B. Kohn, Gerald S. Lipshutz.<br />

572<br />

Poly(2-Dimethylaminoethyl Methacrylate)-<br />

Functionalized Graphene Oxide Nanolakes for Eficient<br />

siRNA Delivery<br />

Jung Eun Lee, Min Sang Lee, Jeong A. Nam, Nak Won Kim, Sung<br />

Young Park, Ji Hoon Jeong.<br />

130<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

DNA Vectorology & <strong>Gene</strong> Targeting II<br />

573<br />

Eficient Delivery DNA Vaccine for Alzheimer’s Disease<br />

by Triggered Release <strong>of</strong> Polyplexes from Microneedles<br />

Kim Nak Won, Lee Kyuri, Lee Min Sang, Jeong Ji Hoon.<br />

574<br />

Improved Lentiviral Formats for Genome Editing Using<br />

Zinc Finger Nucleases<br />

Monika Gjoka, Kevin Kang, Yuping Huang, Gregory D. Davis.<br />

575<br />

CFTR Reporter Construct for Optimization <strong>of</strong> Airway<br />

Epithelium Differentiation<br />

Myra E. Gordon, Alaleh Esmaeili-Shandiz, Shingo Suzuki, Roy G.<br />

Sargent, Dieter C. Gruenert.<br />

576<br />

Non-Viral <strong>Gene</strong> Delivery to Oral Squamous <strong>Cell</strong><br />

Carcinoma and Cervical Carcinoma <strong>Cell</strong>s and Suicide<br />

<strong>Gene</strong> <strong>Therapy</strong><br />

Nejat Düzgünes, Aruna Singh, Senait Gebremedhin, Krystyna<br />

Konopka.<br />

577<br />

Orphan Product Development for DNA Therapeutics<br />

Gladice Wallraven, Phillip B. Maples, John Nemunaitis.<br />

<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Diabetes, Metabolic<br />

and <strong>Gene</strong>tic Diseases II<br />

578<br />

Development <strong>of</strong> Lentiviral <strong>Gene</strong> <strong>Therapy</strong> for Type VII<br />

Collagen Deicient Epidermolysis Bullosa<br />

Christos Georgiadis, Ekaterina Semenova, Andy P. South, Adrian<br />

Thrasher, John A. McGrath, Wei-Li Di, Waseem Qasim.<br />

579<br />

Reprogramming <strong>of</strong> Murine Gallbladder <strong>Cell</strong>s towards<br />

the Pancreatic b-<strong>Cell</strong> Fate In Vitro<br />

Yuhan Wang, Ray D. Hickey, Markus Grompe.<br />

580<br />

Fetal <strong>Gene</strong> <strong>Therapy</strong> at Early and Late Gestation:<br />

Analysis <strong>of</strong> Outcomes and Postnatal Vector Challenge in<br />

a Macaque Model<br />

Citra Mattar, Cecilia Rosales, Rowell Fragata, Nuryanti Johana,<br />

Simon Waddington, Arijit Biswas, Mahesh Choolani, Amit<br />

Nathwani, Jerry Chan.<br />

581<br />

Factors Inluencing Direct Reprogramming <strong>of</strong> Primary<br />

Human Extrahepatic Biliary <strong>Cell</strong>s into Pancreatic beta<br />

<strong>Cell</strong>s<br />

Feorillo Galivo, Eric Benedetti, Craig Dorrell, Olga Smirnova,<br />

Jonathan Schug, Klaus Kaestner, Markus Grompe.<br />

582<br />

Mesenchymal Stem <strong>Cell</strong>s Do Not Prevent Alloantibody<br />

Response Against IDUA Used To Treat MPSI<br />

Priscila K. Matsumoto, Roberta S. Stilhano, Flavia H. da Silva,<br />

Vivian Y. Samoto, Giovani B. Perez, Sang W. Han.<br />

583<br />

Comparison <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> Vectors in a New<br />

Hypomorphic Model <strong>of</strong> Propionic Acidemia<br />

Adam J. Guenzel, Sean E. Hoherr, Matthew Hillestad, Mary Barry,<br />

Eric Weaver, Jan P. Kraus, Dietrich Matern, Michael A. Barry.<br />

584<br />

Transcription Activator-Like Effector Nuclease-Based<br />

Genome Editing for Mucopolysaccharidosis Type I<br />

Mark J. Osborn, Colby G. Starker, Anthony P. DeFeo, Daniel F.<br />

Voytas, Bruce R. Blazar, Jakub Tolar.<br />

585<br />

<strong>Gene</strong> <strong>Therapy</strong> for Mouse Model <strong>of</strong> Krabbe Disease<br />

Hiroshi Kobayashi, Masamichi Ariga, Takahiro Fukuda, Takeo<br />

Iwamoto, Sayoko Izuka, Yota Shimada, Yoshikatsu Eto, Toya<br />

Ohashi.<br />

586<br />

Choroid Plexus-Directed Viral <strong>Gene</strong> <strong>Therapy</strong> as a<br />

Source <strong>of</strong> alpha-N-Acetyl-Glucosaminidase Enzyme<br />

Replacement in Cerebrospinal Fluid for Sanilippo B<br />

Syndrome<br />

Patricia I. Dickson, Shih-hsin Kan, Steven Q. Le, Maria Reina<br />

Haddad, Eun-Young Choi, Anthony Donsante, Stephen G. Kaler.<br />

587<br />

Mitigation <strong>of</strong> DNA Damage Responses and Oxidative<br />

Stress in <strong>Cell</strong>s with Impaired Telomerase Function<br />

Larisa Pereboeva, Erik Westin, Mary Gannon, Lawrence Lamb,<br />

Aloysius Klingelhutz, Frederick Goldman.<br />

588 Abstract Withdrawn<br />

Neurologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

589<br />

CNS Administration <strong>of</strong> an AAVrh.10 <strong>Gene</strong> Transfer<br />

Vector Expressing the Human ARSA cDNA to Nonhuman<br />

Primates Provides Widespread Activity across the CNS<br />

Jonathan B. Rosenberg, Dolan Sondhi, David G. Rubin, Sébastien<br />

Monette, Alvin Chen, Sara A. Cram, Benjamin Van de Graaf, Bishnu<br />

P. De, Stephen M. Kaminsky, Caroline Sevin, Patrick Aubourg,<br />

Ronald G. Crystal.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

131


Abstract Directory, Saturday, May 18, 2013<br />

Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Neurologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

590 (Moved to Poster Session II after Abstract 391)<br />

Intracranial AAV <strong>Gene</strong> <strong>Therapy</strong> Extends the Life Span<br />

<strong>of</strong> GM2 Gangliosidosis Cats >Four-Fold with No Clinical<br />

Evidence <strong>of</strong> Vector Toxicity<br />

Allison M. Bradbury, Victoria J. McCurdy, Aime K. Johnson, Heather<br />

Gray-Edwards, Brandon L. Brunson, Ashley N. Randle, Nancy R.<br />

Cox, Miguel Sena-Esteves, Douglas R. Martin.<br />

591<br />

Prophylactic and Therapeutic Treatment <strong>of</strong> Pain<br />

in a Varicella- Zoster Virus (VZV) Rodent Model <strong>of</strong><br />

Post-Herpetic Neuralgia (PHN) Using an HSV Vector<br />

Expressing Enkephalin<br />

William F. Goins, Jean-Marc Guedon, Mingdi Zhang, Joseph C.<br />

Glorioso, Paul R. Kinchington.<br />

592<br />

AAV <strong>Gene</strong> <strong>Therapy</strong> Normalizes Disease Phenotype<br />

and Extends Life Span >Four-Fold in Feline GM1<br />

Gangliosidosis<br />

Aime K. Johnson, Victoria J. McCurdy, Allison M. Bradbury, Heather<br />

Gray-Edwards, Ashley N. Randle, Misako Hwang, Nancy R. Cox,<br />

Stanley G. Leroy, Miguel Sena-Esteves, Douglas R. Martin.<br />

593<br />

MECP2e1 Is<strong>of</strong>orm-Speciic Lentivirus Rescues Rett<br />

Syndrome Neuronal Soma Size Defects in a <strong>Cell</strong><br />

Autonomous Manner<br />

Ugljesa Djuric, Aaron Cheung, Alina Piekna, Jason Hendry, Joel<br />

Ross, Peter Pasceri, Dae-Sung Kim, James Ellis.<br />

594<br />

Immune Response Activation and Neurotoxicity after<br />

Intrathecal Infusion <strong>of</strong> AAV9 Vector Encoding a Non-Self<br />

Reporter Protein in the Non-Human Primate<br />

Lluis Samaranch, Waldy San Sebastian, Adrian P. Kells, John<br />

Bringas, Phillip Pivirotto, John Forsayeth, Kryst<strong>of</strong> S. Bankiewicz.<br />

595<br />

Intracranial Injection <strong>of</strong> AAVrh8-mbgal in a GM1<br />

Gangliosidosis Mouse Model Delays Disease Onset and<br />

Signiicantly Extends Life Span<br />

Cara M. Weismann, Jennifer Ferreira, Stacy Maitland, Miguel<br />

Sena-Esteves.<br />

596<br />

Enhanced CNS Transduction and Transgene Expression<br />

by rAAV Capsid Tyrosine Mutants<br />

Nicholas M. Kanaan, Caryl E. Sortwell, Sara E. Gombash, Nathan<br />

M. Kuhn, William W. Hauswirth, Sanford E. Boye, Vince A. Chiodo,<br />

Tessa Grabinski, Fredric P. Manfredsson.<br />

597<br />

Peripheral Blood White <strong>Cell</strong>s Present Molecular<br />

Signatures <strong>of</strong> Neurodegeneration and Respond to a<br />

Single Intravenous rAAV9-hNAGLU <strong>Gene</strong> Delivery in<br />

MPS IIIB Mice<br />

Bartholomew J. Naughton, F. Jason Duncan, Tierra Ware, Darren<br />

Murrey, Aaron Meadows, Douglas M. McCarty, Haiyan Fu.<br />

598<br />

The Therapeutic Potential <strong>of</strong> MicroRNA Regulation in a<br />

Rat Intracerebral Hemorrhage Model<br />

Jangsup Moon, Jeong-Min Kim, Jung Ick Byun Byun, Kon Chu,<br />

Keun-Hwa Jung, Soon-Tae Lee, Jin-Hee Kim, Dong-Kyu Park, So-<br />

Yoon Kim, Jae-Kyu Roh.<br />

599<br />

Adeno-Associated Virus Type 6 Is Retrogradely<br />

Transported in the Non-Human Primate Brain,<br />

Implications for <strong>Gene</strong> Delivery in Huntington’s Disease<br />

Waldy San Sebastian, Lluis Samaranch, Adrian P. Kells, John<br />

Bringas, Phillip Pivirotto, John Forsayeth, Kryst<strong>of</strong> S. Bankiewicz.<br />

600<br />

Herpes Simplex Virus 2 <strong>Gene</strong>, ICP10PK, Protects<br />

Against Neuronal <strong>Cell</strong> Death Associated with Valproic<br />

Acid-Induced Autism Spectrum Disorder<br />

Dominique Bollino, Laure Aurelian.<br />

601<br />

Targeted <strong>Gene</strong> Transfer into the Ependymal <strong>Cell</strong>s<br />

and Long-Term Enzyme Replacement in the CSF by<br />

Intraventricular Injection <strong>of</strong> AAV Vector Serotype 1<br />

Yoshiyuki Yamazaki, Kohei Hironaka, Yukihiko Hirai, Koichi<br />

Miyake, Takashi Shimada.<br />

602<br />

Neuroprotective Effect <strong>of</strong> a <strong>Cell</strong>-Free Extract Derived<br />

from Human Adipose Stem <strong>Cell</strong>s in Experimental Stroke<br />

Models<br />

Jung Ick Byun, Daejong Jeon, Kon Chu, Soon-Tae Lee, Keun-Hwa<br />

Jung, Jae-Jun Ban, Hye-Jin Yoon, Seungmoon Jung, Hyunwoo Yang,<br />

Byung Sun Kim, Ji Ye Choi, Jeong-Min Kim, Chong-Hyun Won,<br />

Manho Kim, Sang Kun Lee, Jae-Kyu Roh.<br />

603<br />

Artiicial MicroRNAs Against Spliced Variants <strong>of</strong><br />

the <strong>Gene</strong> C9ORF72, the Major Cause for Familial<br />

Amyotrophic Lateral Sclerosis<br />

Gabriela Toro, Florie Borel, Peter Sapp, Lina Song, Robert Brown,<br />

Christian Mueller.<br />

604<br />

Reduction <strong>of</strong> Hyperammonemia In Vitro and In Vivo by<br />

a Baculovirus-Delivered Glutamine Synthetase as a New<br />

Approach for the Treatment <strong>of</strong> Hepatic Encephalopathy<br />

Miguel A. Torres-Vega, Lizbeth M. Vázquez-Carcaño, Roxana<br />

Y. Vargas-Jerónimo, Ana G. Montiel-Martínez, Rosa M. Muñoz-<br />

Fuentes, Misael Uribe, Absalom Zamorano-Carrillo, Ana R. Pastor-<br />

Flores, Laura A. Palomares.<br />

132<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />

605<br />

MTMR2 Ameliorates the Phenotype <strong>of</strong> Myotubular<br />

Myopathy in Mice<br />

Nathalie Danièle, Thibaud Jamet, Christelle Moal, Romain Joubert,<br />

Nadia Messaddeq, Michael W. Lawlor, Alban Vignaud, Anna<br />

Buj-Bello.<br />

606<br />

Restricting MTM1 Transgene Expression to Skeletal<br />

Muscle in AAV-Mediated <strong>Gene</strong> <strong>Therapy</strong> for Myotubular<br />

Myopathy<br />

Romain Joubert, Christelle Moal, Alban Vignaud, Samia Martin,<br />

Isabelle Richard, Philippe Moullier, Alan H. Beggs, Martin K.<br />

Childers, Anna Buj-Bello.<br />

607<br />

Long Term Intra-Articular Expression <strong>of</strong> PRG4 Prevents<br />

Post-Traumatic Osteoarthritis<br />

Zhechao Ruan, Vincenzo Cerullo, Kilian Guse, Ayelet Erez, Brian<br />

Dawson, Frank Gannon, Brendan Lee.<br />

608<br />

Immune Tolerance Induction in Canine X-Linked<br />

Muscular Dystrophy with Trans-Placental rAAV9-<br />

Microdystrophin Transduction<br />

Hiromi Hayashita-Kinoh, Hironori Okada, Yuko Nitahara-Kasahara,<br />

Tomoko Chiyo, Naoko Yugeta, Takashi Okada, Shin’ichi Takeda.<br />

609<br />

Low Dystrophin Levels Increase Survival and Improve<br />

Muscle Pathology and Function in Dystrophin/Utrophin<br />

Double Knockout Mice<br />

Maaike van Putten, Margriet Hulsker, Courtney Young, Peter A. ‘t<br />

Hoen, Gert-Jan B. van Ommen, Annemieke M. Aartsma-Rus.<br />

610<br />

Limb Girdle Muscular Dystrophy 2I: <strong>Gene</strong>ration <strong>of</strong> a<br />

New Mouse Model and Test <strong>of</strong> Therapeutic Approaches<br />

by rAAV2/9 <strong>Gene</strong> Transfer<br />

Evelyne Gicquel, Karine Charton, Nathalie Daniele, Isabelle<br />

Richard.<br />

611<br />

Hepatocyte Growth Factor Contributes to the Improved<br />

Pathology <strong>of</strong> mdx:p65+/- Mice<br />

Jonathan D. Proto, Ying Tang, Aiping Lu, Minakshi Poddar, Sarah<br />

Beckman, Kayla Imbrogno, Timothy Hannigan, Wendy Mars, Bing<br />

Wang, Johnny Huard.<br />

612<br />

Urine Biomarkers for Duchenne Muscular Dystrophy<br />

and Its Animal Models<br />

Jérémy Rouillon, Thibaut Léger, Jean-Michel Camadro, Tomas Voit,<br />

Fedor Svinartchouk.<br />

613<br />

Systemic <strong>Gene</strong> Transfer in Neonatal Dogs Using<br />

Tyrosine Mutant AAV-1,6 and9<br />

Chady H. Hakim, Yongping Yue, Jin-Hong Shin, Regina R. Williams,<br />

Keqing Zhang, Arun Srivastava, Bruce F. Smith, Dongsheng Duan.<br />

614<br />

Effect <strong>of</strong> Angiogenesis on the Regenerative Capacity <strong>of</strong><br />

ACL-Derived CD34+ <strong>Cell</strong>s in ACL Reconstruction<br />

Koji Takayama, Tang Ying, Wang Bing, Freddie Fu, Johnny Huard.<br />

615<br />

The Phenotype <strong>of</strong> Dysferlin-Deicient Mice Is Not<br />

Rescued by AAV-Mediated Transfer <strong>of</strong> Anoctamin 5<br />

Karine Charton, Laurence Suel-Petat, François Monjaret, Nathalie<br />

Bourg-Alibert, Carinne Roudaut, Evelyne Gicquel, Bjarne Udd,<br />

Isabelle Richard.<br />

616<br />

Transfection <strong>of</strong> Murine Dermis Via Topical DNA<br />

Plasmid Delivery<br />

Chunqing Dou, Guy P. Marti, Lixin Liu, Frank Lay, Donald J. Rees,<br />

Aaron T. Tabor, Junkai Du, Sayed Mohammd Hosseini, Amir Mehdi<br />

Ansari, Ali Karim Ahmed, James A. Williams, John W. Harmon.<br />

617<br />

Clinical Trial Readiness for <strong>Gene</strong> Replacement to the<br />

Diaphragm: Translational Respiratory Endpoints in<br />

Ventilator-Dependent Neuromuscular Diseases<br />

Barbara K. Smith, Melissa A. Goddard, Martin K. Childers, Barry J.<br />

Byrne.<br />

618<br />

Adjunctive b2-Agonist <strong>Therapy</strong> Enhances Traficking <strong>of</strong><br />

Acid a-Glucosidase to Lysosomes in the Skeletal Muscle<br />

<strong>of</strong> Mice with Pompe Disease<br />

Dwight D. Koeberl, Songtao Li, Benjamin Farah, Andrew Bird, Paul<br />

M. Yen, Sarah P. Young.<br />

619<br />

Comparative In Vitro Potency <strong>of</strong> a Novel Disc-Derived<br />

<strong>Cell</strong> Population (Discospheres) and Mesenchymal Stem<br />

<strong>Cell</strong>s for the Treatment <strong>of</strong> Degenerative Disc Disease<br />

Lara I. Silverman, Galina Dulatova, Terry Tandeski, Kevin T. Foley.<br />

620<br />

Functional Analysis <strong>of</strong> GNE Expression Plasmids in<br />

Immortalized Human Myoblasts<br />

Yadira Valles-Ayoub, Rosangela Carbajo, Lucia Sandoval, Jorge<br />

Garcia-Figueroa, Sarah Stein, Zeshan Khokher, Daniel No, Babak<br />

Darvish, Jacques P. Tremblay, Daniel Darvish.<br />

Cancer Immunotherapy III<br />

621<br />

Tethered IL-15 Mutein on CD19-Speciic T <strong>Cell</strong>s<br />

Sustains Persistence When Tumor Antigen Is Low and<br />

Can Treat Minimal Residual Disease<br />

Lenka V. Hurton, Kirsten Switzer, Harjeet Singh, Marie A. Forget,<br />

Tiejuan Mi, Simon Olivares, Richard E. Champlin, Dean A. Lee,<br />

Laurence J. N. Cooper.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

133


Abstract Directory, Saturday, May 18, 2013<br />

Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Cancer Immunotherapy III<br />

622<br />

Rapid Assessment <strong>of</strong> T-<strong>Cell</strong> Function in an Animal-Free<br />

Model – The Artiicial-Mouse Model<br />

Usanarat Anurathapan, Pradip Bajgain, Norihiro Watanabe,<br />

Malcolm K. Brenner, Cliona M. Rooney, John R. Wilson, Juan F. Vera.<br />

623<br />

Distinct Signaling from Chimeric Antigen (CAR) and T<br />

<strong>Cell</strong> Receptors in T <strong>Cell</strong>s<br />

Omkar U. Kawalekar, Avery D. Posey Jr, Sonia Guedan, Jihyun Lee,<br />

Matthew J. Frigault, Maria C. Basil, John Scholler, Yangbing Zhao,<br />

Carl H. June.<br />

624<br />

Long Term F/U – Phase I Study <strong>of</strong> the “Triad”<br />

Autologous (FANG) Vaccine, Incorporating<br />

Bifunctional shRNAfurin and GMCSF Transgene<br />

Expression, in Advanced Cancer Patients<br />

John Nemunaitis, Neil Senzer, Minal Barve, Cynthia Bedell, Joseph<br />

Kuhn, Peter Beitsch, Robert Steckler, Jeffrey Lamont, Robert<br />

Hebeler, Mitchell J. Magee, Walton Taylor, Brian M. Gogel, Maurizio<br />

Ghisoli, F. Charles Brunicardi, Beena O. Pappen, Padmasini Kumar,<br />

Phillip B. Maples.<br />

625<br />

Phase I Study Results <strong>of</strong> pbi-shRNA STMN1 Nanoplex<br />

Via Intratumoral Injection in Advanced Cancer<br />

John Nemunaitis, F. Charles Brunicardi, Donald D. Rao, Nancy S.<br />

Templeton, Neil Senzer, Zhaohui Wang, Minal Barve, Padmasini<br />

Kumar, Gladice Wallraven, Christopher M. Jay, Joseph Kuhn, Peter<br />

Beitsch, Phillip B. Maples.<br />

626<br />

T-<strong>Cell</strong> Immunotherapy for Multiple Myeloma<br />

Sonny O. Ang, Sourindra N. Maiti, Ippei Sakamaki, Hong Qin, Larry<br />

W. Kwak, Richard E. Champlin, Laurence J. N. Cooper.<br />

627<br />

<strong>Gene</strong> Transfer <strong>of</strong> Chondroitin Sulfate-Coated<br />

Granulocyte Macrophage-Colony-Stimulating Factor in<br />

Mouse Ovarian Tumor Model<br />

Katsuyuki Hamada, Kazuko Takagi, Chieko Yoshihara, Tomoko Ito,<br />

Yoshiyuki Koyama, Hiroshi Ito, Akihiro Nawa.<br />

628<br />

EphrinA1-EphA2 Interaction-Mediated Apoptosis and<br />

Flt3L-Induced Immunotherapy in Inhibiting Tumor<br />

Progression in an Immunocompetent Mouse Model <strong>of</strong><br />

Breast Cancer<br />

Sai vikram V. vemula, Manish Tandon, Suresh K. Mittal, Anurag<br />

Sharma, Dinesh Bangari.<br />

629<br />

Optimization <strong>of</strong> Chimeric Antigen Receptors Design:<br />

Novel Retroviral Vectors Expressing CAR with<br />

Intracellular Signaling Domain <strong>of</strong> Glucocorticoid-<br />

Induced TNF-Receptor<br />

Yasunori Amaishi, Sachiko Okamoto, Yoshikazu Kurosawa, Hiroshi<br />

Shiku, Junichi Mineno, Kazuto Takesako.<br />

630<br />

Combined p19Arf and Interferon-beta <strong>Gene</strong> <strong>Therapy</strong>:<br />

Evidence <strong>of</strong> Immune Response in Murine Models <strong>of</strong><br />

Melanoma and Lung Carcinoma<br />

Bryan E. Strauss, Ruan Felipe V. Medrano, Aline H. Ribeiro, Joao<br />

Paulo P. Catani, Christian A. Merkel.<br />

631<br />

Histidine-Rich Glycoprotein (HRG): A Novel <strong>Gene</strong>-<br />

<strong>Therapy</strong> Effector for the Treatment <strong>of</strong> Cancer<br />

Francis P. Roche, K. Elisabet Ohlin, Magnus Essand, Lena<br />

Claesson-Welsh.<br />

632<br />

Effect <strong>of</strong> Interferon-Omega <strong>Gene</strong> Transfer on Feline<br />

Mammary Carcinoma and Melanoma <strong>Cell</strong>s<br />

Marcela S. Villaverde, Alexandra M. Targovnik, Daniel R. Bafico,<br />

Maria V. Miranda, Gerardo C. Glikin, Liliana M. E. Finocchiaro.<br />

633<br />

HLA Typing Identity Test for Patients and Their FANG<br />

Autologous Cancer Vaccines – Update<br />

Yang Yu, Padmasini Kumar, Fabienne Norvell, Connor Phalon,<br />

Nicolas Taquet, Phillip B. Maples.<br />

Cancer-Oncolytic Viruses II<br />

634<br />

Therapeutic Targeting <strong>of</strong> Chitosan-PEG-Folate-<br />

Complexed Oncolytic Adenovirus for Active and<br />

Systemic Cancer <strong>Gene</strong> <strong>Therapy</strong><br />

Oh-Joon Kwon, Eunah Kang, Sung Wan Kim, Chae-Ok Yun.<br />

635<br />

Human Ovarian Cancer-Derived Ascitic Fluid Has Mixed<br />

Effects on CRAds Eficacy<br />

Veronica M. Lopez, Nicasio Cuneo, Mariela A. Gangemi, Leonardo<br />

Sganga, Marina Demonte, Alejandro Soderini, Osvaldo L.<br />

Podhajcer.<br />

636<br />

The Oncolytic Virus DPK Lyses <strong>Cell</strong>s with Cancer<br />

Stem <strong>Cell</strong> (CSC) Properties through Calpain-Mediated<br />

Clearance <strong>of</strong> the Selective Autophagy Protein p62/<br />

SQSTM1<br />

Aric Colunga, Dominique Bollino, Amanda Schech, Laure Aurelian.<br />

637<br />

Demonstration <strong>of</strong> Anti-Metastasis Activity <strong>of</strong> Oncolytic<br />

Measles Virus Retarging Urokinase Receptor in<br />

Experimental Breast Cancer Metastasis Model<br />

Yuqi Jing, Krisztina Kovacs, Jaime Merchan.<br />

134<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Cancer-Oncolytic Viruses II<br />

638<br />

Development <strong>of</strong> Dual Targeted Oncolytic Adenovirus<br />

for Human Malignant Mesothelioma<br />

Shuji Kubo, Misato Takagi-Kimura, Atsuko Tamamoto, Tomoko<br />

Hashimoto-Tamaoki, Noriyuki Kasahara, Masatoshi Tagawa.<br />

639<br />

MicroRNA-Mediated Multi-Tissue-Detargeting <strong>of</strong><br />

Oncolytic Measles Virus<br />

Marc-Andrea Bärtsch, Mathias F. Leber, Sascha Bossow,<br />

Martin Singh, Jessica Albert, Dirk Jäger, Christ<strong>of</strong> von Kalle, Guy<br />

Ungerechts.<br />

646 Abstract Withdrawn from Presentation<br />

647<br />

Iraqi Newcastle Disease Virus Virulent Strain as Cancer<br />

Antiangiogenic Agent<br />

Ahmed M. Al-Shammari, Zaid A. Al-Hili, Nahi Y. Yaseen.<br />

Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>: <strong>Cell</strong><br />

<strong>Therapy</strong> / Immunotherapy / <strong>Cell</strong>ular Targets<br />

648<br />

Neural Stem <strong>Cell</strong>s Expressing a Modiied Human<br />

Carboxylesterase Potentiate Anti-Cancer Activity <strong>of</strong><br />

Irinotecan in Murine Glioma Model<br />

Karen S. Aboody, Lucy Y. Ghoda, Margarita Gutova, Megan<br />

Gilchrist, Christine Brown, Vazgen Kankaldyyan, Elizabth Garcia,<br />

Lauren H<strong>of</strong>fman, Rex A. Moats, Phil Potter, Timothy W. Synold,<br />

Michael Barish.<br />

640<br />

In Vivo Therapeutic Eficacy <strong>of</strong> Oncolytic Adenovirus<br />

Delivered by New Biodegradable Polymers through<br />

Systemic Injection<br />

Jaesung Kim, Yi Li, Sung Wan Kim, Doo Sung Lee, Chae-Ok Yun.<br />

641<br />

Eficacy <strong>of</strong> Measles Virotherapy in Osteosarcoma<br />

Evidio Domingo Musibay, Cory Allen, Ianko D. Iankov, Jayson J.<br />

Hardcastle, Evanthia Galanis.<br />

642<br />

A Cancer-Targeting Ligand Strongly Enhances Oncolytic<br />

Activity <strong>of</strong> a Conditionally Replicative Adenovirus<br />

Yuki Yamamoto, Naoko Goto, Shumpei Ohnami, Masatoshi Tagawa,<br />

Kazunori Aoki.<br />

643<br />

Cyclophosphamide Enhances Antitumor<br />

Eficacy <strong>of</strong> Oncolytic Adenovirus Expressing<br />

Uracil Phosphoribosyltransferase (UPRT) in<br />

Immunocompetent Syrian Hamsters<br />

Naoyuki Hasegawa, Masato Abei, Kazunari K. Yokoyama, Kuniaki<br />

Fukuda, Emiko Seo, Rei Kawashima, Yuri Nakano, Takeshi Yamada,<br />

Koji Nakade, Hir<strong>of</strong>umi Hamada, Yuichi Obata, Ichinosuke Hyodo.<br />

644<br />

Therapeutic Evaluation <strong>of</strong> Prostate Cancer Speciic<br />

Oncolytic Adenovirus Armed with Fusion Protein <strong>Gene</strong><br />

PSA-IZ-CD40L<br />

Yue-feng Yang, Shu-Ya Xue, Hua Wang, Feng-jun Xiao, Yue Yin,<br />

Zhuo-zhuang Lu, Qun-wei Zhang, Chu-tse Wu, Li-sheng Wang.<br />

645<br />

Bioreducible Polymer-Conjugated Oncolytic<br />

Adenovirus for Hepatoma-Speciic <strong>Therapy</strong> Via<br />

Systemic Administration<br />

Pyung-Hwan Kim, Jaesung Kim, Tae-il Kim, Hye Yeong Nam, James<br />

W. Yockman, Minjung Kim, Sung Wan Kim, Chae-Ok Yun.<br />

649<br />

Re-Directing T <strong>Cell</strong>s with Chimeric Antigen Receptors<br />

To Target CD123+ Leukemia<br />

Radhika Thokala, Kirsten Switzer, Mi Ti juan, Simon Olivares,<br />

Harjeet Singh, Helen Huls, Richard E. Champlin, Laurence J. N.<br />

Cooper.<br />

650<br />

The Speciicity <strong>of</strong> Rhesus T <strong>Cell</strong>s Can Be Redirected<br />

to CD20 Using the Sleeping Beauty Transposon/<br />

Transposase System To Express a Chimeric Antigen<br />

Receptor<br />

Simon Olivares, Colleen O’Connor, Sonny Ang, Leslie Kean, Perry<br />

Hackett, Amer Najjar, Harjeet Singh, Helen Huls, Elizabeth Shpall,<br />

Laurence Cooper.<br />

651<br />

Tumor Targeting Using CD19-Speciic CAR (Chimeric<br />

Antigen Receptor) for B-<strong>Cell</strong> Lymphoma<br />

Tomonori Tsukahara, Ken Ohmine, Ryosuke Uchibori, Hiroyuki<br />

Ido, Masashi Urabe, Hiroaki Mizukami, Akihiro Kume, Masataka<br />

Nakamura, Junichi Mineno, Kazutoh Takesako, Isabelle Riviere,<br />

Michel Sadelain, Renier Brentjens, Keiya Ozawa.<br />

652<br />

Tumor Relapse Is Associated with an Innate Immune<br />

Resistant Phenotype across Tumor and Treatment<br />

Types Which Can Be Targeted with Rational Second<br />

Line Therapies<br />

Timothy Kottke, Oliver Donnelly, Nicolas Boisgerault, Rosa<br />

Diaz, Diana Rommelfanger-Konkol, Jose Pulido, Jill Thompson,<br />

Debabrata Mukhopadhyay, Keith Knutson, Marshall Behrens,<br />

Roger Kaspar, Matt C<strong>of</strong>fey, Peter Selby, Kevin Harrington, Alan<br />

Melcher, Hardev Pandha, Richard Vile.<br />

653<br />

Chimeric Antigen Receptor T-<strong>Cell</strong> <strong>Therapy</strong> for<br />

Companion Canines with Spontaneous B-<strong>Cell</strong> Non-<br />

Hodgkin Lymphoma<br />

Colleen M. O’Connor, Simon Olivares, Sonny Ang, Richard E.<br />

Champlin, Heather M. Wilson-Robles, Laurence J. N. Cooper.<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

135


Abstract Directory, Saturday, May 18, 2013<br />

Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>: <strong>Cell</strong><br />

<strong>Therapy</strong> / Immunotherapy / <strong>Cell</strong>ular Targets<br />

654<br />

Combination <strong>of</strong> CD3+CD56+ (NKT) <strong>Cell</strong>s<br />

Immunotherapy and Adenovirus-p53 <strong>Gene</strong> <strong>Therapy</strong> for<br />

Head and Neck Squamous <strong>Cell</strong> Carcinoma<br />

Hiroki Saito, Naoya Morishita, Kyung-Mi Lee, Dante Dator, Masato<br />

Kawabata, Masato Fujisawa, Toshiro Shirakawa.<br />

655<br />

Interfering Peptides Targeting Transcription Factor<br />

AP1 for Pancreatic Cancer <strong>Gene</strong> <strong>Therapy</strong><br />

Soukaina Rejiba, Megan Frelan, Alex Hermann, Katja Arndt, Amor<br />

Hajri.<br />

656<br />

JMJD3 Regulates Senescence-Associated Secretory<br />

Phenotype Factors Responsible for Robust Neural Stem<br />

<strong>Cell</strong> Tropism toward Glioma<br />

Michael E. Silva, Patrick M. Perrigue, Daniel Mota, Lauren Joseph,<br />

Nathan Feng, Michael Reid, Joseph Najbauer, Karen S. Aboody.<br />

657<br />

Bioengineering ACE Synthetic Chromosomes for Anti-<br />

Cancer <strong>Gene</strong> <strong>Therapy</strong><br />

Edward Perkins, Jon Holy, Teresa Rose-Hellkant, Amy Greene.<br />

658<br />

DNA Vaccine with scFv6.C4 Prevent the Growth <strong>of</strong><br />

Tumor Expressing CEA<br />

Priscila M. A. Denapoli, Roberta S. Stilhano, Priscila K. Matsumoto,<br />

Carolina B. Parise, Jane Z. de Moraes, Wolfgang Zimmermann, Sang<br />

W. Han.<br />

659<br />

Presumptive Oncogenic Transcriptional Factor PDX1<br />

Regulates Pancreatic Cancer Via an Ampliication Loop<br />

Involving the RAS, PI3K and p53 Signaling Pathways<br />

Juehua Yu, Guisheng Zhou, Shi-he Liu, James Wu, John Nemunaitis,<br />

Neil Senzer, Donald Rao, Enrique Rosengurt, F. C. Brunicardi.<br />

660<br />

Targeting Lysosome Integrity as a Method To Restore<br />

Sensitivity to Ceramide-Induced <strong>Cell</strong> Death<br />

Lorianne S. Turner, Krissy Smith, Lenton Holley, Christopher<br />

Johnson, Timothy Prince, Heather Yancey.<br />

Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong> II<br />

661<br />

Lentiviral <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> RAG Severe Combined<br />

Immunodeiciency<br />

Niek P. van Til, Guus van der Velden, Helen de Boer, Pietro L.<br />

Poliani, Michael N. Antoniou, Anna Villa, Chantal Lagresle-Peyrou,<br />

Marina Cavazzana-Calvo, Fang Zhang, Adrian J. Thrasher, Gerard<br />

Wagemaker.<br />

662<br />

Stem <strong>Cell</strong> and T-<strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> Using SIN-<br />

Lentiviral Vector in Type 3 Familial Hematophagocytic<br />

Lymphohistocytosis: A Comparative Approach<br />

Julie Rivière, Tayebeh Soheili, Els Verhoeyen, Anne Galy, <strong>Gene</strong>viève<br />

De Saint Basile, Marina Cavazzana-Calvo.<br />

663<br />

High Expression Bioengineered Factor VIII Enables<br />

AAV-Based <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Hemophilia A<br />

H. Trent Spencer, Harrison C. Brown, Jordan E. Shields, J. Fraser<br />

Wright, Christopher B. Doering.<br />

664<br />

Identiication <strong>of</strong> Novel Combination <strong>of</strong> Elements in<br />

cHS4 with Optimal Insulator Activity and Improved<br />

Titers in g-Globin Carrying SIN Lentiviral Vectors<br />

Paritha Arumugam, Michael Wourms, Joseph Starnes, Catherine<br />

Fox, Xiaoming Li, Punam Malik.<br />

665<br />

Intraosseous Delivery <strong>of</strong> Lentiviral Vectors Expressing<br />

Factor VIII under the Control <strong>of</strong> the Platelet-Speciic<br />

Glycoprotein 1ba Promoter Leads to Long-Term<br />

Correction <strong>of</strong> Bleeding in Hemophilia A Mice<br />

Xuefeng Wang, Andy Chiang, Simon C. Shin, Liping Chen, Dao Pan,<br />

David J. Rawlings, Carol H. Miao.<br />

666<br />

Lentiviral Vectors Tailored for Liver-Directed <strong>Gene</strong><br />

<strong>Therapy</strong> Do Not Show Any Detectable Genotoxicity in<br />

Sensitive In Vivo Biosafety Assays<br />

Marco Ranzani, Alessio Cantore, Monica Volpin, Pierangela Gallina,<br />

Stefano Annuziato, Francesca Sanvito, Fabrizio Benedicenti,<br />

Cynthia Bartholomae, Lucia Sergi Sergi, Christ<strong>of</strong> von Kalle,<br />

Manfred Schmidt, Claudio Doglioni, Luigi Naldini, Eugenio<br />

Montini.<br />

667<br />

Successful Liver <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Hemophilia B<br />

Dogs Using Lentiviral Vectors and Hyperfunctional<br />

Transgene<br />

Alessio Cantore, Patrizia Della Valle, Sara Bartolaccini, Lucia Sergi<br />

Sergi, Thierry VandenDriessche, Marinee Chuah, Dwight Bellinger,<br />

Armando D’Angelo, Timothy Nichols, Luigi Naldini.<br />

136<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Directory, Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong><br />

<strong>Therapy</strong> II<br />

Late Breaking Abstracts III<br />

733<br />

Correction <strong>of</strong> canine Factor VII (FVII) deiciency by<br />

AAV-mediated expression <strong>of</strong> canine FVII zymogen<br />

Paris Margaritis, Dwight A. Bellinger, Shangzhen Zhou, Armida<br />

Faella, Timothy C. Nichols, Katherine A. High<br />

668<br />

Engineering <strong>of</strong> a HIV-Resistant Immune System with<br />

Hematopoietic Stem <strong>Cell</strong>s – A Polycistronic Approach<br />

Janet Chung, Chy-Anh Tran, Angel Gu, Lisa Scherer, Haitang Li,<br />

David L. DiGiusto, John J. Rossi.<br />

669<br />

Direct and Indirect Immune Suppressive Effects <strong>of</strong> High<br />

Hepatic Expression Direct Effective Reversal <strong>of</strong> Factor<br />

IX Inhibitors by AAV <strong>Gene</strong> Transfer<br />

David Markusic, Roland Herzog.<br />

670<br />

Combination <strong>Therapy</strong> <strong>of</strong> Anti-CD20, AMD3100, G-CSF<br />

and Factor VIII Plasmid-Mediated <strong>Gene</strong> <strong>Therapy</strong><br />

Can Successfully Promote Tolerance to Factor VIII in<br />

Hemophilia A Mice with Pre-Existing Inhibitors<br />

Chao Lien Liu, Meghan Lyle, Simon C. Shin, Carol H. Miao.<br />

671<br />

Identiication <strong>of</strong> Novel Chromatin Insulator<br />

Elements for Use in Lentiviral <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> T <strong>Cell</strong><br />

Immunodeiciencies<br />

Sheng Zhou, Taihe Lu, Zhijun Ma, John T. Gray, Brian P. Sorrentino.<br />

672<br />

Transduction <strong>of</strong> Human CD34+ <strong>Cell</strong>s in the NOD SCIDg<br />

(NSG) Mouse Model Using Lenti-hWASP-Vectors Derived<br />

from Stable Producer Clones<br />

Matthew M. Wielgosz, Yoon S. Kim, Robert E. Throm, Gael G.<br />

Carney, John T. Gray, Arthur W. Nienhuis.<br />

673<br />

Pre-Clinical Modeling <strong>of</strong> Foamy Virus Vector Based<br />

<strong>Gene</strong> <strong>Therapy</strong> for SCID-X1<br />

Gabrielle M. Curinga, Iram Khan, Swati Singh, Joey Pangallo, Brian<br />

Beard, Troy Torgerson, Andrew Scharenberg, Grant Trobridge,<br />

Hans-Peter Kiem, David Rawlings.<br />

674<br />

Long Term Safety <strong>of</strong> Clinical Grade LentiGlobin Vectors<br />

in a b-Thalassemic and Normal Mice<br />

Olivier Negre, Cynthia Bartholoma, Robert Kutner, Beatrix Gillet-<br />

Legrand, Celine Courne, Anais Paulard, Byoung Ryu, Maria Denaro,<br />

Christ<strong>of</strong> von Kalle, Emmanual Payan, Michell Finer, Gabor Veres.<br />

675 Abstract Withdrawn from Presentation<br />

734 Abstract Withdrawn from Presentation<br />

735<br />

Optimization <strong>of</strong> dual-function vectors for Alpha-1<br />

Antitrypsin Deiciency<br />

Qiushi Tang, Christian Mueller, Lina Song, Terence Flotte<br />

736<br />

Targeting dendritic cells with lentiviral vectors induces<br />

tolerance <strong>of</strong> effector T cells and protects mice from<br />

experimental autoimmune encephalomyelitis<br />

Bruna de Andrade Pereira, Mathias Ackermann, Christiane Dresch,<br />

Cornel Fraefel<br />

737<br />

Novel adenoviral vectors induce robust T cell responses<br />

to HSV2 and signiicantly boost responses after repeat<br />

homologous administration<br />

Christopher A. Lazarski, Douglas E. Brough, Lisa L. Wei<br />

738<br />

TALEN-based Individualized <strong>Gene</strong> Medicine for<br />

Epidermolysis Bullosa<br />

Mark J. Osborn, Colby G. Starker, Amber N. McElroy, Beau R.<br />

Webber, Anthony P. DeFeo, Richard Gabriel, Manfred Schmidt,<br />

Christ<strong>of</strong> von Kalle, Daniel F. Carlson, Morgan L. Maeder, J. Keith<br />

Joung, John E. Wagner, Daniel F. Voytas, Bruce R. Blazar, Jakub<br />

Tolar<br />

739<br />

Prevention <strong>of</strong> Anti-Capsid Immune Response Following<br />

Systemic AAV9 Dosing in Infant Rhesus Monkeys<br />

Darin Falk<br />

740<br />

Inhibition <strong>of</strong> ocular neovascularization by<br />

subconjunctival gene delivery <strong>of</strong> calreticulin-derived<br />

peptide, vasostatin 112<br />

Guei-Sheung Liu, Youn-Shen Bee, Gregory J. Dusting, Ming-Hong<br />

Tai<br />

741<br />

Transient Epigenetic <strong>Gene</strong> <strong>Therapy</strong> as a New<br />

Therapeutic/Prophylactic Avenue for Aging/<br />

Degenerative Diseases and Neurodevelopmental<br />

Disorders<br />

Roger Bertolotti<br />

742<br />

Successful Systemic Cancer Targeting by Adenovirus<br />

Vector with AB-loop Redesigned Fiber via Reducing<br />

Liver Sequestration<br />

Yoshiaki Miura, Joohee Han, Julia Davydova, Masato Yamamoto<br />

Saturday, May 18, 2013<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

137


Abstract Directory, Saturday, May 18, 2013<br />

Poster Session III, continued<br />

3:45 PM - 5:45 PM<br />

Room: Exhibit Hall C/D<br />

Late Breaking Abstracts III<br />

743<br />

Prevention <strong>of</strong> radiation-induced salivary hyp<strong>of</strong>unction<br />

by delivering hSFRP2 into submandibular glands<br />

Changyu Zheng, Ana P. Cotrim, Corinne Goldsmith, Stefanie<br />

Aquilina, Anastasia Sowers, Indu S. Ambudkar, James B. Mitchell,<br />

Bruce J. Baum<br />

744<br />

The non-signaling extracellular spacer domain <strong>of</strong><br />

CD19-speciic chimeric antigen receptors is decisive for<br />

in vivo antitumor activity<br />

Michael Hudecek, Lingfeng Liu, Anne Silva, Paula Kosasih, Yvonne<br />

Y. Chen, Cameron J. Turtle, Michael C. Jensen, Stanley R. Riddell<br />

745 Abstract Withdrawn from Presentation<br />

746<br />

Determining the physiologic effect <strong>of</strong> B-Type<br />

Natriuretic Peptide on cardio-renal homeostasis<br />

Sara J Holditch, Alessandro Cataliotti, Aron Geurts, Yasuhiro Ikeda<br />

747<br />

Bortezomib induced unfolded protein response<br />

synergizes with oHSV to induce necroptic cell death in<br />

solid tumors<br />

Ji Young Yoo, Brian Hurwitz, Chelsea Bolyard, Jun-Ge Yu, Jeffrey<br />

Wojton, Jianying Zhang, Matthew Old, Balveen Kaur<br />

753<br />

Non-myeloablative preconditioning with Ack-2 for cell<br />

therapy for Hunter disease<br />

Takayuki Yokoi, Kentaro Yokoi, Kazumasa Akiyama, Takashi<br />

Higuchi, Yohta Shimada, Hiroshi Kobayashi, Yoshikatsu Eto, Taku<br />

Sato, Makoto Otsu, Hiromitsu Nakauchi, Shinichi Nishikawa,<br />

Hiroyuki Ida, Toya Ohashi<br />

754<br />

Human placenta-derived mesenchymal stem cells<br />

augments spinal cord functional recovery in scid mice<br />

model<br />

Vikram Sabapathy, Dorai Murugan, George Tharion, Sanjay Kumar<br />

755<br />

Correlation <strong>of</strong> molecular parameters with lipoplex<br />

structure and transfection eficacy in pyridinium-based<br />

cationic lipids<br />

Paria Parvizi, Emile Jubeli, Liji Raju, Nada Abdul Khalique, Ahmed<br />

Almeer, Hebatalla Allam, Maryem Al Manaa, Helge Larsen, David<br />

Nicholson, Michael D. Pungente, Thomas M. Fyles<br />

756<br />

Transplantation <strong>of</strong> human adipose tissue-derived stem<br />

cells provides behavioral improvement, clinical onset<br />

delay and life extension in mouse<br />

Hong J. Lee,Jin An, Kwang S. Kim, In J. Lim, Seung U. Kim<br />

748<br />

Assessing Small Vector Pharmacology Using the Cre-<br />

LoxP System in Mice<br />

Matthew L. Hillestad, Adam Guenzel, Michael A. Barry<br />

749 Abstract Withdrawn from Presentation<br />

750<br />

Hydrodynamic Delivery <strong>of</strong> mIL10 <strong>Gene</strong> Protects Mice<br />

from High-Fat Diet-induced Obesity and Glucose<br />

Intolerance<br />

Mingming Gao, Chunbo Zhang, Yongjie Ma, Le Bu, Linna Yan, Dexi<br />

Liu<br />

Saturday, May 18, 2013<br />

751<br />

Heparin afinity puriication <strong>of</strong> extracellular vesicles<br />

Leonora Balaj, Nadia A. Atai, Weilin Chen, Dakai Mu, Bakhos A.<br />

Tannous, Johan Skog, Xandra O. Breakeield, Casey A. Maguire<br />

752<br />

Preclinical study <strong>of</strong> AAV-sTRAIL: pharmaceutical<br />

eficacy, tissue distribution, and animal safety<br />

Dexian Zheng, Xin Wang, Wei Li, Yanxin Liu<br />

138<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Aartsma-Rus, Annemieke M. ........................................................609<br />

Abate-Daga, Daniel ...........................................................................716<br />

Abdalla, Renne J. ................................................................................265<br />

Abdul-Razak, Hayder H ..................................................................678<br />

Abei, Masato ........................................................................................643<br />

Abels, Erik R. .......................................................................................304<br />

Abernathy, Corinne .................................................................. 55, 721<br />

Abhyankar, Harshal ..........................................................................305<br />

Aboody, Karen S. ......................................................................648, 656<br />

Abramihina, Tatiana .........................................................................465<br />

Abuin, Allison M....................................................................................31<br />

Acchione, Mauro ................................................................................477<br />

Ackermann, Mania ...............................................................................84<br />

Ackermann, Mathias ........................................................................736<br />

Adachi, Kei ........................................................72, 78, 119, 124, 259<br />

Adair, Jennifer E. ........................................................................ 25, 421<br />

Adamo, Richard F. ...................................................................366, 372<br />

Adams, Katherine ..............................................................................508<br />

Aderca, Ileana ........................................................................................17<br />

Adjali, Oumeya ...................................................................................111<br />

Agapova, Larisa ........................................................................137, 470<br />

Agarwal, Prachi ..................................................................................537<br />

Agbandje-McKenna, Mavis ................. 4, 71, 333, 334, 335, 541<br />

Aghi, Manish K. ...................................................................................676<br />

Aguiar, Rodrigo ..................................................................................519<br />

Aguilar, Tania ......................................................................................476<br />

Ahmed, Ali Karim ..............................................................................616<br />

Ahmed, Seemin S. .................................................................................35<br />

Ahonen, Marko ...................................................................................501<br />

Aiuti, Alessandro ......................................................28, 63, 309, 517<br />

Ai-Young, Lee .......................................................................................699<br />

Akbarpour, Mahzad ................................................................323, 441<br />

Akbuga, Jülide .....................................................................................452<br />

Akinfenwa, Patricia Y. ......................................................................131<br />

Akiyama, Kazumasa ...............................................................365, 753<br />

Akpek, Gorgon ....................................................................................298<br />

Al Manaa, Maryem ............................................................................755<br />

Alan, Saadet .........................................................................................452<br />

Albert, Jessica .....................................................................................639<br />

Albert, Lee ............................................................................................471<br />

Alberti, Michael O. .............................................................................438<br />

Alexander, Ian E. ................................................................................356<br />

Alexandrov, Krill ................................................................................224<br />

Alferiev, Ivan........................................................................................372<br />

Al-Hili, Zaid A. .....................................................................................647<br />

Allam, Hebatalla.................................................................................755<br />

Allen, Cory .......................................................................... 23, 417, 641<br />

Allen, James M. ...................................................................................543<br />

Allen, Margaret D. ................................................................................96<br />

Almeer, Ahmed ...................................................................................755<br />

Almeida-Porada, Graca ...................................................................253<br />

Alonso-Ferrero, María Eugenia ...................................................678<br />

Al-Shammari, Ahmed M. ................................................................647<br />

Altaleb, Naderah ................................................................................379<br />

Alusi, Ghassan .....................................................................................561<br />

Amaishi, Yasunori ..................................................................... 16, 629<br />

Amano, Shinya U. ..................................................................................96<br />

Amante, Dinah ....................................................................................153<br />

Amante, Romain ................................................................................458<br />

Amarante, Trish .................................................................................339<br />

Ambudkar, Indu S. .............................................................................743<br />

Ammayappan, Arun .........................................................................413<br />

An, Dong Sung ....................................................................................530<br />

An, Jin .....................................................................................................756<br />

An, Songtao ..........................................................................................369<br />

Anagnostopoulos, Achilles .................................................... 27, 427<br />

Andino, Lourdes M. ..........................................................................542<br />

Ando, Dale ...............................................................................................58<br />

Ando, Miki ............................................................................................684<br />

Andre, Franck M. ...............................................................................148<br />

Ang, Sonny ............................................................ 198, 626, 650, 653<br />

Angelino, Mark D. ....................................................................260, 262<br />

Anguela, Xavier M. ..................................................................110, 488<br />

Ankoudinova, Irina ...........................................................................184<br />

Anna, Stornaiuolo .............................................................................520<br />

Annan, Anand C..................................................................................438<br />

Annoni, Andrea ........................................................................323, 441<br />

Annunziata, Patrizia .........................................................................362<br />

Annunziato, Stefano ...............................................................233, 666<br />

Ansari, Amir Mehdi ..........................................................................616<br />

Anstaett, Olivia ...................................................................................185<br />

Antico, Christopher J........................................................................324<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

139


Abstract Author Index<br />

Antignac, Corinne..............................................................................546<br />

Antoniou, Michael N. ..............................................................430, 661<br />

Anurathapan, Usanarat ........................................................398, 622<br />

Anwer, Khursheed ............................................................................461<br />

Aoki, Kazunori ..........................................................................414, 642<br />

Aouadi, Myriam.....................................................................................96<br />

Aprile, Annamaria .............................................................................420<br />

Aquilina, Stefanie ..............................................................................743<br />

Aramaki, Yukihiko .............................................................................142<br />

Arambula, Claudia ............................................................................394<br />

Aras, Rahul ...........................................................................................500<br />

Arbeit, Jeffrey M. ................................................................................560<br />

Arbel-Ornath, Michal .......................................................................283<br />

Arber, Caroline ...................................................................................305<br />

Arden, Erik ...........................................................................................538<br />

Ardinger, Jeffery .................................................................................338<br />

Arens, Anne .........................................................................................204<br />

Ariga, Masamichi ...............................................................................585<br />

Armentano, Donna ...........................................................................338<br />

Arndt, Katja .........................................................................................655<br />

Arndt, Michaela A. E. ...........................................................................21<br />

Arnold, Eric ..........................................................................................454<br />

Arnould, Sylvain .................................................................................401<br />

Aronovich, Elena L. .................................................................102, 447<br />

Aronowitz, Eric .....................................................................................11<br />

Arpke, Robert W.................................................................................168<br />

Arruda, Valder R. ...............................................................................498<br />

Artus, Alexandre ...................................................................................64<br />

Arumugam, Paritha ..........................................................................664<br />

Arumugam, Ramamani ...................................................................276<br />

Arya, Suresh ..............................................................................531, 696<br />

Asaad, Wael..........................................................................................387<br />

Aschbacher, Kirstin A. .....................................................................369<br />

Ashley, Scott ........................................................................................108<br />

Ashtari, M. ...............................................................................................53<br />

Aslanidi, George ............................................................ 333, 334, 541<br />

Aslanidi, George V. ......................................75, 118, 314, 328, 542<br />

Asokan, Aravind ....................................................................... 2, 73, 77<br />

Aswani, Vijay H. .................................................................................280<br />

Atai, Nadia A. .......................................................................................751<br />

Atala, Anthony ....................................................................................253<br />

Athanasopoulos, Takis ....................................................................734<br />

Atherton, Pamela ..................................................................................17<br />

Aubourg, Patrick ....................................................62, 278, 279, 589<br />

Aucher, Anne ..........................................................................................24<br />

Aurelian, Laure .........................................................................600, 636<br />

Auricchio, Alberto .............................................. 340, 359, 360, 499<br />

Badr, Christian E. ...............................................................................458<br />

Badros, Ashraf Z. ...............................................................................298<br />

Bae, You Han ........................................................................................556<br />

Baek, Sun-Young ................................................................................375<br />

Baert, Miranda R. M. ........................................................................313<br />

Bafico, Daniel R. ................................................................................632<br />

Bagel, Jessica .......................................................................................289<br />

Baird, Michelle....................................................................................255<br />

Bajgain, Pradip ...................................................................................622<br />

Bake, Erin .............................................................................................712<br />

Baker, David ...............................................................................188, 318<br />

Balaj, Leonora .....................................................................................751<br />

Balakrishnan, Amritha ............................................................ 45, 397<br />

Balakrishnan, Balaji .........................................................................337<br />

Baliakas, Panayotis ...........................................................................427<br />

Ballon, Douglas J. ..................................................................................11<br />

Balzer, Frederick ...................................................................................92<br />

Ban, Jae-Jun ..........................................................................................602<br />

Bangari, Dinesh ..................................................................................628<br />

Bankiewicz, Kryst<strong>of</strong> S. ...................................... 288, 594, 599, 703<br />

Bao, Gang ......................................................................... 471, 489, 567<br />

Bao, Jialing ...........................................................................................312<br />

Barber, Glen N. ....................................................................................413<br />

Barber, Jane .............................................................................................33<br />

Baricordi, Cristina ........................................................................ 28, 63<br />

Barish, Michael ...................................................................................648<br />

Barnard, Alun R. ................................................................................229<br />

Barnes, Josephine L. .........................................................................434<br />

Barnes, Justin A. .................................................................................560<br />

Barrera-L, Araceli ..............................................................................534<br />

Barrera-Lopez, Araceli ..........................................................246, 564<br />

Barrett, J. ..................................................................................................15<br />

Barry, Mary ..........................................................................................583<br />

Barry, Michael A. ................................................. 132, 481, 583, 748<br />

Bartel, Melissa A. .................................................................................... 3<br />

140<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Bartel, Ronnda L. ...............................................................................371<br />

Bartholomae, Cynthia C. .......................................37, 62, 210, 233,<br />

.......................................................................... 279, 518, 666, 674, 678<br />

Bartido, Shirley ...................................................................50, 61, 506<br />

Bartlett, Jeffrey S. .................................................................................48<br />

Bartolaccini, Sara ................................................................... 441, 667<br />

Bärtsch, Marc-Andrea .....................................................................639<br />

Baruchel, André ....................................................................................62<br />

Barve, Minal ......................................199, 273, 402, 503, 624, 625<br />

Barzel, Adi ............................................................................................343<br />

Bashkirova, Lisa .................................................................................277<br />

Basil, Maria C. .....................................................................................623<br />

Basner-Tschakarjan, Etiena ................................................110, 224<br />

Batshaw, Mark L. ...............................................................................128<br />

Baum, Bruce J. .....................................................................................743<br />

Baum, Christopher ........................................37, 66, 313, 320, 425<br />

Baumgart, J. .........................................................................................694<br />

Baumhover, Nick J. ...............................................................................41<br />

Baylink, David J. .................................................................................468<br />

Beadlescomb, Patricia M. ....................................................... 36, 377<br />

Bear, Adham S. ....................................................................................269<br />

Beard, Brian .........................................................................................673<br />

Beard, Brian C. .................................................................. 25, 311, 421<br />

Beard, Rachel E. .................................................................................716<br />

Beaton, Brendan ...................................................................................24<br />

Beattie, Stuart .....................................................................................274<br />

Beckman, Sarah .................................................................................611<br />

Bedell, Cynthia .......................................... 273, 351, 479, 503, 624<br />

Bee, Youn-Shen ...................................................................................740<br />

Beggs, Alan H. ............................................................................. 33, 606<br />

Beggs, Alan ..............................................................................................90<br />

Begum, Laila ................................................................................ 89, 257<br />

Behrens, Marshall .............................................................................652<br />

Beitsch, Peter ................................................................. 199, 624, 625<br />

Belay, Eyayu ...............................................................................419, 423<br />

Belbellaa, Brahim ..............................................................................278<br />

Bell, Jason B. ..............................................................................102, 447<br />

Bell, John C. ..................................................................................... 19, 22<br />

Bell, Peter ...................................................................................108, 444<br />

Bellinger, Dwight A. ..........................................................................733<br />

Bellinger, Dwight ...............................................................................667<br />

Bellio, Laura.........................................................................................420<br />

Belliveau, N. .........................................................................................708<br />

Bello, Alexander .................................................................................379<br />

Belur, Lalitha .......................................................................................364<br />

Bemelmans, Alexis-Pierre .............................................................225<br />

Bender, Christian ...............................................................................516<br />

Benedetti, Eric ....................................................................................581<br />

Benedicenti, Fabrizio .................................64, 233, 309, 517, 666<br />

Bennet, Alan ...........................................................................................59<br />

Bennett, Alan ......................................................................................508<br />

Bennett, Alan D. .................................................................................298<br />

Bennett, Jean .......................................53, 222, 224, 227, 231, 330<br />

Bennicelli, Jeannette L. .........................................................224, 227<br />

Benson, Janet ......................................................................................106<br />

Berger, Adeline ...................................................................................225<br />

Berger, Mitchel ...................................................................................703<br />

Bergeron, E. .........................................................................................694<br />

Berkley, Brown ...................................................................................307<br />

Bernal, Yvette ......................................................................................506<br />

Bernt, William ....................................................................................264<br />

Berry, Charles .....................................................................................310<br />

Bertolotti, Roger ......................................................................700, 741<br />

Betensky, Rebecca A.........................................................................283<br />

Beyer, Ines .................................................................................... 13, 201<br />

Beyers, R. J. ..............................................................................................40<br />

Bhakta, Vipul .......................................................................................561<br />

Bhargava, Ragini ......................................................................497, 571<br />

Bian, Tao ................................................................................................449<br />

Bianchi, Frayne...................................................................................508<br />

Biasco, Luca ................................................................28, 63, 309, 517<br />

Bienemann, Alison S. .......................................................................158<br />

Bifi, Alessandra .......................................................................309, 517<br />

Binder-Scholl, Gwen .........................................................................508<br />

Binder-Scholl, Gwendolyn K. ................................................ 59, 298<br />

Bing, Wang ...........................................................................................614<br />

Binley, Katie ................................................................................. 56, 232<br />

Bird, Andrew .......................................................................................618<br />

Birkett, Ashley .......................................................................................45<br />

Bishop, Nina ........................................................................................387<br />

Bisset, Darren R. ................................................................................450<br />

Bissig, Karl-Dimiter ..........................................................................454<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

141


Abstract Author Index<br />

Biswas, Arijit .............................................................................363, 580<br />

Bjornson, Christopher R. ...............................................................174<br />

Black, Aaron D. ...................................................................................227<br />

Black, Aaron H. ...................................................................................224<br />

Blake, Derek J. .....................................................................................296<br />

Blanche, Stéphane ................................................................................62<br />

Blanche, Stephane .............................................................................306<br />

Blau, C. Anthony.......................................................................419, 423<br />

Blau, Helen M. .....................................................................................255<br />

Blazar, Bruce R. ............................................................. 270, 584, 738<br />

Block, Matthew .....................................................................................17<br />

Blondeau, Johanna ............................................................................306<br />

Bloom, Matthew D. ...........................................................................332<br />

Blumenkrnz, Mark S. ..........................................................................54<br />

Blundell, Michael ...............................................................................678<br />

Bobbin, Maggie L. ..............................................................................454<br />

Bochner, Bernard H. ............................................................................70<br />

Boerner, Kathleen ...................................................................514, 725<br />

Bogan, Brooke ....................................................................................522<br />

Bogan, Dan ..............................................................................................92<br />

Bogan, Janet ................................................................................. 92, 391<br />

Bogdanov, R. ........................................................................................724<br />

Boisgerault, Nicolas ...............................................................395, 652<br />

Boissel, Sandrine ...............................................................................318<br />

Bole-Richard, Elodie ........................................................................399<br />

Bollino, Dominique .................................................................600, 636<br />

Bolyard, Chelsea M. ................................................................409, 747<br />

Bonato, Riccardo ...............................................................................433<br />

Bond, Wesley S. ..................................................................................131<br />

Bondanza, Attilio ...............................................................................197<br />

Bonifacino, Aylin ........................................................................ 30, 428<br />

Bonini, Chiara ................................................................... 28, 197, 504<br />

Bonnin, Delphine ..................................................................................52<br />

Bonten, Erik .........................................................................................702<br />

Bordignon, Claudio .................................................................197, 504<br />

Borel, Florie ...............................................................................211, 603<br />

Borelli, Primavera .............................................................................519<br />

Borg, Christophe ................................................................................399<br />

Börner, Kathleen ................................................................................123<br />

Boros, Gábor ........................................................................................147<br />

Borquez-Ojeda, Oriana ...................................................................506<br />

Borretta, Lisa ......................................................................................115<br />

Bortolotti, Francesca ............................................................... 95, 368<br />

Borzone, Roberta ..............................................................................362<br />

Boscolo, Francesca ...........................................................................465<br />

Bosnakovski, Darko ................................................................168, 169<br />

Bosque, Doyle ........................................................................................10<br />

Bossi, Giovanna ..................................................................................508<br />

Bossow, Sascha .............................................................. 405, 554, 639<br />

Botta, Salvatore ..................................................................................539<br />

Bouchier-Hayes, Lisa .......................................................................684<br />

Bougnères, Pierre ................................................................................62<br />

Bouinta, Asimina ..................................................................................27<br />

Boulad, Farid ..........................................................................................61<br />

Boulis, Nicholas M. ...........................................................................287<br />

Bourdel, Alix ........................................................................................731<br />

Bourg-Alibert, Nathalie ..................................................................615<br />

Boutin Fontaine, Marjorie ................................................................52<br />

Boyd, Maureen P. ..................................................................................48<br />

Boye, Sanford E. .................................................................................596<br />

Boye, Sanford L. ............................................................... 55, 115, 223<br />

Boye, Shannon E. ....................................................................... 55, 223<br />

Bradbury, A. M. ......................................................................................40<br />

Bradbury, Allison M. .............................................36, 377, 590, 592<br />

Braga, Luca ..............................................................................................95<br />

Brambilla, Aurora ..............................................................................504<br />

Brantly, Mark .......................................................................................545<br />

Braun, Stephen E. ..............................................................................195<br />

Breakeield, Xandra O. ...................................... 103, 286, 304, 751<br />

Bredius, Robbert G. M. ....................................................................313<br />

Breitbach, Caroline H. ........................................................................22<br />

Breitbach, Caroline J. ..........................................................................19<br />

Bremer, William G. ...............................................................................91<br />

Brendel, Christian ................................................................................66<br />

Brendler, Charles ...............................................................................555<br />

Brenner, Gary J. ..................................................................................286<br />

Brenner, Malcolm K. .........................14, 299, 300, 398, 622, 684<br />

Brennig, Sebastian ..................................................................320, 429<br />

Brentjens, Renier.....................................................................506, 651<br />

Breton, Louis R. .....................................................................................48<br />

Brewer, Joanna ........................................................................... 59, 508<br />

Brewer, Joanna E. ..............................................................................298<br />

142<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Bridges, Charles R. ............................................................................374<br />

Bringas, John .................................................................. 288, 594, 599<br />

Broderick, Kate E. ...................................................................153, 341<br />

Brooks, Elizabeth J. ...........................................................................276<br />

Brooks, Susan .....................................................................................295<br />

Broome, Ted ...........................................................................................88<br />

Brough, Douglas E. ............................................................................737<br />

Brown, Ami S..........................................................................................45<br />

Brown, Christine ...............................................................................648<br />

Brown, Harrison C. ...........................................................................663<br />

Brown, Jillian R. .................................................................................365<br />

Brown, Jr, Robert H. .............................................................................93<br />

Brown, Kevin ..........................................................................................51<br />

Brown, Matthew T. ..................................................................292, 491<br />

Brown, Patricia...................................................................................351<br />

Brown, Rachel E. ................................................................................434<br />

Brown, Robert ..........................................................................388, 603<br />

Brown, Ryan ........................................................................................721<br />

Brownlie, Joe .......................................................................................185<br />

Brugman, Martijn H. ..............................................................319, 425<br />

Brunetti-Pierri, Nicola ..................................... 353, 362, 499, 553<br />

Brunger, Jonathan M. .......................................................................241<br />

Brunhoeber, Elaine ...........................................................................461<br />

Brunicardi, F. C. ..................................................................................659<br />

Brunicardi, F. Charles ................................................. 272, 624, 625<br />

Brunson, Brandon L. ........................................................................590<br />

Brusko, Todd M. .................................................................................109<br />

Bu, Le ......................................................................................................750<br />

Buckvold, Megan P. ...........................................................................495<br />

Bueren, Juan Antonio ......................................................................678<br />

Buggio, Maurizio ...............................................................................438<br />

Bui, Jacquelin H. .................................................................................107<br />

Buj-Bello, Anna ...............................................33, 90, 240, 605, 606<br />

Bundschuh, Ralf .................................................................................412<br />

Bunnell, Bruce A. ...............................................................................195<br />

Burcus, Niculina ....................................................................................99<br />

Burke, Bryan P. ......................................................................................48<br />

Burke, James ...........................................................................................19<br />

Burkin, Dean J. ....................................................................................175<br />

Burnett, Ryan ......................................................................................703<br />

Burrascano, Cindy .............................................................................703<br />

Burtner, Christopher R. ........................................................311, 421<br />

Bushman, Frederic .................................................................306, 310<br />

Butts, Tiffany .......................................................................................443<br />

Byrne, Barry J............................................ 57, 60, 90,376, 446, 617<br />

Byrne, Leah C. .......................................................................................... 5<br />

Byrnes, Andrew P. .............................................................................133<br />

Byun, Jung-Ick ............................................................... 143, 598, 602<br />

Byung-Rok, Do ....................................................................................699<br />

Caccavelli, Laure ......................................................................306, 310<br />

Cagnina, Shannon..............................................................................351<br />

Cai, Ying .................................................................................................263<br />

Calabria, Andrea .......................................................28, 63, 309, 517<br />

Calcedo, Roberto ...............................................................................360<br />

Calos, Michele P. .................................................................................174<br />

Camadro, Jean-Michel .....................................................................612<br />

Camba-Colon, Joanna .........................................................................48<br />

Cameron, Brian ..................................................................................508<br />

Camisa, Barbara .................................................................................197<br />

Campell-Thompson, Martha .........................................................721<br />

Campo, John ........................................................................................184<br />

Campos, Maria ....................................................................................709<br />

Cancelas, Jose ......................................................................................426<br />

Candotti, Fabio .........................................................................307, 437<br />

Cannizzo, Stefania E. ..............................................................315, 469<br />

Cannon, Paula M. .......................................................... 183, 184, 487<br />

Cantore, Alessio .................................................. 441, 496, 666, 667<br />

Cao, Chunxia ........................................................................................335<br />

Cao, Hua .............................................................................. 13, 201, 303<br />

Cao, Hua ................................................................................................679<br />

Cao, Huibi .............................................................................................433<br />

Cao, Ou ...................................................................................................190<br />

Cao, Phuong .........................................................................................248<br />

Cappellini, Maria Domenica .........................................................420<br />

Capracotta, Sonja ..............................................................................264<br />

Carbajo, Rosangela .................................................................152, 620<br />

Carbonaro, Denise A. .......................................................................307<br />

Carlier, Pierre ......................................................................................734<br />

Carlisle, Holly ............................................................................339, 550<br />

Carlson, Daniel F. ...............................................................................738<br />

Carnes, Aaron E. .................................................................................263<br />

Carnes, Aaron .....................................................................................261<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

143


Abstract Author Index<br />

Carney, Gael G. ....................................................................................672<br />

Carroll, Maria V......................................................................................48<br />

Carruthers, K. ......................................................................................695<br />

Cartier, Nathalie ......................................................................... 62, 279<br />

Caruana, Ignazio ................................................................................392<br />

Cassinerio, Elena ...............................................................................420<br />

Castaldo, Sigismondo ......................................................................353<br />

Castello, Raffaele ...............................................................................362<br />

Castle, Michael J. ................................................................................116<br />

Castleman, William ..........................................................................721<br />

Castleton, Anna Z. .............................................................................411<br />

Castleton, Anna .....................................................................................24<br />

Casucci, Monica ..................................................................................197<br />

Caswell, Debbie ..................................................................................436<br />

Cataldi, Marcela P. .............................................................................125<br />

Catalgol, Betul .....................................................................................697<br />

Cataliotti, Alessandro ......................................................................746<br />

Catani, Joao Paulo P. .........................................................................630<br />

Cathomen, Toni ..................................................................................539<br />

Cattaneo, Roberto .............................................................................415<br />

Cavazzana-Calvo, Marina .....62, 279, 306, 310, 313, 661, 662<br />

Cederbaum, Stephen D. ..................................................................497<br />

Celis, Esteban ......................................................................................395<br />

Certoux, Jean-Marie .........................................................................399<br />

Cerullo, Vincenzo ....................................................................501, 607<br />

Cesana, Daniela .......................................................................... 64, 233<br />

Cesani, Martina ........................................................................309, 517<br />

Chérel, Yan ...........................................................................................111<br />

Chai, Jing ...............................................................................................476<br />

Chai, Kuan .............................................................................................216<br />

Chalberg, Thomas W. ..........................................................................54<br />

Chamberlain, Jeffrey S. ....................................................................543<br />

Chamberlain, Joel R. .........................................................................450<br />

Chambers, Christopher B. ........................................... 26, 200, 235<br />

Champlin, Richard E. .................................10, 621, 626, 649, 653<br />

Chan, Jerry ....................................................................... 363, 430, 580<br />

Chan, Jerry K. Y. ..................................................................................254<br />

Chan, T. ......................................................................................................15<br />

Chandler, Randy J. .............................................................................113<br />

Chandra, Manasa ...............................................................................542<br />

Chandrasekaran, Devikha..............................................................421<br />

Chang, Esther H. ................................................................................273<br />

Chang, Susan M. .................................................................................676<br />

Chang, Wen-Teng ...............................................................................723<br />

Chan-Seng, Delphine ........................................................................157<br />

Chapdelaine, Pierre ..........................................................................389<br />

Chapman, Michael S. ........................................................................336<br />

Chard, Louisa S. ..................................................................................507<br />

Charrier, Sabine .................................................................................306<br />

Charton, Karine ........................................................................610, 615<br />

Chatterjee, Saswati ...........................................................................542<br />

Chaudhuri, Aadel A. ..........................................................................712<br />

Chaurasiya, Shyambabu .................................................................403<br />

Chavez, Christopher L. ....................................................................174<br />

Chen, Alvin ...........................................................................................589<br />

Chen, Dalin ...........................................................................................474<br />

Chen, Hsing-Yu ....................................................................................348<br />

Chen, Jeremy. J.W. ..............................................................................348<br />

Chen, Li ........................................................................................464, 570<br />

Chen, Liping .........................................................................................665<br />

Chen, Mong-Jen ..................................................................................545<br />

Chen, Pao-Rong ..................................................................................723<br />

Chen, Qiumei .......................................................................................369<br />

Chen, S....................................................................................................708<br />

Chen, Stacey .........................................................................................373<br />

Chen, Thomas .....................................................................................703<br />

Chen, Vincent C. .................................................................................474<br />

Chen, Vincent ......................................................................................476<br />

Chen, Weilin .........................................................................................751<br />

Chen, Wenyi .........................................................................................474<br />

Chen, Xinglu .........................................................................................221<br />

Chen, Yifeng ...............................................................................110, 498<br />

Chen, Yvonne Y. ..................................................................................744<br />

Chen, Zhi-Ying .....................................................................................270<br />

Cheng, Seng H. .................................................................. 34, 282, 453<br />

Chen-Wichmann, Linping .................................................................66<br />

Cherel, Yan ...........................................................................................734<br />

Cherqui, Stephanie ...................................................... 493, 494, 546<br />

Cheung, Aaron ....................................................................................593<br />

Chi, Yudan .............................................................................................562<br />

Chiang, Andy .......................................................................................665<br />

Chiara, Bovolenta ..............................................................................520<br />

144<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Chicoine, Louis G. .................................................................................91<br />

Chien, Yin-Hsiu ........................................................................... 60, 376<br />

Chikovani, T .........................................................................................682<br />

Childers, Martin ......................................................................... 90, 391<br />

Childers, Martin K. ................................................33, 473, 606, 617<br />

Chiocca, E. Antonio .................................................................676, 690<br />

Chiodo, Vince A. .................................................................................596<br />

Chiodo, Vince ......................................................................................545<br />

Chion-Sotinel, Isabelle ....................................................................401<br />

Chiou, Shih-Hwa ................................................................................720<br />

Chiuchiolo, Maria J. ................................................................... 11, 106<br />

Chiyo, Tomoko ............................................................... 120, 176, 608<br />

Cho, Jung Jong .....................................................................................565<br />

Cho, Mong ........................................................................................ 19, 22<br />

Cho, Soo Kyung ........................................................................... 42, 163<br />

Chodon, Thinle ...................................................................................302<br />

Choi, Boyoung .....................................................................................238<br />

Choi, E. ...................................................................................................695<br />

Choi, Eun-Young .......................................................................383, 586<br />

Choi, H. ...................................................................................................708<br />

Choi, Il-Kyu ...................................................................... 129, 679, 689<br />

Choi, Ji Ye ..............................................................................................602<br />

Choi, Joung-Woo ......................................................................556, 689<br />

Choi, Ju Hyun .......................................................................................375<br />

Choi, Kyoung Baek ............................................................................138<br />

Choi, Min Jeong ..................................................................................375<br />

Choi, Uimook ............................................................................... 82, 308<br />

Choolani, Mahesh ......................................................... 363, 430, 580<br />

Chorny, Michael............................................................. 144, 366, 372<br />

Chou, Alice Y. .......................................................................................115<br />

Chou, Szu-Ting .......................................................................................44<br />

Choudhury, Sourav ................................................................................ 1<br />

Christiansen, Lauryn ............................................................... 37, 251<br />

Christiansen, Lauryn M. .................................................................258<br />

Christiansen-Weber, Trudy .................................................137, 470<br />

Chu, Jun .................................................................................................255<br />

Chu, Kirk ................................................................................7, 191, 681<br />

Chu, Kon ........................................................................... 143, 598, 602<br />

Chu, Tiffany ................................................................................137, 470<br />

Chu, Yongchao ....................................................................................561<br />

Chuah, Marinee K. .................................................................................. 8<br />

Chuah, Marinee ............................................................. 355, 496, 667<br />

Chuah, Marinne ..................................................................................354<br />

Chuang, Chen-Hua ............................................................................436<br />

Chung, Daniel C. .......................................................................160, 227<br />

Chung, Daniel ......................................................................................224<br />

Chung, Janet .........................................................................................668<br />

Chung, Su I. ..........................................................................................513<br />

Ciceri, Fabio ...............................................................................420, 504<br />

Cicieri, Fabio ........................................................................................197<br />

Cieri, Nicoletta ............................................................................ 28, 504<br />

Cingoz, Ahmet .....................................................................................697<br />

Ciriello, Giovanni ...............................................................................728<br />

Claesson-Welsh, Lena ......................................................................631<br />

Clark, K. R. ...............................................................................................91<br />

Clark, K. Reed ................................................................. 171, 182, 291<br />

Clark, Katherine A. ............................................................................366<br />

Clark, Randall ......................................................................................284<br />

Claudiani, Pamela ....................................................................359, 360<br />

Claudio, Bordignon ...........................................................................520<br />

Clayton, Nicholas P. ...........................................................................453<br />

Cleaver, Brian .........................................................................................55<br />

Clemens, Paula R. .................................................................................94<br />

Clemente, Nathalie ..............................................................................55<br />

Clevers, Hans ..........................................................................................85<br />

Cliby, William .........................................................................................17<br />

Clifford, Brian T. .................................................................................369<br />

Cloer, Caryn ..........................................................................................451<br />

Cloughesy, Timothy F. ......................................................................676<br />

Coates, Allan L. ...................................................................................433<br />

Cocchiarella, Fabienne ....................................................................347<br />

C<strong>of</strong>fey, Matt .................................................................................. 18, 652<br />

Cohen, Justus B. ............................................................. 416, 478, 566<br />

Cohen, Justus .......................................................................................285<br />

Cohen-Haguenauer, Odile .................................................................64<br />

Colahan, Patrick ....................................................................................88<br />

Cole-Strauss, Allyson .......................................................................386<br />

Collier, T. H. ..........................................................................................381<br />

Collier, Timothy J. ..............................................................................386<br />

Collins, Christopher J. ......................................................................745<br />

Collins, Shelley ......................................................................................57<br />

Colosi, Peter .........................................................................................709<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

145


Abstract Author Index<br />

Colunga, Aric .......................................................................................636<br />

Conlon, Thomas J.......................................................................... 55, 57<br />

Conlon, Thomas .......................................................................545, 721<br />

Connolly, Jeanne M. ..........................................................................366<br />

Constable, Ian J. .....................................................................................54<br />

Constantinou, Varnavas .....................................................................27<br />

Contag, Christopher H. ....................................................................255<br />

Cook, P. ......................................................................................................53<br />

Cooper, Laurence J. N. .........................................10, 198, 202, 393,<br />

......................................................431, 502, 621, 626, 649, 650, 653<br />

Cooper, Mark J. ...................................................................................344<br />

Corbel, Stephane Y. ...........................................................................255<br />

Cornetta, Kenneth .............................................................................703<br />

Corrales, Ricardo A. ..........................................................................366<br />

Cortado, Ruth ......................................................................................530<br />

Cossette, Travis L. ................................................................................55<br />

Cossette, Travis ..................................................................................721<br />

Cost, Gregory J. ...................................................................................568<br />

Cotrim, Ana P. ......................................................................................743<br />

Cotugno, Gabriella ..................................................................359, 360<br />

Coulombe, Zoé ....................................................................................389<br />

Courne, Celine ....................................................................................674<br />

Courtney, Amy .......................................................................................12<br />

Couture, Larry ..........................................................................474, 476<br />

Cox, N. R....................................................................................................40<br />

Cox, Nancy R. .............................................................................590, 592<br />

Cradick, Thomas J. ............................................. 324, 471, 489, 567<br />

Cram, Sara A. .......................................................................................589<br />

Crane, Ana M. ......................................................................................107<br />

Cranill, Palula J. .................................................................................255<br />

Crawford, Brett E. ..............................................................................365<br />

Crawford, Gregory E. .......................................................................241<br />

Cripe, Timothy P. ...............................................................................412<br />

Cristea, Sandra ...................................................................................568<br />

Crommelin, Daan ...............................................................................707<br />

Crommentuijn, Matheus H. W. .....................................................540<br />

Crosby, Catherine M. ........................................................................132<br />

Cross, Guillem .....................................................................................306<br />

Crossland, Denise L. .........................................................................198<br />

Crudele, Julie M. .................................................................................498<br />

Crystal, Ronald G. ..............................11, 106, 278, 373, 589, 727<br />

Cullis, P. ..................................................................................................708<br />

Cuneo, Nicasio ....................................................................................635<br />

Curiel, David T. .................................127, 246, 438, 558, 560, 564<br />

Curinga, Gabrielle ................................................................................32<br />

Curinga, Gabrielle M. .......................................................................673<br />

Curren, Elizabeth...............................................................................387<br />

Curtis, Sarah ........................................................................................276<br />

Cutler, Benjamin ................................................................................108<br />

Cutrera, Jeffry .....................................................................................139<br />

Cutz, Ernest..........................................................................................433<br />

Cyckowski, L. ..........................................................................................53<br />

Czarnecki, Kevin ................................................................................429<br />

Czech, Michael P. ...................................................................................96<br />

da Silva, Flavia H. ...............................................................................582<br />

Daenthanasanmak, Anusara............................................................47<br />

Daguindau, Etienne ..........................................................................399<br />

Dahlmann, Julia ..................................................................................320<br />

Dai, Jihong ............................................................................................681<br />

Dai, Mei .......................................................................................... 38, 248<br />

Dai, Mushui .............................................................................................72<br />

Dai, Yifan ...............................................................................................281<br />

Dal Ferro, Matteo..................................................................................95<br />

Dal-Cortivo, Liliane ...........................................................................306<br />

Dalkara, Deniz ......................................................................................... 5<br />

Dalle, Jean-Hughes ...............................................................................62<br />

Dandapat, Abhijit ..............................................................................169<br />

Dane, Allison P. ...................................................................................356<br />

Daneshmand, Manijeh .......................................................................19<br />

Dang, Wei ....................................................................................474, 476<br />

D’Angelo, Armando .................................................................496, 667<br />

Daniele, Nathalie ......................................................33, 90, 605, 610<br />

D”Aria, Stefania ...................................................................................362<br />

Danos, Olivier .....................................................................................731<br />

Danuta, Jarocha ..................................................................................714<br />

Dar, Gulam H. ......................................................................................156<br />

Darabi, Radbod ........................................................................168, 169<br />

Darvish, Babak .........................................................................152, 620<br />

Darvish, Daniel .........................................................................152, 620<br />

Dashk<strong>of</strong>f, Jonathan ...........................................................................283<br />

Dassie, Justin P. ...................................................................................509<br />

Dator, Dante .........................................................................................654<br />

146<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Daukandt, Marc ..................................................................................261<br />

Davidson, Beverly L. .........................................................................283<br />

Davidson, Michael W. .......................................................................255<br />

Davidson, Robert H. .........................................................................110<br />

Davidson, Robert J. ...........................................................................488<br />

Davila, Alejandra ...............................................................................307<br />

Davila, Marco L. ..................................................................................506<br />

Davis, Brian R. ....................................................................................107<br />

Davis, Carol ..........................................................................................295<br />

Davis, Daniel ...........................................................................................24<br />

Davis, Gregory D. ...............................................................................574<br />

Davydova, Julia .................................................... 408, 414, 705, 742<br />

Dawson, Brian ....................................................................................607<br />

Dawson, Margaret ................................................................................10<br />

d’Azzo, Alessandra ............................................................................702<br />

de Alencastro, Gustavo ...................................................................356<br />

de Andreade Pereira, Bruna .........................................................736<br />

De Bleser, Pieter .................................................................................355<br />

de Boer, Helen ...........................................................................275, 661<br />

De Deyn, Peter ....................................................................................497<br />

de Fougerolles, Antonin .................................................................463<br />

de Leeuw, Charles N. ........................................................................115<br />

de Mollerat du Jeu, Xavier .............................................................706<br />

de Moraes, Jane Z. .............................................................................658<br />

de Oliveira, Satiro ..............................................................................307<br />

De Palma, Michele .............................................................................301<br />

de Prisco, Nicola ................................................................................539<br />

De Ravin, Suk See ..............................................................................308<br />

De Saint Basile, <strong>Gene</strong>viève ............................................................662<br />

De Silva Feelixge, Harshana ..........................................................187<br />

De, Bishnu P. ................................................................................ 11, 589<br />

Dean, David A. ........................................................................................43<br />

Deconinck, Eric ..................................................................................399<br />

Deeg, H. Joachim ................................................................................525<br />

DeFeo, Anthony P. ...................................................................584, 738<br />

DeFrees, Kyle .......................................................................................745<br />

Degele, Meghan ..................................................................................273<br />

Deichmann, Annette ........................................................................210<br />

Del Vecchio, Michele ........................................................................394<br />

Delaney, Colleen .................................................................................249<br />

Delaney, Kyle .......................................................................................524<br />

Delebecque, Frederic ..........................................................................48<br />

Delhove, Juliette M. ...........................................................................435<br />

Della Valle, Patrizia .................................................................496, 667<br />

DeMaster, Amanda ............................................................................276<br />

Demonte, Marina ...............................................................................635<br />

Denapoli, Priscila M. A. .........................................................265, 658<br />

Denard, Jerome ..................................................................................445<br />

Denaro, Maria ............................................................................. 37, 674<br />

Denes, Bela ...........................................................................................507<br />

Deng, Wen-Tao .......................................................................................55<br />

Deniger, Drew C. ................................................................................502<br />

Denney, T. S. ............................................................................................40<br />

Denning, Gabriela .............................................................................528<br />

Dennis, James E. ....................................................................................96<br />

DeRavin, Suk See ..................................................................................82<br />

Derniame, Sophie ..............................................................................401<br />

Deschamps, Jack-Yves ......................................................................111<br />

Deschamps, Marina ..........................................................................399<br />

Desrosiers, Mélissa ...........................................................................225<br />

Devaux, Marie .....................................................................................111<br />

Dey, Aditi ....................................................................................... 24, 411<br />

Deyle, David R. ....................................................................................266<br />

Dhamne, Chetan ................................................................................431<br />

Di Matteo, Mario ......................................................................355, 496<br />

Di Serio, Clelia ........................................................................................63<br />

Di Stasi, Antonio ................................................................................684<br />

Di Tomaso, Tiziano ...........................................................................486<br />

Di, Wei-Li ..............................................................................................578<br />

Diago, Oscar .........................................................................................703<br />

Diamond, Scott L. ..............................................................................374<br />

Diao, Yong .............................................................................................154<br />

Diaz, Rosa .................................................................18, 395, 505, 652<br />

Dichek, David ......................................................................................559<br />

Dickey, David D. ..................................................................................327<br />

Dickson, Georges ...............................................................................734<br />

Dickson, Patricia I. ............................................................................586<br />

Dietz, Wynette M. ..............................................................................270<br />

Dighe, Niraja ........................................................................................430<br />

DiGiusto, David L. ..............................................................................668<br />

Dillberger, Alexa.................................................................................137<br />

Ding, W. ..................................................................................................694<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

147


Abstract Author Index<br />

Dionisio, Francesca .............................................................................63<br />

Discher, Dennis E. ..............................................................................523<br />

Disis, Nora ...............................................................................................13<br />

Dismuke, David J. ..................................................................................54<br />

Dissen, Gregory A. ................................................................................78<br />

Djuric, Ugljesa .....................................................................................593<br />

Do, Byung-Rok ....................................................................................722<br />

Dobbins, George C. ............................................................................127<br />

Doerler, Phillip A. .............................................................................446<br />

Doering, Christopher B. ................................................ 31, 528, 663<br />

Doering, Jon ............................................................................................33<br />

Doglioni, Claudio .....................................................................233, 666<br />

Doherty, Joseph E. .............................................................................269<br />

Doki, Yuichiro .....................................................................................749<br />

Domingo Musibay, Evidio ...................................................... 23, 641<br />

Donahue, Robert .................................................................29, 30, 428<br />

Donahue, Robert E. ..............................................................................65<br />

Dondero, Richard ..............................................................................214<br />

Dong, Biao ............................................................................................681<br />

Donnelly, Eleanor M. ........................................................................287<br />

Donnelly, Oliver ......................................................18, 395, 505, 652<br />

Donsante, Anthony .................................................................383, 586<br />

Dore, Franca ........................................................................................368<br />

Dorer, Dominik E. .................................................................................21<br />

Doria, Monica ......................................................................................340<br />

Doronin, Konstantin ........................................................................477<br />

Dorrell, Craig ............................................................................... 85, 581<br />

Dorward, Heidi ...................................................................................437<br />

Dotti, Gianpietro ............................................. 12, 14, 49, 197, 299,<br />

.......................................................................... 300, 305, 392, 394, 684<br />

Dou, Chunqing ....................................................................................616<br />

Dow, David ...........................................................................................309<br />

Dowdy, Sean ...........................................................................................17<br />

Doyal, Mark F. ......................................................................................285<br />

Doyon, Yannick ...................................................................................488<br />

Dresch, Christiane .............................................................................736<br />

Driessen, Gertjan J. A. ......................................................................313<br />

Drivas, Theodore G. ................................................................222, 231<br />

Dropulic, Boro ....................................................................................495<br />

Du, Junkai .............................................................................................616<br />

Du, Kai ....................................................................................................433<br />

Du, Liang ...............................................................................................559<br />

Duan, Cathleen ...................................................................................433<br />

Duan, Dongsheng ..................................................98, 166, 175, 613<br />

Duan, Yuyou .........................................................................................468<br />

Dubois, Kara ...........................................................................................19<br />

Dubreil, Laurence ...................................................................... 76, 111<br />

Duchateau, Philippe .........................................................................731<br />

Dufour, Brett ........................................................................................284<br />

Dukes, Joseph ......................................................................................508<br />

Dulatova, Galina .................................................................................619<br />

Dumitriu, Bogden .................................................................................65<br />

Dunbar, Cynthia E. ....................................................................... 29, 65<br />

Duncan, F. Jason ......................................................................... 39, 597<br />

Duncker, Dirk J. ...................................................................................275<br />

Duong, Jennifer .....................................................................................46<br />

Dupont, Jean Baptiste .........................................................................76<br />

Duros, Caroline .....................................................................................64<br />

Duskey, Jason ......................................................................................155<br />

Dusting, Gregory J. ..................................................................230, 740<br />

Dutilleul, Maeva .................................................................................111<br />

Düzgünes, Nejat .................................................................................576<br />

Dyka, Frank M. ..........................................................................115, 223<br />

Dyke, Jonathan P. ..................................................................................11<br />

Earley, Lauriel F. ....................................................................................72<br />

Earley, Lauriel .....................................................................................259<br />

Eastlund, Erik R. ................................................................................243<br />

Ebihara, Yasuhiro .................................................................................86<br />

Edelman, Aleksander .......................................................................731<br />

Edelman, Gerald ................................................................................273<br />

Egerer, Lisa ...........................................................................................195<br />

Egger, Erica ..........................................................................................530<br />

Eguchi, Akiko ......................................................................................706<br />

Ehrhardt, Anja ....................................................................................557<br />

Eiden, Maribeth V. .............................................................................524<br />

El Khoury, Joseph ..............................................................................304<br />

Elahi, Seyyed Mehdy ........................................................................135<br />

Elamouri, Salim S. .............................................................................248<br />

El-Amouri, Salim S. ..............................................................................38<br />

El-Attar, Laila M..................................................................................185<br />

Elazar, Menashe .................................................................................191<br />

Elder, James .........................................................................................676<br />

148<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Eleftheriadou, Ioanna .........................................................................67<br />

Elizabeth, Garabedian .....................................................................307<br />

Elkouby, Liron .....................................................................................110<br />

Ellis, James .................................................................................322, 593<br />

Ellis, Scott ..................................................................................... 56, 232<br />

Ellison, Stuart M. ..................................................................................67<br />

Elnaggar, Atif .......................................................................................208<br />

Emara, M.M. .........................................................................................682<br />

Embry, Addie .......................................................................................505<br />

Emery, David W. .......................................................................419, 423<br />

Emery, Lyndsey A. ................................................................................59<br />

Emri, Eszter .........................................................................................147<br />

Emri, Gabriella ...................................................................................147<br />

Emrick, Todd .......................................................................................157<br />

Endo-Takahashi, Yoko......................................................................142<br />

Engeland, Christine E. .....................................................................405<br />

Engelhardt, John F. ............................................................................535<br />

Engelhardt, Sarah ...................................................................... 21, 554<br />

Engler, Tatjana ..........................................................................126, 484<br />

Epperly, Michael W. ..........................................................................239<br />

Eren, Fatih ............................................................................................452<br />

Erez, Ayelet ..........................................................................................607<br />

Erger, Kirsten E. ....................................................................................55<br />

Erger, Kirsten ......................................................................................545<br />

Erger, Kirsten ......................................................................................721<br />

Ericson, Mark E. ....................................................................................41<br />

Escamilla-Powers, Julie ..................................................................454<br />

Escobar, Giulia ..........................................................................301, 486<br />

Escolar, Maria ........................................................................................62<br />

Esko, Jeffrey D. ....................................................................................448<br />

Esmaeili Shandiz, Alaleh ................................................................472<br />

Esmaeili-Shandiz, Alaleh ................................................................575<br />

Espenlaub, Sigrid ..............................................................................134<br />

Espinoza, Luis A. ................................................................................217<br />

Essand, Magnus .................................................................................631<br />

Estévez, Molina ..................................................................................678<br />

Eto, Yoshikatsu .........................................................................365, 585<br />

Eto, Yoshikatsu ...................................................................................753<br />

Evans, Molly ................................................................................. 30, 428<br />

Evens, Hanneke ............................................................................. 8, 496<br />

Exc<strong>of</strong>fon, Katherine J. ......................................................................327<br />

Exc<strong>of</strong>fon, Katherine J. D. A. ............................................................267<br />

Exline, Colin .........................................................................................184<br />

Exline, Colin M. ...................................................................................487<br />

Eyquem, Justin ....................................................................................401<br />

Fabre, Peggy ........................................................................................225<br />

Facher, Evan .........................................................................................500<br />

Faella, Armida .....................................................................................110<br />

Faella, Arminda ..................................................................................733<br />

Fairbanks, Carolyn A. .......................................................................364<br />

Falcione, Antonella ..............................................................................95<br />

Falcone, Laura ....................................................................................197<br />

Falk, Darin ............................................................................................739<br />

Fan, Luping ................................................................................101, 140<br />

Fang, Jin ....................................................................................................23<br />

Farag, Jacqueline ..................................................................................92<br />

Farah, Benjamin .................................................................................618<br />

Fargnoli, Anthony S. .........................................................................374<br />

Farin, Alicia M. ....................................................................................241<br />

Fariss, Robert ......................................................................................709<br />

Farmer, Andrew .................................................................................532<br />

Farrugio, Alfonso P. ...........................................................................174<br />

Faure-Kumar, Emmanuelle ...........................................................522<br />

Faust, Susan ...............................................................................108, 444<br />

Federici, Thais ....................................................................................287<br />

Feder<strong>of</strong>f, Howard J. ...........................................................................457<br />

Federspiel, Mark J. ............................................................................413<br />

Federspiel, Mark ...................................................................................17<br />

Fedsteinand, Ariel E. ........................................................................706<br />

Fehling, Hans Jörg .............................................................................445<br />

Feldman, Steve A. ..............................................................................716<br />

Felsburg, Peter J. ................................................................................311<br />

Fender, Pascal .....................................................................................552<br />

Fender, Pascal .....................................................................................729<br />

Feng, Nathan .......................................................................................656<br />

Feng, Yi ..................................................................................................533<br />

Fergus, Jeffrey .....................................................................................244<br />

Ferla, Rita ....................................................................................359, 360<br />

Fernandez-Ulibarri, Ines ...................................................................21<br />

Ferrand, Christophe .........................................................................399<br />

Ferrara, Antonella .............................................................................340<br />

Ferrari, Giuliana .................................................................................420<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

149


Abstract Author Index<br />

Ferraro, Bernadette .................................................................. 45, 397<br />

Ferreira, Jennifer ................................................................1, 384, 595<br />

Ferro, Leda ..............................................................................................61<br />

Ferrone, Soldano ...............................................................................394<br />

Festag, Marvin .......................................................................................81<br />

Fewell, Jason G. ...................................................................................461<br />

Fibbe, Willem E. .................................................................................319<br />

Fielding, Adele K. ....................................................................... 24, 411<br />

Fife, Jeremy ..........................................................................................162<br />

Figliola, Matthew J. ..............................................................................10<br />

Figueiredo, Constanca ........................................................................47<br />

Filareto, Antonio ................................................................................168<br />

Findlay, Andrew R. ............................................................................180<br />

Fine, Bruce ...........................................................................................503<br />

Fine, Eli J. ......................................................................... 324, 489, 567<br />

Finegold, Milton .......................................................................316, 466<br />

Fineman, Jeffrey R. ............................................................................369<br />

Finer, Michell .......................................................................................674<br />

Finer, Mitch ................................................................................260, 262<br />

Finer, Mitchell ............................................................................. 37, 251<br />

Finkelstein, Jeffrey ............................................................................298<br />

Finlayson, Neil ....................................................................................263<br />

Finn, Eric ...............................................................................................543<br />

Finn, Jonathan D. ...............................................................................498<br />

Finocchiaro, Liliana M. E. ...............................................................632<br />

Firrito, Claudia ...................................................................................486<br />

Fischbeck, Kenneth H. .....................................................................378<br />

Fischer, Alain ...........................................................62, 279, 306, 310<br />

Fischer, Anne C. ..................................................................................361<br />

Fischer, Ashley L. ...............................................................................243<br />

Fischer, David L. .................................................................................386<br />

Fishbein, Ilia ..............................................................................366, 372<br />

Fitzgibbons, Timothy P. .....................................................................96<br />

Flake, Alan W. ............................................................................236, 418<br />

Flanigan, Kevin M. .............................................................................180<br />

Flannery, John G. ..................................................................................... 5<br />

Flatt, Justin W. .....................................................................................477<br />

Fleming, S. M. ......................................................................................381<br />

Fleminig, Sheila M. ............................................................................386<br />

Flotte, Terence R. .............................................4, 211, 326 361, 735<br />

Fodor, Istvan ..............................................................................507, 561<br />

Foley, Erin .............................................................................................448<br />

Foley, Kevin T.......................................................................................619<br />

Follenzi, Antonia ......................................................................315, 469<br />

Foltz Greg ..............................................................................................676<br />

Fong, Mei ...............................................................................................532<br />

Fontes, Andrew ..................................................................................244<br />

Forbes, Scott P. ..........................................................................366, 372<br />

Forget, Marie A. ..................................................................................621<br />

Forsayeth, John ............................................................. 288, 594, 599<br />

Fortuno, Lowella V. ...........................................................................382<br />

Foster, Aaron .......................................................................................269<br />

Fox, Catherine .....................................................................................664<br />

Fox, Tara L. ...........................................................................................477<br />

Fraefel, Cornel ....................................................................................736<br />

Fragata, Rowell .........................................................................363, 580<br />

Francis, Sarah......................................................................................214<br />

Franco-Bourland, Rebecca E. .............................................246, 564<br />

Frederick, Amy ...................................................................................338<br />

Freemark, Michael S.........................................................................276<br />

Frelan, Megan .....................................................................................655<br />

French, Deborah L.............................................................................224<br />

French, Martyn ......................................................................................54<br />

Frenk, Esther Z. .......................................................................... 11, 106<br />

Frenzke, Marie ....................................................................................415<br />

Frey, William H. ..................................................................................364<br />

Freyvert, Yevgeniy ............................................................................568<br />

Frigault, Matthew J. ..........................................................................623<br />

Frittoli, Marta ......................................................................................420<br />

Fritz, Ashley .........................................................................................692<br />

Fronza, Raffaele .................................................. 204, 210, 274, 518<br />

Fry, Terry J. ...........................................................................................325<br />

Fu, Freddie ...................................................................... 281, 290, 614<br />

Fu, Haiyan ........................................................................... 39, 125, 597<br />

Fu, Pei-yu ..............................................................................................307<br />

Fujimoto, Naoko ......................................................................357, 715<br />

Fujisawa, Masato .....................................................................192, 654<br />

Fujita, Ryo ................................................................................................80<br />

Fukuda, Kuniaki .................................................................................643<br />

Fukuda, Takahiro .....................................................................365, 585<br />

Fulci, Giulia ..........................................................................................286<br />

Funato, Kosuke ......................................................................................11<br />

150<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Furth, Mark E. ........................................................................................33<br />

Furth, Mark ..........................................................................................473<br />

Furukawa, Yoichi ..................................................................................86<br />

Fyles, Thomas M. ...............................................................................755<br />

Gabriel, Nishanth ....................................................................114, 549<br />

Gabriel, Richard ............................................................ 518, 678, 738<br />

Gabrielse, Kari ....................................................................................710<br />

Gaddameedi, Rajashekhar ...................................................224, 227<br />

Gadkari, Rupali ...................................................................................536<br />

Gadkari, Rupali A. ..............................................................................114<br />

Gadue, Paul ..........................................................................................224<br />

Gahl, William A. ..................................................................................437<br />

Galanis, Evanthia ......................................................17, 23, 417, 641<br />

Galetto, Roman ...................................................................................401<br />

Galetto, Roman ...................................................................................683<br />

Galibert, Lionel ......................................................................................52<br />

Galivo, Feorillo ..........................................................................466, 581<br />

Gallina, Pierangela ..................................................................233, 666<br />

Galtseva, I. ............................................................................................724<br />

Galy, Anne ...................................................................................306, 662<br />

Gan, Chih Hao V..................................................................................678<br />

Gangemi, Mariela A. .........................................................................635<br />

Gannon, Frank ....................................................................................607<br />

Gannon, Mary......................................................................................587<br />

Ganser, Arnold .......................................................................................47<br />

Gao, Chun ..............................................................................................709<br />

Gao, Ehre ...............................................................................................444<br />

Gao, Guangping .......................4, 35, 93,128, 326, 328, 384, 512<br />

Gao, Mingming....................................................................................750<br />

Gao, Shijuan .........................................................................................194<br />

Gao, Xueqin ..........................................................................................178<br />

Gaponova, T..........................................................................................724<br />

Garcia, Elizabth ..................................................................................648<br />

Garcia, Luis...........................................................................................225<br />

Garcia-Figueroa, Jorge ..........................................................152, 620<br />

Garín, Marina I....................................................................................678<br />

Garitaonandia, Ibon .........................................................................465<br />

Garwick-Coppens, Sara ...................................................................295<br />

Gaudet, Daniel ....................................................................................274<br />

Gebremedhin, Senait .......................................................................576<br />

Gee, Adrian P. .............................................................................. 14, 299<br />

Gee, J. .........................................................................................................53<br />

Geekiyanage, Hirosha .........................................................................23<br />

Geguchadze, Ramaz ...............................................................141, 149<br />

Geiger, Sabine.........................................................................................26<br />

Geisinger, Jonathan M. .....................................................................174<br />

Genovese, Pietro ........................................................... 197, 486, 504<br />

Gentner, Bernhard ..................................................................197, 420<br />

Georger, Christophe ............................................................................76<br />

Georgiadis, Christos .........................................................................578<br />

Gerber, Mark A....................................................................................243<br />

Gerdemann, Ulrike............................................................................396<br />

Gernoux, Gwladys .............................................................................111<br />

Gerry, Andrew ....................................................................................508<br />

Gerry, Andrew B. ....................................................................... 59, 298<br />

Gersbach, Charles A. ...........167, 170, 177, 241, 292, 293, 491<br />

Getz, Matthew .....................................................................................721<br />

Geurten, Olivier ..................................................................................261<br />

Geurts, Aron ........................................................................................746<br />

Ghandeharian, Omid ............................................................................. 8<br />

Ghashghaei, Troy .................................................................................... 2<br />

Ghatrora, Rupinder K. .....................................................................434<br />

Ghisoli, Maurizio......................................................................203, 624<br />

Ghivizzani, Steve ................................................................................335<br />

Ghivizzani, Steven ................................................................................88<br />

Ghoda, Lucy Y. .....................................................................................648<br />

Gholizadeh, Shervin .........................................................................390<br />

Giacca, Mauro ............................................................................. 95, 368<br />

Gian Paolo, Rizzardi .........................................................................520<br />

Giangrande, Paloma H. ..........................................................509, 511<br />

Giannini, Caterina .............................................................................417<br />

Giardina, Patricia ..................................................................................61<br />

Gicquel, Evelyne .......................................................................610, 615<br />

Giedlin, Marty ........................................................................................58<br />

Gilbert, Daniel .....................................................................................514<br />

Gilbert, Rénald ....................................................................................135<br />

Gilbert, Shawn ....................................................................................548<br />

Gilchrist, Megan .................................................................................648<br />

Giles, April ............................................................................................116<br />

Gilkes, Janine A. ..................................................................................332<br />

Gill, Deborah R....................................................................................460<br />

Gillet-Legrand, Beatrix ....................................................................674<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

151


Abstract Author Index<br />

Giordano, Frank .................................................................................518<br />

Giovani, Michelle ...............................................................................679<br />

Gjoka, Monika .....................................................................................574<br />

Glass, Katherine A. ............................................................................241<br />

Glenn, Jeffrey S. ..................................................................................191<br />

Glikin, Gerardo C. ..............................................................................632<br />

Glimm, Hanno ...........................................................................204, 274<br />

Glorioso, Joseph C. ............................................. 285, 478, 566, 591<br />

Gochuico, Bernadette ......................................................................437<br />

Goddard, Melissa .......................................................................... 33, 90<br />

Goddard, Melissa A. ..........................................................................617<br />

Goerdt, Sergij ......................................................................................204<br />

Goetzmann, Jason................................................................................... 4<br />

Gogel, Brian M. .........................................................................199, 624<br />

Goins, William F. ................................................. 285, 478, 591, 690<br />

Gold, Michael .......................................................................................285<br />

Goldman, Frederick ..........................................................................587<br />

Goldman, Yale .....................................................................................523<br />

Goldowitz, Daniel ..............................................................................115<br />

Goldsmith, Corinne...........................................................................743<br />

Golebiowski, Diane ...........................................................................387<br />

Gombash, S. E. .....................................................................................381<br />

Gombash, Sara E. .....................................................................386, 596<br />

Gomero, Elida .....................................................................................702<br />

Gonçalves, Cristine ...........................................................................342<br />

Gonçalves, Manuel ............................................................................347<br />

Gong, Wenhui ......................................................................................369<br />

Gong, Zi ..................................................................................................495<br />

Gonzalez, Rodolfo....................................................................137, 465<br />

Gonzalez-Garay, Manuel .................................................................107<br />

Gonzalez-Gonzalez, Emilio ............................................................255<br />

Goodyer, Paul ......................................................................................247<br />

Gopal, Vijaya ..............................................................................150, 156<br />

Gordon, Myra E. .................................................................................575<br />

Gorham, Taron C. .................................................................................... 9<br />

Gorman, Kristen ................................................................................524<br />

Gorman, Wesley .................................................................................260<br />

Gorman, Wesley C. ............................................................................262<br />

Gornalusse, German ............................................................................81<br />

Gorsky, Joshua ....................................................................................544<br />

Goss, James R. .....................................................................................478<br />

Gosset, David .......................................................................................342<br />

Goto, Naoko .........................................................................................642<br />

Gottschalk, Stephen................................................................396, 400<br />

Gottschalk, Stephen M. ...................................................................410<br />

Gouble, Agnes .....................................................................................401<br />

Gouble, Agnès .....................................................................................731<br />

Goudy, Kevin ........................................................................................441<br />

Goudy, Kevin S. ...................................................................................323<br />

Gounis, Matthew................................................................................387<br />

Govindarajan, Srinath .....................................................................150<br />

Govindasamy, Lakshmanan ................................................334, 335<br />

Grabinski, Tessa .................................................................................596<br />

Gralow, Julie .........................................................................................303<br />

Grand, Francis .....................................................................................508<br />

Grandi, Paola .............................................................................416, 566<br />

Grange, Robert ......................................................................................90<br />

Grange, Robert W. ................................................................................33<br />

Gray, John T. .......................................................... 308, 671, 672, 702<br />

Gray, Steven J. ......................................................................................112<br />

Gray-Edwards, H. L. .............................................................................40<br />

Gray-Edwards, Heather ........................................................590, 592<br />

Gray-Edwards, Heather L....................................................... 36, 377<br />

Greco, Dario .........................................................................................501<br />

Greenberger, Joel S. ..........................................................................239<br />

Greene, Amy ........................................................................................657<br />

Greene, Michael R. ............................................................................527<br />

Gregory, Philip D. ............................................................ 46, 107, 183,<br />

......................................................184, 486, 487, 488, 504, 568, 678<br />

Grez, Manuel ..........................................................................................66<br />

Grieger, Joshua C. ..................................................................................54<br />

Grifin, Danielle ..................................................................................171<br />

Grifin, Danielle A. ..................................................................... 91, 172<br />

Grifiths, Duncan ...............................................................................264<br />

Grilley, Bambi .............................................................................. 14, 299<br />

Grimm, Dirk ............................................... 122, 123, 514, 516, 725<br />

Grizzle, William E. .............................................................................560<br />

Grody, Wayne W. ................................................................................497<br />

Grompe, Markus ..........................................85, 316, 466, 579, 581<br />

Grose, William E. ...............................................................................172<br />

Grossardt, Christian .........................................................................405<br />

Grosse, Stephanie ..............................................................................401<br />

152<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Grosso, Chantal ..................................................................................469<br />

Gruber, Harry ......................................................................................703<br />

Gruber, Harry E. .................................................................................676<br />

Gruenert, Dieter C. ....................................................... 471, 472, 575<br />

Gruh, Ina ...............................................................................................320<br />

Grunseich, Christopher...................................................................378<br />

Gu, Angel ...............................................................................................668<br />

Gu, Weiwang ........................................................................................533<br />

Guan, Xuan ...........................................................................................473<br />

Guan, Yue ..............................................................................................200<br />

Gubrij, Igor B. ......................................................................................439<br />

Guckes, Susan .....................................................................................295<br />

Guedan, Sonia .....................................................................................623<br />

Guedon, Jean-Marc ...........................................................................591<br />

Güenechea, Guillermo .....................................................................678<br />

Guenzel, Adam J. ................................................................................583<br />

Guenzel, Adam ....................................................................................748<br />

Guevara, Bruno ..................................................................................534<br />

GuhaSarkar, Dwijit ............................................................................212<br />

Guilak, Farshid ...................................................................................241<br />

Guilbaud, Mickaël ..............................................................................111<br />

Guilbault, Claire .................................................................................135<br />

Gül-Uludag, Hilal ...............................................................................462<br />

Gunther, Roland .................................................................................102<br />

Guo, Junjing..........................................................................................344<br />

Guo, Peixuan ........................................................................................515<br />

Gupta, Minnal ............................................................................298, 508<br />

Guschin, Dmitry Y. .............................................................................107<br />

Guschin, Dmitry .................................................................................184<br />

Guse, Kilian ................................................................................501, 607<br />

Guse, Kilian ..........................................................................................730<br />

Gutmann, Theresia ...........................................................................730<br />

Gutova, Margarita .............................................................................648<br />

Guy, John ...............................................................................................385<br />

Guzman-M, Karina ............................................................................564<br />

Haber, Tom ...........................................................................................719<br />

Habib, N.A. ............................................................................................682<br />

Hacein-Bey-Abina, Salima .......................62, 279, 306, 310, 313<br />

Hacke, Katrin .......................................................................................530<br />

Hackett, Neil R. ................................................................. 11, 106, 373<br />

Hackett, Perry .....................................................................................650<br />

Hackett, Perry B. .............................................................. 10, 102, 447<br />

Hadac, Elizabeth M. ..........................................................................407<br />

Haddad, Daniel J. ...............................................................................369<br />

Haddad, Marie Reine .............................................................383, 586<br />

Haemmerle, Reinhard .....................................................................422<br />

Haeusl, Martin ....................................................................................557<br />

Hafez, I. ..................................................................................................708<br />

Haft, Annelise......................................................................................316<br />

Haga, Kazunori ......................................................................................70<br />

Hagemann, Thorsten .......................................................................507<br />

Haggarty, Beth .......................................................................................46<br />

Hajri, Amor ..........................................................................................655<br />

Hakim, Chady H. ................................................. 166, 175, 295, 613<br />

Halama, Niels ......................................................................................405<br />

Halbert, Christine L. ...............................................................117, 443<br />

Hall, Bryan C. .......................................................................................447<br />

Halonen, Paavo J. ..................................................................................97<br />

Haluska, Jr, Paul .....................................................................................17<br />

Hamada, Hir<strong>of</strong>umi ............................................................................643<br />

Hamada, Katsuyuki ..........................................................................627<br />

Hamazaki, Takashi ............................................................................545<br />

Hamid, O. ..................................................................................................15<br />

Hamilton, Sara E. ...............................................................................270<br />

Hammer, Caroline ........................................................................ 33, 90<br />

Hammerschmidt-Kamper, Christiane ......................................725<br />

Hampson, David R. ...........................................................................390<br />

Hamzaoui-Nord, Silke .....................................................................405<br />

Han, Hye-Eun ......................................................................................380<br />

Han, Jingfen..........................................................................................248<br />

Han, Joohee ................................................................................408, 414<br />

Han, Joohee ................................................................................705, 742<br />

Han, Jun-Ming .....................................................................................720<br />

Han, Moon-Hee ..................................................................................143<br />

Han, Na ..................................................................................................151<br />

Han, Sang W. ................................................................... 265, 582, 658<br />

Han, Sung Yeol ....................................................................................375<br />

Han, Su-Youne .....................................................................................722<br />

Han, Zongchao ....................................................................................344<br />

Handy, Chalonda R. ...........................................................................287<br />

Hannigan, Timothy ...........................................................................611<br />

Hansen, C. .............................................................................................708<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

153


Abstract Author Index<br />

Hansen, Gesine ......................................................................................84<br />

Hanson, Leah R. .................................................................................364<br />

Haodi, A. ................................................................................................682<br />

Happle, Christine ..................................................................................84<br />

Harbottle, Richard P. ..............................................................346, 354<br />

Hardcastle, Jayson J. ................................................................. 23, 641<br />

Harding, Cary O. .................................................................................354<br />

Harding-Smith, Rebekka E. ...........................................................460<br />

Hareendran, Sangeetha ..................................................................331<br />

Harel, Asaff ...........................................................................................478<br />

Hargrove, Phillip W................................................................... 26, 424<br />

Harmon, John W. ................................................................................616<br />

Harper, Jane ................................................................................. 59, 508<br />

Harper, Scott ........................................................................................295<br />

Harper, Scott Q..........................................................................171, 182<br />

Harrington, Kevin ........................................................... 18, 395, 652<br />

Hart, Stephen L. ............................................................ 158, 434, 435<br />

Hartemink, Alexander J. .................................................................241<br />

Hartig, Jörg S. ......................................................................................554<br />

Hartmann, Lynn ....................................................................................17<br />

Hartweck, Linn ...................................................................................169<br />

Harvey, Brandon K. ...........................................................................382<br />

Hasegawa, Mamoru ..................................................... 237, 432, 442<br />

Hasegawa, Naoyuki ..........................................................................643<br />

Hashimoto, Tadafumi ......................................................................283<br />

Hashimoto-Tamaoki, Tomoko ............................................218, 638<br />

Haskins, Mark .....................................................................................360<br />

Haskins, Mark E. ...................................................................................87<br />

Haso, Waleed .......................................................................................325<br />

Hassan, Namir .......................................................................................59<br />

Hassan, Namir J. .................................................................................508<br />

Hata, Taishi ..........................................................................................749<br />

Hatley, Mark E. ....................................................................................566<br />

Hauck, Bernd.............................................................................529, 547<br />

Haugwitz, Michael ............................................................................532<br />

Haurigot, Virginia .............................................................................488<br />

Hauser, Michael ..................................................................................295<br />

Hauswirth, William W. ..............................55, 115, 223, 545, 596<br />

Havlicek, David F. .................................................................................11<br />

Hayashita-Kinoh, Hiromi .....................................................120, 608<br />

Haynes, Russell D. .............................................................................255<br />

He, Bo .....................................................................................................367<br />

He, Chenxia ..........................................................................................731<br />

He, Ran ....................................................................................4, 326, 512<br />

He, Xianghui ..............................................................................207, 404<br />

He, Zhijian ............................................................................................691<br />

Hearl, William G. ................................................................................186<br />

Hebeler, Robert ..................................................................................624<br />

Heczey, Andras ......................................................................................12<br />

Heffernan, Thomas P. .......................................................................503<br />

Heffner, Garrett C. ...................................................................251, 258<br />

Heffner, Garrett .....................................................................................37<br />

Heiland, Teri L. ...................................................................................186<br />

Heinz, Niels ................................................................................320, 429<br />

Heiss, Christian ..................................................................................369<br />

Heiss, Kirsten ......................................................................................725<br />

Heitfeld, Suzanne ..............................................................................270<br />

Heldermon, Coy D. ............................................................................332<br />

Heller, Glenn ...........................................................................................61<br />

Heller, Kristin N. ............................................................... 91, 172, 291<br />

Heller, Richard .......................................................................................99<br />

Hemming, Richard ............................................................................379<br />

Hemminki, Akseli ............................................... 501, 680, 704, 730<br />

Hendry, Jason ......................................................................................593<br />

Henley, Jill E. ........................................................................................183<br />

Henley, Jill ...................................................................................184, 487<br />

Henley, Tom .........................................................................................551<br />

Henson, Karissa .................................................................................500<br />

Hentzschel, Franziska .....................................................................725<br />

Heo, Jeong ........................................................................................ 19, 22<br />

Hergenrother, Paul J. ........................................................................403<br />

Hermann, Alex ....................................................................................655<br />

Hermetet, Gregory ...............................................................................50<br />

Hernandez, Frank J. ..........................................................................509<br />

Hernandez, Luiza I. ...........................................................................509<br />

Herschman, Harvey R. .....................................................................448<br />

Hershield, Michael ..........................................................................307<br />

Herzog, Roland W. .............................................. 109, 190, 446, 669<br />

Heslop, Helen E. ............................................................ 299, 305, 398<br />

Hess, Richard ......................................................................................437<br />

Hetzel, Miriam ....................................................................................429<br />

Hew, Paggy ...........................................................................................403<br />

154<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Hickey, Ray D. ......................................................................................579<br />

Hickman, Suzanne E. .......................................................................304<br />

Hickman, Theresa ................................................................................19<br />

Hicks, Martin J. ........................................................................... 11, 727<br />

High, Katherine A. ..................... 8, 110, 488, 498, 529, 547, 733<br />

Higuchi, Takashi.......................................................................365, 753<br />

Hilje, Roman ........................................................................................320<br />

Hillestad, Matthew L. .............................................................583, 748<br />

Hinderer, Christian J.........................................................................110<br />

Hirai, Yukihiko ....................................................................................601<br />

Hiramoto, Takafumi ............................................................................86<br />

Hiraoka, Kei ................................................................................. 70, 522<br />

Hirata, Roli ..............................................................................................81<br />

Hiriyanna, Suja ...................................................................................709<br />

Hironaka, Kohei .................................................................................601<br />

Hiroshima, Kenzo ..............................................................................216<br />

Hirsch, Matthew L. ............................................................................268<br />

Hirschberg, Henry ............................................................................220<br />

Hirst, Rob A. .........................................................................................435<br />

Hirvinen, Mari ....................................................................................501<br />

Hishikawa, Shuji ................................................................................121<br />

Hitt, Mary ..............................................................................................403<br />

Ho, Ivy A. W. .........................................................................................254<br />

Ho, Michelle .........................................................................................492<br />

Hoeben, Rob C. ...................................................................................313<br />

Hogrel, Jean-Yves ...............................................................................734<br />

Holczbauer, Agnes.............................................................................696<br />

Holditch, Sara J ...................................................................................746<br />

H<strong>of</strong>fman, Brad E. ................................................................................190<br />

H<strong>of</strong>fman, Lauren ................................................................................648<br />

Hoherr, Sean E. ........................................................................481, 583<br />

Hogarth, Michael ...............................................................................161<br />

Hogg, Claire ..........................................................................................435<br />

Holczbauer, Agnes.............................................................................531<br />

Holder, Melanie N. ................................................................................33<br />

Hole, Patrick ........................................................................................264<br />

Holley, Lenton .....................................................................................660<br />

Hollis, Roger P. ............................................................................ 26, 492<br />

Holmes, Michael C. .....................................46, 107, 183, 184, 486,<br />

.......................................................................... 487, 488, 504, 568, 678<br />

Holt, Robert A. ....................................................................................115<br />

Holy, Jon ................................................................................................657<br />

Holzbaur, Erika L. F. ..........................................................................116<br />

Hom, Kellie ..............................................................................................44<br />

Hoon, Pak Seoung .............................................................................699<br />

Hope, Bruce T. .....................................................................................382<br />

Horkay, Iren .........................................................................................147<br />

Horvath, Staci .....................................................................................479<br />

Hosseini, Sayed Mohammd ...........................................................616<br />

Hotta, Akitsu .............................................................................357, 715<br />

Houghton, Frank ................................................................................239<br />

Howard, Carolann .............................................................................110<br />

Howard, Douglas B. ..........................................................................382<br />

Howe, Annett .........................................................................................48<br />

Howe, Steven J. .............................................................. 434, 435, 678<br />

Howell, Craig A. ..................................................................................509<br />

Howes, Rob ..........................................................................................245<br />

Hoxie, James A. ......................................................................................46<br />

Hoyos, Valentina ......................................................................392, 394<br />

Hoyos, Valentina ................................................................................684<br />

Hsieh, Matthew .......................................................................... 30, 428<br />

Hsieh, Pei-fang ....................................................................................723<br />

Hsu, David ..................................................................................474, 476<br />

Hu, Chuhong ........................................................................................497<br />

Hu, Huimin ...........................................................................................702<br />

Hu, Jim....................................................................................................433<br />

Hu, Ruozhen ........................................................................................712<br />

Hu, Yun...................................................................................................550<br />

Hu, Zebin ...............................................................................................555<br />

Hua, Giau ...............................................................................................474<br />

Hua, Kevin L............................................................................................46<br />

Huang, George ....................................................................................285<br />

Huang, Jeremiah ................................................................................287<br />

Huang, K.W. ..........................................................................................682<br />

Huang, Liang .......................................................................................457<br />

Huang, Patricia .........................................................................474, 476<br />

Huang, Wenlin ....................................................................................194<br />

Huang, Yuping.....................................................................................574<br />

Huard, Johnny ........................178, 179, 250, 281, 290, 611, 614<br />

Hubbard, S. M. ........................................................................................40<br />

Huch, Meritxell ......................................................................................85<br />

Hudecek, Michael ..............................................................................744<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

155


Abstract Author Index<br />

Hudry, Eloise .............................................................................283, 540<br />

Hudson, J. A. ............................................................................................40<br />

Huffaker, Thomas B. .........................................................................712<br />

Hughes, Jonathan ....................................................................507, 561<br />

Hui, Daniel H. ......................................................................................110<br />

Huls, Helen ...........................................10, 198, 431, 502, 649, 650<br />

Hulsker, Margriet ..............................................................................609<br />

Humbert, L. ..........................................................................................694<br />

Hung, Chien-Ya ...................................................................................723<br />

Hung, Ming-Chuan ............................................................................723<br />

Hung, Tsuing-Jeu ...............................................................................723<br />

Hunter, David W. ................................................................................102<br />

Hurton, Lenka V. ......................................................................502, 621<br />

Hurwitz, Brian ....................................................................................747<br />

Hurwitz, Mary Y. ................................................................................131<br />

Hurwitz, Richard L. ..........................................................................131<br />

Hussain, Syed-Rehan A. ..................................................................171<br />

Hustedt, Jason ........................................................................................44<br />

Huston, Marshall W. ...............................................................275, 521<br />

Hutnick, Natalie A. ...............................................................................45<br />

Hutnick, Natalie .................................................................................341<br />

Hwang, M. ................................................................................................40<br />

Hwang, Misako ........................................................................... 36, 592<br />

Hwang, Tae-Ho .............................................................................. 19, 22<br />

Hwang, Yihharn .................................................................................106<br />

Hwu, Patrick ........................................................................................270<br />

Hwu, Wuh-Liang ........................................................................ 60, 376<br />

Hyang, Kim Ji .......................................................................................699<br />

Hyde, Stephen C. ................................................................................460<br />

Hyland, Kendra A. .............................................................................102<br />

Hyman, Bradley T. .............................................................................283<br />

Hyman, Bradley .................................................................................540<br />

Hyodo, Ichinosuke ............................................................................643<br />

Iankov, Ianko D. ..................................................................................641<br />

Iankov, Ianko .......................................................................................417<br />

Ibanez, Carlos .....................................................................................676<br />

Ibañez, Carlos .....................................................................................703<br />

Ida, Hiroyuki ........................................................................................365<br />

Ida, Hiroyuki ........................................................................................753<br />

Idirene, Idir ..........................................................................................399<br />

Ido, Hiroyuki .......................................................................................651<br />

Igarashi, Tsutomu .............................................................................228<br />

Iglesias, Diana .....................................................................................247<br />

Ihara, Hirotaka ...................................................................................150<br />

Iijima, Osamu ......................................................................................228<br />

Iinuma, Shin............................................................................................80<br />

Iizuka, Sayoko .....................................................................................365<br />

Ikawa, Eriko ............................................................................................80<br />

Ikawa, Yasuhiro ..................................................................................437<br />

Ikeda, Hiroaki ........................................................................................16<br />

Ikeda, Yasuhiro ......................................................................................68<br />

Ikeda, Yasuhiro .........................................................................726, 746<br />

Ikemoto, Tomokazu ..........................................................................121<br />

Ilett, Elizabeth .......................................................................................18<br />

Ilia, Fishbein ........................................................................................144<br />

Ilmarinen, T .........................................................................................732<br />

Imbrogno, Kara ..................................................................................290<br />

Imbrogno, Kayla ................................................................................611<br />

Impey, Helen ...........................................................................................48<br />

Inagaki, Aki ..........................................................................................703<br />

Inagaki, Akihito .......................................................................... 70, 522<br />

Ingham, Sheila J. M............................................................................265<br />

Inoue, Hiroyuki ......................................................69, 432, 440, 442<br />

Inoue, Makoto ................................................................ 237, 432, 442<br />

Inoue, Tomoko ....................................................................................442<br />

Iqball, Sharifah ......................................................................................56<br />

Irons, Eric E. ........................................................................................477<br />

Ishibashi, Hidetoshi .........................................................................120<br />

Ishii, Masaru ...........................................................................................80<br />

Islam, Saleem .........................................................................................57<br />

Ito, Hiroshi ...........................................................................................627<br />

Ito, Tomoko ..........................................................................................627<br />

Ivan, Alferiev S. ...................................................................................144<br />

Ivanovska, Irena I. .............................................................................523<br />

Ivics, Zoltan ..........................................................................................347<br />

Iwamoto, Takeo ..................................................................................585<br />

Iyombe, Jean-Paul ...................................................................293, 389<br />

Izsvak, Zsuzsanna .............................................................................347<br />

Izuka, Sayoko ......................................................................................585<br />

Jackson, Mark W.................................................................................276<br />

Jackson, Rineka .....................................................................................10<br />

Jacob, Aurélien ......................................................................................52<br />

156<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Jacobs, Edwin H. ................................................................................275<br />

Jagadeesh, Jayashree ........................................................................307<br />

Jäger, Dirk ...................................................................................405, 639<br />

Jahr, Holger ..........................................................................................275<br />

Jakobsen, Bent ....................................................................................508<br />

Jakobsen, Bent K. ....................................................................... 59, 298<br />

Jamet, Thibaud ....................................................................33, 90, 605<br />

Janas, Michelle L. ...............................................................................209<br />

Jang, Jae-Hyung ....................................................................................... 3<br />

Janssen, Paul M. L. .............................................................................291<br />

Janumala, Hadassah .........................................................................160<br />

Jares, Alexander ....................................................................................29<br />

Jarjour, Jordan ................................................................ 188, 193, 318<br />

Jaulin, Nicolas .....................................................................................111<br />

Javier, Francisco .................................................................................678<br />

Jay, Christopher M. ................................... 206, 272, 464, 510, 625<br />

Jayandharan, Giridhara R....................................................114, 328,<br />

................................................................331, 337, 536, 537, 542, 549<br />

Jena, Bipulendu .....................................................................................10<br />

Jensen, Michael C. ..............................................................................744<br />

Jensen, S ................................................................................................682<br />

Jeon, Daejong ......................................................................................602<br />

Jeong, Eu <strong>Gene</strong> ....................................................................................565<br />

Jeong, Hwa Yeon ................................................................................159<br />

Jeong, Ji Hoon ............................................................................349, 572<br />

Jerome, Keith R. ............................................................ 187, 188, 193<br />

Jessup, John M. ...................................................................................217<br />

Ji Hoon, Jeong ......................................................................................573<br />

Ji, Qingzhou ..........................................................................................243<br />

Jiang, Shuxia ........................................................................................511<br />

Jiang, Wei ..............................................................................................194<br />

Jiang, Yuanyuan ..................................................................................216<br />

Jiang, Yuhang .......................................................................................691<br />

Jiang, Zhong .........................................................................................512<br />

Jiang, Ziyue Karen .............................................................................215<br />

Jiao, L.R. .................................................................................................682<br />

Jie, Feilong ..................................................................................221, 563<br />

Jimenez-Orozco, Alejandro ...........................................................564<br />

Jin, Sheng-Yu ........................................................................................312<br />

Jing, Yuqi ...............................................................................................637<br />

Joglekar, Alok V. ........................................................................492, 571<br />

Johana, Nuryanti ......................................................................363, 580<br />

Johnson, Aaron ......................................................................................23<br />

Johnson, Aime K. ....................................................36, 377, 590, 592<br />

Johnson, Christopher .......................................................................660<br />

Johnson, J. A. ...........................................................................................40<br />

Johnson, Larry G. ...............................................................................439<br />

Johnson, Mai ........................................................................................215<br />

Johnston, Jennifer M. .......................................................................528<br />

Johnston, Sandra K. .............................................................................25<br />

Jolly, Douglas J...........................................................................676, 703<br />

Jone, Takako ...........................................................................................93<br />

Jones, Jeanne .......................................................................................351<br />

Jones, Pamela ......................................................................................139<br />

Jones, Steven J. M. ..............................................................................115<br />

Jones, Tara ............................................................................................473<br />

Jonlin, Erica .............................................................................................27<br />

Jordon, Andrea P. ..................................................................................46<br />

Joséphine, Charlène .........................................................................225<br />

Joseph, Glorioso C. ............................................................................416<br />

Joseph, Lauren ....................................................................................656<br />

Jossot, Laurent....................................................................................399<br />

Jost, Laurent ........................................................................................261<br />

Joubert, Romain ..............................................33, 90, 240, 605, 606<br />

Joung, J. Keith ............................................................................490, 738<br />

Jubeli, Emile .........................................................................................755<br />

Juckem, Laura .....................................................................................454<br />

Jund, Michelle D. ................................................................................270<br />

June, Carl H. .............................................................59, 298, 508, 623<br />

Jung, Hyesook .....................................................................................151<br />

Jung, Keun-Hwa ............................................................ 143, 598, 602<br />

Jung, Seungmoon ...............................................................................602<br />

Jung, Ulrike ..........................................................................................456<br />

Kabadi, Ami M. .........................................................................170, 491<br />

Kabanov, Alexander V. ...........................................................691, 693<br />

Kabasakal, Levent .............................................................................452<br />

Kaeppel, Christine.............................................................................274<br />

Kaestner, Klaus ...................................................................................581<br />

Kagele, Dominique A. ......................................................................712<br />

Kahn, Jason .............................................................................................44<br />

Kakarla, Sunitha.................................................................................400<br />

Kalaivani, V. ................................................................................536, 537<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

157


Abstract Author Index<br />

Kaler, Stephen G. ......................................................................383, 586<br />

Kaliberov, Sergey A. ..........................................................................560<br />

Kaliberova, Lyudmila N. .................................................................560<br />

Kalinin, N. .............................................................................................724<br />

Kalle, Christ<strong>of</strong> von .............................................................................210<br />

Kalos, Michael ................................................................... 59, 298, 508<br />

Kalra, Mamta .......................................................................................396<br />

Kamijima, Shuichi ..................................................................... 70, 522<br />

Kaminoh, Yuuki J. ..............................................................................180<br />

Kühn, Anna Luisa ..............................................................................387<br />

Kaminsky, Stephen M. ...............................11, 106, 373, 589, 727<br />

Kan, Shih-hsin .....................................................................................586<br />

Kanaan, Nicholas M. .........................................................................596<br />

Kaneda, Yasuhumi ...............................................................................80<br />

Kaneshiro, Kayleigh .........................................................................709<br />

Kang, Dae Hwang .................................................................................22<br />

Kang, Elizabeth ..................................................................................308<br />

Kang, Eunah .........................................................................................634<br />

Kang, Kevin ..........................................................................................574<br />

Kang, Robert ........................................................................................290<br />

Kang, Soyeong ....................................................................................375<br />

Kankaldyyan, Vazgen .......................................................................648<br />

Kannan, Vivekanandan ...................................................................508<br />

Kao, Chinghai .........................................................................................70<br />

Kapoor, Neena ....................................................................................307<br />

Kapp, Kerstin ......................................................................................686<br />

Kapranov, Philipp ..............................................................................681<br />

Karikó, Katalin ..........................................................................146, 147<br />

Karlen, Andrea D. ..............................................................................495<br />

Karli, Eerika .........................................................................................501<br />

Karponi, Garie........................................................................................61<br />

Karponi, Garyfalia ..................................................................... 27, 427<br />

Kasahara, Noriyuki ...... 70, 218, 522, 530, 638, 676, 682, 703<br />

Kasahara, Yuko N. ..............................................................................176<br />

Kashiwakura, Yuji ..............................................................................237<br />

Kaspar, Roger ......................................................................................652<br />

Kassner, Paul .............................................................................339, 550<br />

Katakowski, Joseph ..........................................................................205<br />

Kataoka, Kazunori ............................................................................350<br />

Kato, Kazunori ....................................................................................216<br />

Katz, Michael G. ..................................................................................374<br />

Kaufman, Michael L. ............................................................................26<br />

Kaufmann, Johanna K. .....................................................................554<br />

Kaufmann, Kerstin B. ..........................................................................66<br />

Kaur, Balveen ............................................................................409, 747<br />

Kauss, M. Ariel ....................................................................................542<br />

Kawabata, Masato ...................................................................192, 654<br />

Kawalekar, Omkar U. ........................................................................623<br />

Kawamura, Kiyoko ............................................................................216<br />

Kawano, Yasuhiro.................................................................................78<br />

Kawashima, Rei ..................................................................................643<br />

Kay, Mark A. ........................................... 7, 191, 271, 277, 343, 436<br />

Kaye, Frederic J. .................................................................................335<br />

Kean, Leslie ..........................................................................................650<br />

Kearns-Jonker, Mary ........................................................................468<br />

Kebriaei, Partow ...................................................................................10<br />

Keech, Naomi .........................................................................................48<br />

Keilman, George W. ..........................................................................140<br />

Kelleher, Michelle ..............................................................................232<br />

Kells, Adrian P. ............................................................... 288, 594, 599<br />

Kemp, C. J. .............................................................................................381<br />

Kemp, Christopher H. ......................................................................386<br />

Kennedy, Douglas R. .........................................................................311<br />

Kenny, Gavin D. ...................................................................................158<br />

Keramaris, Elizabeth .......................................................................296<br />

Kesari, Santosh ...................................................................................676<br />

Keshavjee, Shaf ...................................................................................433<br />

Ketzer, Patrick .....................................................................................554<br />

Khalique, Nada Abdul ......................................................................755<br />

Khan, Amir S. ..................................................................... 45, 341, 397<br />

Khan, Iram .......................................................................... 32, 318, 673<br />

Khargharia, Sanjib ...............................................................................41<br />

Khati, Makobetsa ...............................................................................189<br />

Khattak, Shahryar .............................................................................322<br />

Khayter, Cyd .........................................................................................490<br />

Khokher, Zeshan ......................................................................152, 620<br />

Khosravi-Far, R. .....................................................................................15<br />

Kicenuik, Kristin ................................................................................139<br />

Kichaev, Gleb .......................................................................................153<br />

Kiem, Hans-Peter ........................................25, 249, 311, 421, 673<br />

Kienle, Eike ................................................................................122, 123<br />

Kikuchi, Yasuhi .....................................................................................80<br />

158<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Kildebeck, Eric ..........................................................................324, 489<br />

Kim, Byung Sun ..................................................................................602<br />

Kim, Chang Won ...................................................................................19<br />

Kim, Dae Wook ...................................................................................138<br />

Kim, Dae-Sung ....................................................................................593<br />

Kim, Dong-Eun ...................................................................................159<br />

Kim, Hak Kyun ....................................................................................436<br />

Kim, Hyesung ......................................................................................256<br />

Kim, Hyun Ah ......................................................................................717<br />

Kim, Hyun .............................................................................................703<br />

Kim, Jaesung ..............................................................................640, 645<br />

Kim, Jane ..................................................................................................42<br />

Kim, Jeong-Min .............................................................. 143, 598, 602<br />

Kim, Ji Hyang .......................................................................................722<br />

Kim, Jin Tac ..........................................................................................722<br />

Kim, Jin-Hee .........................................................................................598<br />

Kim, Joon-Hyung ..................................................................................75<br />

Kim, Joseph J. ........................................................................................... 9<br />

Kim, Kenneth ............................................................................183, 487<br />

Kim, Keun-Sik .....................................................................................159<br />

Kim, Kwang S. .....................................................................................756<br />

Kim, Manho ................................................................................143, 602<br />

Kim, Marie ............................................................................................287<br />

Kim, Mi Kyung ........................................................................................22<br />

Kim, Mikyung ......................................................................................151<br />

Kim, Minjung .......................................................................................645<br />

Kim, Na Hyung ....................................................................................711<br />

Kim, Nak Won ...........................................................................349, 572<br />

Kim, Pyung-Hwan .............................................................................645<br />

Kim, Seung Geun...................................................................................22<br />

Kim, Seung U. ......................................................................................756<br />

Kim, So-Yoon ........................................................................................598<br />

Kim, Su Jeong ......................................................................................138<br />

Kim, Sung Wan .............................................................. 634, 640, 645<br />

Kim, Sung Wan .........................................................................685, 717<br />

Kim, Tae Won ......................................................................................565<br />

Kim, Tae-il ............................................................................................645<br />

Kim, Taekyun ......................................................................................151<br />

Kim, Yoon Jun ......................................................................................233<br />

Kim, Yoon S. .........................................................................................672<br />

Kimura, Takahiro ..................................................................................70<br />

Kincaid, Tiffany ..................................................................................529<br />

Kinchington, Paul R. .........................................................................591<br />

King, Christiaan D. ...............................................................................43<br />

King, Glenn ...........................................................................................139<br />

King, Oliver .............................................................................................93<br />

Kinnon, Christine ..............................................................................678<br />

Kinoh, Hiromi H. ................................................................................176<br />

Kipps, Thomas H. ..............................................................................502<br />

Kirn, David H. ................................................................................. 19, 22<br />

Kiroyan, Jason B. ................................................................................468<br />

Kishnani, Priya ...................................................................................276<br />

Kitagawa, Koichi ................................................................................192<br />

Kitaura, Kumiko .................................................................................150<br />

Kitchen, Scott G. ....................................................................................48<br />

Kizzire, Koby ..........................................................................................41<br />

Kleuss, Christiane .............................................................................686<br />

Klimczak, Ryan R. ................................................................................... 5<br />

Klingelhutz, Aloysius .......................................................................587<br />

Kloss, Christopher C. ........................................................................728<br />

Knight, Scott W. ..................................................................................243<br />

Knott, Christine ..................................................................................153<br />

Knovich, Mary Ann ...........................................................................253<br />

Knox, Van W. ...........................................................................................87<br />

Knutson, Keith ............................................................................ 17, 652<br />

Kobayashi, Hiroshi ..................................................................365, 585<br />

Kobayashi, Hiroshi ............................................................................753<br />

Kobayashi, Masao .................................................................................86<br />

Kobinger, Gary P. ................................................................................379<br />

Kocak, E. ................................................................................................695<br />

Koch, Walter ........................................................................................444<br />

Kochanek, Stefan .....................................................................126, 484<br />

Koeberl, Dwight D. ..................................................................276, 618<br />

K<strong>of</strong>ie, Robert M. ................................................................................283<br />

Kohn, Donald B.............................................26, 307, 492, 494, 571<br />

Kohnke, Monica .................................................................................224<br />

Kolarich, Andrew R. .........................................................................332<br />

Koldej, Rachel ........................................................................................48<br />

Komori, Junji ..........................................................................................79<br />

Konopka, Krystyna ...........................................................................576<br />

Koo, Taeyoung ....................................................................................734<br />

Koon, E. Colin ......................................................................................503<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

159


Abstract Author Index<br />

Kopin, Etana ........................................................................................542<br />

Kornegay, Joe ..........................................................................................92<br />

Kortum, Amanda ...............................................................................419<br />

Kosasih, Paula .....................................................................................744<br />

Kostomitsopoulos, N. .......................................................................682<br />

Kottke, Timothy .....................................................18, 395, 505, 652<br />

Kotton, Darrell N. ..............................................................................107<br />

Kovacs, Krisztina ...............................................................................637<br />

Koya, Richard C. .................................................................................302<br />

Koyama, Yoshiyuki ............................................................................627<br />

Kozarsky, Karen .................................................................................364<br />

Kozlowski, Merek ..............................................................................418<br />

Kozlowski, Miroslaw ........................................................................236<br />

Kozyak, Benjamin..............................................................................391<br />

Kraeusslich, Hans-Georg ......................................................123, 514<br />

Kramer, Philipp ..................................................................................107<br />

Krammer, Peter H. .............................................................................204<br />

Kraus, Jan P. .........................................................................................583<br />

Krauss, Jürgen........................................................................................21<br />

Kreader, Carol A. ................................................................................243<br />

Kreppel, Florian ............................................................ 126, 134, 484<br />

Krishnagopal, Akshaya .........................................................331, 337<br />

Krishnamoorthy, Janani..................................................................431<br />

Krishnan, Aparna ..............................................................................476<br />

Krouse, Allen ............................................................................... 30, 428<br />

Kruck, Christa .....................................................................................379<br />

Krutzke, Lea ...............................................................................126, 484<br />

Kubo, Shuji ...................................................................... 216, 218, 638<br />

Kucharski, Cezary .............................................................................162<br />

Kuhn, Joseph .............................................. 199, 402, 503, 624, 625<br />

Kuhn, N. C .............................................................................................381<br />

Kuhn, Nathan C. .................................................................................386<br />

Kuhn, Nathan M. ................................................................................596<br />

Kuivanen, Antti ......................................................................................97<br />

Kulikovskaya, Irina .................................................................298, 508<br />

Kulkarni, Aditya .................................................................................745<br />

Kumar, Padmasini .........................199, 203, 206, 272, 317, 402,<br />

.................................................................................... 503, 624, 625, 633<br />

Kumar, Priti ..........................................................................................238<br />

Kumar, Sanjay .....................................................................................754<br />

Kumaresan, Pappanaicken ............................................................431<br />

Kumari, Monika..................................................................................549<br />

Kume, Akihiro ...........................................................................121, 651<br />

Kunkel, Hana ..........................................................................................66<br />

Kunkel, Louis M. ....................................................................................93<br />

Kuo, Chung-Jung ................................................................................253<br />

Kuo, Jennifer ........................................................................................215<br />

Kurosawa, Yoshikazu .......................................................................629<br />

Kurtzberg, Joanne ................................................................................62<br />

Kustikova, Olga S. ..............................................................................425<br />

Kutner, Robert ........................................................37, 251, 258, 674<br />

Kutner, Robert H. .....................................................................260, 262<br />

Kutschera, Ina .....................................................................................279<br />

Kuzmina, L............................................................................................724<br />

Kwak, Larry W. ...................................................................................626<br />

Kwiatkowski, Stanislaw ..................................................................714<br />

Kwon, Churl-Su ...................................................................................387<br />

Kwon, Minjung ...................................................................................151<br />

Kwon, Oh-Joon ....................................................................................634<br />

Kwon, Young Jik ............................................................... 42, 163, 220<br />

Kwong, King F. ....................................................................................513<br />

Kyba, Michael ............................................................................168, 169<br />

Kyeong, Lee Hyeon ...........................................................................699<br />

Kyuri, Lee ..............................................................................................573<br />

Lachmann, Nico ............................................................... 84, 320, 429<br />

Lad, Yatish ............................................................................................232<br />

Ladd, Bryan M. ....................................................................................102<br />

Laer, Dorothee von ...........................................................................195<br />

Lagasse, Eric ...........................................................................................79<br />

Lagresle-Peyrou, Chantal .....................................................313, 661<br />

Lai, Charles P. ......................................................................................103<br />

Lai, May C. ................................................................................................54<br />

Lai, Zhaohui .........................................................................................207<br />

Lake, John R. ........................................................................................102<br />

Lakshmipathy, Uma ..........................................................................244<br />

Lalezari, Jay .............................................................................................58<br />

Lam, Paula YP .....................................................................................254<br />

Lamb, Lawrence ................................................................................587<br />

Lamont, Jeffrey ...................................................................................624<br />

Landoli, Joseph .................................................................................676<br />

Landry, Breanne ................................................................................462<br />

Langlet-Bertin, Bérangère ................................................................52<br />

160<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Lankester, Arjen C. ............................................................................313<br />

Lapointe, M-O. ....................................................................................694<br />

Laprise, Stephanie ............................................................................115<br />

Lapteva, Natalia ....................................................................................14<br />

Larcher, Fernando .............................................................................347<br />

Larcher, Thibaut ................................................................................111<br />

Larochelle, Andre .................................................................................65<br />

Larosa, Fabrice ...................................................................................399<br />

Larsen, Helfe .......................................................................................755<br />

Latella, Maria Carmela ....................................................................347<br />

Lau, K.-H William ..............................................................................468<br />

Lauer, Anthony ...................................................................................454<br />

Laufs, Stephanie .......................................................................210, 518<br />

Laurent, Louise ..................................................................................465<br />

Lawlor, Michael W. .................................................................... 33, 605<br />

Lawlor, Michael .......................................................................... 90, 473<br />

Lawrence, Roger ................................................................................448<br />

Lawson, Lee Ann ..................................................................................57<br />

Lay, Frank .............................................................................................616<br />

Lazar, Daniel ........................................................................................189<br />

Lazarski, Christopher A. .................................................................737<br />

Le Clerre, Diane ..................................................................................401<br />

Le Guiner, Caroline .................................................................111, 734<br />

Le Roy, Florence .................................................................................294<br />

Le, Mickaël ...........................................................................................240<br />

Le, Steven Q..........................................................................................586<br />

Leaver, T. ................................................................................................708<br />

Lebel, Carl ................................................................................................83<br />

Leber, Mathias F. ................................................................................639<br />

Lebrun, J-J. ............................................................................................694<br />

Lebuhotel, Céline .....................................................................401, 683<br />

Lecomte, Christophe ...........................................................................52<br />

Lecomte, Emilie ....................................................................................76<br />

Ledent, Philippe .................................................................................261<br />

Lee, Albert ............................................................................................472<br />

Lee, Allyson ..........................................................................................283<br />

Lee, Amy ...................................................................................................44<br />

Lee, Brendan .............................................................................128, 607<br />

Lee, Bum Sup ......................................................................................565<br />

Lee, Dahye ............................................................................................238<br />

Lee, Daniel W. ......................................................................................325<br />

Lee, Dean A. .........................................................................................621<br />

Lee, Dean ..............................................................................................431<br />

Lee, Donghoon ....................................................................................443<br />

Lee, Doo Sung .....................................................................................640<br />

Lee, Edward .........................................................................................229<br />

Lee, Ellen K. .........................................................................................497<br />

Lee, Gary K. .............................................................................................58<br />

Lee, Gary ...............................................................................................183<br />

Lee, Gwang-Hyun ..............................................................................159<br />

Lee, Hong J. ..........................................................................................756<br />

Lee, Hyeon Kyeong ...........................................................................722<br />

Lee, Hyeon Youl ..................................................................................138<br />

Lee, Hyun Woo ...................................................................................722<br />

Lee, J. .......................................................................................................708<br />

Lee, Jae Chul ........................................................................................710<br />

Lee, Janet ..............................................................................................308<br />

Lee, Jangwook .....................................................................................238<br />

Lee, Jihyun ............................................................................................623<br />

Lee, Jong Young ..................................................................................143<br />

Lee, Jun Woo ...........................................................................................22<br />

Lee, Jung Eun.......................................................................................572<br />

Lee, Jung-Sun ......................................................................................130<br />

Lee, Ki Jeong ..............................................................................339, 550<br />

Lee, Kuen Yong ...................................................................................238<br />

Lee, Kwan Hee ....................................................................................565<br />

Lee, Kyung-Mi .....................................................................................654<br />

Lee, Kyuri ..............................................................................................349<br />

Lee, Lily .................................................................................................532<br />

Lee, Min Sang ............................................................................349, 572<br />

Lee, Minhyung ..........................................................................685, 717<br />

Lee, Narae .............................................................................................195<br />

Lee, Ni-Chung .............................................................................. 60, 376<br />

Lee, Sang Kun ............................................................................143, 602<br />

Lee, Sang-Kyung.................................................................................238<br />

Lee, Soonhee .......................................................................................151<br />

Lee, Soon-Tae ................................................................. 143, 598, 602<br />

Lee, Tao-Chen .....................................................................................723<br />

Lee, Won Jai .........................................................................................130<br />

Lee, Yeon Sook .......................................................................................19<br />

Lee, Youngsook...................................................................................685<br />

Lee, Yu Kyung .........................................................................................22<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

161


Abstract Author Index<br />

Leen, Ann ..............................................................................................396<br />

Leen, Ann M. ........................................................................................398<br />

Leger, Adrien ..........................................................................................76<br />

Leger, Andrew J. .................................................................................453<br />

Léger, Thibaut .....................................................................................612<br />

Legg, Alison..........................................................................................508<br />

Lei-butters, Diana CM......................................................................535<br />

Lemaire, Laetitia ................................................................................401<br />

Lemoine, Nicholas ............................................................................561<br />

Lemoine, Nicholas R. .......................................................................507<br />

Lenarsky, Carl .....................................................................................203<br />

Leng, Qixin ..............................................................................................44<br />

Leo, Simone ...............................................................................309, 517<br />

Lerch, Thomas F. ................................................................................336<br />

Leroy, Stanley G. .................................................................................592<br />

Leslie, George J. .....................................................................................46<br />

Lesueur, Léa L. ....................................................................................148<br />

Letteri, Rachel .....................................................................................157<br />

Leung, A. ................................................................................................708<br />

Leung, Kitty .........................................................................................433<br />

Levin, Bernard R. ..................................................................................48<br />

Levine, Bruce L. ................................................................ 59, 298, 508<br />

Levy, Matthew.....................................................................................205<br />

Levy, Robert J. ................................................................ 144, 366, 372<br />

Levy, Robert .........................................................................................374<br />

Levy, Seth G. .........................................................................................548<br />

Li, Baozheng ..............................................................................541, 542<br />

Li, Brian ....................................................................................................29<br />

Li, Fanying ...............................................................................................99<br />

Li, Feng ...................................................................................................345<br />

Li, Haitang ............................................................................................668<br />

Li, Hojun ................................................................................................488<br />

Li, Hongmei ..........................................................................................715<br />

Li, Hongtao ...........................................................................................406<br />

Li, Hongwei ..................................................................... 221, 533, 563<br />

Li, Huapeng ............................................................................................... 4<br />

Li, Jia ........................................................................................4, 326, 512<br />

Li, Jianbin ....................................................................................367, 370<br />

Li, Jing.....................................................................................................155<br />

Li, Jinlong ..............................................................................................221<br />

Li, Juan .............................................................................. 367, 370, 449<br />

Li, Leping ..............................................................................................242<br />

Li, Li B. ...................................................................................................266<br />

Li, Liyuan ..............................................................................................136<br />

Li, Mengxin ............................................................................4, 128, 326<br />

Li, Pengpeng ........................................................................................255<br />

Li, Pingjuan ..........................................................................................467<br />

Li, Shaoyong .........................................................................4, 128, 326<br />

Li, Shulin ...............................................................................................139<br />

Li, Songtao ............................................................................................618<br />

Li, Tianbai .............................................................................................533<br />

Li, Tiansen ............................................................................................709<br />

Li, Wei .....................................................................................................752<br />

Li, Wenpeng .........................................................................................195<br />

Li, Xiaodan ............................................................................................404<br />

Li, Xiaomiao ...............................................................................328, 542<br />

Li, Xiaoming .........................................................................................664<br />

Li, Xuan S...............................................................................................107<br />

Li, Yan .....................................................................................................129<br />

Li, Yi ........................................................................................................640<br />

Li, Yonghai ............................................................................................529<br />

Li, Zongyi ..............................................................................................729<br />

Liadi, Ivan .............................................................................................393<br />

Liang, Zhibing .....................................................................................533<br />

Liao, Sophia H. Y. ................................................................................356<br />

Liao, Wei ................................................................................................107<br />

Lidonnici, Maria Rosa ......................................................................420<br />

Lieber, Andre .................................................13, 201, 303, 483,552,<br />

.......................................................................... 679, 680, 689, 704, 729<br />

Lifshitz, Samuel ..................................................................................503<br />

Liikanen, Ilkka ....................................................................................730<br />

Lim, In J. .................................................................................................756<br />

Lin, Amy ......................................................................................676, 703<br />

Lin, Chi-Chen .......................................................................................348<br />

Lin, Michael Z. .....................................................................................255<br />

Lin, P. .......................................................................................................708<br />

Lin, Yanni ....................................................................................489, 567<br />

Lin, Yun ........................................................................................339, 550<br />

Lin, Ziguang .........................................................................................474<br />

Lindqvist, Johan M. ...........................................................................173<br />

Lindsay, Cory R. ..................................................................................324<br />

Linette, Gerald P. ........................................................................ 59, 508<br />

162<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Ling, Changquan ....................................................75, 118, 314, 328<br />

Ling, Chen ........................ 75, 118, 314, 328, 333, 334, 541, 542<br />

Lipinski, Daniel M. ............................................................................229<br />

Lipshutz, Gerald S. ..................................................................497, 571<br />

Lipton, Jack W. ....................................................................................386<br />

Lisowski, Leszek .................................................................7, 191, 277<br />

Litterman, Adam J. ............................................................................270<br />

Little, Dianne .......................................................................................276<br />

Litzky, Leslie ...........................................................................................59<br />

Liu, C. ......................................................................................................682<br />

Liu, Chao Lien .....................................................................................670<br />

Liu, Da<strong>of</strong>eng ............................................................................................12<br />

Liu, Dexi .......................................................................................242, 750<br />

Liu, Enli ..................................................................................................299<br />

Liu, Guei-Sheung ......................................................................230, 740<br />

Liu, Guihua ...........................................................................................473<br />

Liu, Hao .................................................................................................300<br />

Liu, Jian ..................................................................................................295<br />

Liu, Lingfeng ........................................................................................744<br />

Liu, Lixin ...............................................................................................616<br />

Liu, Mingyao ........................................................................................433<br />

Liu, Pingguo .........................................................................................208<br />

Liu, Shi-he ...................................................................................272, 659<br />

Liu, Shu-Fen .........................................................................................723<br />

Liu, X.X. ..................................................................................................682<br />

Liu, Xiang ..............................................................................................219<br />

Liu, Xiu Y. ...............................................................................................509<br />

Liu, Xiuying ..........................................................................................511<br />

Liu, Yanxin ............................................................................................752<br />

Liu, Yijia .................................................................................................455<br />

Liu, Yuli .....................................................................................................87<br />

Liu, Yu-Ping .............................................................................................20<br />

Liu, Zhongda ........................................................................................214<br />

Livingston, Justin ...............................................................................208<br />

Llewellyn, Nick .........................................................................184, 487<br />

Lo, Mandy .............................................................................................322<br />

Loeb, Keith R. ......................................................................................140<br />

Logan, Grant J. .....................................................................................356<br />

Logg, Christopher R. ...................................................... 70, 522, 703<br />

Lombardo, Angelo ....................................................... 469, 486, 504<br />

Lomeli-R, Christian Y. ......................................................................564<br />

Lonard, David M. ...............................................................................459<br />

Long, Harry .............................................................................................17<br />

Lopez, Patricia ....................................................................................476<br />

Lopez, Veronica M. ............................................................................635<br />

Lorain, Stéphanie ..............................................................................225<br />

Lorincz, Matthew ..............................................................................322<br />

Lostal, William.......................................................................................98<br />

Lothrop Jr, Clinton D. .......................................................................498<br />

Louis, Chrystal ....................................................................................396<br />

Low, Walter C. ...........................................................................364, 495<br />

Lu, Aiping ..................................................... 178, 179, 250, 290, 611<br />

Lu, Jiamiao ............................................................................................271<br />

Lu, Maomin ..........................................................................................533<br />

Lu, Pei Juan ..........................................................................................296<br />

Lu, Peijuan ............................................................................................451<br />

Lu, Qi Long .................................................................................296, 451<br />

Lu, Rong....................................................................................................29<br />

Lu, Taihe ................................................................................................671<br />

Lu, Yi .......................................................................................................136<br />

Lu, Yuan ............................................................................... 75, 118, 335<br />

Lu, Yuanqing ........................................................................................545<br />

Lu, Zhi Hong ........................................................................................560<br />

Lu, Zhuo-zhuang ......................................................................644, 729<br />

Lucas, Cherry ......................................................................................232<br />

Lucke, Colleen .......................................................................................... 9<br />

Luke, Jeremy ........................................................................................185<br />

Lum, Lawrence ...................................................................................711<br />

Luna Velez, María Victoria.............................................................330<br />

Lundberg, Cathryn ...............................................................................99<br />

Luo, Jie .........................................................................................221, 563<br />

Luo, Jun .....................................................................................................96<br />

Luo, Xianghua .....................................................................................414<br />

Luo, Yuxia .............................................................................................338<br />

Lüttge, Doreen .......................................................................................84<br />

Lutzko, Carolyn ..................................................................................426<br />

Lyde, Randolph ....................................................................................... 9<br />

Lydie, Guigand ....................................................................................111<br />

Lyle, Meghan .......................................................................................670<br />

Lythgoe, Mark F. .......................................................................158, 434<br />

Ma, Hsin-I .............................................................................................720<br />

Ma, Wenqin ................................................................................541, 542<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

163


Abstract Author Index<br />

Ma, Yongjie ...........................................................................................750<br />

Ma, Zhijun .............................................................................................671<br />

Mac, Helen ............................................................................................224<br />

MacAldaz, Margarita E. ...................................................................390<br />

MacDonald, Kelvin D. .......................................................................361<br />

Machen, Laurie .........................................................................141, 149<br />

Machluf, Marcelle ..............................................................................719<br />

Machuca, Tiago N. .............................................................................433<br />

Machuca-R, Catalina ........................................................................534<br />

Mack, David .........................................................................................473<br />

Mackall, Crystal L. .............................................................................325<br />

MacLaren, Robert E. .........................................................................229<br />

MacVicar, B. ..........................................................................................708<br />

Madinaveitia-V, Juan A. ...................................................................246<br />

Madoiwa, Seiji .....................................................................................121<br />

Madtes, David K. ................................................................................117<br />

Maeder, Morgan L. ............................................................................738<br />

Magee, Mitchell J. ...............................................................................624<br />

Maggio, Aurelio .....................................................................................61<br />

Magnani, Zulma..................................................................................504<br />

Magno, Aaron L. ....................................................................................54<br />

Maguire, A. ..............................................................................................53<br />

Maguire, Albert M. ..................................................................224, 227<br />

Maguire, Casey A. ......................................................... 103, 540, 751<br />

Maguire-Zeiss, Kathleen .................................................................457<br />

Mah, Cathryn S. .....................................................................................57<br />

Mahadevan, Lavanya ............................................................................. 9<br />

Mahajan, Vivek ...................................................................................693<br />

Mahdipoor, Parvin ............................................................................213<br />

Mahendravada, Aruna ............................................................. 49, 300<br />

Maiti, Sourindra N. ............................................................................626<br />

Maiti, Sourindra .......................................................................431, 502<br />

Maitland, Stacy ..........................................................1, 384, 387, 595<br />

Majka, Marcin .....................................................................................714<br />

Makkia, Rasha .....................................................................................344<br />

Malani, Nirav .............................................................................306, 310<br />

Male, Frances ......................................................................................310<br />

Malech, Harry L. ......................................................................... 82, 308<br />

Malerba, Alberto ................................................................................734<br />

Malik, Alock ................................................................................. 92, 391<br />

Malik, Punam ......................................................................................664<br />

Maltais, Chantale ..................................................................................83<br />

Malvilio, Fulvio ...................................................................................734<br />

Mamchaoui, Kamel ...........................................................................491<br />

Mandel, R. J. .........................................................................................381<br />

Mandel, Ronald J. .....................................................................386, 721<br />

Mandelli, Giacomo ............................................................................420<br />

Manfredsson, F. P. ..............................................................................381<br />

Manfredsson, Fredric P. ........................................................386, 596<br />

Mangena, Ramu .................................................................................551<br />

Maniati, Eleni ......................................................................................507<br />

Mann, Trenae ......................................................................................200<br />

Mannioui, Cécile Schiffer ...............................................................683<br />

Manoli, Irini .........................................................................................280<br />

Mao, Qin ................................................................................................512<br />

Mao, Sunnie .........................................................................................692<br />

Mao, Yingying .....................................................................................533<br />

Maples, Phillip B. ..................................... 199, 203, 206, 234, 272,<br />

....................... 352, 402, 464, 503, 510, 570, 577, 624, 625, 633<br />

Maranzano, Michael .........................................................................276<br />

Marchetti, Dario .................................................................................392<br />

Marcus, Nancy ....................................................................................211<br />

Mardini, Osama ..................................................................................103<br />

Marescau, Bart ...................................................................................497<br />

Margaritis, Paris ................................................................................733<br />

Margulies, Kenneth B. .....................................................................374<br />

Marinova, Ekaterina ............................................................................12<br />

Markert, Chad .....................................................................................473<br />

Marktel, Sarah ....................................................................................420<br />

Markusic, David .................................................................................669<br />

Markusic, David M. ...........................................................................109<br />

Marolleau, Beatrice .............................................................................76<br />

Marquez, Laura I. ...............................................................................466<br />

Marrocco, Elena .................................................................................539<br />

Mars, Wendy ........................................................................................611<br />

Marsh, A. ..................................................................................................15<br />

Marshall, K. .............................................................................................53<br />

Marsic, Damien ........................................................................335, 548<br />

Martell, L. A. ............................................................................................15<br />

Marti, Guy P. .........................................................................................616<br />

Martin, D. R. ............................................................................................40<br />

Martin, Daniel ........................................................................................57<br />

164<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Martin, Douglas R. .......................................36, 377, 387, 590, 592<br />

Martin, John .........................................................................................338<br />

Martin, Samia .......................................................................33, 90, 606<br />

Martinelli, Valentina ........................................................................368<br />

Martinez-F, Francisco ................................................. 246, 534, 564<br />

Maruyama, Kazuo ...................................................................142, 145<br />

Marzulli, Marco ........................................................................416, 566<br />

Massie, Bernard .................................................................................135<br />

Mastaglio, Sara ...................................................................................504<br />

Masurier, Carole ............................................................................ 33, 90<br />

Mata, Melinda .....................................................................................400<br />

Matalon, Reuben ...................................................................................35<br />

Matar, Majed ........................................................................................461<br />

Matern, Dietrich .................................................................................583<br />

Matrai, Janka .......................................................................................496<br />

Matrobattista, Enrico ......................................................................707<br />

Matsui, Hideto ....................................................................................357<br />

Matsumoto, Priscila K. ..........................................................582, 658<br />

Mattar, Citra .................................................................... 363, 430, 580<br />

Matthews, Carolyn M. ......................................................................503<br />

Mattoo, Abid ........................................................................................217<br />

Maus, Marcela V. ...................................................................................59<br />

Mavilio, Fulvio ............................................................................ 76, 347<br />

Maynard, Ryan ....................................................................................525<br />

Mays, Lauren E. .....................................................................................71<br />

Mazarakis, Nicholas D. .......................................................................67<br />

Mazzacurati, Lucia ..................................................................416, 566<br />

Mazzieri, Roberta ..............................................................................301<br />

McAnulty, Robin J. .............................................................................434<br />

McBride, Jodi .......................................................................................284<br />

McCaffrey, Anton P. ...........................................................................454<br />

McCart, Andrea ..................................................................................561<br />

McCarty, Douglas ..................................................................................39<br />

McCarty, Douglas M. ...............................................................125, 597<br />

McClure, Diane ...................................................................................461<br />

McCown, Thomas J. ..........................................................................112<br />

McCraw, Dustin ..................................................................................336<br />

McCurdy, V. J. ..........................................................................................40<br />

McCurdy, Victoria J. ..............................................36, 377, 590, 592<br />

McDoom, Isaam ....................................................................................55<br />

McElroy, Amber N. ............................................................................738<br />

McGinley, Lisa M. ...............................................................................475<br />

McGinn, Arlo N. ..................................................................................685<br />

McGrath, John A. ................................................................................578<br />

McGrath, John ........................................................................................80<br />

McInerny, Simone C. .........................................................................115<br />

McIvor, R. Scott .................................................... 102, 364, 447, 495<br />

Mckay, Tristan R. ...............................................................................435<br />

McKenna, Robert ..................................................................................71<br />

McLeod, Cameron W. .......................................................................158<br />

McNeish, Iain ......................................................................................561<br />

McNiece, Ian ...........................................................................................10<br />

McVicar, Daniel W..............................................................................308<br />

Mead, Andrew ............................................................................ 92, 391<br />

Meadows, Aaron ........................................................................ 39, 597<br />

Medrano, Ruan Felipe V. .................................................................630<br />

Medzikovic, Lejla ...............................................................................369<br />

Mei, Zhuyong .......................................................................................299<br />

Melcher, Alan ...........................................................18, 395, 505, 652<br />

Melo, Sandra ........................................................................................277<br />

Memmott, Trevor ..............................................................................208<br />

Mendeleeva, L. ....................................................................................724<br />

Mendell, Jerry R. ....................................................91, 172, 291, 295<br />

Mendoza, Janess ................................................................................341<br />

Mendoza, Janess M. ..........................................................................153<br />

Meng, Xianmei ....................................................................................468<br />

Merchan, Jaime ...................................................................................637<br />

Merigan, William H. ............................................................................... 5<br />

Merkel, Christian A. ..........................................................................630<br />

Merkel, Olivia ......................................................................................711<br />

Merkert, Sylvia ......................................................................................84<br />

Merlin, Simone .........................................................................315, 469<br />

Merten, Otto W. .....................................................................................52<br />

Merwin, Miles J. ..................................................................................344<br />

Messaddeq, Nadia ........................................................ 240, 278, 605<br />

Metelitsa, Leonid ..................................................................................12<br />

Metzge, Mark ..........................................................................................30<br />

Metzger, G. ............................................................................................695<br />

Metzger, Joseph M. ............................................................................538<br />

Metzger, Mark .....................................................................................428<br />

Meunier, M. ..........................................................................................694<br />

Meyer, Nancy .......................................................................................336<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

165


Abstract Author Index<br />

Mi, Tiejuan ...................................................................... 198, 502, 621<br />

Miao, Carol H. ....................................................... 101, 140, 665, 670<br />

Miao, Lei ................................................................................................691<br />

Michel, Gérard .......................................................................................62<br />

Midoux, Patrick ..................................................................................342<br />

Miest, Tanner S. ..................................................................................415<br />

Mikals, Kyle .............................................................................................71<br />

Mikkelsen, Tom ..................................................................................676<br />

Miko, Edit ..............................................................................................147<br />

Milazi, Stephanie ...............................................................................451<br />

Milczarek, Olga ...................................................................................714<br />

Miller, A. D. ...........................................................................................117<br />

Miller, Andrew ....................................................................................387<br />

Miller, Auston ......................................................................................168<br />

Miller, Christopher P. .......................................................................423<br />

Miller, Christophre P.........................................................................419<br />

Miller, Dusty ........................................................................................443<br />

Miller, Erin ............................................................................................542<br />

Miller, Jeffrey C. ..................................................................................184<br />

Miller, Jr, Francis J. .............................................................................511<br />

Miller, Timothy J. ...............................................................................500<br />

Millington, Michelle L. ........................................................................48<br />

Millroy, Laura ......................................................................................189<br />

Mills, Jason A. ......................................................................................224<br />

Mimuro, Jun .........................................................................................121<br />

Min Sang, Lee ......................................................................................573<br />

Mineno, Junichi ................................................................ 16, 629, 651<br />

Mingozzi, Federico ..................................................................110, 498<br />

Mingozzi, Frederico ............................................................................... 8<br />

Mintz, P.J. ...............................................................................................682<br />

Mintzer, Esther ...................................................................................188<br />

Mir, Lluis M. .........................................................................................148<br />

Miranda, Maria V. ..............................................................................632<br />

Mishra, Suparna .................................................................................307<br />

Miskin, James ......................................................................................232<br />

Mitchell, Erin .................................................................................. 33, 90<br />

Mitchell, James B. ..............................................................................743<br />

Mitchell, Marilyn...................................................................................92<br />

Mithbaokar, Pratibha .......................................................................553<br />

Mitrophanous, Kyriacos ......................................................... 56, 232<br />

Mitsuyasu, Ronald ................................................................................58<br />

Mittal, Suresh K. .................................................................................628<br />

Miura, Yoshi .........................................................................................414<br />

Miura, Yoshiaki .............................................................. 408, 705, 742<br />

Mixson, Archibald J. .............................................................................44<br />

Miyake, Koichi ................................................................ 228, 358, 601<br />

Miyake, Noriko .........................................................................228, 358<br />

Miyamoto, Shohei..................................................69, 432, 440, 442<br />

Mizandara, M. .....................................................................................682<br />

Mizoguchi, Yoko ....................................................................................86<br />

Mizuguchi, Hiroyuki .........................................................................482<br />

Mizukami, Hiroaki ..................................................................121, 651<br />

Mizushima, Tsunekazu ...................................................................749<br />

Moal, Christelle ...............................................33, 90, 240, 605, 606<br />

Moats, Rex A. .......................................................................................648<br />

Mochizuki, Shinji ..................................................................................86<br />

Modlich, Ute...............................................................................422, 425<br />

Moi, Davide ................................................................................301, 486<br />

Moisyadi, Stefan .................................................................................569<br />

Mok, Steven..........................................................................................302<br />

Mokhtari, Saloomeh .........................................................................253<br />

Monassier, Laurent ...........................................................................278<br />

Monette, Sébastien .................................................................373, 589<br />

Monjaret, François ............................................................................615<br />

Montazeri Aliabadi, Hamidreza ..................................................213<br />

Montgomery, Chrystal .....................................................................171<br />

Montgomery, Chrystal L. ........................................................ 91, 291<br />

Montiel-Martínez, Ana G. ...............................................................604<br />

Montini, Eugenio ..........................28, 63, 64, 233, 309, 517, 666<br />

Montus, Marie .....................................................................................734<br />

Moon, Jangsup ....................................................................................598<br />

Mooney, Michael ................................................................................378<br />

Moore, Malcolm A.S. .........................................................................727<br />

Moore, Theodore ...............................................................................307<br />

Mookherjee, Suddhasil ...................................................................709<br />

Moore, Andrea R. ...............................................................................681<br />

Mooreield, Emily ..............................................................................473<br />

Moreo, Andrew ..................................................................................182<br />

Morgan, Mary .........................................................................................65<br />

Morgan, Richard A. ...........................................................................716<br />

Mori, Masaki ........................................................................................749<br />

Moon, Anne ..................................................................................... 19, 22<br />

166<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Morishita, Naoya .....................................................................192, 654<br />

Moritz, Thomas ......................................................84, 320, 422, 429<br />

Morrison, Kyle P. ................................................................................140<br />

Morrison, Nancy ...................................................................................36<br />

Morrow, Matthew P .............................................................................45<br />

Moser, Anne ............................................................................................37<br />

Mosquea, Leocadia M. .....................................................................453<br />

Moss, Bernard .....................................................................................681<br />

Mota, Daniel ........................................................................................656<br />

Moughon, Diana .................................................................................215<br />

Moullier, Philippe .........................33, 76, 90, 111, 445, 606, 734<br />

Moulton, Hong M. ..............................................................................451<br />

Mrugala, Maciej M. ...............................................................................25<br />

Mu, Anbin .............................................................................................374<br />

Mu, Dakai ..............................................................................................540<br />

Mu, Dakai ..............................................................................................751<br />

Mu, Xiaodong ......................................................................................179<br />

Mucci, Adele ...........................................................................................84<br />

Mueller, Ann-Kristin ........................................................................725<br />

Mueller, Christian ..................................... 211, 361, 388, 603, 735<br />

Mueller, Martin ...................................................................................123<br />

Muenzer, Joseph .................................................................................495<br />

Muether, Nadine ................................................................................557<br />

Mukhopadhyay, Debabrata ...........................................................652<br />

Mulhern, Orla ......................................................................................184<br />

Mulhern, Orla L. .................................................................................487<br />

Müller-Kuller, Uta .................................................................................66<br />

Muñoz-Fuentes, Rosa M. ................................................................604<br />

Munye, Mustafa M. ..................................................................434, 435<br />

Muramatsu, Hiromi ................................................................146, 147<br />

Muramatsu, Shin-ichi .............................................................. 60, 376<br />

Murlidharan, Giridhar .......................................................................... 2<br />

Murrey, Darren ........................................................................... 39, 597<br />

Murugan, Dorai ..................................................................................754<br />

Mussolino, Claudio ...........................................................................539<br />

Muthumani, Karuppiah ............................................................. 9, 341<br />

Muthuswamy, Jit ................................................................................100<br />

Myers, Doug ............................................................................................14<br />

Myles, Devin J. ............................................................................. 45, 397<br />

Naash, Muna I. ....................................................................................344<br />

Naissi, Naiseh .........................................................................688, 713<br />

Nagabhushan Kalburgi, Sahana ..................................................112<br />

Nagamoto, Yasuhito .........................................................................482<br />

Nagasaki, Masao ...................................................................................86<br />

Nair, Nisha ....................................................................................... 8, 496<br />

Nair, Sukesh C. ....................................................................................114<br />

Najbauer, Joseph ................................................................................656<br />

Najjar, Amer .........................................................................................650<br />

Nak Won, Kim .....................................................................................573<br />

Nakade, Koji .........................................................................................643<br />

Nakai, Hiroyuki ...............................................72, 78, 119, 124, 259<br />

Nakajima, Yoshiyuki ............................................................................79<br />

Nakamura, Kazuhiro ...........................................................................86<br />

Nakamura, Masataka .......................................................................651<br />

Nakamura, Shin-ichiro ....................................................................482<br />

Nakanishi, Yoichi ...................................................69, 432, 440, 442<br />

Nakano, Yuki .......................................................................................440<br />

Nakano, Yuri ........................................................................................643<br />

Nakashima, Hiroshi ..........................................................................690<br />

Nakauchi, Hiromitsu ...................................................... 86, 365, 753<br />

Naldini, Luigi ........................................ 63, 64, 197, 233, 301, 309,<br />

......................................................................... 323, 441, 469, 486, 496,<br />

.................................................................................... 504, 517, 666, 667<br />

Nam, Hye Yeong .................................................................................645<br />

Nam, Hyun-Joo ......................................................................................71<br />

Nam, Jeong A. ......................................................................................572<br />

Nam, Kihoon ..............................................................................685, 717<br />

Nan, Zenhong ......................................................................................495<br />

Nan, Zhenhong ...................................................................................364<br />

Narayan, Poornima K. L. .................................................................267<br />

Nargarkhan, Simon ...........................................................................169<br />

Nariai, Naoki ..........................................................................................86<br />

Narukawa, Munetoshi .....................................................................530<br />

Narusawa, Megumi .................................................................432, 442<br />

Nathan, Erica .......................................................................................156<br />

Nathwani, Amit ........................................................................363, 580<br />

Naughton, Bartholomew J. .................................................... 39, 597<br />

Nawa, Akihiro .....................................................................................627<br />

Nayak, Ramesh ...................................................................................426<br />

Nayak, Sushrusha ..............................................................................446<br />

Naylor, Stuart .............................................................................. 56, 232<br />

Neal, Tawny L. .....................................................................................174<br />

Neduva, Victor ....................................................................................309<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

167


Abstract Author Index<br />

Negishi, Yoichi ..........................................................................142, 145<br />

Negre, Olivier ......................................................................................674<br />

Neiswender, James............................................................................212<br />

Nektaria, Andronikou ......................................................................706<br />

Nelson, Carol A. ..................................................................................453<br />

Nelson, Jared .......................................................................................263<br />

Nemnaitis, John ..................................................................................317<br />

Nemunaitis, Derek ............................................................................273<br />

Nemunaitis, John J. ....................................15, 199, 203, 206, 219,<br />

...........................................234, 272, 273, 351, 352, 402, 459, 464,<br />

............................................479, 503, 510, 570, 577, 624, 625, 659<br />

Nerem, Robert M. ..............................................................................475<br />

Nettelbeck, Dirk .................................................................................483<br />

Nettelbeck, Dirk M. ................................................................... 21, 554<br />

Ng, Philip...............................................................................................353<br />

Ngo, Minhtran C. ................................................................................396<br />

Nguyen, Tran T....................................................................................690<br />

Nichol, Ge<strong>of</strong>f ...........................................................................................58<br />

Nichols, Timothy ...............................................................................667<br />

Nicolay, Jan P. .......................................................................................204<br />

Nicolis di Robilant, Benedetta .....................................................197<br />

Nicholls, J.P. ..........................................................................................682<br />

Nichols, Timothy C............................................................................733<br />

Nicholson, David ................................................................................755<br />

Nicolson, Sarah C. .................................................................................74<br />

Nicolson, Tamara ..................................................................................48<br />

Nie, Daibang ........................................................................................281<br />

Niemeyer, Glenn P. ............................................................................498<br />

Nienhuis, Arthur W. ..........................................................................672<br />

Nienhuis, Arthur ................................................................................702<br />

Nieses, Amanda ..................................................................................468<br />

Nilsson, Bradley L. ...............................................................................43<br />

Nilsson, Jonas ......................................................................................321<br />

Nimgaonkar, Vishwajit ....................................................................239<br />

Niopek, Dominik ................................................................................514<br />

Nishikawa, Shinichi ..........................................................................753<br />

Nishimura, Junichi ............................................................................749<br />

Nitahara-Kasahara, Yuko .....................................................120, 608<br />

Nixon, Alan J. ...........................................................89, 257, 297, 718<br />

No, Daniel ...................................................................................152, 620<br />

Noble, Misty L. ..........................................................................101, 140<br />

Noh, Moon Jong ..................................................................................565<br />

Norris, James .......................................................................................219<br />

Norvell, Fabienne ....................................................................206, 633<br />

Noske, David P. ...................................................................................321<br />

Noskov, Alexander ............................................................................465<br />

Novic<strong>of</strong>f, Sarah .........................................................................497, 571<br />

Nowrouzi, Ali ............................................................................204, 274<br />

Noyes, Marcus B.................................................................................485<br />

Nunan, Robert ....................................................................................273<br />

Nurro, Jussi .............................................................................................97<br />

Nusco, Edoardo ..................................................................................353<br />

Nygaard, Sean C. ................................................................................316<br />

Oakes, Benjamin L. ...........................................................................485<br />

Obata, Yuichi .......................................................................................643<br />

Obeng-Adjei, Nyamekye ....................................................................45<br />

O’Callaghan, Christopher ...............................................................435<br />

Ochala, Julien ......................................................................................173<br />

O’Connell, Ryan M. ............................................................................712<br />

O’Connor, Colleen ..............................................................................650<br />

O’Connor, Colleen M. ........................................................................653<br />

O’Connor, Geraldine .........................................................................308<br />

Oda, Yusuke .........................................................................................145<br />

Odom, Guy L. .......................................................................................543<br />

O’Donnell, Patricia ............................................................................360<br />

O’Donnell, Patricia A. ............................................................... 87, 289<br />

Ogino, Atsushi .....................................................................................216<br />

Ogris, Manfred ....................................................................................134<br />

Oh, Eonju...............................................................................................129<br />

Oh, Il Ung ..............................................................................................375<br />

Oh, Jonathan ........................................................................................503<br />

Ohashi, Kazuo ............................................................................. 79, 237<br />

Ohashi, Toya ..............................................................................365, 585<br />

Ohashi, Toya ........................................................................................753<br />

Ohlfest, John R. ...................................................................................270<br />

Ohlin, K. Elisabet ...............................................................................631<br />

Ohlstein, Jason ....................................................................................444<br />

Ohmine, Ken ........................................................................................651<br />

Ohmori, Tsukasa ......................................................................121, 237<br />

Ohnami, Shumpei ..............................................................................642<br />

Ojeda, Sergio R. .....................................................................................78<br />

Okada, Hironori ............................................................ 120, 176, 608<br />

Okada, Takashi .............................................................. 120, 176, 608<br />

168<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Okamoto, Sachiko ..................................................................... 16, 629<br />

Okano, Teruo ............................................................................... 79, 237<br />

Old, Matthew .......................................................................................747<br />

Olivares, Simon ........................10, 198, 502, 621, 649, 650, 653<br />

Oliviera, Anna V. .................................................................................160<br />

Olsen, Curtis ........................................................................................685<br />

Olsen, John C. ......................................................................................535<br />

Olson, Erik R. .......................................................................................102<br />

Olson, Susan ........................................................................................466<br />

Olzzewska, Malgorzata ......................................................................50<br />

O’Malley, Bert W. ................................................................................459<br />

O’Malley, Thomas ..............................................................................360<br />

Omata, Daiki ........................................................................................145<br />

O’Neill, Kim ..........................................................................................208<br />

Orchard, Paul .........................................................................................62<br />

Orentas, Rimas J. ................................................................................325<br />

Orl<strong>of</strong>f, Lisa A. .......................................................................................472<br />

Oro, Anthony E. ..................................................................................277<br />

Ortiz, Luis ...................................................................................333, 334<br />

Ortuno, Danny ..........................................................................339, 550<br />

Ortved, Kyla ...............................................................................297, 718<br />

Osborn, Mark J. .............................................................. 270, 584, 738<br />

Ostertag, Derek ..................................................................................676<br />

Ostrowska, Alina .......................................................... 137, 465, 470<br />

Otsu, Makoto .......................................................................................365<br />

Otus, Mokoto .......................................................................................753<br />

Ou, K........................................................................................................708<br />

Ou, Wu ....................................................................................................467<br />

Ousterout, David G. ................................. 167, 177, 241, 292, 491<br />

Owen, John ...........................................................................................253<br />

Owens, Jesse B. ...................................................................................569<br />

Oyster, Nick ..........................................................................................178<br />

Ozaki, Suzuka ......................................................................................192<br />

Ozawa, Keiya .............................................................................121, 651<br />

Özbas-Turan, Suna ............................................................................452<br />

Özkan, Naziye......................................................................................452<br />

Pagliara, Daria ....................................................................................300<br />

Pahujani, Shweta ..................................................................................66<br />

Pai, M. .....................................................................................................682<br />

Pak, Seung Hoon ................................................................................722<br />

Palliser, Debborah .............................................................................205<br />

Palmer, Donna ....................................................................................353<br />

Palomares, Laura A...........................................................................604<br />

Pan, Changchuan ...............................................................................194<br />

Pan, Dao............................................................................... 38, 248, 665<br />

Pan, Xiufang ................................................................................. 98, 166<br />

Pandha, Hardev ................................................................ 18, 395, 652<br />

Pandya, Jhell ........................................................................................333<br />

Pang, Li ..................................................................................................439<br />

Pangallo, Joey ......................................................................................673<br />

Pangallo, Joseph .................................................................................318<br />

Pangle, Amanda K. ............................................................................439<br />

Papapetrou, Eirini ...................................................................679, 680<br />

Papayannopoulou, Thalia ...................................................... 27, 427<br />

Pappen, Beena O. ............................199, 206, 402, 479, 503, 624<br />

Pâques, Frédéric ................................................................................731<br />

Pardi, Norbert .....................................................................................146<br />

Parelkar, Sangram S..........................................................................157<br />

Parise, Carolina B. .............................................................................658<br />

Park, Byung Ho ......................................................................................22<br />

Park, Dong-Kyu ..................................................................................598<br />

Park, Hana ..................................................................................497, 571<br />

Park, Jae .................................................................................................506<br />

Park, Jeonghyun .................................................................................151<br />

Park, Ki Dae .........................................................................................375<br />

Park, Sang Min ....................................................................................380<br />

Park, Sung Young ...............................................................................572<br />

Park, Woo Jin .......................................................................................380<br />

Park, Yeo Myeong ..............................................................................565<br />

Park, Yong Serk ..................................................................................159<br />

Parney, Ian ............................................................................................417<br />

Parovichnikova, E. .............................................................................724<br />

Partridge, Emily A. ............................................................................418<br />

Partridge, Terence A. ..........................................................................93<br />

Paruzynski, Anna ..............................................................................204<br />

Parvizi, Paria .......................................................................................755<br />

Pasceri, Peter ............................................................................322, 593<br />

Paschon, David E. ....................................................................107, 488<br />

Passineau, Michael J. ..............................................................141, 149<br />

Pastore, Nunzia ........................................................................353, 499<br />

Pastor-Flores, Ana R. .......................................................................604<br />

Patel, Anant B......................................................................................150<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

169


Abstract Author Index<br />

Patel, Bella .................................................................................... 24, 411<br />

Patel, Manij ..........................................................................................535<br />

Patt, Richard ...........................................................................................19<br />

Paulard, Anais .....................................................................................674<br />

Paun, Marla ..........................................................................................140<br />

Pavani, Giulia .......................................................................................110<br />

Payan, Emmanual ..............................................................................674<br />

Payne, Kimberly J. .............................................................................468<br />

Peccate, Cecile ....................................................................................225<br />

Pei, Nana ...............................................................................................221<br />

Pellin, Danilo ..........................................................................................63<br />

Pence, Casey ........................................................................................461<br />

Peng, Kah Whye ....................................................................................17<br />

Peng, Kah-Whye ......................................................................... 20, 413<br />

Peng, L. ...................................................................................................682<br />

Peng, Rui-Yun ......................................................................................105<br />

Penn, Marc S. .......................................................................................500<br />

Pennell, Christopher A. ...................................................................270<br />

Perdomini, Morgane ........................................................................278<br />

Pereboeva, Larisa ..............................................................................587<br />

Perez, Giovani B. ................................................................................582<br />

Perez, Omar .........................................................................................703<br />

Perez-Pinera, Pablo ........................................... 167, 241, 292, 491<br />

Perkins, Edward .................................................................................657<br />

Perlingeiro, Rita C. R. .......................................................................168<br />

Perlingeiro, Rita .................................................................................169<br />

Perna, Serena K. .................................................................................300<br />

Perrigue, Patrick M. ..........................................................................656<br />

Persikov, Anton V. ..............................................................................485<br />

Persons, Derek A. ............................................................ 26, 235, 424<br />

Persson, Jonas ...........................................................................201, 679<br />

Pertschuk, Dan ...................................................................................676<br />

Pestina, Tamara I. ..............................................................................424<br />

Peterson, Jonathan ...........................................................................544<br />

Petrey, Aaron .......................................................................................359<br />

Petrov, Mihail ......................................................................................391<br />

Petrov, Mike ............................................................................................92<br />

Petry, Harald ........................................................................................274<br />

Pettigrew, Amy ...................................................................................461<br />

Phalon, Connor .............................................................. 206, 570, 633<br />

Phaltane, Ruhi.....................................................................................422<br />

Phan-Lai, Vy ............................................................................................13<br />

Phelan, Dane........................................................................................335<br />

Phillips, Dawn ........................................................................................57<br />

Phillips, Lucy .......................................................................................453<br />

Picard, Capucine ................................................................................306<br />

Piccolo, Pasquale .......................................................... 353, 362, 553<br />

Pichon, Chantal ..................................................................................342<br />

Piekna, Alina .......................................................................................593<br />

Piepenhagen, Peter A. .....................................................................453<br />

Pierce, Cora .............................................................................................54<br />

Pierciey, John ..........................................................................................37<br />

Pierciey, Jr, Francis H. .........................................................................51<br />

Pierciey, Jr, Francis J. ..............................................................251, 258<br />

Pierre-Destine, Lorraine ................................................................373<br />

Pierson, Tyler M. ................................................................................378<br />

Pigeon, Lucie .......................................................................................342<br />

Pike-Overzet, Karin ................................................................313, 319<br />

Pirollo, Kathleen F. ............................................................................273<br />

Pivirotto, Phillip ............................................................ 288, 594, 599<br />

Plati, Tiziana ........................................................................................309<br />

Plesa, Gabriela ....................................................................................508<br />

Plewa, Cherylene .....................................................................339, 550<br />

Poddar, Minakshi .....................................................................179, 611<br />

Podetz-Pedersen, Kelly M. ...................................................364, 495<br />

Podhajcer, Osvaldo L. .......................................................................635<br />

Podsak<strong>of</strong>f, Gregory M. .....................................................................110<br />

Poirot, Laurent .............................................................. 401, 683, 731<br />

Polach, Kevin J. ...................................................................................461<br />

Poliani, Pietro L. .................................................................................661<br />

Ponde, Datta ........................................................................................289<br />

Ponder, Katherine P. ............................................................................87<br />

Ponnazhagan, Selvarangan ...........................................................548<br />

Ponnusamy, Ravi ...............................................................................497<br />

Poppante, Kimberly ............................................................................33<br />

Poptani, Harish...................................................................................289<br />

Porada, Christopher .........................................................................253<br />

Portales-Casamar, Elodie ...............................................................115<br />

Porteus, Matthew H. ..............................................................324, 489<br />

Porteus, Matthew ..............................................................................471<br />

Posey Jr, Avery D. ...............................................................................623<br />

Potter, Mark ............................................................................................55<br />

170<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Potter, Phil ............................................................................................648<br />

Poulard, Karine .....................................................................................90<br />

Powlesland, Alex................................................................................508<br />

Pozsgai, Eric R. ...................................................................................172<br />

Prabhakar, Shilpa ..............................................................................286<br />

Preston, Thomas J. ...............................................................................91<br />

Preuss, Meredith A. ..........................................................................560<br />

Price, Sandra ............................................................................... 30, 428<br />

Prill, Jan-Michael .....................................................................126, 484<br />

Prince, Timothy .................................................................................660<br />

Prockop, Susan E. .................................................................................61<br />

Proto, Jonathan D. ...................................................................179, 611<br />

Provasi, Elena .....................................................................................504<br />

Psatha, Nikoleta ......................................................................... 27, 427<br />

Puccio, Hélène ....................................................................................278<br />

Pugh, John A. T. ...................................................................................158<br />

Pule, Martin .........................................................................................434<br />

Pulicherla, Nagesh ...............................................................................77<br />

Pulido, Jose ................................................................................395, 652<br />

Pumphrey, Nick J. ...................................................................... 59, 298<br />

Pumphrey, Nick ..................................................................................508<br />

Pungente, Michael D. .......................................................................755<br />

Qasim, Waseem ..................................................................................578<br />

Qi, Feng ..................................................................................................404<br />

Qian, Haohua .......................................................................................709<br />

Qiao, Chunping .............................................................. 296, 367, 370<br />

Qin, Hong ..............................................................................................626<br />

Qin, Su ....................................................................................................326<br />

Qiu, Jianping ........................................................................................106<br />

Qiu, Yujie ...............................................................................................404<br />

Qu, Guang .............................................................................................529<br />

Qu, Jinrong ...................................................................................... 50, 61<br />

Quach, Lucy .........................................................................................373<br />

Quinn, Thomas P. ...............................................................................532<br />

Quintanilla, Rene H...........................................................................244<br />

Rabinowitz, Joseph ...................................................... 108, 444, 544<br />

Radu, Antoneta ...................................................................................236<br />

Rae, Dustin T. .......................................................................................525<br />

Raii, Arash ...........................................................................................727<br />

Ragan, Regina .....................................................................................163<br />

Raghavarchari, Nalini .........................................................................65<br />

Ragni, Margaret C. .............................................................................110<br />

Rahimov, Fedik ......................................................................................93<br />

Rait, Antonina .....................................................................................273<br />

Raju, Liji ................................................................................................755<br />

Rakoczy, Elizabeth P. ...........................................................................54<br />

Ramos, Carlos A. ......................................................................299, 684<br />

Ramos, Julian N. .................................................................................543<br />

Ramsay, E. .............................................................................................708<br />

Ramya, V. ...............................................................................................114<br />

Ranaldo, Gabriella .............................................................................469<br />

Randle, A. E. ............................................................................................40<br />

Randle, Ashley N. ...................................................36, 377, 590, 592<br />

Ranghetti, Anna .................................................................................301<br />

Ranzani, Marco .........................................................................233, 666<br />

Rao, Donald ................................................................................459, 659<br />

Rao, Donald D. .. 199, 206, 219, 234, 272, 317, 402, 510, 625<br />

Rao, Nalam M. .....................................................................................156<br />

Rapoport, Aaron P. .......................................................... 59, 298, 508<br />

Rauschhuber, Christina ..................................................................557<br />

Rawlings, David..................................................................................673<br />

Rawlings, David J. ..................................................32, 311, 318, 665<br />

Raya, Angel ...........................................................................................469<br />

Razban, Vahid .....................................................................................368<br />

Rea-Ramsey, Angela .........................................................................461<br />

Reay, Daniel P. ........................................................................................94<br />

Rebar, Edward J. ............................................................... 46, 184, 488<br />

Recchia, Alessandra .........................................................................347<br />

Redlich, Shira ......................................................................................366<br />

Redmond, Eugene .............................................................................465<br />

Reebye, V. ..............................................................................................682<br />

Reed, T. D. .................................................................................................15<br />

Rees, Donald J. ....................................................................................616<br />

Reid, Michael .......................................................................................656<br />

Reik, Andreas ......................................................................................504<br />

Reinhart, Bonnie......................................................................416, 566<br />

Reinhart, Bonnie L. ...........................................................................478<br />

Reiser, Jakob ........................................................................................467<br />

Rejiba, Soukaina ................................................................................655<br />

Remenyik, Eva ....................................................................................147<br />

Reuser, Arnold J. J. .............................................................................275<br />

Reutenauer, Laurence .....................................................................278<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

171


Abstract Author Index<br />

Rex, Tonia S. .........................................................................................226<br />

Reyon, Deepak ....................................................................................490<br />

Rezek, Valerie.........................................................................................48<br />

Rhee, Byungdoo .................................................................................151<br />

Rhodes, Eric ...............................................................................245, 551<br />

Riba, Michela .......................................................................................233<br />

Ribas, Antoni .......................................................................................302<br />

Ribeiro, Aline H. .................................................................................630<br />

Riberdy, Janice M. ..............................................................................235<br />

Rice, Jennifer .......................................................................................461<br />

Rice, Kevin G. ............................................................................... 41, 155<br />

Richard, Champlin ............................................................................431<br />

Richard, Isabelle ................................................. 294, 606, 610, 615<br />

Richie, Christopher T. ......................................................................382<br />

Richter, Miximilian ...................................................... 303, 483, 552<br />

Riddell, K. P. ............................................................................................40<br />

Riddell, Stan ...........................................................................................81<br />

Riddell, Stanley R. .............................................................................744<br />

Rieck, Alex ............................................................................................245<br />

Riggs, Arthur .......................................................................................474<br />

Riley, James L. .....................................................................................508<br />

Rinaldi, Fabrizio .......................................................................168, 169<br />

Riolobos, Laura .....................................................................................81<br />

Rissanen, Tuomas T. ............................................................................97<br />

Rival-Gervier, Sylvie .........................................................................322<br />

Rivers, Angela ...........................................................................333, 334<br />

Rivers, Angela E. ................................................................................542<br />

Rivière, Christel ............................................................................ 52, 90<br />

Rivière, Julie ........................................................................................662<br />

Riviere, Christel ....................................................................................33<br />

Riviere, Isabelle...............................................50, 61, 427, 506, 651<br />

Robbins, Joan M. ................................................................................676<br />

Robbins, Joan ......................................................................................703<br />

Robbins, Paul D. ....................................................................................94<br />

Roberts, Alison ...................................................................................678<br />

Roberts, Errin .....................................................................................453<br />

Roberts, Sean ......................................................................................681<br />

Roberts, Thomas C. ...........................................................................181<br />

Robison, Richard ...............................................................................208<br />

Rocca, Celine J. ............................................................... 493, 494, 546<br />

Rocca, Céline .......................................................................................678<br />

Roche, Francis P. ................................................................................631<br />

Rockey, William M. ............................................................................509<br />

Rockne, Russell C. ................................................................................25<br />

Rodino-Klapac, Louise R. ............................................. 91, 172, 291<br />

Rödl, Wolfgang ...................................................................................134<br />

Rodriguez, Stephen ..........................................................................263<br />

Roh, Jae-Kyu ................................................................... 143, 598, 602<br />

Romain, Gabrielle ..............................................................................393<br />

Romano, Josephine ..............................................................................46<br />

Romero, Zulema ....................................................................................26<br />

Rommelfanger-Konkol, Diana ...........................................505, 652<br />

Roncarolo, Maria Grazia .......................................................323, 441<br />

Rondon, Gabriela ..................................................................................10<br />

Rooney, Cliona M. ..............................14, 299, 396, 398, 400, 622<br />

Roovers, Onno ....................................................................................275<br />

Rosales, Cecilia .........................................................................363, 580<br />

Rose, Laura ................................................................................161, 162<br />

Rose-Hellkant, Teresa .....................................................................657<br />

Rosenberg, Jonathan B. .........................................................373, 589<br />

Rosenberg, Steven A. .......................................................................716<br />

Rosengurt, Enrique ..........................................................................659<br />

Ross, Joel ...............................................................................................593<br />

Rossi, John J. ............................................... 454, 456, 515, 668, 682<br />

Rossini, Silvano ..................................................................................420<br />

Roth, David B.......................................................................................324<br />

Roth, Justin C. ......................................................................................438<br />

Rothe, Michael .................................................................. 37, 422, 425<br />

Rottier, Peter .......................................................................................707<br />

Roudaut, Carinne ....................................................................294, 615<br />

Rouillon, Jérémy ................................................................................612<br />

Round, June L. .....................................................................................712<br />

Rousseau, Joel .....................................................................................293<br />

Rousseau, Joël ............................................................................. 83, 389<br />

Rowland, Elizabeth F. ......................................................................485<br />

Roy, Andre ............................................................................................495<br />

Roy, Aparna ................................................................................474, 476<br />

Roy-Chaudhuri, Biswajoy ..............................................................436<br />

Roy-Chaudhuri, Biswajoy ..............................................................701<br />

Rozengurt, Nora .................................................................................497<br />

Ruan, Zhechao ....................................................................................607<br />

Rubin, David G. ...................................................................................589<br />

172<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Ruggiero, Eliana ......................................................................... 47, 204<br />

Ruiz, Autumn ......................................................................................407<br />

Rungta, R. ..............................................................................................708<br />

Runtsch, Marah C. .............................................................................712<br />

Ruozi, Giulia ................................................................................. 95, 368<br />

Rushworth, David .............................................................................202<br />

Russ, Jill .................................................................................................524<br />

Russell, David W......................................................................... 81, 266<br />

Russell, Rob .........................................................................................516<br />

Russell, Stephen J. ..........................................17, 20, 406, 407, 413<br />

Russo, Fabio .........................................................................................441<br />

Rusten, Myra C. ..................................................................................102<br />

Ryals, Renee C. .......................................................................................55<br />

Ryan, Robin .............................................................................................14<br />

Ryu, Byoung ................................................................................. 37, 674<br />

Ryu, Byoung Y. .......................................................................................51<br />

Sabapathy, Vikram ............................................................................754<br />

Sabine, Geiger-Schredelseker ......................................................307<br />

Sacher, Anna ........................................................................................123<br />

Sadelain, Michel ................................... 50, 61, 427, 506, 651, 728<br />

Sætrom, P. .............................................................................................682<br />

Sagara, Miyako ............................................................................ 69, 440<br />

Sagawa, Hiroaki .................................................................................532<br />

Sahel, José-Alain ................................................................................225<br />

Sahenk, Zarife .....................................................................................171<br />

Saito, Hiroki ...............................................................................192, 654<br />

Sakamaki, Ippei ..................................................................................626<br />

Sakamoto, Chika ........................................................... 432, 440, 442<br />

Sakata, Asuka ......................................................................................121<br />

Sakata, Yoichi ............................................................................121, 237<br />

Sakuma, Toshie .......................................................................... 68, 726<br />

Sakurai, Fuminori .............................................................................482<br />

Sakurai, Hidetoshi .............................................................................715<br />

Salazar, Andres M. .............................................................................270<br />

Salibi, N. ....................................................................................................40<br />

Salmon, Florence ...............................................................................274<br />

Salomon, Daniel R. ............................................................................493<br />

Salva, Emine ........................................................................................452<br />

Samara-Kuko, Ermira ......................................................................355<br />

Samaranch, Lluis .......................................................... 288, 594, 599<br />

Samoto, Vivian Y. ...............................................................................582<br />

Samulski, R. Jude .......................................6, 54, 74, 112, 268, 546<br />

San Sebastian, Waldy .................................................. 288, 594, 599<br />

Sanadiki, Sara .....................................................................................492<br />

Sanchez, Robbi ...................................................................................272<br />

Sandikin, Daren ..................................................................................430<br />

Sandoval, Lucia ........................................................................152, 620<br />

Sandoval-Zamora, Hugo .......................................................246, 564<br />

Sandoval-Zamora, Hugo E. ............................................................534<br />

Santiago, Yolanda ..............................................................................568<br />

Sanvito, Francesca ....................................................... 233, 323, 666<br />

Saori, Ukai ............................................................................................142<br />

Sapp, Peter ...........................................................................................603<br />

Sardesai, Niranjan Y. ....................................... 9, 45, 153, 341, 397<br />

Sardi, Pablo S..........................................................................................34<br />

Sargent, R. G. .......................................................................................472<br />

Sargent, Roy G. .........................................................................471, 575<br />

Sarkar, Debalina .................................................................................109<br />

Sartin, J. L. ................................................................................................40<br />

Sasakawa, Noriko ..............................................................................715<br />

Sather, Blythe D. ....................................................................................32<br />

Sato, Makoto ........................................................................................215<br />

Sato, Taku .............................................................................................753<br />

Savchenko, V. .......................................................................................724<br />

Savola, Paula ........................................................................................730<br />

Savoldo, Barbara .....................49, 197, 299, 300, 305, 392, 394<br />

Sawaguchi, Yoshikazu .....................................................................145<br />

Saydaminova, Kamola ................................................ 679, 680, 704<br />

Sayles, Leanne C. ................................................................................436<br />

Scala, Serena ...........................................................................................28<br />

Scaramuzza, Samantha ......................................................................63<br />

Scaria, Puthupparampil ..................................................................455<br />

Schaffer, David V. .................................................3, 5, 267, 327, 692<br />

Schambach, Axel .......................................................66, 84, 313, 425<br />

Scharenberg, Andrew M. .............188, 311, 318, 401, 673, 683<br />

Schech, Amanda .................................................................................636<br />

Scheel, Maria .......................................................................................283<br />

Scheff, Nicole .......................................................................................285<br />

Scherer, Lisa.........................................................................................668<br />

Schiedlmeier, Bernd ...............................................................320, 429<br />

Schiffer-Mannioui, Cécile ...............................................................401<br />

Schinco, Piercarla ..............................................................................469<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

173


Abstract Author Index<br />

Schiroli, Giulia .....................................................................................486<br />

Schlichting, Lisa .................................................................................497<br />

Schmidt, Manfred ...........................37, 47, 62, 63, 204, 210, 233,<br />

......................................................274, 279, 309, 518, 666, 678, 738<br />

Schmidt, Manuel ................................................................................686<br />

Schmidt, Sabine .................................................................................274<br />

Schneider, Lynda ...............................................................................721<br />

Schneppendahl, Johannes .............................................................178<br />

Schoield, Christine ..........................................................................551<br />

Scholler, John .......................................................................................623<br />

Schr<strong>of</strong>f, Matthias ................................................................................686<br />

Schubert, Kathryn .............................................................................466<br />

Schuermann, Nina ............................................................................516<br />

Schug, Jonathan .................................................................................581<br />

Schuldt, Ryan A. .................................................................................745<br />

Schwäble, Joachim ...............................................................................66<br />

Schwerk, Nicolaus ................................................................................84<br />

Scripps, Vicky .........................................................................................56<br />

Seabra, Miguel C. ...............................................................................227<br />

Sekaly, Raick-Pierre ...........................................................................58<br />

Selby, Peter ......................................................................... 18, 395, 652<br />

Sellers, Stephanie E. ............................................................................65<br />

Selot, Ruchita ......................................................................................549<br />

Semechkin, Ruslan ....................................................... 137, 465, 470<br />

Semenova, Ekaterina .......................................................................578<br />

Sen, Dwaipayan ......................................... 114, 331, 337, 536, 537<br />

Senac, Julien S. ....................................................................................280<br />

Sena-Esteves, Miguel ...................... 1, 36, 40, 93, 212, 286, 377,<br />

.......................................................384,387, 388, 590, 592, 595, 721<br />

Senzer, Neil ............................199, 206, 219, 234, 272, 273, 317,<br />

............................................459, 479, 503, 510, 570, 624, 625, 659<br />

Seo, Emiko ............................................................................................643<br />

Seog, Joonil ..............................................................................................44<br />

Sergi Sergi, Lucia ...................................................64, 486, 666, 667<br />

Sergio, Bossi ........................................................................................520<br />

Serrano-Pozo, Alberto .....................................................................540<br />

Servais, Laurent .................................................................................734<br />

Sessa, Maria .........................................................................................309<br />

Seth, Prem ............................................................................................555<br />

Seto, Jane T. ..........................................................................................543<br />

Sevin, Caroline ....................................................................................589<br />

Sganga, Leonardo ..............................................................................635<br />

Sgouramali, Eleni ..............................................................................427<br />

Shaban, Mona......................................................................................451<br />

Shah, Riddhi ........................................................................................345<br />

Shah, Sapana N. ..................................................................................451<br />

Shanley, Ryan ......................................................................................414<br />

Shapiro, Michael ...................................................................................44<br />

Sharma, Anurag .......................................................................104, 628<br />

Sharma, Jay ................................................................................493, 494<br />

Sharma, Nitasha .................................................................................288<br />

Sharma, Priyanka ..............................................................................267<br />

Sharma, Rajiv ......................................................................................488<br />

Sharon, David ......................................................................................403<br />

Shaw, Kit L. ...........................................................................................307<br />

Shayakhmetov, Dmitry M. ..............................................................477<br />

Shedlock, Devon J. ................................................................................45<br />

Shelke, Rajani ......................................................................................330<br />

Shen, Kang ............................................................................................255<br />

Shen, Shen ....................................................................................... 73, 77<br />

Shi, Gang................................................................................................361<br />

Shi, Hailiang .........................................................................................561<br />

Shi, Yijun ...............................................................................................378<br />

Shi, Yingai .............................................................................................473<br />

Shields, Jordan E. ...............................................................................663<br />

Shigemura, Katsumi .........................................................................192<br />

Shihabuddin, Lamya S. ............................................................ 34, 282<br />

Shiku, Hiroshi ............................................................................. 16, 629<br />

Shim, Inkyong .....................................................................................237<br />

Shima, Midori ......................................................................................357<br />

Shimada, Hideaki ..............................................................................216<br />

Shimada, Takashi .......................................................... 228, 358, 601<br />

Shimada, Yohta .........................................................................365, 753<br />

Shimada, Yota......................................................................................585<br />

Shimizu, Hiroyuki ..................................................................... 69, 440<br />

Shimizu, Kahori ..................................................................................482<br />

Shimizu, Saki .......................................................................................530<br />

Shin, Bae-Hyun ...................................................................................380<br />

Shin, Jeong-A. ......................................................................................238<br />

Shin, Jin-Hong ................................................................... 98, 166, 613<br />

Shin, Simon C. ...........................................................................665, 670<br />

Shin, Sug Kyun ....................................................................................685<br />

Shindler, K. ..............................................................................................53<br />

174<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Shirakawa, Toshiro .................................................................192, 654<br />

Shires, G. Thomas ..............................................................................402<br />

Shirley, Shawna .....................................................................................99<br />

Shirosaki, Chihiro ..............................................................................192<br />

Shiver, Rachel .........................................................................................45<br />

Shoemark, Amelia .............................................................................435<br />

Shontz, Kim .............................................................................................91<br />

Shontz, Kimberly M. .........................................................................291<br />

Shpall, Elizabeth J. ................................................................................10<br />

Shpall, Elizabeth ................................................................................650<br />

Shreiber, Claire A. ..............................................................................726<br />

Shum, Kato ...........................................................................................515<br />

Siametis, Athanasios ........................................................................427<br />

Sidman, Richard L. ...............................................................................34<br />

Silva, Anne ............................................................................................744<br />

Silva, Gabriela .....................................................................................160<br />

Silva, Michael E. ..................................................................................656<br />

Silva, Nilsa ............................................................................................387<br />

Silverman, Lara I. ...............................................................................619<br />

Silvin, Christopher ............................................................................307<br />

Simoneau, Mélanie ...........................................................................135<br />

Simpson, Elizabeth M. .....................................................................115<br />

Siner, Joshua I. ....................................................................................498<br />

Singh, Aruna ........................................................................................576<br />

Singh, Harjeet .....................................10, 393, 502, 621, 649, 650<br />

Singh, Mandeep S. .............................................................................229<br />

Singh, Martin .......................................................................................639<br />

Singh, Mona .........................................................................................485<br />

Singh, Purba ........................................................................................200<br />

Singh, Swati .........................................................................................673<br />

Singha, Swati ..........................................................................................32<br />

Skinner, Nicole E. B. ..........................................................................270<br />

Skog, Johan .................................................................................304, 751<br />

Skorik, Christian ......................................................................260, 262<br />

Skottman, H .........................................................................................732<br />

Slavcev, Roderick .....................................................................688, 713<br />

Slepushkin, Vladimir .......................................................................495<br />

S-Manickam, Devika .........................................................................691<br />

Smethurst, Dominic P. ............................................................. 59, 298<br />

Smirnova, Olga ...................................................................................581<br />

Smith, Andrew .......................................................................................88<br />

Smith, Barbara K. ...................................................................... 57, 617<br />

Smith, Barbara .......................................................................................90<br />

Smith, Bruce F. ....................................................................................613<br />

Smith, Catherine ................................................................................284<br />

Smith, Claire M. ..................................................................................435<br />

Smith, Julianne ...................................................................................401<br />

Smith, Julianne ...................................................................................683<br />

Smith, Krissy .......................................................................................660<br />

Smith, Trevor R. F. .............................................................................153<br />

Smogorzewska, Monika..................................................................307<br />

Snyder, Evan ........................................................................................465<br />

Snyder, Richard O. ........................................................................ 60, 76<br />

Soderini, Alejandro ...........................................................................635<br />

Soheili, Tayebeh .................................................................................662<br />

Sohn, Jihee ............................................................................................250<br />

Soker, Shay ...........................................................................................253<br />

Soker, Thomas .......................................................................................33<br />

Sokolic, Robert ...................................................................................307<br />

Soland, Melisa .....................................................................................253<br />

Sommerville, Laura ............................................................................... 2<br />

Sondhi, Dolan .................................................................... 11, 373, 589<br />

Song, Lina .............................................................................................603<br />

Song, Lina .............................................................................................735<br />

Song, Liujiang............................................................................328, 542<br />

Song, Shuxian ............................................................................101, 140<br />

Song, Sihong ........................................................................................545<br />

Song, Xiao-Tong ..................................................................................410<br />

Soo, Shin Back .....................................................................................699<br />

Sorrentino, Brian P. ..................................................... 308, 527, 671<br />

Sortwell, C. E. ......................................................................................381<br />

Sortwell, Caryl E. .....................................................................386, 596<br />

Sosale, Nisha G. ..................................................................................523<br />

South, Andy P. .....................................................................................578<br />

Sowers, Anastasia .............................................................................743<br />

Sparks, Jeff............................................................................................461<br />

Spencer, H. Trent ............................................................. 31, 528, 663<br />

Spencer, Jacqueline F. ......................................................................480<br />

Spillman, Michael ..............................................................................336<br />

Spires-Jones, Tara .............................................................................283<br />

Spitzweg, Christine ...........................................................................134<br />

Springer, Matthew L. ........................................................................369<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

175


Abstract Author Index<br />

Squadrito, Mario L. ...........................................................................301<br />

Sridharan, Arati M. ...........................................................................100<br />

Srinivasan, N..............................................................................114, 536<br />

Srivastava, Alok ......................................... 114, 331, 337, 536, 537<br />

Srivastava, Arun ....................................................75, 118, 314, 328,<br />

......................................................331, 333, 334, 541, 542, 545, 613<br />

Staal, Frank J. T. ........................................................................313, 319<br />

Stadtmauer, Edward A. ................................................. 59, 298, 508<br />

Stagg, Scott ...........................................................................................336<br />

Stamatoyannopoulos, George .............................................. 27, 427<br />

Stanek, Lisa M. ....................................................................................282<br />

Stanic, Bojana .....................................................................................511<br />

Starker, Colby G. .......................................................................584, 738<br />

Starnes, Joseph ...................................................................................664<br />

Steckler, Robert ........................................................................199, 624<br />

Stedman, Hansell ....................................................................... 92, 391<br />

Steet, Richard ......................................................................................359<br />

Stefankski, Jolanta ............................................................................506<br />

Stefano, Corna.....................................................................................520<br />

Stein, Libby ..........................................................................................492<br />

Stein, Sarah ................................................................................152, 620<br />

Steines, Benjamin R..........................................................................327<br />

Stewart, Phoebe L. ............................................................................477<br />

Stilhano, Roberta S. ..................................................... 265, 582, 658<br />

Stock, Stuart ........................................................................................555<br />

Stockard, Cecil R. ...............................................................................560<br />

Stoddard, Barry ........................................................................188, 318<br />

Stoddard, Barry L. .............................................................................193<br />

Stoica, Lorelei I. ..................................................................................388<br />

Stojdl, David F. ....................................................................................413<br />

Stok, Merel ...........................................................................................275<br />

Stoltzman, Carrie ...............................................................................450<br />

Stolz, Donna B. .......................................................................................94<br />

Stone, Daniel .................................................................. 187, 188, 193<br />

Storb, Rainer .......................................................................................443<br />

Stout, David .........................................................................................497<br />

Stoytchev, Ilko .....................................................................................569<br />

Strange, Wanda ..................................................................................351<br />

Strauss, Bryan E. ......................................................................519, 630<br />

Streeter, Jennifer ................................................................................511<br />

Streetz, Konrad...................................................................................514<br />

Stringer, C. Allen ................................................................................503<br />

Stripecke, Renata .................................................................................47<br />

Stupka, Elia ................................................................................233, 517<br />

Su, Leonard .............................................................................................92<br />

Su, Qin ........................................................................................4, 93, 512<br />

Su, Quin .................................................................................................384<br />

Su, Rui-Jun ............................................................................................468<br />

Su, Xiaomin ..........................................................................................457<br />

Subrizi, A ...............................................................................................732<br />

Sudha, G. ................................................................................................536<br />

Sudha, Govindarajan ........................................................................114<br />

Suel, Laurence ....................................................................................294<br />

Suel-Petat, Laurence ........................................................................615<br />

Suerbaum, Sebastian .......................................................................425<br />

Suerth, Julia D. ............................................................................ 66, 425<br />

Sugimoto, Mitsuhiko ........................................................................357<br />

Sui, Hongshu .......................................................................................535<br />

Suksanpaisan, Lukkana .....................................................................20<br />

Sullivan, Lisa ........................................................................................224<br />

Sumaroka, Marina V. ........................................................................374<br />

Sumaroka, Marina .............................................................................547<br />

Summers, Alex ....................................................................................119<br />

Sun, Baodong ......................................................................................276<br />

Sun, Helena C. .....................................................................................107<br />

Sun, Jiali ....................................................................................................14<br />

Sun, Ryan R. .........................................................................................140<br />

Sun, Ryan ..............................................................................................101<br />

Sun, Xiao-Xin ..........................................................................................72<br />

Sun, Xingshen .....................................................................................535<br />

Sun, Yu ...................................................................................................550<br />

Sung, Biin ..............................................................................................104<br />

Suppa, Erica .........................................................................................298<br />

Surace, Enrico Maria ........................................................................539<br />

Sutton, Debbie ....................................................................................508<br />

Su-Youne, Han .....................................................................................699<br />

Suzuki, Daichi .....................................................................................142<br />

Suzuki, Ryo .................................................................................142, 145<br />

Suzuki, Shingo ............................................................... 471, 472, 575<br />

Svinartchouk, Fedor ...............................................................445, 612<br />

Swanekamp, Ria L. ...............................................................................43<br />

Swanson, Kristin R. ..............................................................................25<br />

176<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Swanson, Magdalena I. ....................................................................115<br />

Swaroop, Anand .................................................................................709<br />

Sweeney, Colin L. ..................................................................................82<br />

Sweet-Cordero, E. A. .........................................................................436<br />

Swiderski, P. .........................................................................................682<br />

Switzer, Kirsten C. .............................................................................502<br />

Switzer, Kirsten ............................................................. 198, 621, 649<br />

Symonds, Ge<strong>of</strong>f P. .................................................................................48<br />

Synold, Timothy W. ...........................................................................648<br />

Sysol, Justin R. .....................................................................................280<br />

‘t Hoen, Peter A. .................................................................................609<br />

Tabar, Vivianne S. .................................................................................11<br />

Tabor, Aaron T. ....................................................................................616<br />

Tac, Kim Jin ..........................................................................................699<br />

Tachibana, Masashi ..........................................................................482<br />

Tada, Yuji ...............................................................................................216<br />

Taga, Yavuz ...........................................................................................697<br />

Tagalakis, Aristides D. ...........................................................158, 434<br />

Tagawa, Masatoshi ....................................................... 216, 638, 642<br />

Taherian, Mehran ..............................................................................286<br />

Tai, Alex .................................................................................................110<br />

Tai, Chun-Hwei ......................................................................................60<br />

Tai, Ming-Hong ...................................................................................230<br />

Tai, Ming-Hong ...................................................................................740<br />

Takafuji, Makoto ................................................................................150<br />

Takagi, Kazuko ...................................................................................627<br />

Takagi, Norio .......................................................................................142<br />

Takemasa, Ichiro................................................................................749<br />

Takagi-Kimura, Misato ..........................................................218, 638<br />

Takahashi, Hiroshi ............................................................................228<br />

Takahashi, Masamichi ............................................................. 70, 522<br />

Takapoo, Maysam ..............................................................................511<br />

Takayama, Koichi...................................................69, 432, 440, 442<br />

Takayama, Koji ...................................................................................614<br />

Takeda, Shin’ichi ........................................................... 120, 176, 608<br />

Takeda, Shuko .....................................................................................283<br />

Takesako, Kazuto ...............................................................................629<br />

Takesako, Kazutoh ............................................................................651<br />

Takeuchi, Ryo ......................................................................................193<br />

Takiguchi, Yuichi ................................................................................216<br />

Talbot, Kendra T. ...................................................................................45<br />

Talmon, Maria .....................................................................................469<br />

Tam, Hok-Hei.......................................................................................412<br />

Tam, Quincy .........................................................................................522<br />

Tam, Y. ....................................................................................................708<br />

Tamai, Katsuto .......................................................................................80<br />

Tamamoto, Atsuko ............................................................................638<br />

Tan, Jian .................................................................................................178<br />

Tan, Lay Geok ......................................................................................430<br />

Tan, Mengqun .....................................................................................328<br />

Tan, Menqun ........................................................................................542<br />

Tandeski, Terry ..................................................................................619<br />

Tandon, Manish ..................................................................................628<br />

Tang, Qiushi .........................................................................................211<br />

Tang, Qiushi .........................................................................................735<br />

Tang, Ru-Hang ....................................................................................367<br />

Tang, Terence ......................................................................................214<br />

Tang, Winson .........................................................................................58<br />

Tang, Ying ..........................................178, 179, 250, 281, 290, 611<br />

Tani, Kenzaburo ..............................................69, 86, 432, 440, 442<br />

Tannous, Bakhos A. ................................. 103, 321, 458, 540, 751<br />

Tapscott, Stephen H. ........................................................................443<br />

Taquet, Nicolas .............................................................. 352, 464, 633<br />

Tarantal, Alice F. .................................................................................542<br />

Targovnik, Alexandra M. ................................................................632<br />

Tatsumi, Kohei ............................................................................ 79, 237<br />

Tatsumi, Koichiro ..............................................................................216<br />

Taylor, Catherine................................................................................214<br />

Taylor, Clare ............................................................................................61<br />

Taylor, J. .................................................................................................708<br />

Taylor, Walton ...........................................................................199, 624<br />

Tayton-Martin, Helen K. .................................................................298<br />

Teckman, Jeffery ................................................................................211<br />

Templeton, Nancy S. .................................................... 464, 570, 625<br />

Tengood, Jillian E. ..............................................................................144<br />

Tenhu, H ................................................................................................732<br />

Tenney, Rebecca .................................................................................444<br />

Terada, Naohiro .................................................................................545<br />

Terjung, Ronald L. .............................................................................166<br />

Tesfay, Mulu Z. ....................................................................................413<br />

Teunissen, Erik ...................................................................................707<br />

Thakore, Pratiksha I. ............................... 167, 170, 177, 292, 491<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

177


Abstract Author Index<br />

Thakur, Archana, ...............................................................................711<br />

Tharion, George .................................................................................754<br />

Tharmalingam, Sujeenthar ...........................................................390<br />

Themeli, Maria ...................................................................................728<br />

Theobald, Narda ................................................................................308<br />

Thiel, William H. ................................................................................511<br />

Thokala, Radhika .......................................................... 431, 502, 649<br />

Thomas, Amelia H. ...............................................................................51<br />

Thomas, Carole ..................................................................................185<br />

Thompson, David H. .........................................................................745<br />

Thompson, Jill .........................................................18, 395, 505, 652<br />

Thompson, John .................................................................................214<br />

Thony, Beat ..........................................................................................354<br />

Thorgeirsson, Snorri S. ...................................................................217<br />

Thorpe, Robin .....................................................................................526<br />

Thrasher, Adrian J. ................................... 306, 313, 578, 661, 678<br />

Throm, Robert E. ...............................................................................672<br />

Thyme, Summer ................................................................................318<br />

Ti juan, Mi .............................................................................................649<br />

Tian, Gengwen .......................................................................................12<br />

Tian, Jie ..................................................................................................133<br />

Tiberghien, Pierre .............................................................................399<br />

Tisdale, John ................................................................................ 30, 428<br />

Tisdale, John F. .......................................................................................65<br />

Tobin, Lisa A. .......................................................................................513<br />

Todorow, Carlyn A.............................................................................236<br />

Tolar, Jakub ........................................................................ 62, 584, 738<br />

Tolmachova, Tanya ...........................................................................227<br />

Tomalia, D.A. ........................................................................................682<br />

Tomita, Kyoko .....................................................................................482<br />

Tompkins, Josh ...................................................................................474<br />

Tonon, Giovanni .................................................................................233<br />

Torbett, Bruce ........................................................................................32<br />

Torgerson, Troy ..................................................................................673<br />

Torgerson, Troy R. ............................................................................311<br />

Toro, Gabriela .....................................................................................603<br />

Toro, Gabriella ....................................................................................388<br />

Torok-Storb, Beverly ..............................................................419, 423<br />

Torrance, Chris ...................................................................................551<br />

Torres-Vega, Miguel A. .....................................................................604<br />

Torry, Donald S. ..................................................................................200<br />

Toso, Erik ..............................................................................................169<br />

Toth, Karoly .........................................................................................480<br />

Tournaire, Benoit .................................................................................76<br />

Towe, Christopher ............................................................................438<br />

Trabalza, Antonio .................................................................................67<br />

Trabucco, Leonardo .........................................................................516<br />

Tran, Chy-Anh .....................................................................................668<br />

Tran, Dat ...............................................................................................431<br />

Treger, Janet ..............................................................................522, 530<br />

Tremblay, Jacques P. ...................................83, 293, 389, 491, 620<br />

Tricoli, Lucas ..........................................................................................44<br />

Triggs-Raine, Barbara .....................................................................379<br />

Trobridge, Grant ................................................................................673<br />

Trobridge, Grant D. .................................................................311, 525<br />

Troupes, Andrew ..................................................................................77<br />

Trump, Lisa ..........................................................................................426<br />

Truong, Lynn .......................................................................................183<br />

Tsai, Hsin-Yin.......................................................................................545<br />

Tsai, Mu-Rou ........................................................................................723<br />

Tsai, Richard K. ...................................................................................523<br />

Tsai, Shengdar Q. ...............................................................................490<br />

Tschudy-Seney, Benjamin ..............................................................468<br />

Tseng, Sheng-Hong ..............................................................................60<br />

Tsui, Christopher ...............................................................................302<br />

Tsuji, Kohichiro .....................................................................................86<br />

Tsujita, Maristela ...............................................................................519<br />

Tsukahara, Tomonori ............................................................121, 651<br />

Tuan, Rocky .........................................................................................178<br />

Turchiano, Giandomenico .............................................................347<br />

Turner, Lorianne S. ...........................................................................660<br />

Turner, Mallory A. ...................................................................132, 481<br />

Turtle, Cameron J. .............................................................................744<br />

Turtle, Cameron ....................................................................................81<br />

Turunen, Heikki T..............................................................................330<br />

Tzen, Kai-Yuan .......................................................................................60<br />

Uchibori, Ryosuke ...................................................................121, 651<br />

Uchida, Naoya ......................................................................30, 65, 428<br />

Uchino, Junji ........................................................................................558<br />

Udd, Bjarne ..........................................................................................615<br />

Uemura, Mamoru ..............................................................................749<br />

Ueno, Kazuko .........................................................................................86<br />

178<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Ugai, Hideyo...............................................................................127, 558<br />

Ugen, Kenneth E. .................................................................................... 9<br />

Uitto, Jouni ..............................................................................................80<br />

Ukovich, Laura ....................................................................................368<br />

Ul-Hasan, Tahira ................................................................................542<br />

Uludag, Hasan ...................................................... 161, 162, 213, 462<br />

Ungerechts, Guy ............................................................ 405, 554, 639<br />

Ur, Sarah ......................................................................................493, 494<br />

Ur, Sarah M. ..........................................................................................546<br />

Urabe, Masashi .........................................................................121, 651<br />

Urbinati, Fabrizia .................................................................................26<br />

Uribe, Misael .......................................................................................604<br />

Urnov, Fyodor D. ................................................................................568<br />

Ürenden, Gökçe ..................................................................................204<br />

Urschitz, Johann.................................................................................569<br />

Urtti, A ....................................................................................................732<br />

Usas, Arvydas ............................................................................178, 290<br />

Ustoa, Maria.........................................................................................534<br />

Utoh, Rie ...................................................................................................79<br />

Vázquez-Carcaño, Lizbeth M. .......................................................604<br />

Vähä-Koskela, Markus .....................................................................501<br />

Valdmanis, Paul N. ............................................................................436<br />

Valles-Ayoub, Yadira ..............................................................152, 620<br />

Van de Graaf, Benjamin ........................................................373, 589<br />

van der Bom, Imramsjah M. J. ......................................................387<br />

van der Horst, Gijsbertus T. J. .......................................................147<br />

van der Ploeg, Ans T. ........................................................................275<br />

van der Velden, Guus .......................................................................661<br />

van der Vos, Kristan E. ....................................................................304<br />

van Dongen, Jacques J. M. ..............................................................313<br />

van Helsdingen, Yvette ....................................................................521<br />

Van Hoppe, Stephanie .....................................................................458<br />

van Kalle, Christ<strong>of</strong> ................................................................................62<br />

van Logtenstein, Richard ...............................................................274<br />

van Ommen, Gert-Jan B. .................................................................609<br />

van Putten, Maaike ...........................................................................609<br />

van Rijn, Sjoerd ..................................................................................321<br />

van Til, Nico P. .....................................................................................275<br />

van Til, Niek P............................................................................521, 661<br />

Van Vliet, Kim .................................................... 4, 71, 333, 334, 541<br />

Van Wittenberghe, Laetitia ...............................................33, 76, 90<br />

Vandenberghe, Luk H. ............................................................. 71, 330<br />

VandenDriessche, Thierry ..........................8, 354, 355, 496, 667<br />

Vandertop, W. Peter ..........................................................................321<br />

Varadarajan, K. S. ...............................................................................150<br />

Varadarajan, Navin ...........................................................................393<br />

Varela-Rohena, Angel ......................................................................508<br />

Varga, Monika .....................................................................................369<br />

Vargas-Jerónimo, Roxana Y. ..........................................................604<br />

Vasireddy, Vidyullatha ..........................................................224, 227<br />

Vatakis, Dimitrios N. ...........................................................................48<br />

Vazin, Tandis ............................................................................................ 3<br />

vemula, Sai vikram V. .......................................................................628<br />

Venditti, Charles P. ..................................................................113, 280<br />

Vera, Juan ..............................................................................................400<br />

Vera, Juan F. ................................................................................398, 622<br />

Veres, Gabor .....................................................37, 51, 251, 258, 674<br />

Verga, Michael ....................................................................................124<br />

Vergara-Silva, A. ....................................................................................15<br />

VerHeul, Ross ......................................................................................745<br />

Verhoeyen, Els ....................................................................................662<br />

Vetrini, Francesco .............................................................................353<br />

Vetter, Alexandra ...............................................................................134<br />

Vickers, Selwyn M. ............................................................................414<br />

Viecelli, Hiu Man ................................................................................354<br />

Vignaud, Alban ................................................33, 90, 240, 605, 606<br />

Vile, Richard ............................................................18, 395, 505, 652<br />

Villa, Anna ............................................................................................661<br />

Villamizar, Olga ..................................................................................235<br />

Villaverde, Marcela S. ......................................................................632<br />

Vincent, Karen ....................................................................................338<br />

Vincent, Phil ........................................................................................264<br />

Virdi, Kulpreet S. ................................................................................134<br />

Visel, Meike ............................................................................................... 5<br />

Visser, Trudi P. ....................................................................................275<br />

Vite, Charles H. ...................................................................................289<br />

Vitek, Libor ..........................................................................................353<br />

Vizcaino-Dorado, Pablo ..................................................................534<br />

Vlahu, Alexander ...............................................................................745<br />

Vogelbaum, Michael A. ....................................................................676<br />

Vogl, Dan T. ...........................................................................................298<br />

Voit, Thomas .............................................................................225, 734<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

179


Abstract Author Index<br />

Voit, Tomas .................................................................................445, 612<br />

Volpin, Monica ............................................................................ 64, 666<br />

von Kalle, Christ<strong>of</strong> ......................................63, 204, 233, 274, 279,<br />

.............................................309, 405,518, 639, 666, 674, 678, 738<br />

Vossough, A. ............................................................................................53<br />

Voytas, Daniel F. .......................................................................584, 738<br />

Voziyanov, Yuri ...................................................................................345<br />

Voziyanova, Eugenia ........................................................................345<br />

Vrecenak, Jesse ...................................................................................418<br />

Vrecenak, Jesse D. ..............................................................................236<br />

Vuidepot, Annelise ............................................................................508<br />

Vulin, Adeline ......................................................................................180<br />

Wack, Katy ...............................................................................................94<br />

Waddington, Simon ..................................................... 363, 430, 580<br />

Wadsworth, Sam................................................................................338<br />

Wagemaker, Gerard ..................................................... 275, 521, 661<br />

Wagner, C. R. ........................................................................................710<br />

Wagner, Ernst .....................................................................................134<br />

Wagner, John E. ..................................................................................738<br />

Wagner, Kathryn R. ..............................................................................93<br />

Wake, Kenjiro .........................................................................................79<br />

Walia, Jagdeep S. ................................................................................379<br />

Walker, Christopher M. ......................................................................91<br />

Walker, Edith .......................................................................................195<br />

Walker, Timothy.................................................................................284<br />

Wallace, Kirby .....................................................................................461<br />

Wallace, Lindsay ......................................................................171, 295<br />

Wallace, Lindsay M. ..........................................................................182<br />

Wallraven, Gladice ...............199, 203, 206, 351, 402, 577, 625<br />

Walsh, C. ................................................................................................708<br />

Walters, Jewell N. ..............................................................................397<br />

Wambua, Gerald ................................................................................465<br />

Wanatabe, Ayumi ..............................................................................432<br />

Wang, Beibei ...........................................................................................69<br />

Wang, Bing ........................................178, 179, 250, 281, 290, 611<br />

Wang, Chi-Hsien ......................................................................296, 370<br />

Wang, Dan ................................................................................................. 4<br />

Wang, Gensheng ................................................................................106<br />

Wang, Hongjie ...........................................................................483, 552<br />

Wang, Hongmei ..................................................................................308<br />

Wang, Hua ..................................................................................105, 644<br />

Wang, Jianbin ................................................46, 107, 183, 184, 487<br />

Wang, Jinhui ........................................................................................544<br />

Wang, Jiwei ..........................................................................................507<br />

Wang, Juan ...........................................................................................457<br />

Wang, Lan ................................................................................................11<br />

Wang, Lina .......................................................................... 75, 118, 314<br />

Wang, Lisa ............................................................................................400<br />

Wang, Li-Sheng .........................................................................105, 644<br />

Wang, Minghui....................................................................................127<br />

Wang, Ningqing ..................................................................................154<br />

Wang, Pengju.............................................................................507, 561<br />

Wang, Ping ...........................................................................................360<br />

Wang, Pin-Yi.........................................................................................412<br />

Wang, Qingtao ....................................................................................194<br />

Wang, Shelley .........................................................................................58<br />

Wang, Shengyao .................................................................................563<br />

Wang, Sheri ..........................................................................................281<br />

Wang, Weijun ......................................................................................703<br />

Wang, Xi.................................................................................................163<br />

Wang, Xiang .........................................................................................562<br />

Wang, Xia<strong>of</strong>ei ......................................................................................512<br />

Wang, Xiaoyin .....................................................................................369<br />

Wang, Xin ..............................................................................................752<br />

Wang, Xiuyan .......................................................................50, 61, 506<br />

Wang, Xuefeng ....................................................................................665<br />

Wang, Xueqian .......................................................................................32<br />

Wang, Yaohe ..............................................................................507, 561<br />

Wang, Yuan ..............................................................75, 118, 314, 328<br />

Wang, Yuhan ................................................................................ 85, 579<br />

Wang, Yupeng .....................................................................................318<br />

Wang, Zejing ........................................................................................443<br />

Wang, Zhaohui .................................206, 219, 234, 317, 510, 625<br />

Wang, Zhimin ............................................................................141, 149<br />

Ware, Tierra................................................................................. 39, 597<br />

Warischalk, Jayme K. ............................................................................ 6<br />

Wasielewska, Teresa ...........................................................................50<br />

Wasserman, Wyeth W. .....................................................................115<br />

Watanabe, Natsumi ..........................................................................237<br />

Watanabe, Norihiro ................................................................398, 622<br />

Watson, Rachael S. ...............................................................................88<br />

Watts, Ashlee E. .....................................................................................89<br />

180<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Watts, Korashon L. ............................................................................249<br />

Wayne, Alan .........................................................................................307<br />

Wayne, Alan S. ....................................................................................325<br />

Weagel, Evita .......................................................................................208<br />

Weaver, Eric .........................................................................................583<br />

Weaver, Matthew S. .............................................................................96<br />

Weber, Gerrit .......................................................................................392<br />

Weber, Nicholas D. ............................................................................193<br />

Weber, Nick ................................................................................187, 188<br />

Webber, Beau R. .................................................................................738<br />

Weeden, Timothy ..............................................................................453<br />

Wei, Dong ..............................................................................................281<br />

Wei, Jie ......................................................................................................12<br />

Wei, Lisa L. ...........................................................................................737<br />

Wein, Nicolas .......................................................................................180<br />

Weinberg, Marc S. .............................................................................189<br />

Weiner, David B. ................................................ 9, 45, 341, 374, 397<br />

Weinstein, John ..................................................................................267<br />

Weismann, Cara M. .................................................................384, 595<br />

Weiss, Brendan...................................................................................298<br />

Weissman, Drew ......................................................................146, 147<br />

Weissman, Irving ..................................................................................29<br />

Weitzel, Richard .................................................................................428<br />

Welch, Peter .........................................................................................706<br />

Wellman, J. ...............................................................................................53<br />

Wendland, Rebecca ..........................................................................104<br />

Wengerter, Brian C. ...........................................................................205<br />

Wentworth, Bruce M. .......................................................................453<br />

Werling, Natalie .................................................................................526<br />

Wernersson, Karin ............................................................................209<br />

Westin, Erik .........................................................................................587<br />

Westmoreland, Susan ......................................................................387<br />

Wetzke, Martin ......................................................................................84<br />

Wherley, Jennifer ..................................................................................26<br />

Whisenant, Thomas .........................................................................493<br />

Whitaker, Leslie R. ............................................................................382<br />

White, Edward A. ...............................................................................158<br />

Whitlock, B. K.........................................................................................40<br />

Wiekmeijer, Anna-Sophia ....................................................313, 319<br />

Wielgosz, Matthew M. .....................................................................672<br />

Wierda, William G. ............................................................................502<br />

Wilber, Andrew ................................................................ 26, 200, 235<br />

Wild, A ....................................................................................................708<br />

Wilkinson, Leslie ...............................................................................461<br />

Willems, Jessica ............................................................................ 8, 496<br />

Wille-Reece, Ulrike ..............................................................................45<br />

Williams, Daniel .................................................................................298<br />

Williams, James ..................................................................................185<br />

Williams, James A. .............................................. 186, 261, 263, 616<br />

Williams, Regina R. ...........................................................................613<br />

Williams, Richard D. .........................................................................374<br />

Wilson, D. U. ............................................................................................40<br />

Wilson, Heather .................................................................................400<br />

Wilson, James ...........................................................................108, 444<br />

Wilson, James M. ............................................................. 71, 128, 360<br />

Wilson, John R. ...................................................................................622<br />

Wilson, Matthew H. ..........................................................................269<br />

Wilson-Robles, Heather M. ...........................................................653<br />

Winslow, Monte .................................................................................436<br />

Wise, Megan ........................................................................................341<br />

Witt, William .......................................................................................281<br />

Witten, J .................................................................................................718<br />

Witting, Burghardt ...........................................................................686<br />

Wohlgenant, S. L. ...............................................................................381<br />

Wojno, Adam P. ...................................................................................231<br />

Wojton, Jeffrey ....................................................................................747<br />

Wold, William S. M. ...........................................................................480<br />

Wolf, Stephan ......................................................................................274<br />

Wolf, Walter .........................................................................................703<br />

Wolfe, John H. ............................................................................116, 289<br />

Wolfe, Thomas G. ...............................................................................550<br />

Wolfe, Tom ...........................................................................................339<br />

Wolstein, Orit .........................................................................................48<br />

Woltjen, Knut ......................................................................................715<br />

Won, Chong-Hyun .............................................................................602<br />

Wong, Jr, Kamehameha K. ..............................................................542<br />

Wong, Suet Ping .......................................................................346, 354<br />

Wong, Sunnie Y. ..................................................................................488<br />

Woo, Lee Hyun ...................................................................................699<br />

Wood, Steve .........................................................................................339<br />

Wood, Travis........................................................................................183<br />

Woodard, Lauren E. ..........................................................................269<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

181


Abstract Author Index<br />

Woodle, Martin ...................................................................................455<br />

Wooley, Dawn P. .................................................................................267<br />

Worgall, Stefan ...................................................................................104<br />

Wourms, Michael ...............................................................................664<br />

Wright, J. Fraser ........................................ 110, 312, 529, 547, 663<br />

Wu, Bo ....................................................................................................451<br />

Wu, Chuanfeng ......................................................................................29<br />

Wu, Chu-Tse ...............................................................................105, 644<br />

Wu, Colin O. .............................................................................................65<br />

Wu, I.-Huan ..........................................................................................453<br />

Wu, James .............................................................................................659<br />

Wu, Jing .................................................................................................433<br />

Wu, Joseph ...........................................................................................474<br />

Wu, Lily ..................................................................................................215<br />

Wu, Ruey-Meei ......................................................................................60<br />

Wu, Ruilin .............................................................................................476<br />

Wu, Susan ................................................................................................87<br />

Wu, Wendy ...........................................................................................104<br />

Wu, Xiaolin ...........................................................................................308<br />

Wu, Xin ...................................................................................................749<br />

Wu, Zhijian ...........................................................................................709<br />

Würdinger, Thomas ..........................................................................321<br />

Wyszynski, Mike ................................................................................339<br />

Xia, Danny.............................................................................................184<br />

Xia, Xueqing .........................................................................................139<br />

Xiao, Bin ......................................................................................296, 367<br />

Xiao, Feng-jun ...........................................................................105, 644<br />

Xiao, Juan ..............................................................................................312<br />

Xiao, Ru ..................................................................................................330<br />

Xiao, Weidong .....................................................................................681<br />

Xiao, Xiao ..................................................... 167, 296, 367, 370, 449<br />

Xie, Jun .............................................................................................. 4, 512<br />

Xie, Qing ................................................................................................336<br />

Xie, Yi ......................................................................................................727<br />

Xie, Yili ...................................................................................................513<br />

Xie, Yuran ..............................................................................................711<br />

Xing, Elizabeth M. .................................................................................87<br />

Xu, Ding .................................................................................................448<br />

Xu, Lei .....................................................................................................296<br />

Xu, Weidong .........................................................................................555<br />

Xu, Wenqin ...........................................................................................524<br />

Xu, Yang ....................................................................................................49<br />

Xu, Zhili ..................................................................................................133<br />

Xue, Shu-Ya ...........................................................................................644<br />

Yadak, Rana ..........................................................................................521<br />

Yaguchi, Chiemi ..................................................................................228<br />

Yagyu, Shigeki .....................................................................................684<br />

Yakovief, Galina ..................................................................................495<br />

Yamada, Takeshi ................................................................................643<br />

Yamaguchi, Kiyoshi..............................................................................86<br />

Yamaguchi, Naoto .............................................................................216<br />

Yamamoto, Masato .................................................................408, 414<br />

Yamamoto, Masato .................................................................705, 742<br />

Yamamoto, Motoko ...........................................................................358<br />

Yamamoto, Shohei ...............................................................................86<br />

Yamamoto, Takashi ..........................................................................715<br />

Yamamoto, Yuki .................................................................................642<br />

Yamanaka, Shinya .............................................................................715<br />

Yamatmoto, Hir<strong>of</strong>umi ......................................................................749<br />

Yamazaki, Yoshiyuki .........................................................................601<br />

Yan, Jenny J. .............................................................................................46<br />

Yan, Jenny ...................................................................................183, 487<br />

Yan, Jian ............................................................................... 45, 341, 397<br />

Yan, Junjie .............................................................................................164<br />

Yan, Linna .............................................................................................750<br />

Yan, Pearlly...........................................................................................412<br />

Yan, Renhe ............................................................................................533<br />

Yan, Ziying ............................................................................................535<br />

Yancey, Heather ..................................................................................660<br />

Yáñez-Muñoz, Rafael J .....................................................................678<br />

Yang, Hsiao T. ......................................................................................166<br />

Yang, Hyunwoo ..................................................................................602<br />

Yang, Maria .................................................................................. 45, 341<br />

Yang, Qing .............................................................................................290<br />

Yang, Shan ............................................................................................216<br />

Yang, Shu ...............................................................................................374<br />

Yang, Xia<strong>of</strong>ang ....................................................................................512<br />

Yang, Yanqin ...........................................................................................65<br />

Yang, Yong ............................................................................................562<br />

Yang, Yue-feng ..........................................................................105, 644<br />

Yang, Yu-Lin .........................................................................................723<br />

Yannaki, Evangelia .................................................................... 27, 427<br />

182<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013


Abstract Author Index<br />

Yanovich, Saul .....................................................................................298<br />

Yaseen, Nahi Y. ....................................................................................647<br />

Yazicioglu, Mustafa ...........................................................................110<br />

Ye, Jing Jing ...........................................................................................476<br />

Ye, Jingjing ............................................................................................474<br />

Ye, Xun ....................................................................................................680<br />

Yeagy, Brian A. ....................................................................................493<br />

Yeger, Herman.....................................................................................433<br />

Yeghiazarians, Yerem .......................................................................369<br />

Yen, Paul M. ..........................................................................................618<br />

Yeoh, George C. T................................................................................356<br />

Yeung, Jonathan .................................................................................433<br />

Yezzi, Michael H. ................................................................................472<br />

Yin, Lu ......................................................................................................... 5<br />

Yin, Yue ..................................................................................................644<br />

Ying, Tang .............................................................................................614<br />

Ylä-Herttuala, Seppo ...........................................................................97<br />

Yliperttula, M ......................................................................................732<br />

Yockman, James W. ...........................................................................645<br />

Yoder, Mervin C. .......................................................................328, 542<br />

Yokoi, Kentaro ....................................................................................753<br />

Yokoi, Takayuki ..................................................................................753<br />

Yokoyama, Kazunari K. ...................................................................643<br />

Yoo, Hyuk Sang ...................................................................................256<br />

Yoo, James.............................................................................................253<br />

Yoo, Ji Young ........................................................................................747<br />

Yoon, Hye-Jin .......................................................................................602<br />

Yoon, Sea Young .................................................................................289<br />

Yoon, Sung Won .................................................................................143<br />

Yoshihara, Chieko ..............................................................................627<br />

Yoshioka, Akira ......................................................................................79<br />

You, Yezhi ..............................................................................................164<br />

Young, Brittany A. .............................................................................480<br />

Young, Courtney.................................................................................609<br />

Young, Sarah P. ....................................................................................618<br />

Youssouian, H. ......................................................................................15<br />

Yu, Feng .................................................................................................410<br />

Yu, Juehua ...................................................................................272, 659<br />

Yu, Jun-Ge .............................................................................................747<br />

Yu, Yang .......................................................................................206, 633<br />

Yu, Zhiqiang .........................................................................................164<br />

Yuan, Huijan ........................................................................................385<br />

Yuan, Zhenhua ............................................................... 367, 370, 449<br />

Yue, Yongping .............................................................................. 98, 613<br />

Yue, Yougping ......................................................................................166<br />

Yugeta, Naoko .....................................................................................608<br />

Yulyana, Yulyana ................................................................................254<br />

Yumul, Roma .............................................. 201, 303, 483, 552, 704<br />

Yun, Chae-Ok ................129, 130, 556, 634, 640, 645, 679, 689<br />

Yvon, Eric ...................................................................................... 12, 394<br />

Zabner, Joseph ....................................................................................327<br />

Zacchigna, Serena ..................................................................... 95, 368<br />

Zacharoulis, D .....................................................................................682<br />

Zaiss, Anne K. ......................................................................................448<br />

Zamorano-Carrillo, Absalom ........................................................ 604<br />

Zamore, Phillip D. ..............................................................................512<br />

Zanaboni, Laura .................................................................................420<br />

Zanatta, Daniela B. ............................................................................519<br />

Zanetti, Gianluigi .....................................................................309, 517<br />

Zaraspe, Kim .......................................................................................125<br />

Zaraspe, Kimberly ................................................................................39<br />

Zavaljevski, Maja ...............................................................................450<br />

Zeidan, Joumana ...................................................................................58<br />

Zelenaia, Olga ......................................................................................547<br />

Zentella-Dehesa, Alejandro ...........................................................534<br />

Zentilin, Lorena .....................................................................................95<br />

Zerfas, Patricia M. ..............................................................................383<br />

Zervou, Fani ............................................................................................27<br />

Zhang, Chao .........................................................................................562<br />

Zhang, Chunbo..........................................................................242, 750<br />

Zhang, Daoning .....................................................................................44<br />

Zhang, Fang ................................................................................313, 661<br />

Zhang, Feijie ........................................................................................271<br />

Zhang, Feng ..........................................................................................677<br />

Zhang, G. ...................................................................................................53<br />

Zhang, Jane ..............................................................................................48<br />

Zhang, Jianying ...................................................................................747<br />

Zhang, Jingang ..........................................................................533, 563<br />

Zhang, Jingwan ...................................................................................559<br />

Zhang, Jingyu.......................................................................................217<br />

Zhang, Jun .............................................................................................136<br />

Zhang, Keqing ................................................................... 98, 166, 613<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013<br />

183


Abstract Author Index<br />

Zhang, Lei ..................................................................................... 46, 184<br />

Zhang, Ming ............................................................................................49<br />

Zhang, Mingdi ................................................................ 285, 478, 591<br />

Zhang, Na ..............................................................................................563<br />

Zhang, Qun-wei ........................................................................105, 644<br />

Zhang, Ting ..........................................................................................449<br />

Zhang, Tracy Y. .......................................................................................93<br />

Zhang, Wenli ........................................................................................557<br />

Zhang, Xiao-Bing ...............................................................................468<br />

Zhang, Xichen ......................................................................................239<br />

Zhang, Yan ............................................................................................369<br />

Zhang, Yanling ....................................................................................221<br />

Zhang, YiYi ...........................................................................................729<br />

Zhang, Yu ...............................................................................4, 128, 411<br />

Zhang, Yuanyuan ...............................................................................473<br />

Zhang, Zhao .........................................................................................247<br />

Zhang, Zhenwei ..................................................................................555<br />

Zhao, Allan ...........................................................................................281<br />

Zhao, Chunli .........................................................................................174<br />

Zhao, Chunxia ...........................................................................370, 449<br />

Zhao, Hui Fen ......................................................................................424<br />

Zhao, Huiren ..............................................................................339, 550<br />

Zhao, Li ..................................................................................................105<br />

Zhao, Na ......................................................................................207, 404<br />

Zhao, Yangbing ...................................................................................623<br />

Zhao, Yuan ............................................................................................526<br />

Zheng, Changyu ..................................................................................743<br />

Zheng, Dexian .....................................................................................752<br />

Zheng, Qifa ...........................................................................................214<br />

Zheng, X. Long ....................................................................................312<br />

Zheng, Yanyan .....................................................................................436<br />

Zheng, Zhaohui ...................................................................................298<br />

Zhong, Li ............................................................4, 128, 326, 328, 542<br />

Zhou, Betty ...........................................................................................455<br />

Zhou, Dongming ................................................................................562<br />

Zhou, Guisheng .........................................................................272, 659<br />

Zhou, Jiehua .........................................................................................454<br />

Zhou, Michelle ....................................................................................115<br />

Zhou, Qinghui......................................................................................164<br />

Zhou, Shangzhen ...................................... 110, 312, 488, 498, 733<br />

Zhou, Shang-Zhen .............................................................................547<br />

Zhou, Sheng .........................................................................................671<br />

Zhu, Liwei ...................................................................................207, 404<br />

Zimmermann, Wolfgang .................................................................658<br />

Zingone, Adriana ...............................................................................531<br />

Zolotukhin, Irene ...............................................................................190<br />

Zolotukhin, Sergei ...................................................................335, 548<br />

Zoltick, Philip K. .................................................................................523<br />

Zou, Jizhong ............................................................................................82<br />

Zourelias, Lee ............................................................................141, 149<br />

Zwaka, Thomas ..................................................................................169<br />

184<br />

<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!